 
Official Title:  A Randomized,  Double- blind, Placebo- Controlled,  Dose -Ranging 
Phase 2 Study of ISIS 681257 Administered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD)  
Study ID: [REMOVED] 
Document  Date(s) : Protocol  Amendment Version 6: 25-January -2018 
Protocol Amendment Version 5: 30-May-2017 
Protocol Amendment Version 4: 5-January -2017 
Protocol Amendment Version 3: 9-December -2016 
 
 
  
  
Sponsor:  
Akcea Therapeutics  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 Collaborator: 
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 
 
AKCEA THERAPEUTICS  
 
ISIS 681257-CS6 
 
 
A Randomized, Double- blind, P lacebo-Controlled, D ose-Ranging 
Phase 2  Study of ISIS 681257 A dministered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease ( CVD) 
 
Protocol Amendment 6 – 25 January 2018  
  
 
EudraCT No:  2016-003373-18 
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
3  ISIS 681257-CS6 
Ionis Protocol Number ISIS 681257- CS6 
Protocol Amendment 6 
EudraCT No:  2016-003373-18 
Clinical Phase:   2 
A Randomized, Double- blind, P lacebo-Controlled, Dose-Ranging 
Phase 2 Study of ISIS 681257 Administered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD)  
Trial Sponsor:  Akcea Therapeutics, Inc.  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 
Key Sponsor  Contact:   
 Ak cea Therapeutics  
55 Cambridge Parkway, Suite 100 Cambridge, MA  02142 
Phone:   
E-mail:   
Sponsor Medical Monitor:   MD, PhD  
 Ak cea Therapeutics  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 
Phone:  
Mobile:  
E-mail:   
Date:  25 January  2018  
 
Confidentiality Statement  
This document contains confidential information of Ionis  Pharmaceuticals, Inc. and Akcea Therapeutics 
that must not be disclosed to anyone other than the recipient study staff and members of the independent 
ethics committee, institutional review board, or authorized r egulatory agencie s.  This information cannot 
be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc. and Akcea Therapeutics.   

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
4  Protocol Signature Page  
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study 
of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment:  Amendment 6 
Date:  25 January  2018 
I hereby acknowledge that I have read and understand the attached clinical protocol, entitled “ A 
Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 
Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular 
Disease (CVD) ,” dated 25 January  2018, and agree to conduct the study as described herein.  
I agree to comply with the International Conference on Harmonization Tripartite Guideline on Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for any 
purpose other than the evaluation or conduct of the clinic al investigation without the prior written consent 
of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
5  TABLE OF CONTENTS  
Page  
PROTOCOL AMENDMENTS  ............................................................................................................... 10 
PROTOCOL SUMMARY OF CHANGES  ............................................................................................ 11 
PROTOCOL SYNOPSIS  ......................................................................................................................... 13 
STUDY DESIGN AND TREATMENT  SCHEMA ................................................................................ 20 
1. OBJECTIVES  .............................................................................................................................. 25 
1.1 Primary Objective ...................................................................................................................... 25 
1.2 Secondary Objective(s)  ............................................................................................................. 25 
2. BACKGROUND AND RATIONALE  ....................................................................................... 25 
2.1 Overview of Disease .................................................................................................................. 25 
2.1.1 Lipoprotein (a)  ................................................................................................................... 25 
2.1.2 Pathophysiology ................................................................................................................ 27 
2.1.3 Current Treatment Options  ................................................................................................ 27 
2.2 Therapeutic Rationale ................................................................................................................ 28 2.3 ISIS 681257 ............................................................................................................................... 28 
2.3.1 Mechanism of Action  ........................................................................................................ 28 
2.3.2 Chemistry  .......................................................................................................................... 28 
2.3.3 Preclinical Experience  ....................................................................................................... 29 
2.3.4 Clinical Experience  ........................................................................................................... 30 
2.4 Rationale for Dose and Schedule of Administration ................................................................. 31 
3. EXPERIMENTAL PLAN  ........................................................................................................... 32 
3.1 Study Design  ............................................................................................................................. 32 
3.2 Number of Study Centers .......................................................................................................... 32 
3.3 Number of Patients .................................................................................................................... 33 3.4 Overall Study Duration and Follow-up ..................................................................................... 33 
3.4.1 Screening ........................................................................................................................... 33 3.4.2 Treatment  .......................................................................................................................... 33 
3.4.3 Post-Treatment  .................................................................................................................. 33  
3.5 End-of-Study ............................................................................................................................. 34 
3.6 Data and Safety Monitoring Board ............................................................................................ 34 
4. PATIENT ENROLLMENT ........................................................................................................ 34 
4.1 Screening ................................................................................................................................... 34 4.2 Randomization ........................................................................................................................... 34
 
4.3 Replacement of Patients  ............................................................................................................ 35 
4.4 Unblinding of Treatment Assignment ....................................................................................... 35 
5. PATIENT ELIGIBILITY  ........................................................................................................... 35 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
6  5.1 Inclusion Criteria ....................................................................................................................... 35 
5.2 Exclusion Criteria ...................................................................................................................... 36 
6. STUDY PROCEDURES  ............................................................................................................. 37 
6.1 Study Schedule .......................................................................................................................... 37 
6.1.1 Screening ........................................................................................................................... 38 
6.1.2 Treatment Period  ............................................................................................................... 38 
6.1.3 Post-Treatment Period  ....................................................................................................... 38 
6.2 Additional Study Assessments .................................................................................................. 39 
6.2.1 Laboratory Assessments  .................................................................................................... 39 
6.2.2 Physical Exams and Vital Signs ........................................................................................ 40 
6.2.3 Electrocardiography  .......................................................................................................... 40 
6.2.4 PK Sampling  ..................................................................................................................... 40 
6.3 Restriction on the Lifestyle of Patients ...................................................................................... 41 
6.3.1 Contraception Requirements ............................................................................................. 41 6.3.2 Other Requirements ........................................................................................................... 42 
7. STUDY DRUG  ............................................................................................................................. 42 
7.1 Study Drug Description ............................................................................................................. 42 
7.1.1 ISIS 681257 ....................................................................................................................... 42 
7.1.2 Placebo 42 
7.2 Packaging and Labeling  ............................................................................................................ 43 
7.3 Study Drug Accountability ........................................................................................................ 43 
8. TREATMENT OF PATIENTS .................................................................................................. 43 
8.1 Study Drug Administration ....................................................................................................... 43 8.2 Other Protocol -Required Drugs ................................................................................................. 44 
8.3 Other Protocol -Required Treatment Procedures  ....................................................................... 44 
8.4 Treatment Precautions  ............................................................................................................... 44 
8.5 Safety Monitoring Rules ............................................................................................................ 44 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  ......................................................... 45 
8.5.2 Safety Monitoring for Renal Function .............................................................................. 46 8.5.3 Safety Monitorin g
 for Platelet Count Results  ................................................................... 47 
8.5.4 Safety Monitoring for Minor Bleeding Events .................................................................. 48 
8.5.5 Safety Monitoring for Constitutional Symptoms .............................................................. 48 
8.6 Stopping Rules .......................................................................................................................... 48 
8.6.1 Stopping Rules for Liver Chemistry Elevations  ................................................................ 49 
8.6.2 Stopping Rules for Renal Function Test Results ............................................................... 49 
8.6.3 Stopping Rule for Platelet Count Results .......................................................................... 49 
8.7 Adjustment of Dose ................................................................................................................... 52 
8.8 Discontinuation of Study Drug .................................................................................................. 52 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
7  8.8.1 Follow-up Visits for Early Termination from Treatment Period or from Post- Treatment 
Follow-up Period ............................................................................................................... 53 
8.9 Withdrawal of Patients from the Study ..................................................................................... 53 
8.10 Concomitant Therapy and Procedures  ....................................................................................... 54 
8.10.1 Concomitant Therapy  ........................................................................................................ 54 
8.10.2 Concomitant Procedures  .................................................................................................... 54 
8.11 Treatment Compliance .............................................................................................................. 55 8.12 Safety Monitoring Compliance ................................................................................................. 55 
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  .................................... 55 
9.1 Sponsor Review of Safety Information ..................................................................................... 55 9.2 Regulatory Requirements  .......................................................................................................... 55 
9.3 Definitions  ................................................................................................................................. 56 
9.3.1 Adverse Event  ................................................................................................................... 56 
9.3.2 Adverse Reaction and Unexpected Adverse Reaction  ...................................................... 56 
9.3.3 Serious Adverse Event (SAE)  ........................................................................................... 56 
9.3.3.1 Adverse Events of Special Interest  ............................................................................. 57 
9.4 Monitoring and Recording Adverse Events .............................................................................. 57 
9.4.1 Serious Adverse Events/Adverse Events of Special Interest  ............................................. 57 
9.4.2 Non-Serious Adverse Events  ............................................................................................. 58 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  ................................................ 58 
9.4.3.1 Relationship to the Study Drug .................................................................................. 58 9.4.3.2 Severity ....................................................................................................................... 58 
9.4.3.3 Action Taken with Study Drug .................................................................................. 59 9.4.3.4 Treatment Given for Adverse Event ........................................................................... 59 
9.4.3.5 Outcome of the Adverse Event  .................................................................................. 59 
9.5 Procedures for Handling Special Situations .............................................................................. 60 
9.5.1 Abnormalities of Laboratory Tests .................................................................................... 60 9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ....................... 60 
9.5.3 Dosing Errors  .................................................................................................................... 61  
9.5.4 Contraception and Pregnancy ............................................................................................ 61 
10. STATISTICAL CONSIDERATIONS  ....................................................................................... 62 
10.1 Study Endpoints, Subsets, and Covariates................................................................................. 62 
10.1.1 Primary Endpoint(s )
 .......................................................................................................... 62 
10.1.2 Secondary Endpoints ......................................................................................................... 62 10.1.3 Safety Endpoints................................................................................................................ 62 10.1.4 Dose Selection  ................................................................................................................... 63 
10.2 Sample Size Considerations ...................................................................................................... 63 
10.3 Analysis Populations ................................................................................................................. 63 10.4 Definition of Baseline ................................................................................................................ 64 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
8  10.5 Interim Analysis  ........................................................................................................................ 64 
10.6 Planned Methods of Analysis .................................................................................................... 64 
10.6.1 Demographic and Baseline Characteristics  ....................................................................... 64 
10.6.2 Safety Analysis  .................................................................................................................. 64 
10.6.2.1 Adverse Events  ........................................................................................................... 64 
10.6.2.2 Clinical Laboratory Data  ............................................................................................ 65 
10.6.2.3 Vital Signs and Examinations .................................................................................... 65 
10.6.3 Efficacy Analysis  .............................................................................................................. 65 
10.6.3.1 Analysis of Primary Efficacy Endpoint ...................................................................... 65 
10.6.3.2 Analysis of Secondary Efficacy Endpoints ................................................................ 65 
10.6.4 Pharmacokinetic and Immunogenicity Analysis ............................................................... 66 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  .......................................................... 67 
11.1 Informed Consent ...................................................................................................................... 67 
11.2 Ethical Conduct of the Study  ..................................................................................................... 67 
11.3 Independent Ethics Committee (IEC)/Institutional Review Board (IRB) ................................. 67 11.4 Patient Confidentiality  ............................................................................................................... 68 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  .............................................................. 68 
12.1 Protocol Amendments ............................................................................................................... 68 12.2 Study Termination ..................................................................................................................... 68 
12.3 Study Documentation and Storage ............................................................................................ 68 
12.4 Study Monitoring ...................................................................................................................... 69 
12.5 Language  ................................................................................................................................... 70 
12.6 Compensation for Injury  ............................................................................................................ 70 
13. REFERENCES  ............................................................................................................................. 71 
14. APPENDICES  .............................................................................................................................. 74 
Appendix A Schedule of Procedures  .............................................................................................. 75 
Appendix B List of Laboratory Analytes  ....................................................................................... 82 
Appendix C PK Sampling Schedule ............................................................................................... 84  
Appendix D Grading Scale for Adverse Events Relating to Laboratory Abnormalities  ................ 87 
Appendix  E 
 Additional Laboratory Tests for Patients with Platelet Count ˂ 100,000/mm3 .......... 91 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
9  TABLE OF TABLES 
Page  
Table 1  Study Drug Characteristics ............................................................................................... 43 
Table 2  Study Drug Dosing Information ....................................................................................... 44 
Table 3  Actions in Patients with Low Platelet Count  .................................................................... 51 
 
TABLE OF FIGURES 
Page  
Figure 1 Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of apo(a) 
Covalently Bound to apoB ................................................................................................ 26 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
10  PROTOCOL AMENDMENT S 
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Randomized, Double-blind, Placebo-Controlled, Dose- Ranging Phase 
2 Study of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment Number:  6 
Amend ment Date:  25 January  2018 
 
The following table summarizes the history and nature of amendments to the protocol ISIS 681257- CS6. 
None of the antecedent versions of the study protocol has been enacted clinically and therefore no patients 
have been enrolled prior to issuance of Amendment 4. 
Protocol Version  Date  Rationale for Amendments  
Original Protocol  15 August 2016   
Amendment 1  6 October 2016  Regulatory advice on inclusion of more detailed 
description of processes for platelet monitoring, and more frequent monitoring of liver function.  
Amendment 2  29 November 2016  Regulatory advice on inclusion of biomarkers of renal damage and increased frequency of renal 
monitoring.   Addition of a DSMB.  
Amendment 3  30 December 2016  Adjustment of the frequency, and alert and intervention limits, for renal safety and adjustment of the frequency of liver safety testing.   
Amendment 4  5 January  2017  The study population was increased to 270 patients 
(54 per cohort) to support a statistical assessment 
of risk of platelet reduction in this population.  In 
addition, the 10 mg weekly treatment cohort has 
been modified to 20 mg every 2 weeks ( biweekl y). 
Amendment 5  30 May  2017 Regulatory advice on addition of exclusion criteria, 
reduced permitted timeframe for identifying critical 
laboratory results by the investigator and 
replacement of the AE definition.   In addition,  
Section 8.6.2 was edited for consistency.  
Amendment 6  25 January  2018  Updated platelet monitoring to allow for potential to 
return to every 2-week monitoring, clarified 
definition and scheduling of the follow -up period and 
End of Treatment visit for last patient  to complete 
primary endpoint visit.  
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
11  PROTOCOL SUMMARY OF CHANGES  
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Randomized, Double-blind, Placebo-Controlled, Dose- Ranging Phase 
2 Study of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment Number:  6 
Amendment Date:  25 January  2018 
 
The following modifications to Protocol ISIS 681257- CS6 Amendment 5 have been made.  
Minor changes (not included in the list of changes below) have been made throughout the protocol to 
correct errors and/or to improve the overall clarity of the original protocol but these changes do not 
impact subject safety, exposure, or the overall  study design.  
The following table provides a summary list of major changes to the Amendment 5 of the protocol: 
Protocol Section  Description of Change  Rationale  
Throughout  Updated Sponsor to Akcea 
Therapeutics and Collaborator to 
Ionis  Pharmaceuticals, Inc.  Sponsorship has been transferred 
from Ionis Pharmaceuticals, Inc. to 
Akcea Therapeutics  
Section 3.4.2  Added detail around definition 
and scheduling of End of 
Treatment Visit  Clarification and deta il added to 
ensure definition of Treatment 
Period is clear. Additional clarification was also added around scheduling of the End of Treatment 
Visit for all patients once last patient 
is enrolled.  
Section 6.2. 1 
Laboratory Assessments  Added “should” to samples being 
collected and analyzed in parallel 
at the central and local lab.  The word “should” was inadvertently 
left out of the sentence in a prior 
amendment.  
Section 8.5.3  
Safety Monitoring for Platelet Count 
Results  Updated reference to Appendix from D to E for platelet counts  
< 100,000/mm3 Correct Appendix is E  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
12  Protocol Section  Description of Change  Rationale  
Section 8.6.3  
Stopping Rule for Platelet Count 
Results  
Table 3  
Actions in Patients with Low Platelet 
Count  Changed language around weekly monitoring requirement to 
allow for return to every 2-week monitoring if 2 successive platelet values fall within the normal range.  Given the episodic transient nature 
of mild platelet drops recorded to 
date, weekly platelet monitoring for the entire duration of the study even when the platelet count returns to 
the normal range is medically 
unjustified.  
Section 8.6.3  
Stopping Rule for Platelet Count 
Results  
Table 3  
Actions in Patients with Low Platelet 
Count  Clarified platelet ranges and 
updated Section 8.6.3 accordingly.  Clarification to ensure no overlap in 
actions to be taken based on 
platelet value  
Appendix A  
Schedule of Procedures  Clarified that follow -up visits 
should be timed to correspond 
with last visit of the treatment 
period  Clarification to ensure alignment 
among sites in scheduling of follow 
up visits in relation to the last visit of the treatment period rather than the last dose.  
Appendix A  
Schedule of Procedures  Added “(optional)” to genetic testing assessment  This test is only required for patients 
who sign separate consent  
Appendix A  
Schedule of Procedures  Clarified timing of study drug 
administration for weekly and 
every 2 -week dosing  Clarification to account for last dose 
variation between weekly and every 
2-week cohorts.  
Appendix A  
Schedule of Procedures  Added footnote stating the last 
patient to reach 6 months of 
exposure will complete all 
assessments for primary 
endpoint visit (Week 25 or Week 27 based on cohort) and for End of Treatment visit (Week53/ ET), 
and will not receive a dose at 
that visit.  Clarification that  the last patient ’s 
primary endpoint visit will count  as 
Week 25/Week 27 and End of 
Treatment visit (Week53/ ET)  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
13  PROTOCOL SYNOPSIS  
Protocol Title  A Randomized, Double -blind, Placebo-C ontrolled, Dose-R anging Phase 2 Study of 
ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and 
Established Cardiovascular Disease (CVD)   
Study Phase  2 
Indication  Patients with hyperlipoproteinemia(a) and established CVD . 
Investigational Drug  ISIS 681257 is a second generation 2ʹ-MOE modified, GalNAc 3–conjugated antisense 
oligonucleotide inhibitor of apolipoprotein (a) [ apo(a) ]. 
Primary Objective  To evaluate the safety , including tolerability , of ISIS  681257 and to assess the efficacy  of 
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels 
in patients with hyperlipoproteinemia(a) and established CVD.  
Secondary Objective(s)  To evaluate the efficacy of ISIS 681257 on plasma levels of low density lipoprotein 
cholesterol (LDL -C), apolipoprotein B 100 (apoB), oxidized phospholipids ( OxPL ) on 
apo(a)  [OxPL -apo(a)] , and OxPL  on apoB  (OxPL -apoB) . 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose 
regimens in patient s with hyperlipoproteinemia(a) and established CVD.  
Study Design  This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.  
Approximately 270 patients will be randomized in a 5:1 ratio to receive ISIS 681257 or 
placebo.  This number was chosen to provide statistical power for both efficacy and 
safety assessments.  Study Drug (ISIS  681257 or placebo) will be administered SC 
every week, every 2 weeks , or every 4 weeks, depending on cohort assignment,  for up 
to 52 weekly doses, up to 26 every 2-week doses , or up to 13 every 4 -week doses.  
Minimum treatment duration is 6 months.  Maximum treatment duration is 12 months.  
The treatment portion of the study will be complete when the last patient reaches 6 months of exposure.  All patients will then enter a 16-week post -treatment follow -up 
period.  Refer to Section 3.4.2
 for additional detail regarding End of Treatment period and 
scheduling of End of Treatment Visits.  
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4-week dosing (Cohorts A -C) and at Week 27 for patients who received 
every 2 -week or weekly dosing (Cohorts D and E, respectively).  For patients continuing 
treatm ent beyond the primary analysis time point additional supportive efficacy and 
safety analyses will be repeated at the completion of Study Drug treatment.  
An independent Data and Safety Monitoring Board (DSMB) will be established to review safety, tolerability and efficacy (as needed) data collected on ISIS  681257 during this 
study, both individual events and aggregate data.   
Number of Subjects  Approximately 270 
 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
14  PROTOCOL SYNOPSIS Continued  
Study Population  Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any
authorizations required by local law and be able to comply with all study
requirements
2. Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent
3. Clinical diagnosis of CVD defined as documented coronary artery disease, stroke,
or peripheral artery disease
4. Lp(a) plasma level ≥ 60 mg/dL5. Must be on standard- of-care preventative therapy for other than elevated Lp(a)
CVD risk factors
6. Patients on the following medications must be on a stable regimen for at least
4 weeks prior to Screening and expected to remain on a stable regimen through the
end of the post -treatment follow -up period:
a.Lipid lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish
oil or other products containing omega-3 fatty acids including OTC
preparations)
b.Antiplatelet drugs
c.Testosterone, estrogens, progesterone, growth hormone or progestins
7. Females:  must be non-pregnant and non -lactating and either;
a.surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy,
bilateral oophorectomy);
b. post -menopausal (defined as 12 months of spontaneous amenorrhea in
females > 55 years of age or, in females ≤ 55 years, 12 months of
spontaneous amenorrhea without an al ternative medical cause and FSH levels
in the postmenopausal range for the laboratory involved);
c.Abstinent* or,
d.if engaged in sexual relations of child-b earing potential,  agree to use 2 highly  
effective contraceptive methods
 (refer to Section 6.3.1)  from the tim e of signing  
the inform ed consent f orm until at least 1 6 weeks after the last d ose of Study 
Drug (ISIS 6
8125 7 or placebo)
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with
the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g.,calendar, ovulation, symptothermal, post -ovulation methods), declaration of
abstinence for the duration of a trial and withdrawal are not acceptablemethods of contraception
8.
Males must b e surgically steril e or, if engage d in sexual relations with a femal e of 
child-b earing potential, the patient m ust  be using an acceptable contraceptive  
method (refer to Section 6.3.1) from the time of signing the  informed consent form 
unti
l at least 1 6 weeks after the last d ose of ISIS 681257
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
15  PROTOCOL SYNOPSIS Continued  
Study Population 
Continued  Exclusion Criteria  
1. Within 6 months of Screening:   acute coronary syndrome, major cardiac surgery, or 
stroke/transient ischemic attack  
2. Within 3 months of Screening:   coronary, carotid, or peripheral arterial 
revascularization, major non- cardiac surgery, or lipoprotein apheresis  
3. Heart failure NYHA  class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)  
5. History of acute kidney injury within 12 months of Screening  
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day 1 
8.  Known history of or positive test for human immunodeficiency virus (HIV), hepatitis  C or chronic hepatitis B  
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated  
10. Patients with a history of major bleed or high- risk of bleeding diathesis   
11. Recent history of, or current drug or alcohol abuse  
12. Known history or presence of systemic allergic or pseudoallergic (drug) reactions  
13. Hypersensitivity to the active substance or to any of the excipients  
14. Clinically -significant abnormalities in screening laboratory values that would render 
a patient unsuitable for inclusion, including the following:  
a. Urine protein/creatinine ratio (UPCR)  ≥ 0.25 mg/mg.  In the event of a UPCR 
above this threshold, eligibility may be confirmed by a quantitative total urine protein measurement of ˂ 300 mg/24 -hr 
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.   In the event of a UACR 
above this threshold, eligibility may be confirmed by a quantitative total urine 
albumin measurement of ˂ 150 mg/24-hr  
c. Estimated GFR ˂ 60 mL/min as determined by the Chronic Kidney Disease-
Epidemiological Collaboration ( CKD-EPI) Equation for creatinine clearance  
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  
> 2.0 x ULN  
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in which case total bilirubin must be ≤ 3 mg/dL  
f. Alkaline phosphatase (ALP) > ULN  
g. Platelet count ˂ LLN 
15. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors  
16. Treatment with another investigational drug, biological agent, or device within 
1 month of Screening, or 5 half -lives of investigational agent, whichever is longer  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
16  PROTOCOL SYNOPSIS Continued  
Study Population 
Continued  Exclusion Criteria  
17. Treatment with any non- Ionis oligonucleotide (including small interfering ribonucleic 
acid [siRNA]) at any time or prior treatment with an Ionis oligonucleotide or siRNA 
within 9 months of screening.  Patients that have previously received only 1 dose of 
an Ionis ol igonucleotide as part of a clinical study may be included as long as 
≥ 4 months has elapsed since dosing  
18. BMI > 40 kg/m2  
19. Blood donation of 50-499 mL within 30 days of screening or of > 499 mL within 
8 weeks of Screening  
20. Unwillingness to comply with study procedures, including follow -up, as specified by 
this protocol, or unwillingness to cooperate fully with the Investigator  
21.  Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the Study  
Treatment Groups  Patients will be randomized to 5 parallel cohorts:  
Cohort A (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort B (n = 54):  Patients will be randomized 5:1 to receive 40 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort C (n = 54):  Patients will be randomized 5:1 to receive 60 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort D (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every 2 weeks for up to 26 doses.  
Cohort E (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every week for up to 52 doses.  
Cohort  Treatment  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 or placebo 
(Every 4 weeks)  ≤ 13 ≤ 260 mg  
B 40 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 or placebo  
(Every 2 weeks)  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 or placebo  
(Every week) ≤ 52 ≤ 1040 mg  
 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
17  PROTOCOL SYNOPSIS Continued   
Study Drug Dosage 
and Administration  The Sponsor will provide ISIS 681257 in a concentration of 100 mg/mL and matching 
volume placebo:  
Cohort A:  20 mg every 4 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort B:  40 mg every 4 weeks ISIS 681257 or placebo (0.4 mL)  
Cohort C:  60 mg every 4 weeks ISIS 681257 or placebo (0.6 mL)  
Cohort D:  20 mg every 2 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort E:  20 mg every week ISIS 681257 or placebo (0.2 mL)  
All doses will be given by SC injection.  Self -administration will be allowed after 
appropriate training of patient and/or caregiver.  
Rationale for Dose and Schedule Selection  The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given 
weekly that were found to be generally well -tolerated and to induce clinically -relevant 
reductions in Lp(a).  The range of dosing proposed for the present study will provide the 
equivalent drug exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in mean reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% at steady -state.  
The highest dose selected for this study, 20 mg per week, is predicted to provide an approximately 85% reduction in Lp(a) at steady -state that is expected to be sufficient to 
bring almost all patients with hyperlipoproteinemia(a) into the normal range (Lp(a)  ≤ 30 mg/dL).  
 Rationale for Dose and 
Schedule Selection Continued  The present study will also evaluate safety and efficacy at different dosing 
frequencies:   every 4  weeks, every 2 weeks, and weekly.   Patients with 
hyperlipoproteinemia(a) will require chronic treatment and thus every 2 weeks or every 4 weeks dosing regimens, if safe and well -tolerated, may provide advantages over 
weekly dosing in terms of convenience and compliance for patients.  Dosing regimens of 
20 mg every 2 weeks and 40 mg every 4 weeks will test if similar monthly exposure, at 
different frequencies of administration, will achieve similar safety and similar level of Lp(a) reduction since the reduction achieved by a given dose level is principally driven 
by total exposure, while individual dose levels and the related peak concentration (C
max) 
may influence tolerance and safety.  
Adjustment of Dose and/or Treatment 
Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose frequency 
may be allowed for safety or tolerability after consultation with the Sponsor Medical 
Monitor . 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
18  PROTOCOL SYNOPSIS Continued  
Study Visit Schedule 
and Procedures  Detailed information regarding the study procedures  are outlined in Section 6, 
Appendices A and C. 
All patients 
enrolled will be randomized to a minimum of 6 months of treatment in 1 of 
5 treatment cohorts.  On completion of the 6 months, patients may continue treatment 
within the same randomized cohort until the last patient reaches 6 months of exposur e 
(for continuing safety assessments), with a maximal exposure period of 12 months. 
Refer to Section 3.4.2 for additional detail regarding End of Treatment period and 
scheduling of End of Treatment Visits.  
The study for an individual patient will generally consist of the following periods: 
•An up to 4-week screening period
•An up to 52-week treatment period during which Study Drug will beadministered per assigned cohort by SC injection
•A 16-week post -treatment follow -up p eriod
Patients in Cohorts A through C will receiv e up to 13 SC doses of ISIS 68125 7 or 
placebo every  4 weeks.  Pat
ients in Cohort  D will receiv e up to 26 SC doses of 
ISIS 681257 or place bo every  2 weeks and patient s in Cohort E  will receiv e up to 52 SC 
doses of ISIS 68125 7 or place bo weekly.  Patients will return  regularly for outpatient 
visits throughout t he treatment and post-t reatment f ollow-u p periods  according to the 
Schedule of Procedures (Appendix A).  
Blood and urine sam p
les will be collected regularly throughout the study for safety, 
efficacy, and PK analysis.  Appendix B  shows a list of analytes required for the study 
and Appendix C  details the PK sample schedule s. 
Safety and Tolerability Evaluations  Safety and tolerability assessments include:  adverse events, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs and use of concomitant 
medications.  Safety and tolerability results in patients dosed with ISIS 681257 will be 
compared with those dosed with placebo.  
Efficacy Evaluations  The primary analysis time point is at Week 25 for patients who received every 4-week 
dosing (Cohorts A -C) and at Week 27 for patients who received every 2-week or weekly 
dosing (Cohorts  D and E).  
The primary endpoint is the percent change in plasma Lp(a) from baseline at the primary 
analysis time point for ISIS 681257 treatment groups compared to placebo.  
The secondary endpoints comprise the effect of ISIS  681257 as compared to placebo at 
the primary analysis time point on the following:  
•Percent change from baseline in LDL-C
•Proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL (≤ 125 nmol/L)
•Proportion of patients who achieve plasma Lp(a) ≤ 30 mg/dL (≤ 75 nmol/L)
•Percent change from baseline in apoB
•Percent change from baseline in OxPL-apo(a)
•Percent change from baseline in OxPL -apoB
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
19  PROTOCOL SYNOPSIS Continued  
Pharmacokinetic 
Evaluations  Plasm a samples will be taken from all patients for the measurement o f ISIS 681257 
plasm a tro
ugh levels throughout t reatment a nd during the post-treatment f ollow -up 
period .  In addition, in a subset of patients (approximately 12 patients per cohort),  more 
frequent p lasm a samples will be taken followi ng the first a nd Day 169 (f or Cohorts A, B, 
and C) or Day 183 (for Cohorts D  and E) dose to determine PK parameters.  Plasma 
sample collection tim
e points are detaile d in Appendices A and  C. 
The plasma 
ISIS 681257 levels over time will be descriptively summarized by treatment 
with stratification by subject immunogenicity status .  Apparent terminal elimination 
half-life will be calculated in patients who received ISIS 681257 treatment using a 
non-compartmental method, if data permitted.  In addition, C max, Tmax, and AUC values 
will be calculated for the PK subgroup .  PK parameters will be descriptively summarized 
by treatment with stratification by subject im munogenicity status.  
Statistical Considerations  The primary efficacy analysis for the primary endpoint will be the pairwise comparison of 
percent change from baseline to the primary analysis time point in fasting Lp(a) between 
ISIS 681257 treated group s and placebo group in the Full Analysis Set.  
The data will be analyzed using an ANCOVA model with the baseline Lp(a) level as a 
covariate. 
Dose selection for the further development will be based on the following efficacy and 
safety considerations; more than 1 dose may meet these criteria.  An effective dose, or 
dose regimen, will be one that achieves a  clinically -meaningful reduction in plasma Lp(a) 
levels .  Safety will be evaluated on the basis of incidence of expected and unexpected 
treatment -related SAEs , and other specific safety considerations including the incidence 
of platelet reductions . 
Sample Size Considerations:  
Efficacy:  
Based upo n prior clinical trial experience with ISIS  681257, it is estimated that the 
standard deviation of the percent change in Lp(a) is approximately 20%.  With 
23 patients in each ISIS 681257 treatment group and 23 in placebo group there would 
be approximately 90% power to detect a 20% difference in percent change in Lp(a) 
levels between the ISIS 681257 treatment groups and placebo group at an alpha level of 
0.05, assuming 30% reduction in the ISIS 681257 patients and 10% reduction in the 
placebo patients.  
Safet y: 
Based upon prior clinical trial experience with ISIS  ASOs, assuming the incidence rate of 
platelet count below lower limit of normal (LLN) in placebo treated patients is 1.9%, in the ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, with 45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to detect at least 1 event.  
A total of approximately 270 patients (54 patients per cohort, including 45 patients per cohort treated with ISIS 681257)  will be randomized to ensure that both the safety and 
efficacy of ISIS 681257 will be adequately characterized in the study.  
Sponsor/Collaborator  Akcea Therapeutics/Ionis Pharmaceuticals  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
20  STUDY DESIGN AND TREATMENT SCHEMA  
  
SCREENING PERIOD  
Weeks -4 to -1 
TREATMENT PERIOD  
Weeks 1 to 52*  
Dosing per assigned cohort:  
Cohorts A, B, and C:  Every 4 weeks SC 
administration of 20, 40, or 60 mg ISIS 681257 or 
placebo  
Cohort D:  Every 2 weeks SC administration of 
20 mg ISIS 681257 or placebo  
Cohort E :  Every  week SC administration of 20 mg 
ISIS 681257 or placebo  
Routine safety assessments :  PK and PD/efficacy 
assessments at specified time points  
*Treatment portion of the study will be complete when the last patient reaches 6 months of exposure.  Refer to Section 3.4.2  for additional 
detail regarding End of Treatment  period and 
scheduling of End of Treatment Visits.  
POST -TREATMENT 
EVALUATIONS  
Weeks 4, 10, and 16 after Treatment 
Period 
3 clinical visits for safety, efficacy,  
PK and PD assessments  
EARLY 
TERMINATION (ET)  
Follow Week 53 Schedule 
of Procedures at ET;  
Patient strongly 
encouraged to visit clinic 
for post -treatment 
assessments  
END -OF-STUDY 
PROCEDURES  
Early Termination or 3rd 
Follow -Up visit (16 Weeks 
after Treatment Period ) 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
21  STUDY GLOSSARY 
Abbreviation  Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase (SGPT)  
ANCOVA  analysis of covariance  
ANA  antinuclear antibody  
apo(a)  apolipoprotein(a)  
apoB  apolipoprotein B  
aPTT  activated partial thromboplastin time  
ASGPR  asialoglycoprotein receptor  
ASO  antisense oligonucleotide  
AST  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time zero to time t  
βhCG  beta-subunit of human chorionic gonadotropin (pregnancy test)  
BP blood pressure  
BUN  blood urea nitrogen  
C centigrade  
C5a complement factor C5a (activated complement split product)  
CAD  coronary artery disease  
Cmax maximum concentration  
CBC  complete blood count  
CKD -EPI Chronic Kidney Disease –Epidemiological Collaboration  
CMV  cytomegalovirus  
CRF  case report form  
CRP  C-reactive protein  
CVD  cardiovascular disease  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
22  STUDY GLOSSARY Continued  
Abbreviation  Definition  
Cys C  Cystatin C  
dL deciliter  
DNA  phosphorothioate -modified oligodeoxynucleotides  
DSMB  Data and Safety Monitoring Board  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
ET early termination  
FAS full analysis set  
FSH follicle -stimulating hormone  
GalNAc 3 triantennary N-acetyl galactosamine  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
HAV  hepatitis A virus  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
hr, hrs  hour(s)  
hsCRP  CRP measured by high sensitivity assay  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee 
IgM immunoglobulin M  
IL-1β interleukin -1 beta  
INR international normalized ratio  
IRB Institutional Review Board  
ISIS 681257  antisense inhibitor of apolipoprotein (a)  
IV intravenous(ly)  
IXRS  interactive voice/internet response system  
KIM -1 kidney injury molecule 1  
kg kilogram  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
23  STUDY GLOSSARY Continued  
Abbreviation  Definition  
L liter 
m2 square meter  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
mg milligram  
MI myocardial infarction  
min minute  
mL milliliter  
mm millimeter  
mRNA  messenger ribonucleic acid  
NAG  N-acetyl -β D-glucosaminidase  
NCS  not clinically -significant  
NGAL  neutrophil gelatinase -associated lipocalin  
NSAID  non-steroidal anti -inflammatory drug  
NYHA  New York Heart Association  
OxPL  oxidized phospholipids  
PAD  peripheral arterial disease  
PBS phosphate buffered saline  
PCSK9  proprotein convertase subtilisin/kexin type 9  
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s)  
PLA 2 Lp(a)-associated Lp -phospholipase A 2 
PPS per protocol set  
PT prothrombin time 
RBC  red blood cells  
RNase H1  an ubiquitous endonuclease that specifically hydrolyzes the RNA strand in 
RNA/DNA hybrids  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
siRNA  small interfering ribonucleic acid  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
24  STUDY GLOSSARY Continued  
Abbreviation  Definition  
SC subcutaneous(ly) 
Study Drug  ISIS 681257  or placebo  
SUSAR  suspected unexpected serious adverse reaction  
Tg transgenic  
Tmax time to maximal concentration  
UACR  urine albumin -creatinine ratio  
ULN  upper limit of normal  
UPCR  urine protein - creatinine ratio  
WBC  white blood cell  
WMA  World Medical Association  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
25  1. OBJECTIVES
1.1 Primary Objective  
To evaluate the safety , including tolerability, of ISIS 681257 and to assess the efficacy of different doses 
and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in patients with 
hyperlipoproteinemia(a) and established cardiovascular disease ( CVD ). 
1.2 Secondary Objective (s) 
To evalua te the efficacy of ISIS 681257 on plasma levels of low density lipoprotein cholesterol (LDL -C), 
apolipoprotein B (apoB), oxidized phospholipids ( OxPL ) on apolipoprotein (a) [apo(a)] [ OxPL -apo(a)] 
and OxPL  on apoB ( OxPL -apoB). 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose regimens in in patients with hyperlipoproteinemia(a) and established CVD.  
2. BACKGROUND AND RATIONALE
2.1 Overview of D isease  
2.1.1 Lipoprotein (a) 
Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein (Figure 1, Koschinsky and Marcovina 2004 ) in which 
the apoB component of LDL is linked by a disulfide bond to apolipoprotein(a) [apo(a)], the distinct 
protein component of Lp(a) that is mainly responsible for its signature structural and functional properties 
(Dubé et
 al. 2012; Kronenberg and Utermann 2013 ).  Lp(a) is now recognized as an independent, genetic, 
causal risk factor for coronary artery disease ( CAD), stroke, peripheral arterial disease (PAD), and 
calcifi
c aortic s tenosis (Erquo e t al.
 2009; N ordestgaard et al. 2010; Thanassoulis et al. 2013).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
26  Figure 1 Schema
tic Representation of the Lp( a) Particle.  Lp(a) is Composed of apo(a) 
Covalently Bound to apoB 
Apo(a) contains 10 unique units of kringle IV repeats, of which KIV2 ar e present in variable copies (1 to  > 40) 
conferring structural heterogeneity to Lp(a).  Apo(a) also contains kringle V  and an inactive protease -like (P) 
domain.  In this model, 4 KIV2 repeats are shown.  Lp(a) also contains OxPL in the lipid phase of apoB as 
well as covalently bound to apo(a).  
Plasma levels of Lp(a) vary substantially among individuals, and most of this variation reflects the effects 
of genetic variation in the LPA gene which encodes the apo(a) protein. 
A second contributor to plasma-l evel variability are L PA single n ucleotide p olymorphisms ( SNPs) that 
can be associated with either hig
her or lower Lp(a) levels (Clarke e t al. 2009; L i et al. 2011).  S ignificant 
associations exist between 2 particular LPA variants, rs10455872 and rs3798220, 
increased Lp(a) levels, 
CVD, and aortic s tenosis, with the C VD risk primarily mediated  by Lp(a) plasma l evels r ather than an 
independent effect of the S NPs (
Clarke et al. 2009; L i et al. 2011). 
Lp(a) plasma levels are generally inversely associated with apo(a) size, and can vary by > 1,000-fold 
(0.1 to > 250 mg/dL or ˂ 0.25 to > 625 nmol/L) between individuals (Merki e t al. 2011) .  Despite
 this 
inter-i ndividual variation, intra-individual Lp(a) levels are thought to be generally stable over time along 
a pre-s et genetically
 determined levels without significant impact from dietary or environmental factors, 
mediating CVD risk throughout the patient’s lifetime. 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
27  2.1.2 Pathophysiology 
Lp(a) adheres to plaque sites and is retained in the artery wall and has proatherogenic and 
pro-inflammatory properties due to its LDL and apo(a) components  
(Spence and Koschinsky 2012).  In addition, Lp(a) may be prothrombotic by inhibiting fibrinolysis 
because o f its structural  similarity  to plasminogen  and its enhancement  of platelet  aggregation 
(Rand  et al. 1998 ).  In vitro studies have provided evidence for both of these pathogenic mechanisms, but 
in vivo data are not definitiv e (Dubé et al. 2012 )
.  In humans, Lp(a) is the main lipoprotein carrier of 
OxPL, which may drive the risk associated with Lp(a) (Bergmark e t al. 2008; Leibundgut et al. 2013; 
Tsimikas et a l. 2014).  In fact, OxPL measured on apoB (OxPL-apoB), which largely reflect the OxPL on 
Lp(a), have been shown to be a prognostic indicator for future CV events (Tsimikas e t al. 2010; Tsimikas 
e
t al. 2012; Tsimikas et al. 2014).  OxPL associated with Lp(a) can be subjected to degradation by the 
Lp(a)
-associated Lp-phospholipase A2 (PLA2), implicating Lp(a) in novel proinflammatory and 
atherogenic pathways (Kiechl et al.
 2007). 
Hyperlipoproteinemia(a) in humans is a ssociated with increased risk of cardiac d eath, myocardial 
infarction (MI), stroke, aortic s tenosis, and peripheral arterial disease ( PAD),  particularly in subjects with 
small apo(a) isoforms (Bennett 2008; Erqou e t al. 2009 ;
 Erqou et al. 
2010; B ertoia e
t al. 2013; 
Thanassoulis et al. 2013)
.  Although prospective, randomized, controlled outcomes studies have 
not been 
conducted, epidemiological, genome-wide association and Mendelian randomized controlled study data to 
date provide supporting eviden
ce for a role of Lp(a) as a risk factor for CVD ( Kamstrup et al. 2009).  F or 
example, in the Copenhagen City Heart Studies of 42,000 subjects with a 15-year follow-up (Ka mstrup et 
al. 2009) using a Mendelian randomization approach, higher Lp(a) levels w ere related to risk of MI. 
2.1.3 Current Treatment  Options  
In 2010, the European Atherosclerosis Society (EAS) Consensus Panel recommended screening for 
elevated Lp(a) in people at moderate to high risk of CVD to reach a treatment goal of ˂ 50 mg/dL (125 
nmol/L), after therapeutic management of LDL-C  (Nordestgaard e t al. 2010).  Approximately 20% of 
people are estimated t o have plasma Lp(a) levels over 50 mg/dL (125 nmol/L) and approximately 0.3% to 
have levels over 175 mg/dL (438 nmol/L).  Ther e are no gender difference s in Lp(a) concentrations  but 
racial differences have b een observed, with whites and Asians h aving lower levels w hile b lacks a nd 
Hispanics generally have s omewhat higher levels (Nordestgaard et al. 2010). 
Lifestyle and diet a re thought t o have little impact o n an individual’s Lp(a) level.  Current treatment 
recommendations from the EAS Consensus Panel are limited to the use of 1 to 3 g of niacin (nicotinic 
acid) daily which could result in an up to 30% reduction in Lp(a).  H owever, niacin is associated with side 
effects ( e.g., flushing) that reduce patient tolerability and compliance (Parker et al. 2006; Guyton 2007). 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are neither indicated nor formally 
recommended for treatment of hyperlipoproteinemia(a) but have b een reported to reduce L p(a) levels b y 
~20%-35% in patients with hypercholesterolemia (Desai et al. 2013; Raal et al. 2015). 
The other current option for patients with significantly elevated Lp(a) levels (≥ 60 mg/dL) is l ipoprotein 
apheresis, either general lipoprotein apheresis (Jaeger et al. 2009; Leebmann e t al. 2013; R osada et al. 
2014) or Lp(a)-s pecific a pheresis (Safarova 2012).  While v ery effective a t acutely  lowering  Lp(a) (acute 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
28  and interval Lp(a) reductions of > 60% and > 30% resp ectively), this treatment option is expensive, 
burdensome for patients, and unavailable/not reimbursed in many countries and regions. 
2.2 T herapeutic Rationale  
Therapeutic modalities to reduce Lp(a) level s in humans  are few, and there are no drugs currently 
availabl e that specifically target Lp(a) alone .  Antisens e oligonucleotides (ASOs) are emerging  as viable 
therapeuti c agents to treat disorder s where overexpression  of protein s is a ssociated with a diseas e process.  
Apo(a) is synthesized primarily in the liver, a target  organ for ASOs,  wher e it is subsequently covalently 
linked to the apoB
-100 component of LDL to form the Lp(a) lipoprotein.  The goal of treatment with 
ISIS 681257 is to reduce the production of apo(a) in the liver a nd thus, the level of Lp(a) lipoprotei n by 
using  an ASO directed against the messenger ribonuclei c acid (mRNA) of apo(a) .  It has been 
hypothesized that a pharmacologic reduction in Lp(a) could slow down or reverse CVD by reducing 
thrombotic, atherogenic, or inflammatory events in patients with elevated Lp(a) levels (Nordestgaard et 
al. 2010). 
Importantly, the
re is no evidence that lowering Lp(a) will result in adverse consequences in individuals, 
and there are no reports linking very low Lp(a) to any deleterious effects.  
2.3 ISIS  681257 
Please refer to the ISIS 681257 Investigator’s Brochure for more details on ISIS 681257 mechanism of 
action, chemistry, pre- clinical and clinical ex perience.  The summary is provided below. 
2.3.1 Mechanism of Action  
ISIS 681257 i s a second -generation ASO drug targeted to apo(a) that has been covalently bond ed to 
triantennary N-acetyl galactosamine  (GalNAc 3), a high-affinity ligand for the hepatocyte- specific 
asialoglycoprotein receptor (ASGPR) to form an ASO- GalNAc 3 conjugate .  This GalNAc 3-conjugate 
approach results i n enhanced ASO delivery to hepatocytes v ersus non-parenchymal cells a nd has 
increased ASO potency by 
approximately 10-fold compared to u nconjugated ASOs i n mice (Prakash 
et al. 2014). 
The ASO portion of ISIS 681257 is complementary to a region spanning the Exon 24-25 splice site at 
position 3901 of apo(a) transcript sequence (NM_005577.2) and binds to the mRNA by Watson and 
Crick base pairing.  The hybridization (binding) of ISIS 681257 to the cognate mRNA results in the 
Ribonuclease H1 (a non-s pecific endonuclease t hat catalyzes t he cleavag e of RNA via h ydrolytic 
mechanism RNase H 1-mediated degradation of the apo(a) mRNA, thus preventing production of the 
apo(a) protein).   Maximal  
antisense-m ediated reduction of target
 mRNA level s is typically  greater than 
90% of control levels in sensitive t issues (Zhang et al. 2010 ) .  Furthermore, reduction in target mRNA 
levels u sing this approach correlates directly with a subsequent reduction in target protein levels.  
ISIS 681257 does not have any complementary homology to plasminogen mRNA  (Graham et al. 2016). 
2.3.2 Chemistry  
Chem
ically, ISIS 681257 is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are connected 
sequentially by phosphorothioate and phosphodiester linkages (mixed backbone design).  The mixed 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
29  backbone design reduces the total number of phosphorothioate linkages, which reduces non- specific 
interactions with proteins and further enhances potency of GalNAc 3 conjugated ASOs. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end and the 5 
nucleotides at the 3′ end, are composed of 2′- O-(2-methoxyethyl) (2′-M OE)-modified ribonucleotides.  
These MOE-m odified nucleotides confer (1) increased affinity for the target mRNA (Altmann e t al. 1996; 
McKay et al. 1999
), (2) increased 
resistance to exonucleases and endonucleases (thereby increasing 
stability in tissue) (Geary et al.
 2003), and (3) amelioration of some of the high-dose toxicities, thereby 
resulting in an improved safety profile compared to first-generation antisense drugs containing 
phosphorothioate-modified oligodeoxynucleotides (DNA) (Henry et al. 2000).  The third region, the 
central portion of the oligonucleotide, is composed of 10 oligodeoxynucleotides.  T his chimeric
 design is 
called a MOE-G apmer, and ISIS 681257 employs this chimeric structure to enable use of the ubiquitous 
endonuclea se that specifically hydrolyzes the RNA strand in RNA/DNA hybrids (RNase H 1
)-mechanism 
for antisense activity.  This is because while the 2′-M OE modification confers increased stability and 
affinity, it does not support RNase H 1-catalyzed cleavage of RNA hybridized to 2′-M OE-modified 
nucleotides (McKay e t al. 1999).  The fourth region is composed of a triantennary cluster of GalNAc 3 
sugars that is linked to the 5ʹ e nd of
 ISIS 681257 via a phosphodiester linkage.  T he GalNAc 3 cluster
 is a 
high
 affinity ligand for the ASGPR, a receptor expressed primarily on the surface of liver hepatocytes 
(Stockert 1995).  The GalNAc 3 cluster enhances delivery of ISIS 681257 to liver hepatocytes over other 
cell
 types and enhances p otency.  A fter internalization into cells, the GalNAc 3 cluster is metabolized to 
release “ free A SO” i nside t he cell (Prakash
 et al. 2014
). 
2.3.3 Preclinical Experien
ce 
The pharmacology of ISIS 681257 has been examined in apo(a) transgenic (Tg) mice w hich express the 
entire human apo(a) genomic sequence (Frazer  et al. 1995 ) and nonhuman primates. 
Administration of IS
IS 681257, a human apo(a) antisense inhibitor, to mice containing the human apo(a) 
transgene produced dose-dependent reductions in human apo(a) liver mRNA and apo(a) plasma protein 
after 6 weeks of ASO administration at 0.3, 1, 3, and 10 mg/kg/wk. 
When ISIS 681257 was administered to normal chow fed cynomolgus monkeys for 4 weeks at the dose of 
12 mg/kg/wk, it significantly reduced hepatic apo(a) mRNA by 90% relative to the cohort administered 
phosphate buffered saline (PBS) .  As there is an 80%  sequence conservation between apo(a) and 
plasminogen nucleotide sequences, plasminogen mRNA levels were also measured, and no change compared to the PBS cohort was observed. 
Findings from the chronic studies with ISIS 681257 (the 26-w eek mice and 39-week monkey studies) 
were similar to those observed in the 4- and 6-w eek studies and were not considered adverse.  The plasma 
and tissue concentrations observed for ISIS
 681257 i n mi
ce and monkeys were generally similar to those 
observed for other unconjugated 20-m er 2ʹ-M OE 
ASOs in this chemical cla
ss with and without GalNAc 3-
conjugation.  However, the proportion of drug in hepatocytes compare to nonparenchymal liver cells was 
greater for ISIS 681257, compared to the parent drug ISIS 494372 (without GalNAc 3-conjugation), which 
is the basis for increased potency of ISIS 681257 (unpublished results; Geary et al. 2003; Yu et al. 2007;  
Prakash et
 al. 2016).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
30  The most noteworthy safety finding in the chronic monkey study was a marked platelet reduction that, 
occurred in 2 male monkeys in the high-dose group (20 mg/kg/wk) and 1 animal (1 female) in the mid-
dose (10 mg/kg/wk) group beginning on Days 44-135, which led to the subsequent early termination (ET)  
of these 3 animals.  An additional male monkey in the 10 mg/kg/wk dose group had a moderate decrease in platelets that was successfully treated with steroid, and was terminated at the scheduled 6-month 
interim sacrifice.  There were no platelet reductions or other toxicologically signi ficant findings in 
monkeys treated with 2 mg/kg/wk for up to 39 weeks.  There were no marked platelet reductions in mice 
at doses up to 70 mg/kg/wk for 26 weeks .  However, mice exposed to ISIS 681257 at doses of ≥ 
10 mg/kg/wk for up to 26 weeks showed evidence of hepatobiliary effects in both sexes as indicated by 
increases in ALT (up to +  10.3x), AST (up to + 10.4x), and/or ALP (+ 2.5x).  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with ISIS 681257 can be found in the 
Investigator’s Brochure.  A summary of the study that has been conducted with ISIS 681257 is included below. 
ISIS 681257- CS1 was a Phase 1 double-blind, placebo-controlled, dose- escalation study designed to 
assess the safety, tolerability, PK, and pharmacodynamics (PD) of single and multiple doses of ISIS 
681257 administered subcutaneously (SC) to 45 healthy subjects with Lp(a) ≥ the upper limit of normal 
(ULN)  (30 mg/dL).  Twenty one (21) subjects received 10 to 120 mg SC (10, 20, 40, 80, and 120 mg ) as a 
single -dose, and 24 subjects received 10, 20, and 40 mg as multiple doses (6 doses in 21 days:  3 loading 
doses during the first week on alternate days (Days 1, 3, and 5), and then once a week for the next 3 
weeks (Days 8, 15, and 22). 
There were no  serious adverse events (S AEs) , or clinically -relevant  changes in laboratory assessments 
and a ll subjects completed the t reatment and post- treatment follow-up periods. 
Constitutional symptoms such as fever, chills, increase in body temperature and arthralgias have been 
observed following parenteral administration of ASOs, primarily during the initial dosing period.  Following SC administration of ISIS 681257 constitutional symptoms were observed in 4 of the 
6 subjects who received a single-dose of 120 mg.  The symptoms were mild in severity and resolved 
spontaneously with or without treatment with acetaminophen. 
Fluctuations in platelet counts to below the lower limit of normal were observed in 5 study subjects on 
active drug and across doses.  These  changes were not considered adverse or clinically -significant by the 
Investigator and did not appear to be dose related. 
Two (2) mild AEs of redness at the site of injection occurred 48 to 72 hours after administration in 1 
subject who received ISIS  681257 in the 20 mg multiple-dose cohort.  Both AEs resolved by the time of 
the subject’s next visit . 
Following SC administration, ISIS 681257 was absorbed rapidly into the systemic circulation, with 
median time to maximum plasma concentrations (T
max) ranging f rom 1 to 4 hours .  Similar T max values 
were observed at all dose levels.  Maximum observed plasma concentrations (C max) and AUC 0-24hr were 
dose- dependent over the studied SC dose range .  The mean peak (C max) and total exposure (AUC 0-24hr) 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
31  increased proportionally with dose at dose levels ranging from 10 to 40 mg, and greater than dose 
proportionally at dose levels ranging from 40 to 120 mg. 
After reaching C max, mean plasma concentrations of ISIS  681257 declined in a biphasic fashion over time, 
with a n initial, relatively fast distribution phase that dominated the plasma clearance followed by a slower 
elimination phase .  Characterization of the terminal elimination phase yielded an apparent terminal 
elimination half -life of approximately 3 to 4 weeks over a dose range of 10 to 120 mg (either single - or 
multiple -dose), and appeared to be independent of dose.  This result is consistent with the slow 
elimination of ISIS  681257 observed from monkey tissues, and the comparatively long elimination half-
lives observed for this chemical class.  
Plasma trough concentrations (168 hours or 7 days from previous dose) monitored during the t reatment 
period in the multiple-dose cohorts increased with increasing dose, consistent with expectations (based on 
preclinical as sessments and experience with other compounds of this chemical class) that trough plasma 
concentrations reflect exposure in tissues.  Plasma trough concentrations did not increase greatly after the 
loading period (Day 15), suggesting that accumulation in major tissues of distribution had approached steady -state after the loading period . 
Overall, the human PK of ISIS 681257 are consistent with the expected PK for compounds within this chemical class.  
2.4 Rationale for Dose and Schedule of Administration  
The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given weekly that were 
found to be generally well -tolerated  and to induce clinically -relevant  reductions in Lp(a) . 
The range of dosing proposed for the present study will provide the equivalent drug exposure of 5 mg, 10 
mg, 15 mg, and 20 mg administered weekly, and is predicted (based on modelling of PK/PD data 
obtained in Phase 1 study) to result in mean reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% at steady- state.  
The highest dose selected for this study, 20 mg per week, is predicted to provide an approximately 85% reduction in Lp(a) at steady- state that is expected to be sufficient t o bring almost all patients with 
hyperlipoproteinemia(a) into the normal range (Lp(a) ≤ 30 mg/dL). 
The present study will also evaluate safety and efficacy at different dosing frequencies:   every 4  weeks, 
every 2 weeks, and weekly.   Patients with hyperlipoproteinemia(a) will require chronic treatment and thus 
every 2 weeks or every 4 weeks dosing regimens, if safe and well- tolerated, may provide advantages over 
weekly dosing in terms of convenience and compliance for patients.   Dosing regimens of 20 mg every 2 
weeks and 40 mg every 4 weeks will test if similar monthly exposure, at different frequencies of 
administration, will achieve similar safety and similar level of Lp(a) reduction since the reduction 
achieved by a given dose level is principally driven b y total exposure, while individual dose levels and the 
related peak concentration (C
max) may influence tolerance and safety.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
32  3. EXPERIMENTAL PLAN
3.1 Study Design  
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose- ranging s tudy.  
Approximately 270 patients will be randomized in a 5:1 ratio ( 225 ISIS 681257 and 45 placebo) to 
receive ISIS 681257 or placebo.  Study Drug (ISIS 681257 or placebo) will be administered SC every 
week , every 2 weeks ( biweekly ), or every 4 weeks, depending on cohort assignment, for up to 52 weekly 
doses, up to 26 every 2- week doses, or up to 13 every-4- week doses. 
The primary analysis time point is at Week 25 for patients who received every 4 -week  dosing (Cohorts A-
C) and at Week 27 for pat ients who received every 2-week or weekly dosing (Cohorts D and E).  For 
patients continuing treatment beyond the primary analysis time point additional supportive efficacy 
analysis (to evaluate whether the treatment effect is maintained)  and safety analysis ( for the purpose of 
dose(s) selection ) will be repeated at the completion of Study Drug treatment . 
The treatment portion of the study will be complete when the last patient reaches 6 months of exposure.  All pati ents will then enter a 16-week p ost-treatment follow-up period. Refer to  Section 3.4.2 for 
additional detail regarding End of Treatment period and scheduling of End of Treatment Visits. 
Patients ≥ 18 and ≤ 80 y ears old with  elevated plasma Lp (a) levels (≥  60 mg/dL) and a clinical diagnosis 
of CVD are eligible for enrollment upon meeting the study specific eligibility criteria .  Patients will be on 
standard -of-care preventative therapy for other than elevated Lp(a) CVD risk factors as per current 
guidelines. 
Clinical diagnosis of CVD is defined as documented coronary artery disease (CAD), stroke, or peripheral 
artery disease (PAD) .  A diagnosis  of CAD has to be documented by any of the following: 
•Angiographic evidence of ≥ 50% stenosis of 1 or more major epicardial coronary arteries
•
History of myocardial infarction documented by positive enzymes, and either symptoms of 
myocardial ischemia, or ECG changes  (Thygesen  et  al. 2012)
•History 
of coronary revascula rization
•Evidence of ca rdiac ischemia on exercise testing, or imaging study
Patient s will be evaluated for study eligibility during Screening, which takes place within 4 weeks prior to 
Day 1 (the first day of Study Drug administration) .  Patient s who are d etermined to be eligible, based on 
screening assessments, will be enrolled in the study at Day 1 and randomly assigned to 1 of the 5 parallel 
dosing cohorts, with each cohort having a 5:1 ratio to receive ISIS 681257 or matching volume of 
placebo, respectively, by SC injection  for up to 52 weeks . 
Following the E nd-of-T reatment , patients will enter the 16- week  post- treatment follow-up period. 
3.2 Number of Study Centers  
This is a multi center , multinational study. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
33  3.3 Number of Patients  
Approximately 270 patients will be randomized in this study, with approximately 54 patients assigned to 
each of the 5 treatment cohorts . 
3.4 Overall Study Duration and Follow -up 
The length of patient s’ participation in the study may  be up to 18 months ( 72 weeks), which i ncludes a 4-
week screening period, an up to 52 -week treatment period with Study Drug (ISIS  681257 or placebo), and 
a 16- week post- treatment follow-up period .  The t reatment portion of the study will be complete when the 
last patient reaches 6 months of exposure. 
Patients may be required to attend additional visits for monitoring of AE s or abnormal investigation 
results.  The frequency of additional monitoring will be determined by the Study Medical Monitor in 
consultation with the Investigato r. 
3.4.1 Screening  
Patient eligibility for the study will be determined within 4 weeks  prior to study . 
3.4.2 Treatment  
For each patient, minimum treatment duration is 6 months and maximum is 52 weeks.  
All patients enrolled will be randomized to a minimum of 6 months of treatment in 1 of 5 treatment 
cohorts.  On completion of the 6 months, patients may continue treatment within the same randomized cohort until the last patient reaches 6 months of exposur e (for continuing safety assessments), with a 
maximal exposure period of 12 months.  End of Treatment visits for all patients on treatment will be scheduled no later than the End of Treatment visit of the last patient to complete 6 months of exposure.  
The End of Treatment  visit should be scheduled one dosing interval post last dose of study drug: one 
week post last dose for weekly dosing (Cohort E), 2 weeks post last dose for every 2-week dosing (Cohort 
D), and 4 weeks p ost last do se for every 4-week  dosing (Cohort A-C).  The procedures scheduled for the 
Week 53/ET visit (Appendix A) will b e performed at the End of Treatment v isit.   Following the End of 
Tre
atment  visit patients will then enter a 16-week post-treatment  follow -up per iod.    
Eligible patients will report to the Study Center for assessments at specified intervals throughout the 52-
week treatment period as detailed in the Schedule of Procedures in Appendix A.  During the Treatment, 
Study Drug (ISIS 681257 or placebo) will be administered by SC injection once-w eekly, every 2 weeks, 
or every 4 weeks, depending on cohort assignment. 
3.4.3 Post-Treatm
ent 
Patients when  completed dosing will enter the 16 -week post -treatment follow -up period and will  return to 
the Study Center for 3 follow -up visits 4, 10, and 16 w eeks after the treatment p eriod  as per  
Appendix A  (Follow -up). 
The final study visit for each patient will be 16 weeks after the treatment p eriod . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
34  3.5 End-of-Study  
The End-of-Study is defined as  last patient , last visit. 
For individual patients, End -of-Study is defined as completion of the ir last study visit. 
3.6 Data and Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) will be assemble d to review safety, 
tolerability and efficacy  (as needed) dat a colle ct ed on ISIS 681257 during this st udy.  T he DSMB will be 
constituted to includ e expertis e in medical specialtie s relevant  to the safety of antisense drugs 
(nephrology, hepatology, hematology and cardiology ).  Specialist member s of the DSMB will be 
informed and consulted on all treatment-r elated SAEs relevant to their expertise and a ll changes o f 
relevant laboratory parameters that trigger stopping rules  (Section 8.6), w ithin 24 hour s of receipt  of 
such results.  In addition, all accrued
 safety data relevant to each of medical area specialist will be 
forwarded monthly for review.  
The full D
SMB review of all accumulated data will be performed quarterly.  Based on its ongoing 
assessment of the safety and tolerability of ISIS  681257, the DSMB will provide recommendations to the 
Sponsor for modifying, stopping or continuing the study as planned.  Details on the safety assessments, 
frequency of review, meeting schedules and controlled access to unblinded data are outlined in the DSMB 
Charter and /or Statistical Analysis Plan (SAP).  
4. PATIENT ENROL LMENT
4.1 Screening  
Before patients  may be enrolled into the study, the Sponsor or designee requires a copy of the Study 
Center ’s written independent ethics committee/institutional review board (IEC/IRB) approval of the 
protocol, informed consent form, and all other patient directed  informa tion and/or recruitment material. 
Patients  or their legally acceptable representatives must sign the consent form  before any screening tests 
or assessments are performed .  At the time of consent , the patient  will be considered enrolled into the 
study and will be assigned  a unique screening number before any study procedures, including s creening 
procedures, are performed.  The screening number and patient  identification number must remain 
constant throughout the entire trial.  In the event the patient is re-consented and re -screened the patient 
must be given a new screening number .  Screening numbers and patient identification numbers, once  
assigned, will not be re-used. 
4.2 Randomization 
Patients w ill be randomized  after all screening  assessments have b een  completed and after the 
Investigator has v erified  that they are eligible per  criteria in Sections 5.1 and 5.2 .  No patient ma y 
begin t reatment p rior to randomization and assignment of a unique patient identification number. 
Using an 
Interactive Web -Response System (IXRS), eligible patients will be randomized in a 1:1:1:1:1  
ratio  to 1 of the 5 parallel -dose cohorts (Cohorts A, B, C, D, or E).  Within each dose cohort, patients will 
be randomized in a 5:1 ratio to receive ISIS 681257 or matching volume of placebo, respectively. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
35  A permuted block schedule will be used .  The randomization schedule will be generated and held by an 
independent vendor. 
4.3 Replacement of Patients  
Patients  who withdraw from the study will not be replaced . 
4.4 Unblinding of Treatment Assignment  
The Sponsor and all patients, m onitors, and Study Center pe rsonnel related to the study will be blinded 
throughout the study and until all patients h ave completed  the study  and the d atabase has b een locked.  
However, if a patient has s uffered  a SAE (as defined in  Section 9.3.3), and/or when knowledge of the 
tr
eatment  assignment  will impact the clinical management  of the  patient , the Investigator will have the 
ability to unblind  the tre atment  assignment  for that patient  using  the IXRS .  The Sponsor will det ermine 
the point at w hich all treatment  assignments will be unblinded .  The Sponsor or designe e will be informed 
of the unblinding of a patient  within 24 hours .  In addition, all SUSARs will be unblinded by the 
Sponsor’s or designee’s Drug Safety and Quality Assurance personnel for the purpose of regulatory 
reportin g (see Section 9.2). 
5. PATIENT  ELI
GIBILITY
To be eligible to participate in this study candidates must meet the following eligibility criteria at within 4 
weeks of Study Day 1 or at the time point specified in the ind ividual eligibility criterion listed.  
5.1 Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations required by
local law and be able to comply with all study requirements
2.Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent
3.Clinical diagnosis of CVD defined as documented coronary artery disease (CAD), stroke, or
peripheral artery disease
4.Lp(a) plasma level ≥  60 mg/dL
5. Must be on standard-of- care preventative therapy for other than elevated Lp(a) CVD risk factors
6. Patients on the following medications must be on a stable regimen for at least 4 weeks prior to
Screening and expected to remain on a stable regimen through the end of the post -treatment
follow-up period:
a.lipid lowering drugs (statins, ezetimibe, proprotein convertase subtilisin/kexin
type 9 [PCSK9s ] inhibitors, niacin, fibrates, fish oil or other products containing omega-3
fatty acids including OTC preparations)
b. antiplatelet drugs
c.testosterone, estrogens, progesterone, growth hormone or progestins
7.Females:  must be non -pregnant and non- lactating and either :
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
36  a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral
oophorectomy)
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females > 55  years of
age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative
medical cause and FSH levels in the postmenopausal range for the laboratory involved)
c. Abstinent* or
d.if engaged in sexual relations of child-b earing potential, agree to use 2  highly  effective  
contraceptive methods 
(refer to Section 6.3.1) from the time of signing the informed consent  
form until at least 16 week s after the last dose of Study Drug (ISIS 681257 or placebo)
*Abstin
ence is only acceptable as true abstinence, i.e., when this is in line with the preferred and
usual lifestyle of the patient .  Periodic abstinence (e.g., calendar,  ovulation, symptothermal,
post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are
not acceptab le methods of contraception
8.Males m ust be surgically sterile o r, if engaged  in  sexual relations w ith  a female o f chi ld-bearing 
potential,  th e patient must b e using an acceptable c ontraceptive m ethod  (refer to Section 6.3.1)  
from the time of signing the informed consent form until at least 16 weeks after the last dose of 
ISIS 681257
5.2 Exclusio
n Criteria  
1. Within 6 months of Screening :  acute coronary syndrome, m ajor cardiac surgery, or
stroke /transient ischemic attack
2. Within 3 months of Screening:  coronary, carotid, or peripheral arterial revascularization, major
non-cardiac surgery , or lipoprotein apheresis
3.Heart failure New York Heart Association ( NYHA) class IV
4.Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)
5.History of acute kidney injury within 12 months of Screening
6.Uncontrolled hyper or hypothyroidism
7.Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed
prior to Study Day 1
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or
chronic hepatitis B
9.Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinomain situ of the cervix that has been successfully treated
10. Patients with a history of major bleed or high- risk of bleeding diathesis
11. Recent history of, or current drug or alcohol abuse
12. Known history or presence of systemic allergic or pseudoallergic (drug) reactions
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
37  13.Hypersensitivity to the active substance or to any of the excipients
14.Clinically -significant  abnormalities in screening laboratory values that would render a patient
unsuitable for inclusion, including the following:
a.Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg.  In the event of a UPCR above this
threshold, eligibility may be confirmed b y a quantitative total urine protein measurement of ˂
300 mg/24 -hr
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.  In the event of a UACR above this
threshold, eligibility may be confirmed by a quantitative total urine albumin measurement of
˂ 150 mg/24-hr
c.Estimated GFR  ˂ 60 mL/min (as determined by the Chronic Kidney Disease- Epidemiological
Collaboration ( CKD -EPI) Equation for creatinine clearance
d.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >  2.0 x ULN
e.Bilirubin > ULN,  unless prior diagnosis and documentation of Gilbert’s syndrome in which
case total bilirubin must be ≤ 3 mg/dL
f.Alkaline phosphatase (ALP)  > ULN
g.Platelet count ˂ LLN
15.Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors
16.Treatmen t with another investigational drug, biological agent, or device within 1 month of
Screening, or 5 half- lives of investigational agent, whichever is longer
17. Treatment with any non-Ionis oligonucleotide (including small interfering ribonucleic acid
[siRN A]) at any time or prior treatment with an Ionis oligonucleotide or siRNA within 9 months
of screening.  Patients that have previously received only 1 dose of an Ionis oligonucleotide as
part of a clinical study may be included as long as ≥ 4 months has elapsed since dosing
18. BMI > 40 kg/m2
19. Blood donati
on of 50-499 mL within 30 days of Screening or of > 499 mL within 8 weeks of
Screening
20.Unwillingness to comply with study procedures, including follow-up, as specified by this
protocol, or unwillingness to cooperate fully with the Investigator
21. Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the
patient unsuitable fo r inclusion, or could interfere with the patient participating in or completing
the Study
6. STUDY PROCEDURES
6.1 Study Schedule 
All required study procedures are outlined in Appendices A , B, and C . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
38  6.1.1 Screening  
Written informed consent for the study will be obtained prior to the performance of any study- related 
procedures including screening procedures.  A 4 -week period is provided for completing screening 
assessments and determining patient eligibility for the study .  Abnormal screening results may be re-
tested once for determination of patient eligibility after consultation with the Sponsor Medical Monitor .  
Patients may be re- screened 1 time in order to determine el igibility . 
During the s creening period, patients will undergo a medical history and physical examination including 
vital signs, 12 -lead electrocardiogram (ECG) and have blood and urine samples taken for clinical 
laboratory testing.  Patients will be screened for HIV, hepatitis B, and hepatitis C .  
On confirmation of eligibility and prior to randomization, patients will also undergo a 24 hr urine 
collection for creatinine , albumin, and protein as a baseline assessment.  
6.1.2 Treatment Period  
Treatment  period  is defined as the time between the first and the last doses of study drug plus one d osing 
interval. D uring  the treatment  period, patients will repor t to the study center for clini c visits .  Patients will 
receiv e 20 m g doses of Study  Drug administered by SC injection once every 4 weeks for up to 49 w eeks 
in Cohort A, 40 mg doses of Study Drug administere d by SC injection once every 4 weeks for up to 49 
weeks in Cohort B, 60 mg doses of Study Drug administered by SC injecti on once every 4 wee ks for up 
to 49 weeks in Cohort C, 20 mg doses of Study Drug administe red by SC injection once every 2 week s 
for up to 51 w eeks in Cohort D, or 20 mg doses of Study Drug administered by SC injection once per 
wee
k (weekly) for
 up to 52 weeks in Cohort E (Section 8.1). 
Collection and measurement of vital signs, physical examination results, ECGs, clinical laboratory 
parameter
s (Appendix B), ISIS 681257 p lasma concentrations, immunogenicity and b iomarker samples, 
AEs
 and c oncomitant medication/procedure information  will be performed according to the Schedule of 
Procedures i n Appendix A . 
Extensive Pharmacokinetic (PK) Subgroup Only: 
Withi n each cohort, a subgroup of approximately 12 pa tients , who will consent  to extensiv e PK sampling , 
will undergo additional PK sampling, in what is referred to as the PK Subgroup in this study.  P atient s in 
this subgroup will have additional PK sampling  time poi nts in order to evaluat e the plasma PK parameters 
of ISIS 681257.  P atients in this subgroup will h ave additional v isits to t he clinic during the treatment 
period in order 
to collect blood samples for PK assessment (Appendix C).  
6.1.3 Post-Treatment  Pe
riod 
Each patient  will be followed for safety assessment s for 16  week s after t he treatment  period.  During the 
post- treatment  follow -up peri od, patients will return to the Study Center for 3 outpatient  visits a t Weeks 
4, 10, and 16 after the treatment period for safety and clinical laboratory evaluations and for blood 
sampling for PK (Appendices A and C). 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
39  6.2 Additional Study Assessments  
6.2.1 Laboratory Assessments 
Laboratory analyte samples will be collected throughout the study as per the Schedule of Procedures in 
Appendix A.
  A list of these a nalytes is contained in  Appendix B. 
Routine blood chem
istry and urine samples (excluding 24-hour urine collection) should be taken after 
fasting for at least 10 hours .  Any confirmatory test, or test  taken for safety reasons , may be taken at any 
time, irrespective of fasting status .  During preparation for fasting samples,  the patient can drink water 
and they should ensure that they consume sufficient water in order to not become dehydrated.  
If tests are uninterpretable (e.g. , due to clumping, hemolysis or quantity not sufficient) or missing, a 
repeat blood or urine specimen should be re-drawn as soon as possible (ideally within 1 week ). 
While on treatment hematology samples will be collected every 14 days.  Each time a hematology lab is 
drawn and sent to the central laboratory for analysis, an additional sample should be collected in parallel 
and analyzed locally .  In the event that both the central and local samples are unreportable (e.g., due to 
hemolyzed or clumped blood samples), patient dosing cannot continue until another sample is repeated 
and determined not to have met a platelet stopping rule . 
If there is no reportable platelet count within 14 days of the last platelet count, the Investigator will contact the patient to hold dosing until a new platelet count is obtained and review ed. 
While on treatment blood and urine samples for renal function testing will also be collected every 1 4 days 
and sent to the central laboratory for analysis, per Section 8.5.2 .
  If there are no test result s available 
within 14 days of the last set of results for parameters considered critical to patient safety , the Investigator 
will contact the patient to hold dosing until a new test set is obtained a nd reviewed. 
While on treatment liver function  testing  will also be collected  every  14 days a nd sent to the central 
laboratory for analysis for the first 3 months of the study treatment, and monthly thereafter during the 
Treatment Period per Section 8.5.1.   
All lab sam
ples sent to  the central laboratory are received on the next day and processed.   Lab Alerts 
issued as per protocol safety monitoring requirements or stopping rules will  indicate the applicable 
protocol section to facilitate review and will be  immediately and s imultaneously sent by email to the 
Investigator , the Sponsor and the CRO Medical Monitors, the Sponsor Drug Safety Physician, and the 
Clinical Trial Manager (CTM), and should be  receiv ed by them  within 2 days from sample collection.  
Hematology results from the site’s local laboratories are received by the study center staff  on the day of 
sample collection , and should be entered as soon as possible in to the eCRF  to inform the Sponsor and 
CRO study monitoring teams. 
All p latelet count r esults m ust be reviewed promptly (within 24 hours of receipt) by the Investigator, o r 
designee, to ensure that the count has not met the stopping rule and to determine whether the rate of 
decline is suggestive t hat the p atient could be approaching th e dose interruption rule of 75,000/mm3 as 
specified in Section 8.6.3 .  Any case o f a platelet count reduction to levels b elow 50,000/mm3 (Grade 3 or 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
40  Grade 4 ) is c onsidered an adverse e vent of special interest and m ust be reported in an expedited fashion to 
the Sponsor as per Sections 9.3.3.1 and 9.4.1. 
All liver and renal function  tests must also be reviewed promptly (within 2 4 hours of receipt) by the 
Investigator, or designee, to ensur e that the result ha s not met the stopping rule.  A ny event  meeting  renal 
stopping rules criteria described in Section 8.6.2 is c onsidered an adverse e vent of special interest and 
must be reported in an expedited fashion to the Sponsor as per Sections  9.3.3.1 
and 9.4.1. 
All lab alerts recei
ved, including those related to platelet , liver, or renal function monitoring/stopping 
rules , are also reviewed promptly by the Sponsor and the CRO Medical Monitors who will  agree on  
actions to be taken.  Within 24 hours of receiving an actionable lab alert the CRO Medical Monitor will 
communicate instructions to the Investigator and the study personnel by emailing them the Safety 
Surveillance Form that needs to be signed by the Investigator/study personnel and promptly returned  to 
the Sponsor and CRO Medical Monitor.  In urgent cases, such as platelets results below  50,000/mm3, or 
liver or renal test results reaching a critical stopping rule the Investigator must  also be contacted by 
phone.  
Further information on safety monitoring and actions to be taken by the Study Investigator in the event of 
reduced  platelet  count  are provided in Section s 8.5.3 and 8.6.3 . 
6.2.2 Physical Exams an
d Vital Signs  
Physical exams a nd vital signs will be performed  as indicated in the Schedul e of Procedures  
(Appendix A
) Vital signs should include weight, blood pressure ( BP), pulse rate, respiratory rate a nd 
body te
mperature.  B P and pulse rate will be recorde d after the patient has been in a sitting position for at 
least 5 minutes.  B P should alway s be m easured on the same arm (preferentially on the left arm).  Height 
will be measured at Screening . 
6.2.3 E lectro cardiograph
y 
Electrocardiography (ECG) will be conducted at Screening, Day 1, (prior to the first dose of Study Drug), and again during the t reatment p eriod  as follows per dosing cohort: 
•Cohorts A, B, and C at Weeks 5, 13, 21, 25, 33, 41, 49, and 53
•Cohorts D and E at Weeks 5, 13, 21, 27, 33, 41, 49, and 53
In all cohorts, ECGs will be conducted during the post-t reatment follow -up period  at 4, 10, and 16 weeks 
after the treatment period . 
ECGs will be recorded after the patient has been resting in a supine position for at least 5 minutes.  ECGs 
will be performed in triplicate . 
6.2.4 PK Sampling  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected prior to 
dosing on Day 1 and at various times throughout the treatment and post-treatment follow-up pe riods a s 
noted in the tables in Appendix C. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
41  Withi n each cohort , patients assigned to the PK Subgroup will have additional PK sampling  time points 
and a dditional v isits to the clinic during the treatment period in order to collect blood samples for PK 
assessment (Appendix C). 
6.3 Restric
tion on the Lifestyle of Patient s 
6.3.1 Contraception Requirements 
All male patient s and women of childbearing potential must refrain from sperm/egg donation and either 
be abstinent† or practice effective contraception from the time of signing the informed consent form until 
at least 16 weeks after their last dose of study treatment .   
Male patient s engaged in sexual relations with a female of child -bearing potenti al must also encourage 
their female partner to use effective contraception from the time of signing the informed consent until 16 
weeks after the patient ’s last dose of study treatment.  
For the purposes of this study, women of childbearing potential are defined as any female who has 
experienced menarche, and who does not  meet 1 of the following conditions:  
•Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, in
females ≤ 55 years, 12 m onths of spontaneous amenorrhea without an alternative medical cause
and FSH levels in the postmenopausal range for the laboratory involved
•6 weeks after surgical bilateral oophorectomy with or without hysterectomy
•Post hysterectomy
For the purposes of the  study, effective contraception is defined as follows: 
For male patients: 
•Effective male contraception includes a vasectomy with negative semen analysis at Follow-up, or
the use of condoms together with spermicidal foam/gel/film/ cream/suppository
•Male patients with partners that are pregnant must use condoms as contraception to ensure that
the fetus is not exposed to the Study Drug
For female patients and female partners of male patients: 
•Using 2 of the following acceptable methods of contraception:  surgical sterilization (e.g.,
bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2
barrier methods (a combination of male or female condom * with  diaphragm, sponge, or cervical
cap) together with spermicidal foam/gel/film/cream/suppository
†Note:  Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and 
usual lifestyle of the patient .  Periodic abstinence (e.g., calendar, ovulation, symptothermal, 
post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are 
not acceptable methods of contraception.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
42  *Note : A female condom and a male condom should not be used together as friction between the
2 can result in either or both product s failing. 
6.3.2 Other Requirements  
All patients will be required to fast for at least 10 hours before visits requiring fasted blood sampling. 
7. STUDY DRUG
7.1 Study Drug Description 
Study Drug (ISIS 681257 or Placebo) characteristics a r
e listed in  Table 1 . 
Study Dr
ug (ISIS 681257 or Placebo)  will be provided as 0.8 mL deliverable volume in 2 mL stoppered 
and sealed glass vials as a sterile solution .   
The Study Drug is clear to slightly yellow  in color, it is for single use , contains no preservatives and must 
be stored between 2 to 8 °Celsius and be protected from light.  
7.1.1 ISIS  681257 
ISIS 681257 vials contains 100 mg/mL ISIS 681257 in Water for Injection.  Additionally, sodium 
phosphate buffer and sodium chloride are added to control the measure of the acidity or basicity of the 
solution (pH) and tonicity, respectively.  The target pH is 7.4. 7.1.2 Placebo  
Placebo vials contain 0.9% sodium chloride in Water for Injection.  1.6 µg/mL riboflavin is added to 
ensure color matching of placebo vials to ISIS 681257 vials.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
43  Table 1 Study Drug  Characteristics  
Study Drug  ISIS 681257  Placebo  
Strength 100 mg/ mL  Not Applicable  
Volume/Formulation  0.8 mL solution per 
2.0 mL vial  0.8 mL solution per  
2.0 mL vial  
Route of Administration  SC SC 
SC = subcutaneous  
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug ( ISIS 681257 or placebo) labeled in 
accordance with specific country regulatory requirements. 7.3 Study Drug  Accountability  
The study staff is required to document the receipt, dispensing, and return of Study Drug (ISIS  681257 or 
placebo) supplies provided by the Sponsor.  The patient must return all used and unused Study Drug  to 
the Study Center for accountability.  The Study Center must return all used and unused Study Drug to the 
Sponsor or designee for destruction.  All used syringes must be disposed of as per the site’s hazardous 
waste destruction policy . 
8. T REATMENT OF PATIENT S 
8.1 Study Drug  Administration  
ISIS 681257 will be administered to patients by Study Center staff as follows: 
Cohort A: a single SC dose of 20  mg once every 4 weeks for up to 49 weeks and a maximum of 13 
doses 
Cohort B: a single SC dose of 40 mg once every 4 weeks for up to 49 weeks and a maximum of 13 
doses 
Cohort C: a single SC dose of 60 mg once every 4 weeks for up to 49 weeks and a maximum of 13 
doses 
Cohort D: a single SC dose of 20 mg every 2 week s for up to 51 weeks and a maximum of 26 
doses 
Cohort E: a single SC dose of 20 mg every week (weekly) for up to 52 weeks  and a maximum of 
52 doses 
Self-administration will be allowed after appropriate training of patient and/or caregiver. 
Patients in Cohorts A, B, and C should receive 1 dose every 4 weeks, patients in Cohort D should receive 
1 dose every 2 weeks and Cohort E should receive 1  dose per week with weeks always defined relative to 
Study Day 1 .  For example if a patient receives the first dose on a Monday, subsequent doses should be 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
44  given on Mondays according to the respective dosing schedule, if possible.  If a patient misses an 
injection, or if dosing on the usual day is not possible, the patient can reschedule the injection provided that 2  doses are administered at least 2  days ap art. 
Every effort should be made to ensure the previous dose is given 7 days prior to a scheduled clinic visit.  
Please refer to the Study Drug Manual provided by the Sponsor or designee for more detailed instructions 
for Study Drug (ISIS  681257 or placebo) preparation and administration. 
Table 2 Study Drug  Dosing Information  
Cohort  Treatment  Volume to Administer/Dose  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.2 mL  ≤ 13 ≤ 260 mg  
B 40 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.4 mL  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.6 mL  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 
or placebo  
(Every 2 weeks)  0.2 mL  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 
or placebo  
(Every week) 0.2 mL  ≤ 52 ≤ 1040 mg  
 
8.2 Other Protocol -Required Drugs  
No other Study Drug treatments are required by the protocol.  
8.3 Other Protocol -Required Treatment Procedures  
No other treatment procedures are required by the protocol. 8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator” section of the Investigator’s Brochure.  
For the purposes of safety monitoring baseline is defined as the average of the pre- dose test closest to Day 
1 and the Day 1  value itself . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are provided 
for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
45  In case of discrepancy between the test results from 2 sources, such as between the central and local lab, 
safety -mandated action must be initiated based on the more critical ( lower or higher, as relevant) of the 2 
values.  
Confirmation Guidance:  At any time during the study (t reatment or post -treatment follow -up periods), 
the clinical laboratory results meeting any of the safety monitoring criteria presented below must be 
confirmed by performing measurements (ideally in the same laboratory that performed the initial 
measurement) on new specimens prior to administering the next dose of Study Drug ( ISIS 681257 or 
placebo).  All new specimen collections should take place as soon as poss ible (ideally within 3 days of the 
initial collection) .  
In addition, as described in Section 6.2.1 hematology labs should be sent in parallel to the central and 
local laboratory for analysis. 
Stopping Rule Guidance:  The Investigator may interrupt or permanently discontinue study treatment for 
any medical reason including changes in clinical laboratory results.   
In the event  of an initia l clini cal laboratory resul t that meets a stopping  criterion,  patients must not be re-
dosed until a confirmatory test result has been reviewed by the Study Medical Monitor.  If any of the 
stopping criteria described below (refer to Sections 8.6.1 to 8.6.3) are met and are confirmed, the patient 
w
ill be perma
nently discontinue d from further treatment with Study Drug (ISIS 681257 or placebo), 
evaluated fully as outlined below and in consultation wit h the Study Medical Monitor or appropriately 
qualified designee, and will be entere d into the post-treatment evaluation portion of the study.  I n general, 
patients who do not meet the stopping rules based upon retest may continue dosing.  However, the 
Investigator and the Study Medical Monitor (or appropriately qualified designee) should confer as to 
whether additional close monitoring of the patient is appropriate. 
Additional Gui
dance:  If possible, a PK sample should be collected as soon as possible after an SAE has 
occurred (preferably within 2 weeks).  In addition, if a patient is asked to return to the clinic for additional 
evaluations due to an AE, then a PK sample should be taken at the time of the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug-Induced Liver Injury:  
Premarketing Clinical Evaluation,” issued by the U.S .  Department of Health and Human Services, Food 
and Drug Administration, July 2009.  For a definition of Baseline, please refer to guidance in Section 8.5  
above. 
All patients will have liver chemistry  tests monitored every 2 weeks for the first 3 months of the study 
treatment, and monthly thereafter during the Treatment Period. 
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, vomiting, 
right upper quadrant pain or tenderness, fever, rash,  abnormal bleeding or bruising, or eosinophilia > 
ULN)  liver  enzymes and bilirubin should be tested as soon as possible.  Testing at a lab that is local to the 
patient is permissible for this purpose.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
46  In the event of an ALT or AST measurement that is > 3 x ULN (or the greater of 2 x baseline value or 3 x 
ULN if the baseline value was > ULN) at any time during the study ( treatment or post- treatment period), 
the initial measurement(s) should be confirmed as described in Section  8.5. 
Patients with confirmed ALT or AST levels > 3 x ULN should have their liver chemistry tests (ALT, AST, ALP, international normalized ratio [INR] and total bilirubin) retested at least once- weekly until 
ALT and AST levels become ≤ 1.2 x ULN. 
All r esults of liver function tests must be reviewed promptly (within 24 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met the stopping rules per Section 8.6.1. 
Further Investigation into Liver Chemistry Elevations :  For patients with confirmed ALT or AST levels > 
3 x ULN,  the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases
2. Obtain further history for concomitant drug use (including nonprescription medications, herbal
and dietary supplement preparations), alcohol use, recreational drug use, and special diets
3.Obtain a history for exposure to environmental chemical agents and travel
4.Serology for viral hepatitis ( hepatitis A vir us [HAV] immunoglobulin M [ IgM], hepatitis B
surface antigen [HBsAg ], hepatitis C virus [ HCV ] antibody, Cytomegalovirus [ CMV ] IgM, and
EBV antibody panel)
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ANA])
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or MRI 
scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical 
Monitor a nd the study DSMB.  Repetition of the above evaluations should be consi dered if a patient’s 
ALT and/or AST levels reach 5 x ULN.  
All routine liver function test results will be reviewed on an ongoing basis at the weekly safety review by 
the Medical Monitor.  
All lab alerts for abnormal liver function tests must be promptly (within 24 hours of receipt) reviewed by 
the Investigator and Medical Monitors . 
Lab alerts for abnormal liv er chemistry tests will be issued for:  1) ALT or AST > 3 x ULN; 2) ALT or 
AST > 2 x baseline ; 3) total bilirubin > ULN; 4) ALP > ULN.  These alert level s are set  to anticipat e the 
risk of a combined elevation of aminotransferases and bilirubin  as per the F DA Guidance referenced  in 
Section 8.5.1. 
8.5.2 Safet
y Monitoring for Renal Function 
While on treatment a ll patients will have renal function tests monitored every 2 weeks throughout the 
study.  Upon completion of the study treatment period, urine renal biomarkers should be monitored every 2 weeks for the first 6 weeks and then at 10 and 16 weeks post treatment period  (as per visit schedule).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
47  In the event of appearance of symptoms or signs consistent with renal dysfunction such as hematuria, 
polyuria, anuria, flank pain, new-onset hypertension, nausea and/or anorexia, renal function should be tested as soon as possible.  Testing at a lab that is local to the patient is permissible for this purpose.  
While on treatment during the course of the study , urinary surveillanc e will includ e urinalysis to include  
urine albumin/creatinine  ratio (UACR ), urine protein/creatinine  ratio (UPCR ) and urinary re d blood cells 
(RBCs ), as well as serum  creatinine  and cystatin -C to estimat e glomerula r fil tration rate (eGFR ), which 
will be monitored every 2 weeks.  In addition, b iomarkers o f acute r enal injury  will also be m easured 
every 2 weeks (Appendix B).  
The assessmen
t of serum creatinine, cystatin -C, and urinalysis more frequently than every 2 weeks will be 
guided by consultation with a local nephrologist.  Any decision taken by the Investigator  to discontinue 
study medication will be made taking into account all available and relevant data.   In addition, t he 
decision to discontinue Study Drug may also be based on lesser changes in these parameters observed in 
isolation or in association with other renal- related abnormalities.  Any decision taken to restart study 
medication will be made in consultation with the Study Medical Monitor taking into  account all available 
and relevant data.  
All renal function test results will be reviewed on an ongoing basis at the weekly safety review by the Medical Monitor.  
All r esults of renal function tests must b e reviewed promptly (within 24 hours o f receipt) by t he 
Investigator or the designee to ensure that the result has not met the stopping rules per Section 8.6.2. 
Lab alerts 
for abnormal renal tests will be issued for:  Creatinine clearance (by CKD -EPI formula) 
decrease from baseline > 25%, urine albumin/creatinine  ratio (UACR) > 250 mg/ g, urine 
protein/creatinine ratio (UPCR)  > 0.5 mg/mg , or an increase in serum creatinine from baseline > 0. 3 
mg/dL).  
These alert levels are set to anticipate and prevent the risk of a medically significant change in renal function while receiving  Study D rug. 
In the e vent of a confirmed  (as d escribed in Section 8.5)  laboratory  result m eeting one or more of the 
above criteria, dosing with the 
Study Drug should be interrupted and 
the Study Medical Monitor 
informed.  In addition, t he following supplemental renal tests s hould be immediately obtained:  
Serum creat
inine, urine culture, 24- hour urine sample for creatinine clearance , urine albumin and 
urine protein, urine microscopy sample with inspection of sediment. 
The Investigator should also review the patient’s concomitant medications for potentially nephrotoxic 
agents, and , with the results of these evaluations, review any decision to continue or discontinue the 
patient  in consultation with the Study Medical Monitor and the medical area specialist consultant of the 
DSMB . 
8.5.3 Safety Monitoring for Platelet Count Results  
All patients will have platelet counts monitored every 2 weeks for the duration of the study treatment 
period and must  not receive S tudy D rug without an interpretable platelet count result in the prior 2 wee ks.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
48  Upon completion of the study treatment perio d, platelets should be monitored every 2 weeks for the first 6 
weeks and then at 10 and 16 weeks post treatment period (as per visit schedule). In addition, platelet 
function will be evaluated by aggregometry, using an approved point-of- care diagnostic device,  in all 
patients at each study site visit ; additional functional testing may be performed at selected study centers.  
As described in Section 6.2.1 , all platelet count results must be reviewed promptl y (within 24 hours  of 
receipt) by  t
he Investigator or the designe e to ensur e that the count has not met the stopping  rule and to 
determin e whether th
e rate of decline is suggestive t hat  the p atient could be approaching the dose 
interruption rule of 75,000/m m3 as specified in Section 8.6.3.   
Any case of a pl
atelet count reduction to levels below  50,000/mm3 (Grade 3 or Grade 4) is considered a n 
adverse event of special interest and should be reported in an expedited fashion to the Sponsor.  
Lab alerts related to platelet monitoring/stopping rules are issued when:  1) platelet count s are < 140, 000 
mm3; 2) when platele t coun t is ≥ 30% decrea s ed from baseline, or  3) when t he hematology sample is 
unreportable.  A ll these lab alerts, are reviewed promptly by the Medical Monitor and i nstructions  are 
communicated to the Investigator and the study personnel within 24 hours of receiving an actionable lab 
alert as described in Section 6.2.1. 
Actions to be 
taken in the event of reduced platelet count are shown in  Table 3 in Section 8.6.3. 
In the event of a platelet count ˂ 100,000/mm3 the laboratory tests outlined in  Appendix E, should be 
performed as soon as possible.  Additional la b tests will be determine d by the Sponsor Medical Monitor 
or designee in consultati on with the Investigator. 
8.5.4 Safety Monit
oring for Minor Bleeding Events 
Patients will be instructe d to promptly report any signs or symptoms of bleeding.  M inor bleeding  events 
are those that do not fulfill the criteria for major bleeding or clinically-relevant, non-m ajor bleeding 
events (which are defined in  Section 8.6.3), for example e xcess b ruising, petechiae, or gingival  bleeding 
on br
ushing teeth.  If a mi
nor bleeding event occurs, the Investigator must notify the Sponsor Medical 
Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT), 
prothrombin time (PT), INR, hepatic enzymes, bilirubin a nd platelet count should be performed. 
8.5.5 Safety Monit
oring for Constitutional Symptoms  
Patients will be instructed to promptly report any signs or symptoms of fever , constitutional symptoms, 
rash, arthralgia or joint swelling  that may arise during the study and the Investigator should closely 
evaluate all potential causes, including concomitant illness.  Patients who experience persistent symptoms 
should be discussed with the Sponsor Medical Monitor or designee to determine whether additional monitoring or laboratory tests are required. 
8.6 Stopping Rules 
For the purposes of stopping rules, Baseline is defined as the average of Day 1 pre -dose assessment and 
the last measurement prior to Day 1.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
49  8.6.1 Stopping Rules for Liver Chemistry Elevations  
In the event of confirmed laboratory results meeting any of the following criteria , dosing of a patient with 
Study Drug will be stopped permanently: 
1. ALT or AST > 8 x ULN, which is confirmed 
2. ALT or AST > 5 x ULN, which is confirmed and persists for ≥ 2 weeks 
3. ALT or AST > 3 x ULN (or the greater of 2 x Baseline value or 3 x ULN if the Baseline value 
was > UL N), which is confirmed and total bilirubin > 2 x ULN or INR > 1.5 
4. ALT or AST > 3 x ULN (or the greater of 2 x Baseline value or 3 x ULN if the Baseline value 
was > ULN), which is confirmed, and the new appearance (i.e., onset coincides with the changes in hepatic enzymes) of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (> ULN) felt by the Investigator to be potentially related to hepatic inflammation  
8.6.2 Stopping Rules for Renal Function Test Results  
In the event of an estimated creatinine clearance (by CKD -EPI formula) meeting any of the following 
criteria, or any change in renal biomarkers deemed by the nephrologist on the DSMB to require further 
evaluation, a serum creatinine, urine culture, 24-hour urine sample for creatinine clearance and protein, 
and urine microscopy sample with inspection of sediment  should be immediately obtained: 
1. CKD- EPI decrease of > 40% from B aseline  
2. CKD-EPI value < 45 mL/min/1.73 m
2 
Dosing of a patient with Study Drug (ISIS  681257 or placebo) will be stopped permanently  if 24 -hour 
urine testing confirms any of the following values in the absence of an alternative explanation: 
1. Urine protein is > 1.0 g 
2. Creatinine clearance decrease of > 40% from baseline 
3. Creatinine clearance < 45  mL/min/1.73 m2 
Irrespective of whether the stopping rule is confirmed or not, the follow-up schedule and frequency of 
renal function monitoring after the initial event will be determined by the Study Medical Monitor in consultatio n with the Investigator and the medical area specialist  on the DSMB .  The Investigator should 
consider consulting a local nephrologist for any change of renal function that presents a concern.  If a 
renal biopsy is performed, a sample specimen should be made available for examination by an 
independent renal pathologist who has been engaged by the Sponsor to review such specimens.  
8.6.3 Stopping Rule for Platelet Count Results  
Stopping Rules for Platelet Count Results 
Actions to be taken in the event of a low platelet count are summarized in  Table 3 below. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
50  In the event of any platelet count less than 5 0,000/mm3, or a platelet count less than 75,000/mm3 that 
occurs w hile the p atient is a lready on reduced dose, dosing of the patient w ith Study D rug will be stopped 
permanently (Table 3 ).  Platelet count will be monitored daily until 2 successive values show 
improvement then monitored every 2-3  days until
 platelet count is stable. 
Administration of steroids is recommended for patients whose platelet count is less than 25,000/mm3.  
Recovery in platelet count may be accelerated by administration of high dose steroids.  Treatment 
guidelines for immune thrombocytopenia (Provan e t al. 2010) recommend Dexamethasone 40 mg 
daily for 4 days e very 2-4 weeks for 1-4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2-4  weeks t hen 
taper; or methylprednisolone 30 mg/kg/day for 7 days  
(note:  may requir e continuation  with oral steroids  after methylprednisol one). 
In the event of a platelet count ˂ 75,000/mm3 and ≥ 50,000/mm3, and in the absence of major bleeding or 
clinically-r elevant non-major bleeding (defined below;  Schulman e t al. 2005), dosing of a patient with 
Study Drug should be suspended temporarily until the platelet count has recovered to > 100,000/mm3.  If 
dosing is continued it must be at a reduced dose 
as shown in Table 3 .  The
 suitability of the patien t for 
continue
d dosing will be det
ermined by the Investigator in consultation wit h the Study Medical Monitor 
and will be based on factor s such as the original rate of decline  in the patient’ s platelet count, whether any  
bleedin g events were experienced by the patient, and the speed of recovery of platelet count after 
interruption of dosing. 
If, after reintrodu
ction of Study Drug, the platelet count again falls below 75,000/mm3, then dosing of the 
patient with Study Drug will be stopped permanently.  
Once a patient commences weekly monitoring this frequency of monitoring should continue until the 
platelet count returns to  the normal range (≥140K/mm3) for 2 successive values. 
Any unreportable platelet count result must be rechecked  and determined not to have met a stopping rule 
before dosing can continue. 
Definition of Major Bleedin g Events (Schulman e t al. 2005): 
•Fatal bleeding, and/or
•Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular,
retroperitoneal, intraarterial or pericardial, or intramuscular with compartment syndrome, and/or
•Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, orleading to transfusion of 2 or more units of whole or red cells
Definition of Clinically-Relevant, Non-Major Bleeding Events (Schulman et al. 2005):  
1.Multiple -source bleeding
2. Spontaneous hematoma > 25 cm2
3.Excessive woun
d hematoma (not injection site related)
4.Macroscopic hematuria (spontaneous or lasting > 24 hours if associated with an intervention)
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
51  5. Spontaneous rectal bleeding; epitasis, gingival bleeding, hemoptysis, hema temesis  
6. Bleeding after venipuncture for > 5 minutes 
Table 3 Actions in Patients with Low Platelet Count  
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, ≥ 140K/mm3 No action  Monitor every 2 weeks  
≥100K  to <140K/mm3 No action  Closer observation  
Monitor every week * 
≥75K to <100K/mm3 Permanently reduce as follows:  
For Cohort A:  reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks   
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week s 
For Cohort E:  reduce to 10 mg every week  Closer observation  
Monitor every week * 
≥50K to <75K/mm3 Pause dosing  
When platelet count returns to >  100K/mm3 restart 
dosing as follows  only if approved by Sponsor 
Medical Monitor : 
For Cohort A:   reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks  
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week  
For Cohort E :  reduce to 10 mg every week  
or 
Permanently discontinue Study Drug  if it occurs 
while on already reduced dose  Closer observation  
Monitor every 2-3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/ non-
steroidal anti-inflammatory drug ( NSAIDS )/ anticoagulant 
medication  
≥25K to <50K/mm3 Permanently discontinue Study Drug Closer observation: 
Monitor daily until 
2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet agents/NSAIDS/anticoagulant medication while platelet count ˂ 50K/mm
3 if possible 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
52  Platelet Count on Rx  Drug Dose  Monitoring  
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 
2 successive values show 
improvement then monitor every 2 -3 day s until platelet 
count stable  
Steroids recommended**  
Consider need for hospitalization and referral to 
hematologist  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet 
count ˂ 50K/mm
3 if possible 
*Once a patient commences weekly monitoring this frequency of monitoring should continue until the platelet
count returns to the normal range (≥ 140K/mm3) for 2 successive values.
** Recovery in platelet count may be accelerated by administration of high dose steroids .  Treatment guidelines for 
immune thrombocytopenia (Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every  
2-4 weeks
 for
 1-4 cy
cles; Prednis(ol)on e 0.5-2  mg/kg/ d for 2-4 weeks then taper;  or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require  continuati on with oral steroids after methylprednisolone) .
8.7 Adjustment of Dose 
Dose frequency adjustments for platelet count reduction must be made in accordance with  Section 8.6.3 
and Table 3 (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for 
safety or tolerability after consultation with the Sponsor Medical Monitor .   
Patients may have their dose interrupted in response to AEs after consultation with Study Medical 
Monitor. 
8.8 Discontinuation of Study Drug  
A patient must permanently discontinue study treatment for any of the following: 
•The patient  becomes pregnant .  Report the pregnancy according to instructions in  Section  9.5.4
•The patient  wi
thdraws consent
•The patient  experiences an AE that necessitates permanent discontinuation of Study Drug
•The patient  develops laboratory test abnormalities that meet any of  the stopping rules listed in
Sections 8.6.1 to 8.6.3
•When a platelet c
ount of  less than 50,000/mm3, or a platelet count less than 75,000/mm3 while the
patient is on a reduced dose .
The reason for discontinuation of Study Drug must be recorded in the electronic Case Report Form 
(eCRF)  and source documentation. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
53  8.8.1 Follow- up Visits for Early Termination from Treatment Period  or from Post -Treatment 
Follow- up Period  
Any patient who disconti nues e arly from the treatment period or from post-tr eatment follow -up period 
should be followed as per the platelet monitoring rules shown in Table 3 , Section 8.6.3 for the first 6 
week s pos t treatment  per
iod.  Following  this period,  if the platele t coun t is stable (at least 3 consecutive 
values that ar
e stable as determined by the Sponsor Medical Monitor and > 100,0 00/mm3), platelets 
should be teste d 10 and 16 week s pos t treatment  period (as per visit schedule).  
If a pa tient early terminates f rom the treatment period, an ET visit (Week 53 visit assessments) should be 
performed at the time of withdrawal , and ideally within 2 weeks from the last dose of Study Drug, and 
patients s hould start the 16-w eek post-tr eatment follow-u p period to collect  th e study assessments in 
accordance w ith the S chedul
e of Procedures i n Appendix A. 
If the patien
t early  terminat es from the post -treatment follow-up period, a final visit ( assessments from the 
Week 16 of post -treatment follow-up period) should be performed at the time of withdrawal.  
8.9 Withdrawal of Patient s from the S tudy  
Patient s must be withdrawn from the study for any of the following: 
•Withdrawal of consent
•The patient  is unwilling or unable to comply with the protocol
•The p atient meets any of the Exclusion Cr iteria (see Section 5.2 ) after enrolling in the study that 
in the opinion of the Investigator  represent s a safety risk to the patient
Other reasons
 for withdrawal of patient s from the study might include:  
•At the discretion of the Investigator for medical reasons
•At the discretion of the Investigator or Sponsor for noncompliance
•Significant protocol deviation
All efforts will be made to complete and report the observations as thoroughly as possible up to the date 
of withdrawal .  All information, including the reason for withdrawal from study, must be recorded in the 
eCRF . 
Any patient w ho withdraws consent to participate in the study  will be removed from further treatment and 
study observation immediately upon the date of request.  T hese patient s should be encouraged to 
complete the ET visit (Week 53 visit assessments) and observations a t the time o f withdrawal  
(Appendix A). 
For patients withdrawn for reasons other than withdrawal of consent every effort should be made to 
complete the ET visit (Week  53 visit assessments)  and observations a t the time of withdrawal  
(
Appendix A). 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
54  8.10 Concomitant Therapy and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the patient ’s eCRF .  
AEs related to administration of these therapies or procedures must also be documented on the 
appropriate eCRF . 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over -the-counter 
medications, herbal medications and vitamin supplements) administered from the time the patient has 
signed the informed consent at screening to the end of the post -treatment  follow-up period . 
Allowed Concomitant Therapy 
Use of the following is allowed only if the patient has been on a stable regimen for at least 4  weeks prior 
to screening and is planned to remain on a stable regimen through the end of the post-t reatment follow -up 
period:  
• Lipid lowering drugs (statins, ez etimibe, PCSK9 inhibitors, niacin, fibrates, fish oil, other 
products containing omega -3 fatty acids (including OTC preparations) 
• Anti-platelet therapies  
• Testosterone, estrogens, progesterone, growth hormone, or progestins. 
Disallowed Concomitant Therapy  
Use of the following is disallowed: 
• Warfarin, direct thrombin inhibitors or Factor Xa inhibitors 
• Other experimental agents during the study including investigational drug, biological agent, or 
device within 1 month of Screening, or 5 half- lives of investigational agent, whichever is longer .  
This includes marketed agents at experimental dosages 
• Treatment with any non- Ionis oligonucleotide (including siRNA) at any time or prior treatment 
with an Ionis oligonucleotide or siRNA within 9 months of screening.  Patients that have 
previously received only 1 dose of an Ionis oligonucleotide as part of a clinical study may be 
included as long as ≥ 4 months has elapsed since dosing 
• Lipoprotein apheresis  
Patients should co nsult with the Site Investigator or designee prior to initiating any new medication, 
including non-prescription or herbal compounds or any other non-drug therapy. 
8.10.2 Concomitant Procedures  
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) or 
diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between  screening and 
the end of the post -treatment follow -up period. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
55  8.11 Treatment Compliance  
Compliance with treatment dosing is to be monitored and documented by the Study Center staff and 
recorded in the eCRF .   
Patients or Study Center Staff will record treatment administered in a dosing diary that will be reviewed by Study Center staff and ent ered into the eCRF . 
8.12 Safety Monitoring Compliance 
Compliance with safety monitoring requirements and treatment stopping rules must be documented by the 
Study Center staff.   
Patients a nd the S tudy Investigators are required to adhere to  a strict program of monitoring of platelet 
count, and liver and renal function as described in  Section 6.2.1, Sections 8.5.1
-8.5.3, and S ections 8.6.1 -
8.6.3. 
While on treat
ment patients will be required to have platelet counts every 2 weeks for the duration of  the 
study and must not receive S tudy D rug without an interpretable platelet count result in the prior 2 weeks , 
in which case the Investigator must contact the patient to hold dosing until a new platelet count is 
obtained and reviewed, and will document this contact.  
While on treatment patients will also be required to have renal function testing and assessment of biomarkers of renal damage every 2 weeks, and must not receive Study Drug if there are no test results 
for parameters considered critical to patient safety available within the prior 2 weeks.  In such a case, the 
Investigator must contact the patient to hold dosing until these  or new tests are obtained and reviewed.  
Adherence to the program will be closely monitored by the Sponsor , and patients and trial sites that are 
unable or unwilling to comply with this important risk mitigation program will be discontinued from the 
study.  
Patients should be informed of the possibility and risks of a reduction in platelet count, and of potential 
hepatic and renal risks,  and the importance of adherence to the monitoring program.  Any case of a 
platelet count reduction to levels below 50,000/mm
3 (Grade 3 or Grade 4) , or any event meeting renal 
stopping rules criteria described in Section 8.6.2 are considered adverse event s of special interest and 
should be reported in an expedited fashion to the Sponsor. 
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING
9.1 Sponsor Review of Safety Information 
Safety information will be collected , reviewed, and evaluated  by the Sponsor or designee i n accordance 
with the Safety Management Plan throughout the conduct of the clinical trial.  
9.2 Regulatory Requirements  
The Sponsor or designee  is responsible for regulatory su bmissions and reporting to the Investigators of 
suspected unexpected serious adverse reactions (SUSARs) per the International Conference on 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
56  Harmonization ( ICH) guidelines E2A and ICH E6.  Country- specific regulatory requirements will be 
followed in accordance with local country regulations and guidelines.  
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any SAE 
according to applicable regulations. 
In addition to the Investigator’s assessment of relatedness, the Sponsor  or designee  will evaluate the 
available information and perform an independent assessment of relatedness.  While the Sponsor may 
upgrade an Investigator ’s decision it is not permissible to downgrade the Investigator ’s opinion for the 
purposes of determining whether the SAE meets the definition of a SUSAR.  
Appropriate personnel at the Sponsor or designee  will unblind SUSARs for the purpose of regulatory 
reporting.  The Sponsor or designee will submit SUSARs to Regulatory Agencies in blinded or unblinded 
fashion according to local law .   
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event  (AE) is any unfavorable and unintended sign (including a clinically -significant 
abnormal laboratory finding, for example ), symptom, or disease temporally associated with the study or 
use of investigational drug product, whether or not the AE is considered related to the investigational drug 
product. 
9.3.2 Adverse Reaction and Unexpected  Adverse Reaction  
Adverse reaction:  All untoward and unintended responses to an investigational medicinal product related 
to any dose administered. 
Unexpected adverse reaction:   an adverse reaction, the nature or severity of which is not consistent with 
the applicable product information (e.g. Investigator's Brochure for an unauthoriz ed investigation al 
product or summary of product characteristics for an authorized product). 
9.3.3 Serious Adverse Event (SAE)  
A SAE  is any AE that in the view of either the Investigator or Sponsor, meets any of the following 
criteria:  
• Results in death  
• Is life threatening,  that is, poses an immediate risk of death at the time of the event  
• An AE  or adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It does not 
include an AE or adverse reaction that , had it occurred in a more severe form, might have caused 
death  
• Requires inpatient hospitalization or prolongation of existing hospitalization 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
57  •Results in a persistent or significant incapacity or substant ial disruption of the ability to conduct
normal life functions
•Results in a congenital anomaly or birth defect in the offspring of the patient  (whether the patient
is male or female)
•Important medical events that may not result in death, are not life- threatening, or do not require
hospitalization may also be considered serious when, based upon appropriate medical judgment,
they may jeopardize the patient  and may require medical or surgical intervention to prevent one
of the outcomes listed in this definition .  Examples of such medical events include allergic
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias
or convulsions that do not result in inpatient hospitalization, or the development of drug
dependency or drug abuse
9.3.3.1 Adverse Events of Special Interest  
For the purpose of this study severe reductions in platelet count < 50,000 mm3 as well as any
 event 
meeting  renal s topping rules criteria described  in  Section 8.6.2 are c onsidered  as AE of special interest 
and should be subject to expediting reporting to the Sponsor following the same requirements as for S AE 
reportin g
 (Section 9.4.1). 
9.4 Monitori
ng and Recording Adverse Events 
Any pre-existing conditions or signs and/or symptoms present in a patient  prior to the start of the study 
(i.e., before informed consent) should be recorded as Medical History and not recorded as AEs  unless the 
pre-existing condition worsened.  The Investigator should always group signs and symptoms into a single 
term that constitutes a  single unifying diagnosis  if possible.  
9.4.1 Serious Adverse Events/Adverse Events of Special Interest  
In the interest of patient safety, and in order to fulfill regulatory requirements , all SAEs and AEs of 
special interest (regardless of their relationship to Study Drug) should be reported to the Sponsor  or 
designee within 24 hours of the Study Center ’s first knowledge  of the  event .  The collection of SAEs will 
begin after the patient signs the informed consent form and stop at the end of the patient ’s follow-up 
period .  When  the Investigator is reporting by telephone, it is important to speak to someone in person 
versus leaving a message.  An  Initial Serious Adverse Event Form should be completed and a copy 
should be emailed or faxed to the Sponsor or designee.  The contact information  for reporting SAEs is as 
follows:  
Attention:   
Email:   
Fax:   
Detailed information should be actively sought and included on Follow- Up Serious Adverse Event Forms 
as soon as additional information becomes available.  All SAEs will be followed until resolution during 
the study period.  SAEs that remain ongoing past the patient ’s last protocol -specified follow -up visit will 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
58  be evaluated by the Investigator and Sponsor.  If the Investigator and Sponsor agree the patient ’s 
condition is unlikely to resolve, the Investigator and Sponsor will deter mine the follow -up requirement. 
All SAEs considered treatment-r elated, as defined in  Section 9.4.3.1, will be reported by the Sponsor to 
the D SMB as described in Section 3.6 .  
9.4.2 Non-Serious 
Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form and will 
stop at the end of the patient ’s follow -up period .  The Investigator will monitor each  patient  closely and 
record all observed or volunteered AEs on the Adverse Event Case Report Form. 
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opinion of the following should be documented on the Adverse Event Case Report 
Form : 
9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug (ISIS  681257 or placebo) is characterized by 1 of the 
following: 
•Related:   There is clear evidence that the event is related to the use of Study Drug, e.g.,
confirmation by positive re- challenge test
•Possible:   The event cannot be explained by the patient’s medical condition, concomitant
therapy, or other causes, and there is a plausible temporal relationship between the event and
Study Drug (ISIS  681257 or placebo) administration
•Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g.,
concomitant medications or ongoing medical conditions.  For repo rting purposes,
Unlikely/Remote will be grouped together with Not Related)
•Not Related:   The event can be readily explained by the patient’s underlying medical condition,
concomitant therapy, or other causes, and therefore, the Investigator believes no relationshipexists between the event and Study Drug
9.4.3.2 Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D).  A ny AE not listed in 
Appendix D will be graded as follows: 
•Mild:   The even
t is easily tolerated by the subject and does not affect the subject’s usual daily
activities
•Moderate:   The event causes the subject more discomfort and interrupts the subject’s usual daily
activities
•Severe:  The event is incapacitating and causes considerable interference with the subject’s usual
daily activities
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
59  If the event is an SAE, then all applicable seriousness criteria must be  indicated (criteria listed in  Section 
9.3.3).  
9.4.3.3 Action Ta
ken with Study Drug  
Action taken with Study Drug ( ISIS 681257 or placebo) due to the event is characterized by 1 of the 
following. 
•None:  No changes were made to Study Drug (ISIS  681257 or placebo) administration and dose
•Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily interrupted or
delayed due to the AE and restarted at the same dose
•Temporarily Interrupted, Restarted Reduced Dose:   Dosing was temporarily interrupted or
delayed due to the AE and restarted at the next lower dose
•Permanently Discontinued:   Study Drug was discontinued and not restarted
9.4.3.4 Treatment Given for Adverse Event  
Any treatment (e.g., medications or procedures) given for an  AE should be recorded on the A dverse 
Event Case Report Form .  Treatment  should also be recorded on the concomitant treatment or ancillary 
procedures eCRF , as appropriate . 
9.4.3.5 Outcome of the Adverse Event  
If the event is a non -serious AE, then the event’s outcome is characterized by 1 of the following:  
•Ongoing :  Patient terminates from  the trial and the AE continues
•Recovered:   Patient r ecovered completely from the AE
•Became Serious:   The event became serious (the date that the event became serious should be
recorded as the Resolution Date of that AE and the Onset  Date of the corresponding SAE)
•Change in Severity (if applicable):   AE severity changed
If the event is an SAE , then the event’s outcome is characterized by 1 of the following: 
•Ongoing:   SAE continuing
•Persists (as non -serious AE):   Patient has not fully recovered but the event no longer meets
serious criteria and should be captured as an AE on the non -serious eCRF  (the SAE resolution
date should be entered as the date of onset of that AE)
•Recovered:   Patient recovered completely from the SAE (the date of recovery should be entered
as the SAE resolution da te)
•Fatal:   Patient died (the date of death should be ente red as the SAE resolution date)
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
60  9.5 Procedures for Handling Special Situations  
9.5.1 Abnormalities of Laboratory Tests  
Clinically -significant  abnormal laboratory test results may, in the opinion of the Investigator, constitute or 
be associated with an AE.  Examples of these include abnormal laboratory results that are associated with 
symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, tetany due to hypocalcemia, or 
cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlyin g diagnosis should be listed 
in preference to  abnormal laboratory values as AEs.  Clinically -significant abnormalities will be 
monitored by the Investigator until the parameter returns to its baseline value or until agreement is 
reached between the Investigator and Sponsor Medical Monitor that monitoring is no longer necessary.  Laboratory abnormalities deemed not clinically -significant  (NCS) by the Investigator should not be 
reported as AEs.  Similarly, laboratory abnormalities reported as AEs by the Investigator should not be 
deemed NCS on the laboratory sheet. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The clinical laboratory 
reports will serve as source documents and should include the Investigator’s assessment of clinical 
significance of out of range/abnormal laboratory values and signatures. 
All platelet count results must be reviewed promptly (within 24 hours of receipt) by the Investigator or 
the designee to ensure that the count has not met the stopping rule an d to determine whether the rate of 
decline is suggestive that the patient could be approaching the dose interruption rule of 75,000/mm3 as 
specified in  Section 8.6.3 . 
Any case of  a platelet count  reduction  to level s below 50,000/mm3 (Grade 3 or Grade 4) is considere d an 
adverse e vent of special interest and should be reported in an expedited fashion to the S ponsor as per 
Sections 9.3.3.1 and 9.4.1).  
All r esults of liver function tests must b e reviewed promptly (within 24 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met 
the stopping rules per Section 8.6.1. 
All r esults of renal function tests must b e reviewed promptly (within 24 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met the stopping rules per Section 8.6.2. 
Any event  meeting  renal stopping  rules criteri a described in Section 8.6.2 is considered an a dvers e event 
of special interest and should be reported in an expedited fashion to the Sponsor as per Sections 9.3.3.1 
and 9.4.1).  
9.5.2 Prescheduled or Elect
ive Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, 
even if the patient  is hospitalized; the Study Center must document all of the following:  
•The prescheduled or elective procedure or routinely scheduled treatment was scheduled (or was
on a waiting list to be scheduled) prior to obtaining the patient ’s cons ent to participate in the
study
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
61  •The condition that required the prescheduled or elective procedure or routinely scheduled
treatment was present before and did not worsen or progress in the opinion of the Investigator
between the patient ’s consent to participate in the study and the timin g of the procedure or
treatment .  The condition is documented in the patient’s medical history.
•The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for theintervention or hospital admission
9.5.3 Dosing Errors 
Study Drug ( ISIS 681257 or placebo) errors should be documented as Protocol Deviations.  A brief 
description should be provided in the deviation, including whether the patient was symptomatic (list 
symptoms) or as ymptomatic, and the ev ent was accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form.  If the patient takes a dose of Study 
Drug (I SIS 681257 or placebo) that exceeds protocol specifications and the patient is symptomatic, then 
the symptom(s) should be documented as an A E and be reported per  Section
 9.4. 
Should an o
verdose occur , the Investigator or designee should contact the Sponsor or designee  within 24 
hours. 
9.5.4 Contraception and Pregnancy 
Male a nd female p atients of childbearing potential must continue to use appropriate contraception with 
their partners, or refrain from sexual activity, as described in  Section 6.3.1. 
If a patien
t becomes pregnant or a pregnancy is suspected, or if a male patient makes or believes that he 
has made someone pregnant during the study, then the Study Center staff must be informed immediately .  
An Initial Pregnancy Form should be submitted to the Sponsor  or designee  within 24 hours  of first 
learning of the occurrence of pregnancy.  Follow-up information including delivery or termination is 
reported by designating as ‘Follow-up’ on the Pregnancy F orms and reported within 24 hours of 
occurrence.  
Payment for all aspects of obstetrical care, child or related care will be the patient ’s responsibility . 
Female patients :  If a suspected pregnancy occurs while on the study (including during the f ollow -up 
period), a pregnancy test will be performed .  The patient with a confirmed pregnancy will be immediately 
withdrawn from treatment with Study Drug.  However, the patient will  be encouraged to complete the 
Post- treatment Follow-up portion of the study to the extent that study procedures do not interfere with the 
pregnancy.  Regardless of continued study participation, the Investigator will assist the patient in getting 
obstetrical care and the progress of the pregnancy will be followed until the outcome of the pregnancy is 
known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth 
of a child, the Study Center and Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth .  Follow-up will be performed to the extent permitted by the 
applicable regulations and privacy considerations . 
Male patients:  The progress of the pregnancy of a male patient’s partner should be followed until the 
outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
62  pregnancy results in the birth of a child, the Study Center and Sponsor may request access to the 
mother and infant’s medical records for an additional 8 weeks after birth .  Fol low-up will be 
performed to the extent permitted by the applicable regulations and privacy considerations.  
10. STATISTICAL CONSIDERATIONS
The sections below indicate the overall structure and approach to the analysis of this study.  A detailed 
Statistical Analysis Plan (SAP) incorporating these sections below will be prepared separately .  The SAP 
will outline all data handling conventions, including software, and specify additional statistical methods 
to be used for analysis.  
The study objectives a re listed  in Section 1 . 
10.1 Study E
ndpoints, Subsets, and Covariates  
Efficacy and safety endpoints that will be evaluated after the last patient has completed the primary analysis time point are identified in the following sections. 
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4 -week  
dosing (Cohorts A-C) and at Week 27 for patients who received weekly or biweekly dosing (Cohorts D 
and E).  For patients continuing treatment beyond the primary analysis time point additional supportive 
efficacy and safety analyses will be repeated at the completion of Study Drug treatment . 
10.1.1 Primary Endpoint(s) 
The primary efficacy endpoint is the percent change in Lp(a) from baseline at the primary analysis time 
point achieved by ISIS 681257 compared to pooled placebo. 
Lp(a) levels will be analyzed from patient blood samples taken at specified time points throughout the 
study. 
10.1.2 Secondary E ndpoints  
The secondary endpoints include the following parameters from baseline at the primary analysis time 
point for ISIS 681257 compared to placebo: 
•Percent change from baseline in LDL -C
•Proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL  (≤ 125 nmol/L)
•Proportion of patients who achieve plasma Lp(a) ≤ 30 mg/dL  (≤ 75 nmol/L)
•Percent change from baseline in apoB
•Percent change from baseline in OxPL -apo(a)
•Percent change from baseline in OxPL -apoB
10.1.3 Safety  Endpoints  
The safety analysis will be performed using the following parameters: 
•AEs
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
63  • Vital signs and weight 
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)  
• Proportion of patients with platelet drop by severity, including platelet drop below lower limit of 
normal (LLN), platelet drop greater than 30% from Baseline, or any platelet drop meeting 
stopping rules. 
• Proportion of patients with liver adverse event s by severity, number of patients meeting liver 
stopping rules, and change in liver  function tests  by severity.   
• Proportion of patients with renal adverse events by severity, number of patients meeting renal 
stopping rules, and change in renal function tests by severity. 
• ECGs  
• Use of concomitant medications 
10.1.4 Dose Selection  
Dose selection for the further development will be based on the following efficacy and safety considerations; more than 1 dose may meet these criteria.  An effective dose, or dose regimen, will be one 
that achieves clinically -meaningful reduction in plasma Lp(a) levels.  Safety will be evaluated on the 
basis of incidence of expected and unexpected treatment- related SAEs and other specific safety 
considerations including the incidence of platelet reductions, and renal or hepatic injury.   
10.2 Sample Size Considerations  
Based upon prior clinical trial experience with ISIS 681257, it is estimated that the standard deviation of 
the percent change in Lp(a) is approximately 20% .  With 23 patients in each ISIS  681257 treatment group 
and 23 in placebo group there would be approximately 90% power to detect a 20% difference in percent 
change in Lp(a) levels between the ISIS 681257 treatment groups and placebo group at an alpha level of 
0.05, assuming 30% reduction in the ISIS 681257 patients and 10% reduction in the placebo patients. 
Based upon prior clinical trial experience with Ionis ASOs, a ssuming the incidence rate of platelet count 
below lower limit of normal (LLN) in placebo treated patients is 1.9 %, in the ISIS  681257 treated patients 
is 3.8%, twice the incidence rate observed in placebo,  with 45 patients in each ISIS 681257 treatment 
group, there would be approximately 80% power to detect at least 1 event. 
Therefore, approximately 270 patients (54 patients per cohort, including 45 patie nts per cohort treated 
with ISIS 681257) will be randomized to ensure that both the safety and efficacy of ISIS 681257 will be 
adequately characterized in the study.  
10.3 Analysis Populations 
Full Analysis Set (FAS):  All patients who are randomized, recei ved at least 1 dose of Study Drug 
(ISIS  681257 or placebo), and have a Baseline Lp(a) assessment.  The FAS represents the practically -
feasible intent- to-treat (ITT) population as delineated in ICH Guideline E9.  This population will be used 
for the primary  analysis of efficacy .   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
64  Per Protocol Set (PPS) :  Subset of the FAS who received within 6 months at least 5 monthly doses of 
Study Drug for patients randomized in Cohorts A, B, and C or at least 11 biweekly doses for patients 
randomized in Cohort D or at least 22 weekly doses for patients randomized in Cohort E, and who have 
no major protocol violations that could compromise the interpretation of efficacy .  Major violations will 
be determined prior to unblinding for statistical analysis.  This population will be used for supportive 
inferences concerning efficacy.  
Safety Set :  All patients who are randomized and receive at least 1 dose of Study Drug.  This population 
will be used for all safety analyses.   
PK Population:  All patients who are randomized and received at least 1 dose of Study Drug, and have 
sufficient data for the analysis of PK parameters.  This population will be used for analysis of PK data. 
10.4 Definition of Baseline  
Baseline for Lp(a), LDL -C, apoB, OxPL-apo(a), OxPL-apoB, and other lipid measurements will be 
defined the pre -dose measurement on Day 1 or closest to Day 1, prior to administration of Study Drug.  
The baseline for other measurements is defined as the last non-missing assessment prior to the first dose 
of Study Drug. 
10.5 Interim Analysis  
No interim efficacy analysis will be performed . 
10.6 Planned Methods of Analysis  
Summary tabulations will be provided for disposition, demographic, baseline, efficacy, and safety data as 
noted in the following sections .  Hypothesis testing will be used for the primary efficacy endpoint and 
select secondary efficacy endpoints. 
All eCRF data, lab data transfers, and any outcomes derived from the data will be provided in the pa tient 
data listings.  Patient data listings will be presented for all patients enrolled into the study .  Descriptive 
summary statistics including n, mean, median, standard deviation, standard error, interquartile range (25th 
percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data.  Where appropriate, p -values 
will be reported .  All statistical tests will be conducted using 2 -sided tests with  5% Type I error rate 
unless otherwise stated.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by treatment group.  The patient disposition will be summarized by treatment group.  All patients enrolled will be included in a summary of patient disposition.  
10.6.2 Safety Analysis  
10.6.2.1 Adverse Events  
Treatment duration and amount of Study Drug (ISIS 681257 or placebo) received will be summarized by treatment group.  Pa tient incidence rates of all AEs will be tabulated by MedDRA system organ class, and 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol  25 January 2018  
65  by MedDRA preferred term .  Narratives of treatment -emergent  deaths, serious and significant AE s, 
including early withdrawals due to AEs, will also be provided. 
All treatment- emergent  AEs, all treatment- emergent  AEs potentially related to Study Drug, all treatment -
emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to Study Drug 
(ISIS  681257 or placebo) will be summarized. 
10.6.2.2 Clinica l Laboratory Data 
Laboratory tests to ensure patient safety including chemistry panel, complete blood count (CBC) with 
differential, coagulation panel, complement, etc., will be summarized by study visits for each treatment 
group.  These safety variables will also be presented as change and percent change from baseline over 
time after Study Drug (ISIS  681257 or placebo) administration, as appropriate.  In addition, the number of 
patients who experience abnormalities in clinical laboratory evaluations will be summarized by treatment 
group. 
10.6.2.3 Vital Signs and Examinations 
Vital sign and ECG measures will be tabulated by treatment group .   
10.6.3 Efficacy Analysis  
10.6.3.1 Analysis of Primary Efficacy Endpoint  
The primary analysis of the primary endpoint will be the pairwise comparis on of percent change from 
baselin e to primary analy sis ti me poi nt in fasting  Lp(a) between ISIS 681257 treatment groups and pooled 
placebo gr oup in the FAS.  The data will be analyzed using  an analysis of covarian ce (ANCOVA) model 
with the B aseline L p(a) as a covariate.  Missing data may be handled by LOCF or multiple imputation 
methods (
Schafer 1997; Schafer 1999). 
The pri mary
 efficacy analysis will take place after the last patient has completed the primary analysis time 
point, and the database has been locked,  
The following sensitivity analyses will be conducted:  
•The primary analysis will be repeated in the PPS
•The primary efficacy endpoint will be analyzed using a Wilcoxon Rank Sum test on both FAS
and PPS, and the treatment effect will be estimated using Ho dges-Lehmann estimator
Additional sensitivity analyses may be conducted as appropriate; the details of these analys es will be 
outlined in the SAP. 
10.6.3.2 Analysis of Secondary Efficacy Endpoints 
•Percent change from baseline at  the primary analysis time point in fasting LDL -C will be
compared between each ISIS  681257 treatment groups and pooled placebo group using an
ANCOVA model with baseline as covariate
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
66  • Proportion of patients who achieve ≤ 50 mg/dL (≤  125 nmol/L) in fasting Lp(a) at the primary 
analysis time point will be compared between each ISIS 681257 treatment group and pooled 
placebo group using a logistic regression model with Baseline Lp(a) as a covariate.  Proportion of 
patients who achieve ≤ 30 mg/dL (≤ 75 nmol/L) in fasting Lp(a) at the primary analysis time 
point will be analyzed similarly  
• Percent change from baseline at  the primary analysis t ime point in fasting apoB, OxPL-apo(a) 
and OxPL- apoB will be compared between ISIS 681257 treatment groups and pooled placebo 
group using an ANCOVA model with baseline as covariate  
All analyses of secondary endpoints will be performed on the FAS as primary and PPS as supportive. 
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
For all patients, trough and post- treatment concentrations of ISIS  681257 in plasma (as total full length 
oligonucleotides, including fully conjugated, partially conjugated, and unconjugated ISIS 681257) will be 
determined and summarized by treatment with stratification by subject immunogenicity status using descriptive statistics . 
In addition, non-compartmental PK  analysis of ISIS  681257 concentrations will be carried out on each 
individual patient data set in patients who received ISIS 681257 treatment , and the plasma disposition 
half- life (t
1/2λz) associated with the apparent terminal elimination phase will be ca lculated, if appropriate, 
using available data at the End-of-T reatment and the post-t reatment follow -up period from the equation, 
t1/2λz = 0.693 /λz, where λz is the rate constant associated with the apparent terminal elimination phase . 
For patients in the PK subgroup only, non- compartmental PK analysis of ISIS 681257 will be carried out 
on each individual patient data set in patients who received ISIS 681257 treatment .  The maximum 
observed drug concentration (C max) and the time taken to reach C max (T max) will be obtained directly from 
the concentration- time data .  Following single dosing (Day 1), area under the plasma concentration- time 
curve from time zero (pre -dose) to 24 hours after the dose (AUC 0-24hr) will be calculated using the linear 
trapezoidal rule .  Following multiple dosing, AUC 0-24hr and area under the plasma concentration -time 
curve during the time of each sampled dosing interval (tau,τ) at steady- state (AUC τ) will be calculated 
using the linear trapezoidal rule. 
Other PK parameters, as approp riate, may be determined or calculated at the discretion of the PK 
scientist .  Plasma PK parameters will be summarized using descriptive statistics with stratification by 
subject immunogenicity status .  Exposure -response relationships between selected PD [e.g., Lp(a)] and 
PK measures (including but may not be limited to plasma trough concentrations) may be explored 
(including with and without stratification by IM status) in this study, or in a separate population PK 
analysis with all clinical studies combin ed. 
The immunogenicity (IM) of ISIS 681257 will be assessed before, during, and after treatment with Study Drug  (ISIS 681257 or placebo).  The IM incidence (number) and incidence rate (percent) will be 
summarized at each evaluated study time point and at the patient level by treatment and dose, as the total number of and percent of evaluated patients with antibody negative, positive, and unknown status.  Study 
patients with positive anti-ISIS 681257 antibody status may be further classified (when applicable ) as 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
67  being either ‘persistent’, ‘transient’, or not determinable.  Potential relationships of immunogenicity with 
selected efficacy, safety, and PK measures may be evaluated.  
Additional details regarding the PK  and immunogenicity analysis will be described  in the S AP. 
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by the Sponsor or designee. 
Before a patient ’s participation in the trial, the Investigator is responsible for obtaining written informed 
consent from the patient  or legally acceptable representative after adequate explanation of the aims, 
methods, anticipated benefits, and potential hazards of the study and before any protocol- specific 
screening procedures or any Study Drug ISIS 681257 or placebo) are administered . 
Importantly, patients should be informed of the possibility and risks of a reduction in platelet count and other potential risks , in particular  hepatic and renal risks , and the importance of strict adherence to the 
monitoring program.  The patient  or legally acceptable representative must be given sufficient time to 
consider whether to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her primary care 
physician should be documented in the patient’s medical records and the informed consent form should 
be signed and personally dated by the patient  or a legally acceptable representative and by the person who 
conducted the informed consent discussion (not necessarily an Investigator ).  The original signed 
informed consent form should be retained in the Study Master File and in any other locations required by institutional policy, and a copy of the signed consent form should be provided to the patient  or legally 
acceptable representative. 
11.2 Ethical Conduct of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October  2013 
the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well as the demands 
of national drug and data protection laws and other applicable regulatory requirements will be strictly 
followed. 
11.3 Independent Ethics Committee  (IEC) /Institutional Review Board  (IRB)  
A copy of the protocol, proposed informed consent form s, other written patient  information, and any 
proposed advertising material must be submitted to the IEC/IRB for written approval.  A copy of the 
written  approval of the protocol and informed consent form must be received by the Sponsor or designee 
before recruitment of patient s into the study and shipment of Study Drug.  A copy of the written approval 
of any other items/materials that must be approved by the Study Center  or IEC/IRB must also be received 
by the Sponsor or designee before recruitment of patient s into the study and shipment of Study Drug.  The 
Investigator’s Brochure must be submitted to the IEC/IRB for acknowledgement. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
68  The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB, for all 
subsequent protocol amendments and changes to the informed consent document.  The Investigator 
should also notify the IEC/IRB of SAEs  occurring at the Study Center and other AE  reports received from 
the Sponsor or designee, in accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout the 
duration of the study in accordance with local procedures.   
11.4 Patient  Confidentiality  
The Investigator and Sponsor must ensure that the patient ’s confidentiality is maintained .  On the case 
report forms or other documents submitted to the Sponsor or designee, patient s should be identified by 
initials (if permitted by local law) and a patient identification  number only.  Documents that are not for 
submission to the Sponsor or designee (e.g., signed informed consent forms) should be kept in strict 
confidence by the I nvestigator.  
In compliance with Federal and local r egulations/ICH GCP Guidelines, it is required that the I nvestigator 
and institution permit authorized representatives of the com pany, of the r egulatory agency(s), and the 
IEC/IRB direct access to review the patient ’s original medical records for verification of study -related 
procedures and data.  Direct access includes examining, analyzing, verifying, and reproducing any 
records an d reports that are important to the evaluation of the study.  The Investigator is obligated to 
inform and obtain the consent of the patient  to permit named representatives to have access to his/her 
study- related records without violating the confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1 Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee.  Agreement from the Investigator must be obtained for all protocol amendments and amendments to the informed consent document.  The regulatory authority and IEC/IRB must be informed of all amendments and give 
approval for any amendments likely to affect the safety of the patients or the conduct of the trial .  The 
Investigator  must send a copy of the approval letter from the IEC/IRB to the Sponsor or designee. 
12.2 Study Termination  
The Sponsor or designee reserves the right to terminate the study.  The Investigator reserves the right to 
terminate their participation in the study, accordi ng to the terms of the site contract .  The 
Investigator/Sponsor or designee should notify the IEC/IRB in writing of the trial’s completion or ET .  
An Investigator who terminates participate is required to send a copy of the IEC/IRB notification to the Sponsor or designee. 
12.3 Study Documentation and Storage  
Source documents are original documents, data, and records from which the patient ’s case report form 
data are obtained .  These include but are not limited to hospital records, clinical and office charts, 
laboratory and pharmacy records, diaries, imaging , and correspondence.  In this study, eCRF  may not be 
used as source documents.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
69  The Investigator and S tudy Center staff are responsible for maintaining a comprehensive and centralized 
filing system o f all study- related (essential) documentation  in accordance with Section 8  of the ICH 
Guidelines (E6) , suitable for inspection at any time by representatives from the Sponsor or designee 
and/or applicable r egulatory authorities .  Elements should include:  
• Patient  files containing completed case report forms, informed consents, and supporting copies of 
source documentation 
• Study files containing the protocol with all amendments, Investigator’s Brochure, copies of pre-
study documentation and all correspondenc e to and from the IEC/IRB  and the Sponsor or 
designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug Product Accountability Record, Return of Study Drug Product for Destruction, final Study Drug product 
reconciliation, and all drug -related correspondence 
In addition, all original source documents supporting entries in the case report forms must be maintained and be readily available for the duration required by GCP or local regulatory requirements, whichever is longer. 
No study document should be destroyed without prior written agreement between the Sponsor or designee 
and the Investigator.  Should the Investigator wish to assign the study records to another party or move 
them to another location, he/she must notify the Sponsor or designee, in accordance with GCP . 
12.4 Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and visiting 
the Investigator for the purpose of inspecting the facilities and, upon request, insp ecting the various 
records of the trial (e.g., case report forms and other pertinent data) provided that patient  confidentiality is 
respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular intervals 
throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the 
data; and adherence to local regulations on the conduct of clinical research .  The monitor should have 
access to patient medical records and other study- related records needed to verify the entries on the case 
report forms .  Source data should be attributable, legible, contemporaneous, original, and accurate 
(ALCOA) and must meet the regulatory requirements for recordkeeping.  
The Investigator agrees to cooperate  with the monitor to ensure that any problems detected in the course 
of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit by 
representatives from the Sponsor’s Clinical Quality Assurance Department (or designees) .  Inspection of 
Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study -related 
records will occur to evaluate the trial condu ct and compliance with the protocol, ICH GCP, and 
applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data 
received by the Sponsor  or designee.  During this review, patie nt data will be checked for consistency, 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
70  omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the 
protocol and GCP.  To resolve any questions arising from the clinical data management review process, 
data quer ies and/or Study Center  notifications will be sent to the Study Center for completion and return 
to Sponsor or design ee. 
The Principal Investigator will sign and date the indicated places on the case report form .  These 
signatures will indicate that the Principal Investigator inspected or reviewed the data on the case report 
form, the data queries, and the Study Center notifications, and agrees with the content  in accordance with 
the general investigational plan . 
12.5 Language 
Case report forms must be completed in English.  Whenever possible, the trade name rather than the 
generic name for concomitant medications should be recorded and if possible, in English.  Generic names 
are acceptable if the trade name is unknown .  Combination medications should be recorded using their 
trade name in English if possible.  
All written information and other material to be used by patients and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow applicable local 
compensation laws.  Patient s will be treated and/or compensated for any study- related illness/injury in 
accordance with the information provided in the Compensation for Injury section of the Informed Consent 
document. 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
71  13. REFERENCES  
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Bennett CF. Pharmacological properties of 2ʹ -O-methoxyethyl -modified olig onucleotides . In: Crooke ST, editor . 
Antisense Drug Technology: Principles, Strategies and Applications, 2nd Edition . Boca Raton, FL . Taylor & Francis 
Group 2008; 365- 400. 
Bergmark C, Dewan A , Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized 
phospholipids in human plasma . J Lipid Res 2008; 49: 2230- 2239.  
Bertoia ML, Pai JK, Lee J -H, et al. Oxidation -specific biomarkers and risk of peripheral artery dis ease. J Am Coll 
Cardiol 2013; 61(21): 2169- 2179.  
Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium . Genetic variants associated with Lp(a) 
lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518- 2528.  
Desai NR, Kohli P, Giugliano RP , et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin 
kexin type 9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: an 
analysis from the LAPLACE -TIMI 57 Trial. Circ 2013; 128:  962-9 69. 
Dubé JB, Boffa MB, Hegele RA, Koschinsky ML . Lipoprotein(a): more interesting than ever after 50 years . Curr 
Opin Lipidol 2012; 23(2): 133 -140. 
Erqou S, Kaptog e S, Perry PL, et al; Emerging R isk Factors Collaboration . Lipoprotein(a) concentration and t he risk 
of coronary heart disease, stroke, and nonvascular mortality . JAMA 2009; 302(4): 412- 423. 
Erqou S, Thompson A, Di Angelantonio E, et al. Apoliporotein(a) isoforms and the risk of vascular disease . JACC 
2010; 55(19): 2160- 2167.  
Frazer KA, Narla G, Z hang JL, Rubin E . The apolipoprotein(a) gene is regulated by sex hormones and acute -phase 
inducers in YAC transgenic mice . Nat Gen 1995; 9: 424- 431. 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma 
lipoprotein (a) levels in humans. J Lipid Research 2016; 57: 340- 351. 
Guyton JR . Niacin in cardiovascular prevention: mechanisms, efficacy, and safety . Curr Opin Lipidol 2007; 18: 
415-420. 
Henry S, Stecker K, Brooks D, et al. Chemically  modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292(2): 468- 479. 
Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to 
reduce high lipoprotei n(a) levels and major adverse coronary events . Nat Clin Pract Cardiovasc Med 2009; 6(3): 
229-239. 
Kamstrup PR, Tybjaerg -Hansen A, Steffensen R, Nordestgaard BG . Genetically elevated lipoprotein(a) and 
increased risk of myocardial infarction . JAMA 2009; 301(22): 2331- 2339.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
72  Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein -associated phospholipase A2 
activity, and 10 -year cardiovascular outcomes: prospective results from the Bruneck study . Arterioscler Thromb 
Vasc Biol 20 07; 27: 1788- 1795.  
Koschinsky ML and Marcovina SM . Structure -function relationships in apolipoprotein(a): insights into 
lipoprotein(a) assembly and pathogenicity . Curr Opin Lipidol 2004; 15(2): 167- 174. 
Kronenberg F and Utermann G . Lipoprotein(a): resurrec ted by genetics . J Intern Med 2013; 273: 6- 30. 
Leebmann J, Roeseler E, Julius U, et al; Pro(a)LiFe Study Group . Lipoprotein apheresis in patients with maximally 
tolerated lipid -lowering therapy, lipoprotein(a) -hyperlipoproteinemia, and progressive cardiova scular disease: 
Prospective observational multicenter study . Circ 2013; 128: 2567- 2576.  
Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and 
lipoprotein(a) . J Lipid Res 2013; 54: 2815- 2830.  
Li Y, Luke MM, Shiffman D, Devlin JJ . Genetic variants in the apolipoprotein(a) gene and coronary heart disease.  
Circ Cardiovasc Genet 2011; 4(5): 565- 573. 
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem 1999; 274: 1715- 1722.  
Merki E, Graham M, Taleb A,  et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) in 
transgenic mice. JACC 2011; 57(15): 1611- 1621.  
Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel . Lipoprotein(a) as 
a cardiovascular risk factor: current status . Euro Heart J 2010; 31: 2844- 2853.  
Parker K, Brunton L, Goodman LS, et al. Goodman & Gilman's the pharmacological basis of therapeutics . New 
York, NY. McGraw -Hill. 2006; ISBN 0- 07-142280- 142283.  
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using 
triantennary N-acetyl galactosamine improves potency 1 0-fold in mice . Nucleic Acids Res 2014; 42: 8796- 8807.  
Prakash TP, Yu J, Migawa MT, et al. Comprehensive structure -activity relationship of triantennary N-Acetyl 
galactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes . J Med Chem 2016 
Mar 24; 59(6): 2718- 2733.  
Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of 
primary immune thrombocytopenia. Blood 2010; 115: 168- 186. 
Raal FJ, Honarpour  N, Blom  DJ, et al. Inhibition of  PCSK9 with evolucomab in homozygous familial 
hypercholesterolemia (TESLA Part B): a randomized, double blind, placebo controlled trial. Lancet 2015; 385: 341-350. 
Rand ML, Sangrar W, Hancock MA, et al. Apoliprotein(a) enhances platelet responses to the th rombin receptor – 
activating peptide SFLLRN . Arterio Thromb Vasc Biol 1998; 18: 1393- 1399.  
Rosada A, Kassner U, Vogt A, et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) 
levels reduce the incidence of cardiovascular even ts? Artif Organs 2014; 38: 135- 141. 
Safarova M . Specific lipoprotein(a) apheresis reduces atherosclerosis progression . 80th Congress of the European 
Atherosclerosis Society, Milan, Italy 28 May 2012.  
Schafer JL . Analysis of Incomplete Multivariate Data, New York: Chapman and Hall 1997.  
Schafer JL . Multiple imputation: a primer, Statistical Methods in Medical Research 1999; 8: 3 –15. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
73  Schulman S and Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medical products in non -surgical patients. J Thromb Haemost 2005; 3(4): 692- 694. 
Spence JD and Koschinsky M . Mechanisms of lipoprot ein(a) pathogenicity . Arterioscler Thromb Vasc Biol 2012; 
32: 1550- 1551.  
Stockert RJ . The asialoglycoprotein receptor: relationships between structure, function, and expression . Physiol  Rev 
1995; 75: 591- 609. 
Thanassoulis G, Campbell CY, Owens DS, et al; C HARGE Extracoronary Calcium Working Group . Genetic 
associations with valvular calcification and aortic stenosis . N Engl J Med 2013; 368(6): 503- 512. 
Thygesen K, Alpert JS, Jaffe AS , et al. Third universal definition of myocardial infarction.  Circ 2012;  126: 
2020- 2035.  
Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation -specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal 
coronary events . J Am Coll Cardiol 2010; 56: 946- 955. 
Tsimikas S, Willeit P, Willeit J, et al. Oxidation -specific biomarkers,  prospective 15- year cardiovascular and stroke 
outcomes, and net reclassification of cardiovascular events . J Am Coll Cardiol 2012; 60: 2218- 2229.  
Tsimikas S, Duff GW, Berger PB, et al. Pro-inflammatory interleukin -1 genotypes potentiate the risk of corona ry 
artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a) . J Am Coll Cardiol 
2014; 63: 1724- 1734.  
Yu RZ, Kim TW, Hong A, et al. Cross- species pharmacokinetic comparison from mouse to man of a second -
generation antise nse oligonucleotide, ISIS 301012, targeting human apolipoprotein B -100.  Drug Metab Dispos 
2007; 35: 460- 468.  
Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway Factor XI by antisense oligonucleotides: a novel antithr ombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684- 4692.  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
74  14. APPENDICES   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6 
Protocol   25 January 2018  
 
75   
 
 
 
 
 
 
Appendix A  Schedule of Procedures 
 
Schedule of Procedures for Week ly and Every 2 -Week Dosing Cohorts 
Schedule of Procedures for Every 4 -Week Dosing Cohorts  
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
76  Appendix A  Schedule of Procedures – Weekly and Every 2- Week Dosing  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27p 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post  Treatment 
Period  
Visit and Testing Window  +/- Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                      
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                     
Medical History  c X                      
Vital Signs  X X  X X X X X X X   X X X X X X X X X X 
Physical Examination  X X  X  X  X  X    X  X  X X X X X 
Body Weight and Height  d X         X      X      X 
12- lead ECG (triplicate)  X X  X  X  X  X    X  X  X X X X X 
24-Hour Urine for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i X X X 
Genetic Testing (optional)   X  
Chemistry Panel j,k X EVERY 14 DAYS f X X X X   X X X X X X X X X X 
Hematology   j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh  Xh  
Platelet Function   X  X X X X X X X   X X X X X X X X X X 
Coagulation  X X        X             
Hepatitis B, C, HIV  X                      
Thyroid Panel  X                      
hsCRP   X        X         X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X X3 X1 X2 X  X    X X X X 
ISIS 681257 Antibodies   X  X X X    X         X   X 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol  25 January 2018  
77  Appendix A  Schedule of Procedures – Weekly and Every 2- Week Dosing  Continued  
Screen  Treatmen t Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27p 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post Treatment
Period  
Visit  and Testing  Window +/ - Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if applicable)  j, m X 
Serum Pregnancy Test m X X X X X X X X X X X X X X X X X X 
Archived Serum & Plasma 
Samples  j, n X X X X X X X X X X 
PD Panel j X X X X X X X X X X X X X X X 
Lipid Panel j X X X X X X X X X X X X X X X 
Lp(a) Characterization  X 
Study Drug:  SC Injection  WEEKLY SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG  (Week 1 through Week 52/Day 358)o
EVERY 2 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 through Week 5 1/Day 351)o
Adverse Events  X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which is the day of first Study Drug  dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in  Appendix B  under Extended Urinalysis should be performed, including routine urinalysis, urine microscopy, UACR and UPCR.  
f Assessments and procedures to be conducted by either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 week s apart  during the treatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, h ematology samplin g for platelet v alues and urine renal biomarker samples are taken every  14 days for 6 weeks post treatment 
period , then at Week 10 and Week 16 Follow -up visits .  
i Serum C
reatinine and Cys -C will be collected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone samples at time 
points when a chemistry panel is not performed.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol  25 January 2018  
78  Appendix A  Schedule of Procedures – Weekly and Every 2 Week Dosing Continued  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis  or quantity not sufficient) a repeat blood  
specimen should be re-drawn as soon as possibl e (ideally  withi n 7 days).  All  platelet c ount results will  be reviewed promptly (within 24 hours of receipt) by  the 
Investigator as per Section 6.2.1.  Any case of a platelet c ount < 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
l Refer t
o Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post-menopausal. 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement o f antibodies, etc.) and will be retained until completion of the final 
study report . 
oPatients will continue treatment in the study for 12 months, or until the last patient reaches 6 months of exposure.  When this milestone  is met, all patients still
on treatment will have an End of Treatment visit, then enter a 16-week post -treatment follow -up period.  
p     For the last patient to reach 6 months of exposure ONLY , the Week 27 visit will count as the End of Treatment Visit, therefore all Week 53/ET assessments 
will be included in this visit . No dose will be administered at this visit.  
Time (time 
is in reference to Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8 hours post SC injection 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
79  Appendix A  Schedule of Procedures – Every 4- Week Dosing  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25p 26 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day  -28 to -1  1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post  Treatment 
Period  
Visit and Testing Window  +/- Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                       
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                      
Medical History  c X                       
Vital Signs  X X  X X X X X X     X X X X X X X X X X 
Physical Examination  X X  X  X  X X      X  X  X X X X X 
Body Weight and Height  d X        X        X      X 
12- lead ECG (triplicate)  X X  X  X  X X      X  X  X X X X X 
24-hour Urine  for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i X X X 
Genetic Testing (optional)   X   
Chemistry Panel  j, k X EVERY 14 DAYS f X X X     X X X X X X X X X X 
Hematology  j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh Xh 
Platelet Function   X  X X X X X X     X X X X X X X X X X 
Coagulation  X X       X               
Hepatitis B, C, HIV  X                       
Thyroid Panel  X                       
hsCRP   X 
      X  
         X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X3 X1 X2 X X X  X    X X X X 
ISIS 681257 Antibodies   X  X X X   X           X   X 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol  25 January 2018  
80  Appendix A  Schedule of Procedures – Every 4-Week Dosing Continued  
Screen  Treatmen t Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25p 26 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post Treatment
Period  
Visit and Testing Window +/ - Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if 
applicable) j, m X 
Serum Pregnancy Test m X X X X X X X X X X X X X X X X X X 
Archived Serum & Plasma 
Samples j, n X X X X X X X X X X X 
PD Panel j X X X X X X X X X X X X X X X X 
Lipid Panel j X X X X X X X X X X X X X X X X X 
Lp(a) Characterization  X 
Study Drug:  SC Injection  EVERY 4 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 through Week 49/Day 337)o 
Adverse Events  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which is the day of first Study Drug dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in  Appendix B  under Extended Urinalysis should be performed, including routine urinalysis, urine microscopy, UACR and UPCR.  
f Ass essments and procedures to be conducted by either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 weeks apart during the t reatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, h ematology samplin g for platelet v alues and urine renal biomarker samples are taken every  14 days for 6 weeks post treatment 
period , then at Week 10 and Week 16 Follow -up visits.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol  25 January 2018  
81  Appendix A  Schedule of Procedures – Every 4-Week Dosing Continued  
i Serum Creatinine and Cys -C will be collected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone samples at time 
points when a chemistry panel is not performed.  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quantity not sufficient) a repeat blood 
specimen should be re-drawn as s oon as possible (ideally withi n 7 days).  All platelet c ount results will be reviewed promptly (within 24 hours  of receipt) by the 
Investigator as per Section 6.2.1.  Any case of a platelet c ount < 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
l Refer t
o Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal. 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.)  and will be retained until completion of the final 
study report. 
oPatients will continue treatment in the study for 12 months, or until the last patient reaches 6 months of exposure.   When  this milestone is  met, all patients still
on treatment will have an End of Treatment visit,  then enter a 16-week post-treatment follow -up period.  
p    For the last patient to reach 6 months of exposure ONLY, the Week 25 visit will count as the End of Treatment Visit, therefore all Week 53/ET assessments will 
be included in this visit. No dose will be administered at this visit. 
Time (time is in reference to Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8, hrs post SC injection  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
82   
 
 
 
 
  
Appendix B  L ist of L aboratory Analytes 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
83  Appendix B  List of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be performed on 
stored samples to better characterize the profile of ISIS  681257 or other similar oligonucleotides. 
Clinical Chemistry 
Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect 
(unconjugated) bilirubin  
• ALT  
• AST  
• ALP  
• Creatinine kinase 
• GGT  
• Cys-C 
 Screening Tests  
• Hepatitis B surface 
antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG (women only)  
• TSH  
• Free T4  
• Free T3  
 
Coagulation  
• aPTT  
• PT 
• INR 
• Fibrinogen  
• Plasminogen  
 
PD Panel  
• Lp(a)  
• OxPL -apoB  
• OxPL -apo(a)  
 
Lipid Panel  
• Total Cholesterol  
• LDL cholesterol  
• HDL cholesterol  
• ApoB  
• Triglycerides  
• VLDL  Lp(a) Characterization  
• Apo(a) isoforms  
 
Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC  
• Platelets  
• White blood cells  (WBC)  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 681257 (total full 
length ASO) levels in 
plasma  
 
Immunogenicity  
• Anti-ISIS 681257 
antibodies  
 
Genetic Testing 
• LPA SNPs associated with elevated Lp(a)   
 Inflammatory  
• hs-CRP  
 
Extended Urinalysis 
• Routine Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Blood 
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio  (UPCR) 
• A/C Ratio  (UACR) 
 
Renal Urine 
Biomarkers2 
• NGAL   
• NAG  
• KIM -1 
• Cys-C 
 
24 Hour Urine Test3 
• Creatinine clearance 
• Protein  
• Albumin  
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments, or to assess other actions of ISIS  681257 with plasma 
constituents  
2 All samples will be collected, handled and stored under the conditions specified for the assays. Please refer to 
the study Laboratory Manual for details on the appropriate handling and storage methods for biomarker and 
other samples.   
3 To be performed during Screening upon confirmation of eligibility   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
84   
 
 
 
 
  
 
Appendix C PK Sampling Schedule  
 
Sampling Schedule for Weekly and Every 2 -Week Dosing Cohorts  
Sampling Schedule for Every 4-Week Dosing Cohorts  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January  2018  
 
85  Appendix C  PK Sampling Schedule  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected prior to dosing, and at various times throughout the 
dosing and post-t reatment follow-up period as noted in the tables below .  Plasm a PK samples may also be used for profiling of drug binding 
proteins, bioanalytical method validation purposes, stability and metabolite assessments, immunogenicity testing (or possibly for purposes of 
immunogenicity assay development and/or validation), or to assess other actions of ISIS  681257 with plasma constituents.  Extensive PK samples 
will be collected in PK subgroup only (12 subjects per cohort) (see tables below):  
Sampling Schedule for Weekly and Every 2 -Week  Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 27 29 37 53/ET 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 183 184 185 197 253 365 *Post Treatment Period  
All 
Patients Pre-
dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group 
Only  Pre-
dose, 1, 2, 4, 
& 8-hr1 24-hr2 Pre-
dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose, 1, 2, 4, 
& 8-hr
1 24-hr2 48-hr3 Pre-
dose  Pre-dose   
Anytime  Anytime  Anytime  Anytime  
1 Window of (-) 2 hrs  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January  2018  
 
86  Appendix C  PK Sampling Schedule Continued  
Sampling Schedule for Every 4-Week Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 26 27 29 37 53/ET 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 170 171 176 183 197 253 365 *Post Treatment Period   
All 
Patients Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose , NA NA NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group 
only Pre-
dose , 
1, 2, 
4, 
and 
8-hr1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose , 
1, 2, 4, and 
8-hr
1 24-hr2 48-hr3 Anytime  Anytime  Pre-dose  Pre-dose   
Anytime  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hours allowed  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours allowed  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours allowed  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
87   
 
 
 
 
  
Appendix D  Grading Scale for Adverse Events Relating to 
Laboratory Abnormalities  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
88  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
The following grading recommendations for adverse events relating to lab test abnormalities are based 
upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. 
 
  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
89  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities Continued  
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
90  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities Continued  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
91   
 
 
 
 
  
Appendix E  Additional Laboratory Tests for Patients with 
Platelet Count ˂ 100,000/mm3 
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 6  
Protocol   25 January 2018  
 
92  Appendix E  Laboratory Tests to Be Performed in the Event of a Platelet Count ˂ 100,000/mm3* 
*Labs only need to be performed once.  Labs may be collected over multiple visits, if blood requirements 
are a concern, as per Investigator discreti on 
Note:  The following labs may change as additional data is assessed, and sites will be updated regarding 
any changes.  
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Fibrinogen  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
von Willebrand factor (vWF) Antigen  
Helicobacter pylori  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
Platelet Antibody Bead Array (PABA) 
 
  
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 Collaborator: 
Akcea Therapeutics  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 
 
IONIS  PHARMACEUTICALS,  INC. 
 
ISIS 681257-CS6 
 
 
A Randomized, Double- blind, P lacebo-Controlled, D ose-Ranging 
Phase 2  Study of ISIS 681257 A dministered Subcutaneously to 
Patients with H yperlipoproteinemia(a) and Established 
Cardiovascular Disease ( CVD) 
 
Protocol  Amendment 5 – 30 May 2017 
 
 
EudraCT No:  2016-003373-18 
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
4  Protocol Signature Page 
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose- Ranging Phase 2 
Study of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment:  Amendment 5 
Date:  30 May 2017  
 
I hereby acknowledge that I have read and understand the attached clinical protocol , entitled “ A 
Randomized, Double-blind, Placebo-C ontrolled, Dose -Ranging Phase 2 Study of ISIS 681257 
Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD) ,” dated 30 May 2017, and agree to conduct the study as described 
herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Ionis Pharmaceut icals, Inc .   
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENTS  ................................................................................................... 9  
PROTOCOL SUMMARY OF CHANGES  .............................................................................. 10  
PROTOCOL SYNOPSIS  ........................................................................................................... 12  
STUDY DESIGN AND TREATMENT SCHEMA  .................................................................. 18  
STUDY GLOSSARY .................................................................................................................. 19  
1. OBJECTIVES  ................................................................................................................. 23  
1.1 Primary Ob jective  ..........................................................................................................23  
1.2 Secondary Objective(s)  ..................................................................................................23  
2. BACKGROUND AND RATIO NALE  .......................................................................... 23  
2.1 Overview of Disease  ......................................................................................................23  
2.1.1  Lipoprotein (a) ........................................................................................................23  
2.1.2  Pathophysiology .....................................................................................................25  
2.1.3  Current Treatment Options .....................................................................................25  
2.2 Therapeutic Rationale  ....................................................................................................26  
2.3 ISIS 681257 ...................................................................................................................26  
2.3.1  Mechanism of Action  .............................................................................................26  
2.3.2  Chemistry  ...............................................................................................................27  
2.3.3  Preclinical Experience  ............................................................................................27  
2.3.4  Clinical Experience ................................................................................................28  
2.4 Rationale for Dose and Schedule of Administration .....................................................29  
3. EXPERIMENTAL PLAN .............................................................................................. 30  
3.1 Study Design  ..................................................................................................................30  
3.2 Number of Study Centers ..............................................................................................31  
3.3 Number of Patients ........................................................................................................31  
3.4 Overall Study Duration and Follow-up .........................................................................31  
3.4.1  Screening  ................................................................................................................31  
3.4.2  Treatment  ................................................................................................................31  
3.4.3  Post- Treatment  .......................................................................................................31  
3.5 End-of-Study ..................................................................................................................31  
3.6 Data and  Safety Monitoring Board ................................................................................32  
4. PATIENT ENROLLMENT ........................................................................................... 32  
4.1 Screening  .......................................................................................................................32  
4.2 Randomization ...............................................................................................................32  
4.3 Replacement of Patients  .................................................................................................33  
4.4 Unblinding of Treatment Assignment ...........................................................................33  
5. PATIENT ELIGIBILITY  .............................................................................................. 33  
5.1 Inclusion Criteria  ...........................................................................................................33  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
6  5.2 Exclusion Criteria  ..........................................................................................................34  
6. STUDY PROCEDURES  ................................................................................................ 35  
6.1 Study Schedule ..............................................................................................................35  
6.1.1  Screening  ................................................................................................................36  
6.1.2  Treatment Period  ....................................................................................................36  
6.1.3  Post- Treatment Period  ............................................................................................36  
6.2 Additional Study Assessments  .......................................................................................37  
6.2.1  Laboratory Assessments  .........................................................................................37  
6.2.2  Physical Exams and Vital Signs  .............................................................................38  
6.2.3  Electrocardiography  ...............................................................................................38  
6.2.4  PK Sampling  ...........................................................................................................38  
6.3 Restriction on the Lifestyle of Patients  ..........................................................................39  
6.3.1  Contraception Requirements ..................................................................................39  
6.3.2  Other Requirements  ................................................................................................40  
7. STUDY DRUG  ................................................................................................................ 40  
7.1 Study Drug  Description  .................................................................................................40  
7.1.1  ISIS 681257 ............................................................................................................40  
7.1.2  Placebo  ...................................................................................................................40  
7.2 Packaging and Labeling  .................................................................................................40  
7.3 Study Drug Accountability ............................................................................................40  
8. TREATMENT OF PATIENTS ..................................................................................... 41  
8.1 Study Drug Administration  ............................................................................................41  
8.2 Other Protocol- Required Drugs  .....................................................................................42  
8.3 Other Protocol- Required Treatment Procedures  ............................................................42  
8.4 Treatment Precautions  ...................................................................................................42  
8.5 Safety Monitoring Rules ................................................................................................42  
8.5.1  Safety Monitoring Rules for Liver Chemistry Tests  ..............................................43  
8.5.2  Safety Monitoring for Renal Function ...................................................................44  
8.5.3  Safety Monitoring for Platelet Count Results  ........................................................45  
8.5.4  Safety Monitoring for Minor Bleeding Events .......................................................46  
8.5.5  Safety Monitoring for Constitutional Symptoms ...................................................46  
8.6 Stopping Rules ...............................................................................................................46  
8.6.1  Stopping Rules for Liver Chemistry Elevations .....................................................46  
8.6.2  Stopping Rules for Renal Function Test R esults  ....................................................47  
8.6.3  Stopping Rule for Platelet Count Results ...............................................................47  
8.7 Adjustment of Dose .......................................................................................................50  
8.8 Discontinuation of Study Drug ......................................................................................50  
8.8.1  Follow- up Visits for Early Termination from Treatment Period or from 
Post- Treatment Follow -up Period ..........................................................................50  
8.9 Withdrawal of Patients from the Study  ..........................................................................50  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
7  8.10  Concomitant Therapy and Procedures ...........................................................................51  
8.10.1  Concomitant Therapy .............................................................................................51  
8.10.2  Concomitant Procedures .........................................................................................52  
8.11  Treatment Compliance  ...................................................................................................52  
8.12  Safety Monitoring Compliance  ......................................................................................52  
9. SERIOUS AND NON- SERIOUS ADVERSE  EVENT REPORTING  ...................... 53  
9.1 Sponsor Review of Safety Information .........................................................................53  
9.2 Regulatory Requirements  ..............................................................................................53  
9.3 Definitions  .....................................................................................................................53  
9.3.1  Advers e Event  ........................................................................................................53  
9.3.2  Adverse Reaction and Unexpected Adverse Reaction  ...........................................54  
9.3.3  Serious Adverse Event (SAE) ................................................................................54  
9.3.3.1  Adverse Events of Special Interest  ..................................................................54  
9.4 Monitoring and Recording Adverse Events ...................................................................54  
9.4.1  Serious Adverse Events/Adverse Events of Special Interest  .................................55  
9.4.2  Non-Serious Adverse Events ..................................................................................55  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................55  
9.4.3.1  Relationship to the Study Drug ........................................................................55  
9.4.3.2  Severity  ............................................................................................................56  
9.4.3.3  Action Taken with Study Drug ........................................................................56  
9.4.3.4  Treatment Given for Adverse Event  ................................................................56  
9.4.3.5  Outcome of the Adverse Event ........................................................................56  
9.5 Procedures for Handling Special Situations ..................................................................57  
9.5.1  Abnormalities of Laboratory Tests .........................................................................57  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............58  
9.5.3  Dosing Errors .........................................................................................................58  
9.5.4  Contraception and Pregnancy .................................................................................58  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 59  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................59  
10.1.1  Primary Endpoint(s) ...............................................................................................59  
10.1.2  Secondary Endpoints ..............................................................................................60  
10.1.3  Safety Endpoints  .....................................................................................................60  
10.1.4  Dose Selection  ........................................................................................................60  
10.2  Sample Size Considerations ...........................................................................................61  
10.3  Analysis Populations ......................................................................................................61  
10.4  Definition of Baseline  ....................................................................................................61  
10.5  Interim Analysis  .............................................................................................................61  
10.6  Planned Methods of Analysis ........................................................................................62  
10.6.1  Demographic and Baseline Characteristics  ............................................................62  
10.6.2  Safety Analysis  .......................................................................................................62  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
8  10.6.2.1  Adverse Events  ................................................................................................62  
10.6.2.2  Clinical Laboratory Data ..................................................................................62  
10.6.2.3  Vital Signs and Examinations  ..........................................................................62  
10.6.3  Efficacy Analysis  ...................................................................................................63  
10.6.3.1  Analysis of Primary Efficacy Endpoint ...........................................................63  
10.6.3.2  Analysis of Secondary Efficacy Endpoints......................................................63  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................63  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. 64  
11.1  Informed Consent ..........................................................................................................64  
11.2  Ethical Conduct of the Study .........................................................................................65  
11.3  Independent Ethics Committee (IEC)/Institutional Review Board (IRB)  .....................65  
11.4  Patient Confidentiality  ...................................................................................................65  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ................................................ 66  
12.1  Protocol Amendments ....................................................................................................66  
12.2  Study Termination  .........................................................................................................66  
12.3  Study Documentation and Storage ................................................................................66  
12.4  Study Monitoring ...........................................................................................................67  
12.5  Language  ........................................................................................................................67  
12.6  Compensation for Injury ................................................................................................67  
13. REFERENCES  ................................................................................................................ 68  
14. APPENDICES  ................................................................................................................. 71  
Appendix A  Schedule of Procedures ....................................................................................72  
Appendix B  List of Laboratory Analytes  .............................................................................79  
Appendix C  PK Sampling Schedule ....................................................................................81  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......84  
Appendix E  Additional Laboratory Tests for Patients with Platelet Count  
˂ 100,000/mm3 .................................................................................................88  
 
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 40 
Table 2  Study Drug Dosing Information  ........................................................................... 42 
Table 3  Actions in Patients with Low Platelet Count  ........................................................ 49 
 
TABLE OF FIGURES 
Page 
Figure 1  Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of 
apo(a) Covalently Bound to apoB..........................................................................24   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
9  PROTOCOL AMENDMENT S 
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose- Ranging 
Phase 2 Study of ISIS 681257 Administered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment Number:  5 
Amendment Date:  30 May 2017 
 
The following table summarizes the history and nature of amendments to the protocol ISIS 681257- CS6. 
None of the antecedent versions of the study protocol has been enacted clinically and therefore no patients have been enrolled prior to issuance of Amendment 5. 
Protocol Version  Date  Rationale for Amendments  
Original Protocol  15 August 2016   
Amendment 1  6 October 2016  Regulatory advice on inclusion of more 
detailed description of processes for platelet monitoring, and more frequent monitoring of liver function.  
Amendment 2  29 November 2016  Regulatory advice on inclusion of biomarkers of renal damage and increased frequency of renal monitoring.   Addition of a 
DSMB.  
Amendment 3  30 December 2016  Adjustment of the frequency, and alert and intervention limits, for renal safety and adjustment of the frequency of liver safety testing.   
Amendment 4  5 January  2017  The study population was increased to 270 patients (54 per cohort) to support a 
statistical assessment of risk of platelet reduction in this population.  In addition, the 
10 mg weekly treatment cohort has been 
modified to 20 mg every 2 weeks 
(biweekly ). 
Amendment 5  30 May  2017 Regulatory advice on addition of exclusion 
criteria, reduced permitted timeframe for identifying critical laboratory results by the 
investigator and replacement of the AE definition.   In addition,  Section 8.6.2 was 
edited for consistency.  
  
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
10  PROTOCOL SUMMARY OF CHANGES 
 
Protocol Number:  ISIS 681257-CS6 
Protocol Title:  A Randomized, Double-blind, Plac ebo-Controlled, Dose-Ranging 
Phase 2 Study of ISIS 681257 Admi nistered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD) 
Amendment Number:  5 
Amendment Date:  30 May 2017 
 
The following modifications to Protocol IS IS 681257-CS6 Amendment 4 have been made. 
Minor changes (not included in the list of changes below) have been made throughout the protocol to correct errors and/or to improve the overall clarity of  the original protocol but these 
changes do not impact subject safety, exposure, or the overall study design.  
The following table provides a summary list of major changes to the Amendment 4 of the 
protocol: 
Protocol Section Description of Change Rationale 
Protocol Synopsis 
(Exclusion Criteria), 
5.2 
Exclusion Criteria Addition of new exclusion criteria, placed at Exclusion 
Number 12 and 13, and shifting 
subsequent exclusion criteria to 
sequentially increased number.   Adding exclusion criteria to exclude 
patients with known allergic or 
pseudo allergic drug reactions and 
those with hypersensitivity to the 
active drug substance. 
Protocol Synopsis 
(Efficacy Evaluations), 
10.1.2 
Secondary Endpoints, 
10.6.3.2 
Analysis of Secondary Efficacy Endpoints Provided Lp(a) values in 
additional alternate unit of measure Laboratories will measure and report Lp(a) values in either mg/dL or nmol/L, so both units will be 
provided in protocol for clarity.  
Efficacy data will be provided only in 
nmol/L. 
6.2.1 
Laboratory Assessments 
8.5.1 
Safety Monitoring Rules for Liver 
Chemistry Tests, 
8.5.2 
Safety Monitoring fo r Renal Function, 
8.5.3 Safety Monitoring for Platelet Count 
Results Revision of window allowed for 
review of key safety laboratory results to within 24 hours by 
Investigator or designee. To ensure more timely review of key 
safety laboratory results while patients are on Study Drug. 
 
 
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
11  Protocol Section Description of Change Rationale 
6.2.1 
Laboratory Assessments, 
9.3.3.1 
Adverse Events of Special Interest Adding additional AE of special 
interest – when patient meets renal stopping rules. To enhance importance of strict monitoring of renal function. 
6.3.1 Contraception Requirements To clarify acceptable use of contraception methods. Clarification. 
8.5.2 Safety Monitoring fo r Renal Function, 
8.5.3 
Safety Monitoring for Platelet Count Results, 
8.8.1 
Follow-up Visits for Early Termination 
from Treatment Period or from 
Post-Treatment Follow-up Period Addition of text to clarify frequency and timing of 
assessments and platelet 
monitoring and urine renal 
biomarkers in post Treatment 
Follow-up period to be consistent 
with the landmark study visits 
after Study Drug dosing has 
ended. Clarification of time points for 
platelet monitoring post last Study Drug dose. 
8.6.2 
Stopping Rules for Renal Function Test 
Results Addition of urine culture and 
urine microscopic sample 
inspection to follow-up testing for 
renal stopping rules Additional laboratory tests added for analysis of renal function to match 
follow-up testing for renal monitoring 
and stopping rules. 
8.8.1 Follow-up Visits for Early Termination 
from Treatment Period or from 
Post-Treatment Follow-up Period Clarification for timing of final visit assessment for treatment 
period and final visit for follow-up 
period for patients who 
discontinue early from treatment 
or during the po st-treatment 
follow-up period. Clarification. 
9.3.2 Adverse Reaction and Unexpected Adverse Reaction Correction of definition of Adverse Drug Reaction and adding definition of Unexpected 
Adverse Reaction. Clarification of definition to be 
consistent with ICH. 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
12  PROTOCOL SYNOPSIS  
Protocol Title A Randomized, Double -blind, Placebo-C ontrolled, Dose-R anging Phase 2 Study of 
ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and 
Established Cardiovascular Disease (CVD)   
Study Phase  2 
Indication  Patients with hyperlipoproteinemia(a) and established CVD. 
Investigational Drug  ISIS 681257 is a second generation 2ʹ -MOE modified, GalNAc 3–conjugated antisense 
oligonucleotide inhibitor of apolipoprotein (a) [ apo(a) ]. 
Primary Objective  To evaluate the safety , including tolerability , of ISIS 681257 and to assess the efficacy  of 
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels 
in patients with hyperlipoproteinemia(a) and established CVD.  
Secondary Objective(s)  To evaluate the efficacy of ISIS 681257 on plasma levels of low density lipoprotein 
cholesterol (LDL -C), apolipoprotein B 100 (apoB), oxidized phospholipids ( OxPL ) on 
apo(a)  [OxPL -apo(a)] , and OxPL  on apoB  (OxPL -apoB) . 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose 
regimens in patient s with hyperlipoproteinemia(a) and established CVD.  
Study Design  This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.  Approximately 270 patients will be randomized in a 5:1 ratio to receive ISIS  681257 or 
placebo.  This number was chosen to provide statistical power for both efficacy and safety assessments.  Study Drug (ISIS  681257 or placebo) will be administered SC 
every week, every 2 weeks , or every 4 weeks, depending on cohort assignment,  for up 
to 52 weekly doses, up to 26 every 2-week doses , or up to 13 every 4 -week doses.  
Minimum treatment duration is 6 months.  Maximum treatment duration is 12 months.  
The treatment portion of the study will be complete when the last enrolled patient reaches 6 months of exposure.  All patients will then enter a 16-week post -treatment 
follow -up period.  
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4-week dosing (Cohorts A -C) and at Week 27 for patients who received 
every 2 -week or weekly dosing (Cohorts D and E, respectively).  For patients continuing 
treatment beyond the primary analysis time point additional supportive efficacy and safety analyses will be repeated at the completion of Study Drug treatm ent. 
An independent Data and Safety Monitoring Board (DSMB) will be established to review safety, tolerability and efficacy (as needed) data collected on ISIS  681257 during this 
study, both individual events and aggregate data.   
Number of Subjects  Approximately 270 
Study Population Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements  
2. Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent  
3. Clinical diagnosis of CVD defined as documented coronary artery disease, strok e, 
or peripheral artery disease  
4. Lp(a) plasma level ≥ 60 mg/dL  
5. Must be on standard- of-care preventative therapy for other than elevated Lp(a) 
CVD risk factors  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
13  PROTOCOL SYNOPSIS Continued  
Study Population 
Continued  Inclusion Criteria  
6. Patients on the following medications must be on a stable regimen for at least 
4 weeks prior to Screening and expected to remain on a stable regimen through the 
end of the post -treatment follow -up p eriod:  
a. Lipid lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing omega-3 fatty  acids including OTC 
preparations)  
b. Antiplatelet drugs  
c. Testosterone, estrogens, progesterone, growth hormone or progestins  
7. Females:  must be non-pregnant and non -lactating and either;  
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy);  
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in 
females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and  FSH le vels 
in the postmenopausal range for the laboratory involved);  
c. Abstinent* or,  
d. if engaged in sexual relations of child- bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to Section 6.3.1 ) from the time of signing 
the informed consent form until at least 16 weeks after the last dose of Study 
Drug  (ISIS 681257 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
8. Males must be surgically sterile or, if engaged in sexual relations with a female of 
child-bearing potential, the patient must be using an acceptable contraceptive 
method (refer to Section 6.3.1) from the time of signing the informed consent form 
until at least 16 weeks after the last dose of ISIS 681257  
Exclusion Criteria  
1. Within 6 months of Screening:   acute coronary syndrome, major cardiac surgery , or 
stroke /transient ischemic attack   
2. Within 3 months of Screening:   coronary , carotid,  or peripheral arterial 
revascularization, major non- cardiac surgery, or lipoprotein apheresis   
3. Heart failure NYHA class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)  
5. History of acute kidney injury  within 12 months of S creening  
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1 
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis  C or chronic hepatitis B  
 
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
14  PROTOCOL SYNOPSIS Continued 
Study Population 
Continued  Exclusion Criteria 
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin 
or carcinoma in situ  of the cervix that has been successfully treated 
10. Patients with a history of major blee d or high-risk of bleeding diathesis  
11. Recent history of, or current drug or alcohol abuse  
12. Known history or presence of systemic al lergic or pseudoallergic (drug) reactions  
13. Hypersensitivity to the active subs tance or to any of the excipients 
14. Clinically-significant abnormalities in screening laboratory values that would render 
a patient unsuitable for inclusion, including the following: 
a. Urine protein/creat inine ratio (UPCR) ≥ 0.25 mg/mg.  In the event of a UPCR 
above this threshold, eligibility may be confirmed by a quantitative total urine 
protein measurement of ˂ 300 mg/24-hr 
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.  In the event of a UACR 
above this threshold, eligibility may be confirmed by a quantitative total urine 
albumin measurement of ˂ 150 mg/24-hr 
c. Estimated GFR ˂ 60 mL/min as determined by the Chronic Kidney Disease-
Epidemiological Collaboration (CKD-EPI) Equation for creatinine clearance 
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  
> 2.0 x ULN 
e. Bilirubin > ULN, unless prior diagn osis and documentation of Gilbert’s 
syndrome in which case total bilirubin must be ≤ 3 mg/dL 
f. Alkaline phosphatase (ALP) > ULN  
g. Platelet count ˂ LLN 
15. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors 16. Treatment with another investigational drug, biological agent, or device within 
1 month of Screening, or 5 half-lives of investigational agent, whichever is longer 
17. Treatment with any non-Ionis oligonucleoti de (including small interfering ribonucleic 
acid [siRNA]) at any time or prior treatm ent with an Ionis oligonucleotide or siRNA 
within 9 months of screening.  Patients that  have previously received only 1 dose of 
an Ionis oligonucleotide as part of a c linical study may be included as long as 
≥ 4 months has elapsed since dosing 
18. BMI > 40 kg/m
2  
19. Blood donation of 50-499 mL within 30 days of screening or of > 499 mL within 
8 weeks of Screening 
20. Unwillingness to comply with study procedures, including follow-up, as specified by 
this protocol, or unwillingness to cooperate fully with the Investigator 
21. Have any other conditions, which, in t he opinion of the Investigator or Sponsor 
would make the patient unsuitable for inclus ion, or could interf ere with the patient 
participating in or completing the Study 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
15  PROTOCOL SYNOPSIS C ontinued  
Treatment Groups  Patients will be randomized to 5 parallel cohorts:  
Cohort A (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort B (n = 54):  Patients will be randomized 5:1 to receive 40 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort C (n = 54):  Patients will be randomized 5:1 to receive 60 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort D (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every 2 weeks for up to 26 doses.  
Cohort E (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every week for up to 52 doses.  
Cohort  Treatment  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 or placebo 
(Every 4 weeks)  ≤ 13 ≤ 260 mg  
B 40 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 or placebo  
(Every 2 weeks)  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 or placebo  
(Every week) ≤ 52 ≤ 1040 mg  
 
Study Drug  Dosage 
and Administration  The Sponsor will provide ISIS 681257 in a concentration of 100 mg/mL and matching volume placebo:  
Cohort A:  20 mg every 4 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort B:  40 mg every 4 weeks ISIS 681257 or placebo (0.4 mL)  
Cohort C:  60 mg every 4 weeks ISIS 681257 or placebo (0.6 mL)  
Cohort D:  20 mg every 2 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort E:  20 mg every week ISIS 681257 or placebo (0.2 mL)  
All doses will be given by SC injection.  Self -administration will be allowed after 
appropriate training of patient and/or caregiver.  
Rationale for Dose and Schedule Selection  The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given 
weekly that were found to be generally well -tolerated and to induce clinically -relevant 
reductions in Lp(a).  The range of dosing proposed for the present study will provide the equivalent drug exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and 
is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in 
mean reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% at steady -state.   
The highest dose selected for this study, 20 mg per week, is predicted to provide an 
approximately 85% reduction in Lp(a) at steady -state that is expected to be sufficient to 
bring almost all patients with hyperlipoproteinemia(a) into the normal range 
(Lp(a)  ≤ 30 mg/dL).  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
16  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and 
Schedule Selection  
Continued  The present study will also evaluate safety and efficacy at different dosing frequencies:   every 4  weeks, every 2 weeks, and weekly.   Patients with  
hyperlipoproteinemia(a) will require chronic treatment and thus every 2 weeks or every 4 weeks dosing regimens, if safe and well -tolerated, may provide advantages over 
weekly dosing in terms of convenien ce and compliance for patients.  Dosing regimens of 
20 mg every 2 weeks and 40 mg every 4 weeks will test if similar monthly exposure, at different frequencies of administration, will achieve similar safety and similar level of Lp(a) reduction since the reduction achieved by a given dose level is principally driven 
by total exposure, while individual dose levels and the related peak concentration (C
max) 
may influence tolerance and safety.  
Adjustment of Dose 
and/or Treatment Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose frequency may be allowed for safety or tolerability after  consultation with the Sponsor Medical 
Monitor . 
Study Visit Schedule and Procedures  Detailed information regarding the study procedures are outlined in Section 6 , 
Appendi ces A  and C. 
All patients enrolled will be randomized to a minimum of 6 months of treatment in 1 of 5 treatment cohorts.  On completion of the 6 months, patients may continue treatment 
within the same randomized cohort until the last enrolled patient reaches 6 months of exposure (for continuing safety assessments), with a maximal exposure period of 
12 months.   
The study for an individual patient will generally consist of the following periods:   
• An up to 4-week s creening period  
• An up to 52-week t reatment period during which Study Drug will be 
administered per assigned cohort by SC injection  
• A 16-week post -treatment follow -up p eriod  
Patients in Cohorts A through C will receive up to 13 SC doses of ISIS  681257 or 
placebo every 4 weeks.  Patients in Cohort D will receive up to 26 SC doses of ISIS 681257 or placebo every 2 weeks and patients in Cohort E will receive up to 52 SC 
doses of ISIS 681257 or placebo weekly .  Patients will return regularly for outpatient 
visits throughout the treatment and post -treatment follow -up periods according to the 
Schedule of Procedures (Appendix A).   
Blood and urine samples will be collected regularly throughout the study for safety, 
efficacy, and PK analysis.  Appendix B  shows a list of analytes required for the study 
and Appendix C details the PK sample schedules.  
Safety and Tolerability 
Evaluations  Safety and tolerability assessments include:  adverse events, vital signs and weight, physical examinations, clinical laboratory tests, ECGs and use of concomitant 
medications.  Safety and tolerability results in patients dosed with ISIS 681257 will be 
comp ared with those dosed with placebo.  
Efficacy Evaluations  The primary analysis time point is at Week 25 for patients who received every 4-week dosing (Cohorts A -C) and at Week 27 for patients who received every 2 -week or weekly 
dosing (Cohorts  D and E) . 
The primary endpoint is the percent change in plasma Lp(a) from baseline at the primary analysis time point for ISIS 681257 treatment groups compared to placebo. 
The secondary endpoints comprise the effect of ISIS 681257 as compared to placebo at 
the primary analysis time point on the following:  
• Percent change from baseline in LDL-C 
• Proportion of patients who achieve plasma Lp(a) ≤  50 mg/dL (≤  125 nmol/L)  
• Proportion of patients who achieve plasma Lp(a) ≤  30 mg/dL (≤  75 nmol/L)  
• Percent change from baseline i n apoB  
• Percent change from baseline in OxPL-apo(a)  
• Percent change from baseline in OxPL -apoB  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
17  PROTOCOL SYNOPSIS Continued  
Pharmacokinetic 
Evaluations  Plasma samples will be taken from all patients for the measurement of ISIS 681257 plasma trough levels  throu ghout treatment and during the p ost-treatment follow -up 
period .  In addition, in a subset of patients (approximately 12 patients per cohort), more 
frequent plasma samples will be taken following the first and D ay 169 (for Cohorts A , B, 
and C) or Day 183 (for Cohorts D and E)  dose to determine PK parameters .  Plasma 
sample collection time points are detailed in Appendi ces A and C. 
The plasma ISIS 681257 levels over time will be descriptively summarized by treatment with stratification by subject immunogenicity status .  Apparent terminal elimination 
half-life will be calculated in patients who received ISIS 681257 treatment using a 
non-compartmental method, if data permitted.  In addition, C
max, Tmax, and AUC values 
will be calculated for the PK subgroup .  PK parameters will be descriptively summarized 
by treatment with stratification by subject immunogenicity status.  
Statistical Considerations  The primary efficacy analysis for the primary endpoint will be the pairwise comparison of 
percent change from baseline to the primary analysis time point in fasting Lp(a) between 
ISIS 681257 treated group s and placebo group in the Full Analysis Set.  
The data will be analyzed using an ANCOVA model with the baseline Lp(a) level as a covariate. 
Dose selection for the further development will be based on the following efficacy and 
safety considerations; more than 1 dose may meet these criteria.  An effective dose, or 
dose regimen, will be one that achieves a  clinically -meaningful  reduc tion in plasma Lp(a) 
levels .  Safety will be evaluated on the basis of incidence of expected and unexpected 
treatment -related SAEs , and other specific safety considerations including the incidence 
of platelet reductions . 
Sample Size Considerations:  
Efficac y: 
Based upon prior clinical trial experience with ISIS  681257, it is estimated that the 
standard deviation of the percent change in Lp(a) is approximately 20%.  With 23 patients in each ISIS 681257 treatment group and 23 in placebo group there would 
be approximately 90% power to detect a 20% difference in percent change in Lp(a) 
levels between the ISIS 681257 treatment groups and placebo group at an alpha level of 
0.05, assuming 30% reduction in the ISIS 681257 patients and 10% reduction in the placebo pat ients.  
Safety:  
Based upon prior clinical trial experience with ISIS  ASOs, assuming the incidence rate of 
platelet count below lower limit of normal (LLN) in placebo treated patients is 1.9%, in the ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, with 45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to detect at least 1 event.  
A total of approximately 270 patients (54 patients per cohort, including 45 patients per cohort treated with ISIS 681257) will be randomized to ensure that both the safety and efficacy of ISIS 681257 will be adequately characterized in the study.  
Sponsor/Collaborator  Ionis Pharmaceuticals/Akcea Therapeutics  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
18  STUDY DESIGN AND TREATMENT SCHEMA  
 
SCREENING PERIOD  
Weeks -4 to -1 
TREATMENT PERIOD  
Weeks 1 to 52*  
Dosing per assigned cohort:  
Cohorts A, B, and C:  Every 4 weeks SC 
administration of 20, 40, or 60 mg ISIS 681257 or 
placebo  
Cohort D:  Every 2 weeks SC administration of 
20 mg ISIS 681257 or placebo  
Cohort E:  Every week SC administration of 20 mg 
ISIS 681257 or placebo  
Routine safety assessments :  PK and PD/efficacy 
assessments at specified time points  
*Treatment portion of the study will be complete 
when the last enrolled patient reaches 6 months of  
exposure.  
POST -TREATMENT 
EVALUATIONS  
Weeks 4, 10, and 16 after last dose of 
Study Drug  
3 clinical visits for safety, efficacy,  
PK and PD assessments  
EARLY 
TERMINATION 
(ET) 
Follow Week 53 Schedule 
of Procedures at ET;  
Patient strongly 
encouraged to v isit clinic 
for post -treatment 
assessments  
END- OF-STUDY 
PROCEDURES  
Early Termination or 3rd 
Follow -Up visit (16 Weeks 
after last dose of Study Drug)  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
19  STUDY GLOSSARY 
Abbreviation Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ALP  alkaline phosphatase 
ALT  alanine aminotransferase (SGPT)  
ANCOVA  analysis of covariance  
ANA  antinuclear antibody  
apo(a) apolipoprotein(a) 
apoB apolipoprotein B 
aPTT  activated partial thromboplastin time  
ASGPR  asialoglycoprotein receptor  
ASO antisense oligonucleotide 
AST  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time zero to 
time t 
βhCG  beta-subunit of human chorionic gonadotropin (pregnancy test) 
BP blood pressure 
BUN  blood urea nitrogen  
C centigrade  
C5a complement factor C5a (activated complement split product)  
CAD coronary artery disease  
Cmax maximum concentration  
CBC  complete blood count 
CKD- EPI Chronic Kidney Disease –Epidemiological Collaboration  
CMV  cytomegalovirus 
CRF  case report form  
CRP  C-reactive protein  
CVD cardiovascular disease  
CT computed tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
20  STUDY GLOSSARY Continued  
Abbreviation Definition  
Cys C  Cystatin C  
dL deciliter  
DNA  phosphorothioate-modified oligodeoxynucleotides 
DSMB  Data and Safety Monitoring Board 
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
ET early termination  
FAS full analysis set  
FSH follicle -stimulating hormone 
GalNAc 3 triantennary N -acetyl galactosamine  
GCP  Good C linical P ractice  
GFR  glomerular filtration rate  
HAV  hepatitis A virus  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV hepatitis C virus  
HIV human immunodeficiency virus 
hr, hrs hour(s) 
hsCRP  CRP measured by high  sensitivity assay  
ICH International Conference on Harmonization 
IEC Independent Ethics Committee 
IgM immunoglobulin M 
IL-1β interleukin -1 beta 
INR international normalized ratio  
IRB Institutional Review Board  
ISIS 681257 antisense inhibitor of apolipoprotein (a) 
IV intravenous(ly) 
IXRS  interactive voice/internet response system  
KIM -1 kidney injury molecule 1 
kg kilogram 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
21  STUDY GLOSSARY Continued  
Abbreviation Definition  
L liter 
m2 square meter  
MCH  mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration 
MCV  mean corpuscular volume 
mg milligram 
MI myocardial infarction  
min minute  
mL milliliter  
mm millimeter  
mRNA messenger ribonucleic acid  
NAG  N-acetyl -β D-glucosaminidase  
NCS  not clinically -significant 
NGAL  neutrophil gelatinase- associated lipocalin  
NSAID  non-steroidal anti- inflammatory drug  
NYHA  New York Heart Association  
OxPL  oxidized phospholipids 
PAD peripheral arterial disease 
PBS phosphate buffered saline 
PCSK9  proprotein convertase subtilisin/kexin type 9  
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s) 
PLA 2 Lp(a) -associated Lp -phospholipase A 2 
PPS per protocol set 
PT prothrombin time 
RBC  red blood cells 
RNase H 1 an ubiquitous endonuclease that specifically hydrolyzes the RNA 
strand in RNA/DNA hybrids  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
siRNA small interfering ribonucleic acid  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
22  STUDY GLOSSARY Continued  
Abbreviation Definition  
SC subcutaneous(ly) 
Study Drug  ISIS 681257 or placebo 
SUSAR  suspected unexpected serious adverse reaction  
Tg transgenic 
Tmax time to maximal concentration  
UACR  urine albumin - creatinine ratio  
ULN  upper limit of normal 
UPCR  urine protein- creatinine ratio  
WBC  white blood cell 
WMA  World Medical Association  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
23  1. OBJECTIVES  
1.1 Primary Objective  
To evaluate the safety , including tolerability, of ISIS 681257 and to assess the efficacy of 
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in 
patients with hyperlipoproteinemia(a) and established cardiovascular disease ( CVD). 
1.2 Secondary Objective(s)  
To evaluate the efficacy  of ISIS 681257 on plasma levels of low density lipoprotein cholesterol  
(LDL-C), apolipoprotein B (apoB), oxidized phospholipids ( OxPL ) on apolipoprotein (a) 
[apo(a)] [ OxPL -apo(a) ] and OxPL  on apoB  (OxPL -apoB). 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose regimens in in patients with hyperlipoproteinemia(a) and established CVD. 
2. BACKGROUND AND RATI ONALE  
2.1 Overview of D isease  
2.1.1 Lipoprotein (a) 
Lipoprotein(a) [ Lp(a) ] is an atherogenic lipoprotein ( Figure 1, Koschinsky and Marcovina 2004) 
in which the apoB component of LDL is linked by a disulfide bond to apolipoprotein(a) [apo(a)], 
the distinct protein component of Lp(a) that is mainly responsible for its signature structural and functional properties ( Dubé et al. 2012; Kronenberg and Utermann  2013 ).  Lp(a) is now 
recognized as an independent, genetic, causal risk factor for coronary artery disease (CAD), stroke, peripheral arterial disease (PAD),  and calcific aortic stenosis ( Erquo et al. 2009; 
Nordestgaard et al. 2010; Thanassoulis et al. 2013 ). 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
24   
Figure 1 Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of apo(a) 
Covalently Bound to apoB 
Apo(a) contains 10 unique units of kringle IV repeats, of which KIV2 ar e present in variable copies (1 to  > 40) 
conferring structural heterogeneity to Lp(a).  Apo(a) also contains kringle V and an inactive protease -like (P) 
domain.  In this model, 4 KIV2 repeats are shown.  Lp(a) also contains OxPL in the lipid phase of apoB as 
well as covalently bound to apo(a).  
 
Plasma levels of Lp(a) vary substantially among individuals, and most of this variation reflects 
the effects of genetic variation in the LPA gene which encodes the apo(a) protein . 
A second contributor to plasma- level variability are LPA single nucleotide polymorphisms 
(SNPs) that can be associated with either higher or lower Lp(a) levels ( Clarke et al. 2009; 
Li et al. 2011 ).  Significant associations exist between 2 particular LPA variants, rs10455872 and 
rs3798220, increased Lp(a) levels, CVD, and aortic stenosis, with the CVD risk primarily 
mediated by Lp(a) plasma levels rather than an independent effect of the SNPs (Clarke et al. 2009; Li  et al. 2011). 
Lp(a) plasma levels are generally inversely associated with apo(a) size, and can vary by > 1,000-fold (0.1 to > 250 mg/dL or ˂  0.25 to > 625 nmol/L) between individuals 
(Merki  et al. 2011).  Despite this inter -individual variation, intra- individual Lp(a) levels are 
thought to be generally stable over time along a pre- set genetically determined levels without 
significant impact from dietary or environmental factors, mediating CVD risk throughout the patient’s lifetime.  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
25  2.1.2 Pathophysiology 
Lp(a) adheres to plaque sites and is retained in the artery wall  and has proatherogenic and 
pro-inflammatory properties due to its LDL and apo(a) components  
(Spence and Koschinsky 2012).  In addition, Lp(a) may be prothrombotic by inhibiting 
fibrinolysis because of its structural similarity  to plasminogen and its enhancement of platelet 
aggregation ( Rand  et al. 1998).  In vitro  studies have provided evidence for both of these 
pathogenic mechanisms, but in  vivo  data are not definitive  (Dubé et al. 2012).  In humans, Lp(a) 
is the main lipoprotein c arrier of OxPL, which may drive the risk associated with  Lp(a) 
(Bergmark et al. 2008; Leibundgut et al. 2013; Tsimikas et al. 2014).  In fact, OxPL measured on 
apoB (OxPL-apoB), which largely reflect the OxPL on Lp(a), have been shown to be a 
prognostic indicator for future CV  events  (Tsimikas et al. 2010; Tsimikas et al. 2012; 
Tsimikas  et al. 2014).  OxPL associated with Lp(a) can be subjected to degradation by the 
Lp(a) -associated Lp -phospholipase A 2 (PLA 2), implicating Lp(a) in novel proinflammatory and 
atherogenic pathway s (Kiechl et al. 2007). 
Hyperlipoproteinemia (a) in humans is  associated with increased risk of cardiac death, 
myocardial infar ction  (MI) , stroke, aortic stenosis, and peripheral arterial disease (PAD), 
particularly in subjects with small apo(a) isoforms ( Bennet t 2008; Erqou et al. 2009; 
Erqou et  al. 2010;  Bertoia et al. 2013; Thanassoulis et al. 2013).  Although prospective, 
randomized, controlled outcomes studies have not been conducted, epidemiological, genome -
wide association and Mendelian randomized controlled study data to date provide supporting evidence for a role of Lp(a) as a risk factor for CVD  (Kamstrup  et al. 2009).  For example, in the 
Copenhagen City Heart Studies of 42,000 subjects with a 15- year follow -up 
(Kamstrup  et al. 2009) using a Mendelian randomization approach, higher Lp(a) levels were 
related to risk of MI. 
2.1.3 Current Treatment  Options 
In 2010, the European Atherosclerosis Society (EAS) Consensus Panel recommended screening 
for elevated Lp(a) in people at moderate to high risk of CVD to reach a treatment goal of ˂ 50 mg/dL (125 nmol/L), after therapeutic management of LDL- C (Nordestgaard  et al. 2010).  
Approximately 20% of people are estimated to have plasma Lp(a) levels over 50 mg/dL 
(125 nmol/L) and approximately 0.3% to have levels over 175 mg/dL (438 nmol/L) .  There are 
no gender differences in Lp(a) concentrations but racial differences have been observed, with whites and Asians having lower levels while blacks and Hispanics generally have somewhat higher levels (Nordestgaard et al. 2010).  
Lifestyle and diet are  thought to have little impact on an individual’ s Lp(a) level .  Current 
treatment recommendations from the EAS Consensus Panel are limited to the use of 1 to 3 g of niacin (nicotinic acid) daily which could result in an up to 30% reduction in Lp(a).  However, niacin is associated with side effects (e.g., flushing) that reduce patient tolerability and 
compliance ( Parker et al. 2006; Guyton 2007). 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are neither indicated nor formally recommended for treatment of hyperlipoproteinemia(a) but have been reported to reduce Lp(a) levels by  ~20%-35% in patients with hypercholesterolemia ( Desai et al . 2013; 
Raal et al . 2015).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
26  The other current option for patients with signif icantly elevated Lp(a) levels ( ≥ 60 mg/dL) is 
lipoprotein apheresis, either general lipoprotein apheresis ( Jaeger et al. 2009;  
Leebmann  et al. 2013; Rosada et al. 2014) or Lp(a)- specific apheresis ( Safarova 2012).  While 
very effective at acutely lowering  Lp(a) (acute and interval Lp(a) reductions of > 60% and 
> 30% respectively), this treatment option is expensive, burdensome for patients, and 
unavailable/not reimbursed in many countries and regions. 
2.2 T herapeutic Rationale 
Therapeutic modalities to reduce Lp(a) levels in humans are few, and there are no drugs 
currently available that specifically target Lp(a) alone.  Antisense oligonucleotides (ASOs) are emerging as viable therapeutic agents to treat disorders where overexpression of proteins is associated with a disease process .  Apo(a) is synthesized primarily in the liver , a target organ for 
ASOs, where it is subsequently covalently linked to the apoB-100 component of LDL to form the Lp(a) lipoprotein.  The goal of treatment with ISIS  681257 is to reduce the production of 
apo(a) in the liver and thus, the level of Lp(a) lipoprotein by using an ASO directed against the messenger ribonucleic acid (mRNA) of apo(a).  It has been hypothesized that a pharmacologic 
reduction in Lp(a) could slow down or reverse CVD  by reducing thrombotic, atherogenic, or 
inflammatory events in patients with elevated Lp(a) levels ( Nordes tgaard et al. 2010).  
Importantly, there is no evidence that lowering Lp(a) will result in adverse consequences in individuals, and there are no reports linking very low Lp(a) to any deleterious effects. 
2.3 ISIS  681257 
Please refer to the ISIS 681257 Investigator’s Brochure for more details on ISIS 681257 
mechanism of action, chemistry, pre- clinical and clinical experience.  The summary is provided 
below. 
2.3.1 Mechanism of Action  
ISIS 681257 is a second -generation ASO drug targeted to apo(a) that has been covalently bonded 
to triantennary N -acetyl galactosamine (GalNAc
3), a high-affinity ligand for the 
hepatocyte- specific asialoglycoprotein receptor (ASGPR) to form an ASO -GalNAc 3 conjugate.  
This GalNAc 3-conjugate approach results in enhanced ASO delivery to hepatocytes versus 
non-parenchymal cells and has increased ASO potency by approximately 10 -fold compared to 
unconjugated ASOs in mice ( Prakash et al. 2014). 
The ASO portion of ISIS 681257 is complementary to a region spanning the Exon 24-25 splice 
site at position 3901 of apo(a) transcript sequence (NM_005577.2) and binds to the mRNA by Watson and Crick base pairing.  The hybridization (binding) of ISIS 681257 to the cognate mRNA results in the Ribonuclease H1 (a non- specific endonuclease that catalyzes the cleavage 
of RNA via hydrolytic mechanism RNase H1 -mediated degradation of the apo(a) mRNA, thus 
preventing production of the apo(a) protein).  Maximal antisense-mediated reduction of target mRNA levels is typically greater than 90% of control levels in  sensitive tissues 
(Zhang  et al. 2010).  Furthermore, reduction in target mRNA levels using this approach 
correlates directly with a subsequent reduction in target protein levels.   
ISIS 681257 does not have any complementary homology to plasminogen mRNA (Graham  et al. 2016).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
27  2.3.2 Chemistry  
Chemically, ISIS 681257 is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by phosphorothioate and phosphodiester linkages (mixed backbone 
design).  The mixed backbone design reduces the total number of phosphorothioate linkages, which reduces non-specific interactions with proteins and further enhances potency of GalNAc
3 
conjugated ASOs. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2′ -O-(2-methoxyethyl) (2′ -MOE) -modified 
ribonucleotides.  These MOE -modified nucleotides confer (1) increased affinity for the target 
mRNA ( Altmann et al. 1996; McKay et al. 1999), (2) increased resistance to exonucleases and 
endonucleases (thereby increasing stability in tissue) ( Geary et al. 2003), and (3) amelioration of 
some of the high-dose toxicities, thereby resulting in an improved safety profile compared to 
first-generation antisense drugs containing phosphorothioate-modified oligodeoxynucleotides 
(DNA) ( Henry et al. 2000).  The third region, the central portion of the oligonucleotide, is 
composed of 10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and 
ISIS 681257 employ s this chimeric structure to enable use of the ubiquitou s endonuclease that 
specifically hydrolyzes the RNA strand in RNA/DNA hybrids ( RNase H1 )-mechanism for 
antisense activity .  This is because while the 2′ -MOE modification confers increased stability an d 
affinity, it does not support RNase H1 -catalyzed cleavage of RNA hybridized to 
2′-MOE -modified nucleotides ( McKay  et al. 1999).  The fourth region is composed of a 
triantennary cluster of GalNAc 3 sugars that is linked to the 5ʹ end of ISIS 681257 via a 
phosphodiester linkage.  The GalNAc 3 cluster is a high affinity ligand for the ASGPR, a receptor 
expressed primarily on the surface of liver hepatocytes ( Stockert 1995).  The GalNAc 3 cluster 
enhances delivery of ISIS 681257 to liver hepatocytes over other cell types and enhances potency.  After internalization into cells, the GalNAc
3 cluster is metabolized to release “free 
ASO” inside the cell ( Prakash et al. 2014). 
2.3.3 Preclinical Experience  
The pharmacology of ISIS 681257 has been examined in apo(a) tra nsgenic (Tg) mice which 
express the entire human apo(a) genomic sequence ( Frazer et al. 1995) and nonhuman primates. 
Administration of ISIS 681257, a human apo(a) antisense inhibitor, to mice containing the human apo(a) transgene produced dose- dependent reductions in human apo(a) liver mRNA and 
apo(a) plasma protein after 6 weeks of ASO administration at 0.3, 1, 3, and 10 mg/kg/wk. 
When ISIS 681257 was administered to normal chow fed cynomolgus monkeys for 4 weeks at 
the dose of 12 mg/kg/wk, it significantly reduced hepatic apo(a) mRNA by 90% relative to the 
cohort administered phosphate buffered saline (PBS).  As there is an 80% sequence conservation between apo(a) and plasminogen nucleotide sequences, plasminogen mRNA levels were also measured , and no change compared to the PBS cohort was observed. 
Findings from the chronic studies with ISIS 681257 (the 26- week mice  and 39-week monkey 
studies) were similar to those observed in the 4- and 6- week studies  and were not considered 
adverse.  The plasm a and tissue concentrations observed for ISIS 681257 in  mice  and monkeys 
were generally similar to those observed for other unconjugated 20- mer 2 ʹ-MOE ASOs in this 
chemical class with and without GalNAc
3-conjugation.  However, the proportion of drug in 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
28  hepatocytes compare to nonparenchymal liver cells was greater for ISIS 68125 7, compared to the 
parent drug ISIS 494372 (without GalNAc 3-conjugation), which is the basis for increased 
potency of ISIS 681257 (unpublished results; Geary et al. 2003;  Yu et al. 2007; 
Prakash  et al. 2016).  
The most noteworth y safety fin ding in the chronic monkey study was  a marked platelet reduction  
that, occurred in 2 male monkeys in the high-dose group (20 mg/kg/wk) and 1 animal (1 female) 
in the mid -dose (10 mg/kg/wk) group beginning on Days 44-135, which led to the subsequent 
early termination  (ET) of these 3 animals .  An additional male monkey in the 10 mg/kg/wk dose 
group had a moderate decrease in platelets  that was successfully treated with steroid , and was 
terminated at th e scheduled 6 -month interim sacrifice .  There were no platelet reductions or other 
toxicologically significant findings in monkeys treated with 2 mg/kg/wk for up to 39 weeks.  
There were no marked platelet reductions in mice at doses up to 70 mg/kg/wk for 26 weeks.  However, mice exposed to ISIS 681257 at doses of ≥ 10 mg/kg/wk for up to 26 weeks showed evidence of hepatobiliary effects in both sexes as indicated by increases in ALT (up to + 10.3x), AST (up to + 10.4x), and/or ALP (+ 2.5x).  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with ISIS 681257 can be found in 
the Investigator’s Brochure .  A summary of the study that has been conducted with ISIS 681257 
is included below. 
ISIS 681257- CS1 was a Phase 1 double-blind, placebo-controlled, dose- escalation study 
designed to assess the safety, tolerability, PK,  and pharmacodynamics (PD) of single and 
multiple doses of ISIS 681257 administered subcutaneously (SC)  to 45 healthy subjects with 
Lp(a) ≥ the upper li mit of normal (ULN)  (30 mg/dL).  Twenty one (21) subjects received 10  to 
120 mg S C (10, 20, 40, 80, and 120 mg) as a single-dose, and 24 subjects received 10, 20, and 
40 mg a s multiple doses (6 doses in 21 days :  3 loading doses during the first week on al ternate 
days (Days 1, 3, and 5), and then once a week for the next 3 weeks (Days 8, 15, and 22). There were no serious adverse events  (SAEs) , or clinically -relevant  changes in laboratory 
assessments and a ll subjects completed the treatment and post- treatme nt follow -up periods. 
Constitutional symptoms such as fever, chills, increase in body temperature and arthralgias have 
been observed following parenteral administration of ASOs, primarily during the initial dosing period.  Following SC administration of ISIS 681257 constitutional symptoms  were observed  in 
4 of the 6 subjects  who received a single -dose of 120 mg.  The symptoms were mild in severity  
and resolved spontaneously with or without treatment with acetaminophen . 
Fluctuations in platelet counts to below the lower limit of normal were obse rved in 5 study 
subjects o n active drug and across doses.  These changes were not considered adverse or 
clinically -significant by the Investigator and did not appear to be dose related. 
Two (2) mild AE s of redness at the site of injection  occurred 48 to 72 hours after administration 
in 1 subject who received ISIS  681257 in the 20 mg multiple-dose cohort.  Both AE s resolved by 
the time of the subject’s next visit. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
29  Following SC administration, ISIS  681257 was absorbed rapidly into the systemic circulation, 
with median time to maximum plasma concentrations (T max) ranging from 1 to 4 hours.  Similar 
Tmax values were observed at all dose levels .  Maximum observed plasma concentrations (C max) 
and AUC 0-24hr were dose-dependent over the studied SC dose range.  The mean peak (C max) and 
total exposure (AUC 0-24hr) increased proportionally with dose at dose levels ranging from 10 to 
40 mg, and greater than dose proportionally at dose levels ranging from 40 to 120 mg. 
After reaching C max, mean plasma concentrations of ISIS 681257 declined in a biphasic fashion 
over time, with an initial, relatively fast distribution phase that dominated the plasma clearance 
followed by a slower elimination ph ase.  Characterization of the terminal elimination phase 
yielded an apparent terminal elimination half -life of appr oximately 3  to 4 weeks over a dose 
range of 10  to 120 mg  (either single - or multiple -dose) , and appeared to be independent of dose.  
This res ult is consistent with the slow elimination of ISIS  681257 observed from monkey tissues, 
and the comparatively long elimination half -lives observed for this chemical class.  
Plasma trough concentrations (168 hours or 7 days from previous dose) monitored dur ing the 
treatment period in the multiple -dose cohorts increased with increasing dose, consistent with 
expectations (based on preclinical assessments and experience with other compounds of this chemical class) that trough plasma concentrations reflect expos ure in tissues.  Plasma trough 
concentrations did not increase greatly after the loading period ( Day 15 ), suggesting that 
accumulation in major tissues of distribution had approached  steady -state after the loading 
period. 
Overall, the human PK  of ISIS  681257 are consistent with the expected PK  for compounds 
within this chemical clas s. 
2.4 Rationale for Dose and Schedule of Administration 
The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given weekly 
that were found to be general ly well -tolerated  and to induce clinically -relevant  reductions in 
Lp(a) . 
The range of dosing proposed for the present study will provide the equivalent drug exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in mean reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% at steady- state.  
The highest dose selected for this study, 20 mg per week, is predicted to provide an approximately 8 5% reduction in Lp(a) at steady- state that is expected to be sufficient to bring 
almost all patients with hyperlipoproteinemia(a) into the normal range (Lp(a) ≤ 30 mg/dL).  
The present study will also evaluate safety and efficacy at different dosing frequencies:   every 
4 weeks, every 2 weeks, and weekly.   Patients with hyperlipoproteinemia(a) will require chronic 
treatment and thus every 2 weeks or every 4 weeks dosing regimens, if safe and well- tolerated, 
may provide advantages over weekly dosing in terms of convenience and compliance for patients.   Dosing regimens of 20 mg every 2 weeks and 40 mg every 4 weeks will test if similar 
monthly exposure, at different frequencies of administration, will achieve similar safety and similar level of Lp(a) reduction s ince the reduction achieved by a given dose level is principally 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
30  driven by total exposure, while individual dose levels and the related peak concentration (C max) 
may influence tolerance and safety.  
3. EXPERIMENTAL PLAN 
3.1 Study Design  
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, dose- ranging study .  
Approximately 270 patients will be randomized in a 5:1 ratio ( 225 ISIS 681257 and 45 placebo) 
to receive ISIS 681257 or placebo.  Study Drug (ISIS 681257 or placebo) will be administered 
SC every week , every 2 weeks (biweekly ), or every 4 weeks, depending on cohort assignment, 
for up to 52 weekly doses, up to 26 every 2- week doses , or up to 13 every-4- week doses . 
The primary analysis time poin t is at Week 25 for patients who received every 4 -week  dosing 
(Cohorts A-C) and at Week 27 for patients who received every 2- week or weekly dosing 
(Cohorts D and E).  For patients continuing treatment beyond the primary analysis time point 
additional supportive efficacy  analysis  (to evaluate whether the treatment effect is maintained ) 
and safety analysi s (for the purpose of dose(s) selection) will be repeated at the completion of 
Study Drug  treatment. 
The treatment portion of the study will be complete when the last enrolled patient reaches 
6 months of exposure.  All patients will then enter a 16 -week p ost-treatment follow-up period. 
Patients ≥  18 and ≤  80 y ears old with  elevated plasma Lp(a) levels (≥  60 mg/dL) and a clinical 
diagnosis of CVD are eligible f or enrollment upon meeting the study specific eligibility criteria .  
Patients will be on standard -of-care preventative therapy for other than elevated Lp(a) CVD risk 
factors as per current guidelines.  
Clinical diagnosis of CVD is defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease (PAD) .  A diagnosis of CAD has to be documented by any of the 
following: 
• Angiographic evidence of ≥ 50% stenosis of 1 or more major epicardial coronary arteries  
• History of myocardial infarction documented by positive enzymes, and either symptoms of myocardial ischemia, or ECG changes  (Thygesen et al . 2012) 
• History of coronary revascularization 
• Evidence of cardiac ischemia on exercise testing, or imaging study  
Patient s will be evaluated for study eligibility during Screening, which takes place within 
4 weeks prior to Day 1 (the first day of Study Drug  administration) .  Patients who are determined 
to be eligible, based on screening assessments, will be enrolled in the study at Day 1 and randomly assigned to 1 of the 5 parallel dosing cohorts, with each cohort having a 5:1 ratio to 
receive ISIS 681257 or matching volume of placebo, respectively, by SC  injection  for up to 
52 weeks . 
Following the End-of-T reatment , patients will enter the 16 -week  post- treatment follow-up 
period . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
31  3.2 Number of Study Centers  
This is a multicenter , multinational study. 
3.3 Number of Patients  
Approximately 270 patients will be randomized  in this study, with approximately 54 patients 
assigned to each of the 5 treatment cohorts . 
3.4 Overall Study Duration and Follow- up 
The length of patient s’ participation in the study may  be up to 18 months (72 weeks),  which 
includes a 4 -week s creening period, an up to 52- week t reatment period  with Study Drug  
(ISIS  681257 or placebo), and a 16- week post- treatment follow-up period .  The t reatment portion 
of the study will be complete when the last enrolled patient reaches 6 months of exposure. 
Patients  may be required to attend additional visits for monitoring of AEs or abnormal 
investigation results .  The frequency of additional monitoring will be determined by the Study 
Medical Monitor in consultation with the Investigator. 
3.4.1 Screening  
Patient  eligibility for the study will be determined within 4 weeks  prior to study. 
3.4.2 Treatment  
For each patient m inimum treatment duration is 6 months and maximum of  52 weeks.  
All patients enrolled will be randomized to a minimum of 6 months of treatment in 1 of 
5 treatment cohorts.  On completion of the 6 months, patients may continue treatment within the same randomized cohort until the last enrolled patient reaches 6 months of exposure (for continuing safety assessments), with a maximal exposure period of 12 months.  When this  
milestone  is met, all patients will then enter a 16 -week p ost-treatment follow-up period. 
Eligible patients will report to the Study Center for assessme nts at specified intervals throughout 
the 52- week treatment period as detailed in the Schedule of Procedures in Appendix A .  During 
the Treatment, Study Drug  (ISIS  681257 or placebo) will be administered by SC injection 
once- weekly , every 2 weeks,  or every 4 weeks, depending on cohort assignment. 
3.4.3 Post-Treatment  
Patients  when  completed dosing will enter the 16 -week post- treatment f ollow-up period and will  
return to the Study Center for 3 follow-up visits 4, 10, and 16 w eeks after their last injection  of 
Study Drug  as per Appendix A ( Follow-up). 
The final study visit for each patient will be 16 weeks after the last dose of Study Drug . 
3.5 End-of-Study  
The End -of-S tudy is  defined as  last patient , last visit.   
For individual patients, End-of-Study is defined as completion of the ir last study visit. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
32  3.6 Data and Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) will be assembled to review safety, 
tolerability and efficacy (as needed) data collected on ISIS  681257 during this study.  The 
DSMB will be constituted to include expertise in medical specialties relevant to the safety of antisense drugs (nephrology, hepatology, hematology and cardiology ).  Specialist members of 
the DSMB will be informed and consulted on all treatment -related SAEs  relevant to their 
experti se and all changes of relevant laboratory parameter s that trigger stopping rules 
(Section  8.6), within 24 hours of receipt of such results.  In addition, all accrued safety data 
relevant to each of medical area specialist will be forwarded monthly for review.  
The full DSMB review of all accumulated data will be performed quarterly.  Based on its 
ongoing assessment of the safety and tolerabilit y of ISIS  681257, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping or continuing the study as planned.  Details on the safety assessments, frequency of review, meeting schedules and controlled access to unblinded data are outlined in the DSMB Charter and/or Statistical Analysis Plan (SAP).  
4. PATIENT ENROL LMENT  
4.1 Screening  
Before patients  may be en rolled into the study, the Sponsor or designee requires a copy of the 
Study Center ’s written  independent ethics committee/institutional review board (IEC/IRB)  
approval of the protocol, informed consent form, and all other patient directed  information 
and/or recruitment material. 
Patients  or their legally acceptable representatives must sign the consent form  before any 
screening tests or assessments are performed .  At the time of consent, the patient  will be 
considered enrolled into the study and will be assigned  a unique screening number before any 
study procedures, including s creening procedures, are performed .  The  screening number and 
patient  identification number must remain constant throughout the entire trial.  In the event the 
patient is re -consented and  re-screened the patient must be given a new screening number.  
Screening numbers and patient  identification numbers, once assigned, will not be re- used.  
4.2 Randomization 
Patients will be randomized  after all  screening  assessments have been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to randomization and assignment of a unique patient identification 
number. 
Using an Interactive Web -Response System (IXRS), eligible patients will be randomized 
in a 
1:1:1:1 :1 ratio  to 1 of the 5 parallel -dose cohorts (Cohorts A, B, C, D, or E).  Within each dose 
cohort, patients will be randomized in a 5:1 ratio to receive ISIS 681257 or matching volume of 
placebo, respectively.  
A permuted block schedule will be used.  The randomization schedule will be generated and held by an independent vendor. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
33  4.3 Replacement of Patients  
Patients  who withdraw from the study will not be replaced . 
4.4 Unblinding of Treatment Assignment  
The Sponsor and all patients , monitors, and Study Center  personnel related to the study will be 
blinded throughout the study and until all patients have completed the study and the database has 
been locked .  However, if a patient  has suffered a SAE  (as defined in Section 9.3.3), and/or when 
knowledge of the treatment assignment will impact the clinical management of the patient , the 
Investigator will have the ability to unblind the treatment assignment for that  patient  using the 
IXRS .  The S ponsor will determine the point at which all treatment assignments will be 
unblinded.  The Sponsor or designee will be informed of the unblinding of a patient  within 
24 hours.  In addition, all SUSARs wil l be unblinded by the Sponsor’s or designee’s Drug Safety 
and Quality Assurance personnel for the purpose of regulatory repor ting (see Section 9.2).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria at within 4 weeks of Study Day 1or at the time point specified in the individual eligibility criterion listed.  
5.1 Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements 
2. Males or females aged ≥ 18 and ≤ 80 years old at the t ime of informed consent 
3. Clinical diagnosis of CVD defined as documented coronary artery disease (CAD), stroke, 
or peripheral artery disease 
4. Lp(a) plasma level ≥  60 mg/dL  
5. Must be on standard-of- care preventative therapy for other than elevated Lp( a) CVD risk 
factors  
6. Patients on the following medications must be on a stable regimen for at least 4 weeks 
prior to Screening and expected to remain on a stable regimen through the end of the post-t reatment follow-up period: 
a. lipid lowering drugs (st atins, ezetimibe, proprotein convertase subtilisin/kexin 
type 9 [PCSK9s ] inhibitors, niacin, fibrates, fish oil or other products containing 
omega-3 fatty acids including OTC preparations)  
b. a ntiplatelet drugs  
c. testosterone, estrogens, progesterone, growth hormone or progestins 
7. Females:  must be non -pregnant and non- lactating and either : 
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) 
  
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
34  b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females 
> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medica l cause and FSH levels in the postmenopausal range for 
the laboratory involved) 
c. Abstinent* or 
d. if engaged in sexual relations of child -bearing potential, ag ree to use 2 highly 
effective contraceptive methods (refer to Section 6.3.1 ) from the time of signing the 
informed consent form until at least 16 weeks after the last dose of Study Drug 
(ISIS 681257 or placebo) 
* Abstinence is only acceptable as true abstin ence, i.e., when this is in line with the 
preferred and usual lifestyl e of the patient.  Periodic  abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods ), declaration of abstinence for the 
duration of a trial and withdrawal ar e not acceptable methods of contraception 
8. Males must be surgically sterile or, if enga ged in sexual relations with a female of child-
bearing potential, the patient must be using an acceptable contraceptive method (refer to 
Section 6.3.1) from the time of signing the informed consent form until at least 16 weeks 
after the last dose of ISIS 681257 
5.2 Exclusion Criteria 
1. Within 6 months of Screening:  acute co ronary syndrome, major cardiac surgery, or 
stroke/transient ischemic attack 
2. Within 3 months of Screening:   coronary, carotid, or peripheral arteri al revascularization, 
major non-cardiac surgery, or  lipoprotein apheresis  
3. Heart failure New York Hear t Association (NYHA) class IV 
4. Uncontrolled hypertension (systo lic > 160 or diastolic > 100 mm Hg) 
5.  History of acute kidney injury within 12 months of Screening 
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day 1 
8. Known history of or positive test for human  immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ of the cervix that has been  successfully treated  
10. Patients with a history of major blee d or high-risk of bleeding diathesis  
11. Recent history of, or current drug or alcohol abuse 12. Known history or presence of systemic allergic or pseudoallergic  (drug) reactions  
13. Hypersensitivity to the active subs tance or to any of  the excipients 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
35  14. Clinically -significant  abnormalities in screening laboratory values that would render a 
patient unsuitable for inclusion, including the following: 
a. Urine protein/creat inine ratio (UPCR) ≥ 0.25 mg/mg .  In the event of a UPCR  above 
this threshold, eligibility may be confirmed by a quantitative total urine protein 
measurement of ˂ 300 mg/24 -hr 
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.  In the event of a UACR  above 
this threshold, eligibility may be confirmed by  a quantitative total urine albumin  
measurement of ˂ 150 mg/24-hr 
c. Estimated GFR  ˂ 60 mL/min (as determined by the Chronic Kidney Disease-
Epidemiological Collaboration ( CKD- EPI) Equation for creatinine clearance 
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN 
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in 
which case total bilirubin must be ≤  3 mg/dL  
f. Alkaline phosphatase (ALP)  > ULN  
g. Platelet count ˂  LLN  
15. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors 
16. Treatment with another investigational drug, biological agent, or device within 1 month 
of Screening, or 5 half-lives of investigational agent, whichever is longer  
17. Treatment with any non -Ionis oligonucleotide (including small interfering ribonucleic 
acid [ siRNA] ) at any time or prior treatment with an Ionis oligonucleotide or siRNA 
within 9 months of screening.  Patients that have previously receiv ed only 1 dose of an 
Ionis oligonucleotide as part of a clinical study may be included as long as ≥ 4 months 
has elapsed since dosing 
18. BMI > 40 kg/m2  
19. Blood donation of 50-499 mL within 30 days of Screening or of > 499 mL within 
8 weeks of S creening  
20. Unwillingness to comply with study procedures, including follow-up, as specified by this 
protocol, or unwillingness to cooperate fully with the Investigator 
21. Have any other conditions, which, in the opinion of the Investigator or Sponsor would 
make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the Study 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, and C . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
36  6.1.1 Screening  
Written informe d consent for the study will be obtained prior to the performance of any 
study- related procedures including screening procedures .  A 4 -week period is provided for 
completing screening assessments and determining patient eligibility for the study .  Abnormal 
screening results may be re- tested once for determination of patient eligibility after consultation 
with the Sponsor Medical Monitor.  Patients may be re -screened 1 time in order to determine 
eligibility . 
During the s creening period, patients  will undergo a medical history and physical examination 
including vital signs, 12-lead electrocardiogram (ECG) and have blood and urine samples taken 
for clinical laboratory testing .  Patients  will be screened for HIV, hepatitis B , and hepatitis C.  
On confirm ation of eligibility and prior to randomization, patients will also undergo a 24 hr urine 
collection for creatinine , albumin, and protein as a baseline assessment.  
6.1.2 Treatment Period  
During the t reatment period, patients will report to the study center  for clinic visits .  Patients will 
receive 20 mg doses of Study Drug  administered by SC injection once every 4 weeks for up to 
52 weeks in Cohort A, 40 mg doses of Study Drug  administered by SC injection once every 
4 weeks for up to 52 weeks in Cohort B, 6 0 mg doses of Study Drug  administered by SC 
injection once every 4 weeks for up to 52 weeks in Cohort C, 20 mg doses of Study Drug  
administered by SC injection once every 2  week s for up to 52 weeks in Cohort D, or 2 0 mg 
doses of Study Drug administered by SC injection once per week (weekly) for up to 52 weeks in Cohort E ( Section 8.1). 
Collection and measurement of vital signs, physical examination results, ECGs, clinical laboratory parameters ( Appendix B ), ISIS  681257 plasma concentrations, immunogenicity and 
biomarker samples , AEs  and concomitant medication/procedure information will be performed 
according to the Schedule of P rocedures in Appendix A . 
Extensive Pharmacokinetic (PK) Subgroup Only: 
Within each cohort, a subgroup of approximately 12 patients , who will consent to extensive PK 
sampling , will undergo additional PK sampling, in what is referred to as the PK Subgroup in this 
study.  Patients in this subgroup will have additional PK  sampling time points in order to 
evaluate the plasma PK parameters o f ISIS  681257.  Patients in this subgroup will have 
additional visits to the clinic during the t reatment p eriod in order to collect blood samples for PK 
assessment ( Appendix C ). 
6.1.3 Post-Treatment  Period  
Each patient will be followed for safety assessments for 16 weeks after the last dose of Study Drug.  During the post- treatment follow-up period, patients will return to the Study Center 
for 3 outpatient visits at Weeks 4, 10, and  16 after the last dose of Study Drug for safety and 
clinical laboratory evaluations and for blood sampling for PK (Appendices A and C). 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
37  6.2 Additional Study Assessments  
6.2.1 Laboratory Assessments  
Laboratory analyte samples will be collected throughout the study as per the Schedule of 
Procedures in Appendix A .  A list of these analytes  is contained in Appendix B . 
Routine blood chemistry and urine samples (excluding 24-hour urine collection) should be taken after fasting for at least 10 hours.  Any confirmatory tes t, or test taken for safety reasons , may be 
taken at any time, irrespective of fasting status .  During preparation for fasting samples, the 
patient can drink water and they should ensure that they consume sufficient water in order to not become dehydrated .  
If tests are uninterpretable (e.g. , due to clumping, hemolysis or quantity not sufficient) or 
missing , a repeat blood or urine specimen should be re-drawn as soon as possible (ideally within 
1 week ). 
While on treatment hematology  samples will be collected every 14 days.  E ach time a 
hematology lab is drawn and sent to the central laboratory for analysis, an additional sample be collected in parallel and analyzed locally .  In the event that both the central and local samples are 
unreportable (e.g., due to hemolyzed or clumped blood samples), patient dosing cannot continue until another sample is repeated and determined not to have met a platelet stopping rule. 
If there is no reportable platelet count within 14 days of the last platelet count, the Investigator 
will contact the patient to hold dosing until a new platelet count is obtained and reviewed. 
While on treatment b lood and urine samples for renal function testing will also be collected 
every 14 days and sent to the central laboratory for analysis, per Section 8.5.2.  If there are no 
test results available within 14 days of the last set of results  for parameters considered critical to 
patient safety , the Investigator will contact the patient to hold dosing until a new test set is 
obtained and reviewed . 
While on treatment liver  function testing will also be collected every 14 days and sent to the 
central laboratory for analysis for the first 3 months of the study treatment, and monthly thereafter during the Treatment Period  per Section 8.5.1.   
All lab samples sent to  the central laboratory are received on the next day and processed.   Lab 
Alerts issued as per protocol safety monitoring requirements or stopping rules will indicat e the 
applicable protocol section to facilitate review and will be  immed iately and simultaneously sent 
by email to the Investigator, the Sponsor and the CRO Medical Monitors, the Sponsor Drug Safety Physician, and the Clinical Trial Manager (CTM), and should be receiv ed by them  within 
2 days from sample collection.  Hematology  results from the site’s local laboratories are received 
by the study center  staff on the day of sample collection , and should be entered as soon as 
possible in to the eCRF  to inform the Sponsor and CRO study monitoring teams. 
All platelet count results must be reviewed promptly (within 24 hours of receipt) by the Investigator, or designee, to ensure that the count has not met the stopping rule and to determine whether the rate of decline is suggestive that the patient could be approaching the dose interruption rule of 75,000/mm
3 as specified in Section 8.6.3.  Any case of a platelet count 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
38  reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is considered  an adverse event of 
special interest and must be reported in an expedited fashion to the Sponsor as per 
Sections  9.3.3.1 and 9.4.1. 
All liver and renal function tests must also be reviewed promptly (within 24 hours of receipt) by the Investigator , or designee, to ensure that the result  has not met the stopping rule.  Any event 
meeting renal stopping rules criteria described in Section 8.6.2 is considered  an adverse event of 
special interest and must  be reported in an expedited fashion to the Sponsor as per 
Sections  9.3.3.1 and 9.4.1. 
All lab alerts received , including thos e related to plate let, liver, or renal function 
monitoring/stopping rules, are also reviewed promptly by the Sponsor and the CRO Medical Monitors who will agree on  actions to be taken.  Within 24 hours of receiving a n actionable  lab 
alert the CRO Medical Monitor will communicate instructions to the Investigator and the study personnel by emailing them the Safety Surveillance Form that needs to be signed by the Investigator/study personnel and promptly returned  to the Sponsor and CRO Medical Monitor.   
In urgent cases, such as platelets  results below 50,000/mm
3, or liver or renal test results reaching 
a critical stopping rule  the Investigator must also be contacted by phone.  
Further information on safety monitoring and actions to be taken by the Study Investigator in the 
event of reduced platelet count are provided in Section s 8.5.3 and 8.6.3. 
6.2.2 Physical Exams and Vital Signs 
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures 
(Appendix A ).  Vital signs should include weight, blood pressure (BP) , pulse rate, respiratory 
rate and body temperature.  BP  and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  BP  should always be measured on the same arm 
(prefe rentially on the left arm) .  Height will be measured at Screening . 
6.2.3 E lectro cardiography  
Electrocardiography (ECG) will be conducted at Screening, Day 1, (prior to the first dose of Study Drug ), and again during the t reatment p eriod  as follows per dosing cohort: 
• Cohorts A, B, and C at Weeks 5, 13, 21, 25, 33, 41, 49, and 53  
• Cohorts D and E at Weeks 5, 13, 21, 27, 33, 41, 49, and 53 
In all cohorts, ECGs will be conducted during the post-t reatment follow-up period  at 4, 10, and 
16 weeks after the last dose of Study Drug. 
ECGs will be recorded after the patient has been resting in a supine position for at least 
5 minutes .  ECGs will be performed in triplicate . 
6.2.4 PK Sampling  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected 
prior to dosing on Day 1 and at various times throughout the t reatment and post-t reatment 
follow-up period s as noted in the tables in Appendix C . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
39  Within each cohort, patients assigned to the PK Subgroup will have additional PK  sampling time 
points and additional visits to the clinic during the t reatment p eriod in order to collect blood 
samples for PK assessment ( Appendix C ). 
6.3 Restriction on the Lifestyle of Patient s 
6.3.1 Contraception Requirements  
All male patient s and women  of childbearing potential must refrain from sperm/egg donation and 
either be abstinent† or pr actice effective contraception from the time of signing the informed 
consent form until at least 16 weeks  after their last dose of study treatment .   
Male patient s engaged in sexual relations with a female of child -bearing potential must a lso 
encourage their female partner to use effective contraception from the time of signing the 
informed consent until 16 weeks  after the patient ’s last dose of study treatment.  
For the purposes of this study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age o r, 
in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hyster ectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patient s: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
Follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository 
• Male patient s with partners that are pregnant must use condoms as contraception to 
ensure that the fetus i s not exposed to the Study Drug 
For female patient s and female partners of male patient s: 
• Using 2 of the following acceptable methods of contraception:  surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, intrauterine contraception/device, or any 2 barrier methods (a combination of male or female condom * with  diaphragm, sponge, or 
cervical cap)  together with spermicidal foam/gel/film/cream/suppository  
†Note: Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
40  *Note : A female condom and a male condom should not be used together as friction 
between the 2 can result in either or both product s failing . 
6.3.2 Other Requirements  
All patients will be required to fast for at least 10 hours before visits requiring fasted blood 
sampling.  
7. STUDY DRUG  
7.1 Study Drug  Description  
Study Drug ( ISIS 681257 or Placebo)  characteristics are listed in  Table 1.  
Study Drug ( ISIS 681257 or Placebo)  will be provided as 0.8 mL deliverable volume in 2 mL 
stoppered and sealed glass vials as a sterile solution .   
The Study Drug  is clear to slightly yellow  in color, it is for single use , contains no preservatives 
and must be stored between 2 to 8 °Celsiu s and be protected from light. 
7.1.1 ISIS  681257 
ISIS 681257 vials contains 100 mg/mL ISIS 681257 in Water for Injection.  Additionally, 
sodium phosphate buffer and sodium chloride are added to control the measure of the acidity or basicity of the  solution (pH) and tonicity, respectively.  The target pH is 7.4. 
7.1.2 Placebo  
Placebo vials contain 0.9% sodium chloride in Water for Injection.  1.6 µ g/mL ribofla vin is 
added to ensure color matching of placebo vials to ISIS 681257 vials.  
Table 1 Study Drug  Characteristics  
Study Drug  ISIS 681257  Placebo  
Strength 100 mg/ mL  Not Applicable  
Volume/Formulation  0.8 mL solution per 
2.0 mL vial  0.8 mL solution per  
2.0 mL vial  
Route of Administration  SC SC 
SC = subcutaneous  
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug  (ISIS 681257 or placebo) 
labeled in accordance with specific country regulatory requirements . 
7.3 Study Drug  Accountability  
The study staff is required to document the receipt, dispensing, and return  of Study Drug  
(ISIS 681257 or placebo) supplies provided by the Sponsor.  The patient must return all used and 
unused Study Drug  to the Study Center for accountability .  The Study Center must return all 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
41  used and unused Study Drug  to the Sponsor or designee for destruction .  All used syringes must 
be disposed of as per the site’s hazardous waste destruction policy. 
8. T REATMENT OF PATIENTS 
8.1 Study Drug  Administration  
ISIS 681257 will be administered to patients by Study Center staff as follows: 
Cohort A: a single SC dose of 20 mg  once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort B: a single SC dose of 40 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort C: a single SC dose of 60 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort D: a single SC dose of 20 mg every 2 week s for up to 52 weeks  and a maximum of 
26 doses 
Cohort E: a single SC dose of 20 mg every week (weekly) for up to 52 weeks  and a 
maximum of 52 doses 
Self-administration will be allowed after appropriate training of patient and/or caregiver.  
Patients in Cohorts A, B, and C should receive 1 dose every 4 weeks, patients in Cohort D 
should receive 1 dose every 2 weeks and Cohort E should receive 1 dose per week with weeks 
always defined relative to Study Day 1 .  For example if a patient receives the first dose on a 
Monday, subsequent doses should be given on Mondays according to the respective dosing schedule, if possible.  If a patient misses an injection, or if dosing on the usual day is not possible, the patient can reschedule the injection provided that 2 doses are administered at least 2 days ap art. 
Every effort should be made to ensure the previous dose is given 7 days prior to a scheduled clinic visit.  
Please refer to the Study Drug  Manual  provided by the Sponsor or designee for more detailed 
instructions for Study Drug ( ISIS 681257 or placebo) preparation and administration. 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
42  Table 2 Study Drug  Dosing Information 
Cohort  Treatment  Volume to Administer/Dose  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.2 mL  ≤ 13 ≤ 260 mg 
B 40 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.4 mL  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.6 mL  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 
or placebo  
(Every 2 weeks)  0.2 mL  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 
or placebo  
(Every week) 0.2 mL  ≤ 52 ≤ 1040 mg  
 
8.2 Other Protocol -Required Drugs  
No other Study Drug  treatments  are required by the protocol. 
8.3 Other Protocol -Required Treatment Procedures  
No other treatment procedures are required by the protocol. 8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator ” section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of the pre- dose test 
closest to Day 1 and the Day 1  value itself . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical observations. 
In case of discrepancy  between the test results from 2 sources, such as between the central and 
local lab, safety -mandated action must be initiated based on the more critical ( lower or higher, as 
relevant) of the 2 values.  
Confirmation Guidance :  At any time during the study (t reatment or post-t reatment follow-up 
periods), the clinical laboratory results meeting any of the safety monitoring criteria presented 
below must be confirmed by performing measurements (ideally in the same laboratory that 
performed the initial measurement) on new specimens prior to administering the next dose of 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
43  Study Drug  (ISIS 681257 or placebo).   All new specimen collections should take place as soon 
as possible (ideally within 3 days of the initial collection) .  
In addition, as described in Section 6.2.1 hematology lab s should be sent in parallel to the central 
and local laboratory for analysis. 
Stopping Rule Guidance:  The Investigator may interrupt or permanently discontinue study 
treatment for any medical reason including changes in clinical laboratory results.   
In the event of an initial clinical laboratory result that meets a stopping criterion, patients must 
not be re-dosed until a confirmatory test result has been reviewed by the Study Medical Monitor.  
If any of the stopping criteria  described below (refer to Sections 8.6.1 to 8.6.3) are met and are 
confirmed, the patient will be permanently discontinued from further treatment with Study Drug (ISIS 681257 or placebo), evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post- treatment 
evaluation portion of the study.  In general, patients who do not meet the stopping rules based upon retest may continue dosing.  However, the Investigator and the Study Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the patient is appropriate. 
Additional Guidance:  If possible, a PK sample should be collected as soon as possible after an 
SAE has occurred (preferably within 2 weeks).  In addition, if a patient is asked to return to the clinic for additional evaluations due to an AE, then a PK sample should be taken a t the time of 
the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by the U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline, please refer to 
guidance in Section 8.5 ab ove. 
All patients will have liver chemistry  tests monitored every 2 weeks for the first 3 months of the 
study tr eatment, and monthly thereafter during the Treatment Period . 
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash,  abnormal bleeding or bruising, or 
eosinophi lia > ULN ) liver  enzymes and bilirubin should be tested as soon as possible.  Testing at 
a lab that is local to the patient is permissible for this purpose.  
In the event of an ALT or AST measurement that is > 3 x ULN (or the greater of 2 x baseline value or 3 x ULN if the baseline value was > ULN) at any time during the s tudy ( treatment or 
post-t reatment period), the initial measurement(s) should be confirmed as described in 
Section  8.5. 
Patients  with confirmed ALT or AST levels > 3 x ULN should have their liver chemistry tests 
(ALT, AST, ALP, international normalized ratio [ INR] and total bi lirubin) retested at least 
once- weekly until ALT and AST levels become ≤ 1.2 x ULN . 
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
44  All results of liver function tests must be reviewed promptly (within 24 ho urs of receipt) by the 
Investigator or the designee to ensure that  the result has not met the stopping rules per 
Section 8.6.1 . 
Further Investigation into Liver Chemistry Eleva tions:  For patients with confirmed ALT or AST 
levels > 3 x ULN, the following evaluations should be performed: 
1. Obtain a more detailed history of symp toms and prior and concurrent diseases 
2. Obtain further history for concomitant dr ug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets 
3. Obtain a history for exposure to envi ronmental chemical agents and travel 
4. Serology for viral hepatitis (hepatitis A virus [HAV] imm unoglobulin M [IgM], hepatitis 
B surface antigen [HBsAg], hepatitis C vi rus [HCV] antibody, Cytomegalovirus [CMV] 
IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatiti s (e.g., antinuclear antibody [ANA]) 
Additional liver evaluations, incl uding gastroenterology /hepatology consultations, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the 
Sponsor Medical Monitor and the study DSMB.  Re petition of the above evaluations should be 
considered if a patient’s ALT a nd/or AST levels reach 5 x ULN. 
All routine liver function test results will be reviewed on an ongoing basis at the weekly safety 
review by the Medical Monitor.  
All lab alerts for abnormal liver function tests mu st be promptly (within 24 hours of receipt) 
reviewed by the Investigat or and Medical Monitors. 
Lab alerts for abnormal liver chemistry tests will  be issued for:  1) ALT or AST > 3 x ULN; 
2) ALT or AST > 2 x baseline; 3)  total bilirubin > ULN;  4) ALP > ULN.  These alert levels are 
set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the 
FDA Guidance referenced in Section 8.5.1 . 
8.5.2 Safety Monitoring for Renal Function 
While on treatment all patients will have re nal function tests monitored every 2 weeks 
throughout the study.   Upon completion of the study treatment period, urine renal biomarkers 
should be monitored every 2 weeks for the first 6 weeks and then at 10 and 16 weeks post last 
dose (as per visit schedule). 
In the event of appearance of symptoms or si gns consistent with renal dysfunction such as 
hematuria, polyuria, anuria, flank pain, new-ons et hypertension, nausea an d/or anorexia, renal 
function should be tested as soon as possible.  Te sting at a lab that is local to the patient is 
permissible for this purpose. 
While on treatment during the course of the study, urinary surveillance will include urinalysis to 
include urine albumin/creatinine ratio (UACR) , urine protein/creatin ine ratio (UPCR) and 
ISIS 681257-CS6 CONFIDENTIAL  Amendment 5 
Protocol  30 Ma y 2017 
 
45  urinary red blood cells (RBCs), as well as serum cr eatinine and cystatin-C to estimate glomerular 
filtration rate (eGFR), which will be monitored ev ery 2 weeks.  In addition, biomarkers of acute 
renal injury will also be measured every 2 weeks ( Appendix B ).  
The assessment of serum creatinin e, cystatin-C, and urinalysis more frequently than every 
2 weeks will be guided by consultation with a local nephrologist.  A ny decision taken by the 
Investigator to discontinue st udy medication will be made taking into account all available and 
relevant data.  In addition, the decision to di scontinue Study Drug may al so be based on lesser 
changes in these parameters observed in isolatio n or in association with other renal-related 
abnormalities.  Any decision taken to restart stud y medication will be made in consultation with 
the Study Medical Monitor taking into account  all available and relevant data.  
All renal function test results wi ll be reviewed on an ongoing basis at the weekly safety review 
by the Medical Monitor. 
All results of renal function tests must be reviewed promptly (within 24 hours of receipt) by the 
Investigator or the designee to ensure that  the result has not met the stopping rules per 
Section 8.6.2 . 
Lab alerts for abnormal renal tests will be i ssued for:  Creatinine clearance (by CKD-EPI 
formula) decrease from baseline > 25%, urine albumin/creatinine ratio  (UACR) > 250 mg/g, 
urine protein/creatinine ratio (UPCR) > 0.5 mg/m g, or an increase in serum creatinine from 
baseline > 0.3 mg/dL). 
These alert levels are set to anti cipate and prevent the risk of a medically significant change in 
renal function while receiving Study Drug.  
In the event of a confirmed (as described in Section 8.5 ) laboratory result mee ting one or more of 
the above criteria, dosing with  the Study Drug should be inte rrupted and the Study Medical 
Monitor informed.  In addition, the following s upplemental renal tests should be immediately 
obtained:  
Serum creatinine, urine culture, 24-hour urine sample for creatin ine clearance, urine 
albumin and urine protein, urine microsc opy sample with inspection of sediment. 
The Investigator should also review the patient’s concomitant  medications for potentially 
nephrotoxic agents, and, with the results of these evaluations, revi ew any decision to continue or 
discontinue the patient in consultation with the Study Medical Monitor and the medical area 
specialist consultant of the DSMB. 
8.5.3 Safety Monitoring for Platelet Count Results 
All patients will have platelet counts monito red every 2 weeks for the duration of the study 
treatment period and must not rece ive Study Drug without an interpre table platelet count result in 
the prior 2 weeks.  Upon completi on of the study treatment period, platelets should be monitored 
every 2 weeks for the first 6 weeks and then at 10 and 16 weeks post last dose (as per visit 
schedule). In addition, platelet function will be  evaluated by aggregometry, using an approved 
point-of-care diagnostic device, in all patients  at each study site visit; additional functional 
testing may be performed at  selected study centers.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
46  As described in Section 6.2.1, a ll platelet count results must be reviewed promptly (within 
24 hours of receipt) by the Investigator or the desi gnee to ensure that the count has not met the 
stopping rule and to determine whether the rate of decline is suggestive that the patient could be 
approaching the dose interruption rule of 75,000/mm3 as specified in Section 8.6.3.   
Any case of a platelet co unt reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered a n adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor.  
Lab alerts related to platelet monitoring/stopping rules are issued when :  1) platelet counts are 
< 140,000 mm3; 2) when platelet count is ≥ 30% decreased from baseline, or 3) when the 
hematology sample is unreportable.  All these lab alert s, are reviewed promptly by the Medical 
Monitor and instructions are communicated to the Investigator and the study personnel within 
24 hours of receiving a n actionable lab alert  as described in Section 6.2.1. 
Actions to be taken in the event of reduced platelet count are shown in Table 3 in Section 8.6.3. 
In the event of a platelet count ˂  100,000/mm3 the laboratory tests outlined in Appendix D , 
should be performed as soon as possible.  Additional lab tests will be determined  by the Sponsor 
Medical Monitor or designee in consultation with the Investigator. 
8.5.4 Safety Monitoring for Minor Bleeding Events 
Patients will be instructed to promptly report any signs or symptoms of bleeding.  Minor 
bleeding events are those that do not fulfill the criteria for major bleeding or clinically -relevant, 
non-major bleeding events (which are defined in Section 8.6.3), for example excess bruising, petechiae, or gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Inves tigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin time (aPTT), prothrombin time (PT), INR , hepatic 
enzymes, bilirubin and platelet count should be performed. 
8.5.5 Safety Monitoring for Constitutional Symptoms  
Patients will be instructed to promptly report any signs o r symptoms of fever, constitutional 
symptoms , rash, arthralgia or joint swelling that may arise during the study and the Investigator 
should closely evaluate all potential causes, including concomitant illness .  Patients who  
experience persistent symptoms should be discussed with the Sponsor Medical Monitor or 
designee to determine whether additional monitoring or laboratory tests are required. 
8.6 Stopping Rules  
For the purposes of stopping rules, Baseline is defined as the average of Day 1 pre-dose 
assessment and the last measurement prior to Day 1.  
8.6.1 Stopping Rules for Liver Ch emistry Elevations  
In the event of confirmed laboratory results meeting any of the following criteria , dosing of a 
patient with Study Drug  will be stopped permanently: 
1. ALT or AST > 8 x ULN , which is confirmed 
2. ALT or AST >  5 x ULN , which is confirmed and persists for ≥ 2 weeks  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
47  3. ALT or AST >  3 x ULN (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), which is confirmed and total bilirubin >  2 x ULN  or INR > 1.5  
4. ALT or AST >  3 x ULN  (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of  fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (> ULN ) felt by the Investigator to be 
potentially related to hepatic inflammation  
8.6.2 Stopping Rules for Renal Function Test Results  
In the event of an estimated creatinine clearance ( by CKD -EPI formula) meeting any of the 
following criteria, or any chan ge in renal biomarkers deemed by the nephrologist on the DSMB 
to require further evaluation, a serum creatinine, urine culture,  24-hour urine sample for 
creatinine clearance and protein , and urine microscopy sample with inspection of sediment 
should be immediately obtained: 
1. CKD- EPI decrease of > 40% from B aseline  
2. CKD- EPI v alue < 45 mL/min/1.73 m2 
Dosing of a patient with Study Drug (ISIS 681257 or placebo) will be stopped permanently  if 
24-hour urine testing confirms any of the following values in the absence of an alternative 
explanation : 
1. Urine protein is > 1.0 g 
2. Creatinine clearance decrease of > 40% from baseline 
3. C reatinine clearance < 45  mL/min/1.73 m2 
Irrespective of whether the stopping rule is confirmed or not, the follow-up schedule and 
frequency of renal function monitoring after the initial event will be determined by the Study Medical Monitor in consultation with the Investigator and the medical area specialist  on the 
DSMB .  The Investigator should consider consulting a local nephrolog ist for any change of renal 
function that presents a concern.  If a renal biopsy is performed, a sample specimen should be made available for examination by an independent renal pathologist who has been engaged by the Sponsor to review such specimens.  
8.6.3 Stopping Rule for Platelet Count Results  
Stopping Rules for Platelet Count Results 
Actions to be taken in the event of a low platelet count are summarized in Table 3 below. 
In the event of any platelet count less than 50,000/mm
3, or a platelet count less than 75,000/mm3 
that occurs while the patient is already on reduced dose, dosing of the patient with S tudy Drug  
will be stopped permanently (Table 3) .  Platelet count will be monitored daily until 2 successive 
values show improvement then monitored every 2- 3 days until platelet count is stable.  
Administration of steroids is recommended for patients whose platelet count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by administration of high dose 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
48  steroids.  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone ). 
In the event of a platelet count ˂  75,000/mm3 and > 5 0,000/mm3, and in the absence of major 
bleeding or clinically -relevant non- major bleeding (defined below; Schulman et al. 2005), dosing 
of a patient with Study Drug should be suspended temporarily until the platelet count has 
recovered to  > 100,000/mm3.  If dosing is continued it must be at a reduced dos e as shown in 
Table 3.  The suitability of the patient for continued dosing will be determined by the Investigator in consultation with the Study Medical Monitor and will be based on factors such as the original r ate of decline in the patient’s platelet count, whether any bleeding events were 
experienced by the patient, and the speed of recovery of platelet count after interruption  of 
dosing. 
If, after reintroduction of Study Drug, the platelet count again falls be low 75,000/mm
3, then 
dosing of the patient with Study Drug  will be stopped permanently.  
Once a patient commences weekly monitoring this frequency of monitoring should continue 
irrespective of whether the platelet count rises into the normal range. 
Any unr eportable platelet count result must be rechecked and determined not to have met a 
stopping rule before dosing can continue. 
Definition of Major Bleeding Events (Schulman et al. 2005):  
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or organ , such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al. 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting > 24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epitasis, gingival bleeding, hemoptysis, hematemesis  6. Bleeding after venipuncture for > 5 minutes  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
49  Table 3 Actions in Patients with Low Platelet Count  
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every week * 
75K-100K/mm3 Permanently reduce as follows:  
For Cohort A:  reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks   
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week s 
For Cohort E:  reduce to 10 mg every week  Closer observation  
Monitor every week * 
50K-75K/mm3 Pause dosing  
When platelet count returns to >  100K/mm3 restart 
dosing as follows  only if approved by Sponsor 
Medical Monitor : 
For Cohort A:   reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks  
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week  
For Cohort E :  reduce to 10 mg every week  
or 
Permanently discontinue Study Drug i f it occurs 
while on already reduced dose  Closer observation  
Monitor every 2 -3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/ non-
steroidal anti -inflammatory 
drug ( NSAIDS )/ anticoagulant 
medication  
25K-50K/mm3 Permanently discontinue Study Drug  Closer observation: 
Monitor daily until 
2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet count ˂ 50K/mm
3 if possible 
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 2 successive values show 
improvement then monitor every 2 -3 days until platelet 
count stable  
Steroids recommended**  
Consider need for hospitalization and referral to hematologist  
Discontinue antiplatelet agents/NSAIDS/anticoagulant 
medication while platelet 
count ˂ 50K/mm
3 if possible 
* Once a patient commences weekly monitoring this frequency of monitoring should continue irrespective of whether the platelet count rises into the normal range. 
** Recovery in platelet  count may be accelerated by administration of high dose steroids .  Treatment guidelines for 
immune thrombocytopenia ( Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1- 4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 we eks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require continuation with oral steroids after methyl prednisolone) . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
50  8.7 Adjustment of Dose  
Dose frequency adjustments for platelet count reduction must be made in accordance with 
Section 8.6.3 and Table 3  (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for safety or tolerab ility after consultation with the Sponsor Medical Monitor.   
Patients may have their dose interrupted in response to AEs after consultation with Study Medical Monitor. 
8.8 Discontinuation of Study Drug  
A patient  must permanently discontinue study treatment for any of the following: 
• The patient  becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patient  withdraws consent  
• The patient  experiences an AE  that necessitates permanent d iscontinuation of Study Drug  
• The patient  develops laboratory test abnormalities that meet any of  the stopping rules 
listed in  Sections  8.6.1 to 8.6.3 
• When a platelet count  of less than 50,000/mm
3, or a platelet count less than 75,000/mm3 
while the patient is on a reduced dose. 
The reason for discontinuation of Study Drug  must be recorded in the electronic Case Report 
Form (eCRF) and source documentation. 
8.8.1 Follow- up Visits for Early Termination from Treatment Period  or from 
Post-Treatment Follow -up Period 
Any patient who discont inues early from the t reatment p eriod or from post-t reatment follow-up 
period  should be followed as per the platelet monitoring rules shown in Table 3 , Section 8.6.3 for 
the first 6 weeks after discontinuing Study Drug .  Following this period, if the platelet count is 
stable (at least 3  consecutive values that are stable as determined by the Sponsor M edical 
Monitor and > 100,000/mm3), platelets should be tested 10 and 16 weeks post last dose (as per 
visit schedule).  
If a patient early terminat es from the treatment period , an ET visit ( Week  53 visit assessments) 
should be performed at the t ime of withdrawal,  and ideally within 2 weeks from the last dose of 
Study Drug, and patients should start the 16- week post-t reatment follow- up period to collect the 
study asse ssments in accordance with the Schedule of P rocedures in Appendix A . 
If the patient early terminates  from the post-t reatment follow-up period, a final visit ( assessments 
from the Week 16 of post-t reatment follow-up period ) should be performed at the time of 
withdrawal.  
8.9 Withdrawal of Patient s from t he Study  
Patient s must be withdrawn from the study for any of the following:  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
51  • Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
• The patient  meets any of the Exclusion C riteria (see Section 5.2) after enrolling in the 
study that in the opinion of the Investigator represents a safety risk to the patient   
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons 
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the eCRF . 
Any patient  who withdraws consent to participate in the study will be removed from fur ther 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET visit ( Week  53 visit assessments) and observations at the time of 
withdrawal  (Appendix A ). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  ET visit ( Week  53 visit assessments) and observations at the time of withdrawal 
(Appendix A) . 
8.10 Concomitant Therapy  and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the patient ’s 
eCRF .  AE s related to administration of these therapies or procedures must also be documented 
on the appropriate eCRF . 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including 
over-the-counter medications, herbal medications and vitamin supplements) administered  from  
the time the patient has signed the informed consent at s creening to the end of the post-t reatment  
follow-up per iod. 
Allowed Concomitant Therapy 
Use of the following is allowed only if the patient has been on a stable regimen for at least 
4 weeks prior to screening and is planned to remain on a stable regimen through the end of the post-t reatment follow-up period:  
• Lipid lowering drugs ( statins, ezetimibe,  PCSK9 inhibitors, niacin, fibrates, fish oil, other 
products containing omega-3 fatty acids (including OTC preparations) 
• Anti- platelet therapies  
• Testosterone, estrogens, progesterone, growth hormone, or progestins. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
52  Disallowed Concomitant Therapy 
Use of the following is disallowed: 
• Warfarin, direct thrombin inhibitors or Factor Xa inhibitors 
• Other experimental agents during the study including investigational drug, biological 
agent, or device within 1 month of Screening, or 5 half- lives of investigational agent, 
whichever is longer.  T his includes marketed agents at experimental dosages  
• Treatment with any non -Ionis oligonucleotide (including siRNA) at any time or prior 
treatment with an Ionis oligonucleotide or siRNA within 9 months of screening.  Patients 
that have previously received only 1 dose of an Ionis oligonucleotide as part of a clinical 
study may be included as long as ≥ 4 months has elapsed since dosing 
• Lipoprotein apheresis  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy . 
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between  
screening and the end of the post-t reatment follow-up period . 
8.11 Treatment Compliance  
Compliance with treatment dosing is to be monitored and documented by the Study Center staff and recorded in the eCRF .   
Patients or Study Center Staff will record treatment administered in a dosing diary that will be reviewed by Study  Center staff and  entered into the eCRF . 
8.12 Safety Monitoring Compliance 
Compliance with  safety monitoring requirements and treatment stopping rules must be 
documented by the Study Center staff.   
Patients and the Study Investigators are required to adhere to a strict program of monitoring of 
platelet count, and liver and renal function as described in Section 6.2.1, Sections  8.5.1- 8.5.3, 
and Sections 8.6.1- 8.6.3. 
While on treatment patients will be  required to have platelet counts every 2 weeks for the 
duration of the study and must not receive S tudy Drug without an interpretable platelet count 
result in the prior 2 weeks, in which case the Investigator must contact the patient to hold dosing until a new platelet count is obtained and reviewed, and will document this contact.  
While on treatment p atients will also be required to have renal function testing and assessment of 
biomarkers of renal damage every 2 weeks, and must not receive Study Drug if there are no test results for parameters considered critical to patient safety available within the prior 2 weeks.  In 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
53  such a case, the Investigator must contact the patient to hold dosing until these  or new tests are 
obtained and reviewed. 
Adherence to the program will be closely monitored by the Sponsor , and patients and trial sites 
that are unable or unwilling to comply with this important risk mitigation program will be 
discontinued from the study.  
Patients should be informed of the possibility and risks of a reduction in platelet count, and of 
potential hepatic and renal risks,  and the importance of adherence to the monitoring program.  
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) , or a ny 
event meeting renal stopping rules criteria described in Section 8.6.2 are considered adverse event s of special interest and should be reported in an expedited fashion to the Sponsor. 
9. SERIOUS AND NON- SER IOUS ADVERSE EVENT REPORTING   
9.1 Sponsor Review of Safety Information 
Safety informatio n will be collected, reviewed, and evaluated  by the Sponsor or designee in 
accordance with the Safety Management P lan throughout the conduct of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators of suspected unexpected serious advers e reactions (SUSARs) per the International 
Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory 
requirements will be followed in accordance with local country regulations and guidelines. 
Institutional Review Boards (IRB )/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations. 
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent a ssessment of relatedness .  While the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the 
Investigator’s opinion for the purposes of determining whether the SAE meets the definition of a SUSAR.  
Appropriate personnel at the Sponsor or designee will unblind SUSARs for the purpose of 
regulatory reporting.  The Sponsor or designee will submit SUSARs to Regulatory Agencies in 
blinded or unblinded fashion according to local law.   
9.3 Definitions  
9.3.1 Adverse Event  
An adverse event (AE) is any unfavorable and unintended sign ( including a clinically -significant 
abnormal laboratory finding, for example ), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is consider ed related to the 
investigational drug product. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
54  9.3.2 Adverse Reaction and Unexpected  Adverse Reaction  
Adverse reaction:  All untoward and unintended responses to an investigational medicinal 
product related to any dose administered. 
Unexpected adverse reaction:   an adverse reaction, the nature or severity of which is not 
consistent with the applicable product information (e.g. Investigator's Brochure for an 
unauthorized investigational product or summary of product characteristics for an authoriz ed 
product).  
9.3.3 Serious Adverse Event (SAE)  
A SAE  is any AE  that in the view of either the Investigator or Sponsor, meets any of the 
following criteria:  
• Results in death  
• Is life threatening,  that is, poses an immediate risk of death at the time of the event  
• An AE or adverse reaction is considered “life-threatening” if, in the view of either the 
Investigator or Sponsor, its occurrence places the patient  at immediate risk of death .  It 
does not include an AE  or adverse reaction that, had it occurred in a more sev ere form, 
might have caused death  
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 
• Results in a congenital anomaly or birth defect in the offspring of the patient (whether the patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization , or the development of drug dependency or drug abuse 
9.3.3.1 Adverse Events of Special Interest  
For the purpose of this study severe reductions in platelet count < 50,000 mm3 as well as  any 
event meeting renal stopping rules criteria described in Section 8.6.2 are considered  as AE of 
special interest  and should be subject to expediting reporting to the Sponsor following the same 
requirements as for SAE reporting (Section 9.4.1). 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior t o the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as AEs unless the pre-existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
55  9.4.1 Serious Adverse Events/Adverse Events of Special Interest  
In the interest of patient  safety, and in order to fulfill regulatory requirements , all SAEs and AEs 
of special interest (regardless of their relationship to Study Drug ) should be reported to the 
Sponsor  or designee within 24 hours of the Study Center’s first knowledge of the  event .  The 
collection of SAEs will begin after the patient  signs the informed consent form and stop at the  
end of the patient ’s follow-up period .  When  the Investigator is reporting by telephone, it is 
important to speak to someone in person versus leaving a message.  An  Initial Serious Adverse 
Event Form should be completed and a copy should be emailed or faxed to the Sponsor or 
designee.  The contact information  for reporting SAEs is as follows:  
Attention:    
Email:    
Fax:    
Detailed information should be actively sought and included on Follow-Up Serious Adverse Event Forms as soon as additional information becomes available.  All SAEs will be followed until resolution  during the study period.  SAEs that remain ongoing past the patient ’s last 
protocol-specified follow- up visit will be ev aluated by the Investigator and Sponsor.  If the 
Investigator and Sponsor agree the patient ’s condition is unlikely to resolve, the Investigator and 
Sponsor will deter mine the follow -up requirement. 
All SAEs considered treatment- related , as defined in Section 9.4.3.1, w ill be reported by the 
Sponsor to the DSMB as described in Section 3.6.  
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patien t’s follow-up period .  The Investigator will monitor each  
patient  closely and record all observed or volunteered AEs on the Adverse Event Case Report 
Form.  
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opinion of the follo wing should be documented on the Adverse Event Case 
Report Form: 9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug  (ISIS  681257 or placebo) is characterized by 1 of the 
following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug , e.g., 
confirmation by positive re- challenge test  
• Possible:   The event cannot be explained by the patient’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug  (ISIS 681257 or placebo) administration  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
56  • Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions.  For repo rting purposes, 
Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by the patient’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug  
9.4.3.2 Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by the subject and does not affect the subject’s usual 
daily activities  
• Moderate:   The event causes the subject more discomfort and interrupts the subject’s 
usual daily activities  
• Severe:  The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3). 
9.4.3.3 Action Taken with Study Drug  
Action taken with Study Drug  (ISIS 681257 or placebo) due to the event is characterized by 1 of 
the following. 
• None:  No changes were made to Study Drug  (ISIS 681257 or placebo) administration 
and dose 
• Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the same dose 
• Temporarily Interrupted, Restarted Reduced Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the next lower dose  
• Permanently Discontinued:   Study Drug  was discontinued and not restarted 
9.4.3.4 Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for an  AE should be recorded on the 
Adverse Event Case Report Form .  Treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  eCRF , as appropriate. 
9.4.3.5 Outcome of the Adverse Event  
If the event is a non -serious AE , then t he event’s outcome is characterized by 1 of the following: 
• Ongoing:   Patient terminates from the trial and the AE continues 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
57  • Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Ons et Date of the 
corresponding SAE) 
• Change in Severity (if applicable):   AE severity changed  
If the event is an SAE , then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious eCRF  (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely fr om the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.5 Procedures for Handling Special Situations  
9.5.1 Abnormalities of Laboratory Tests 
Clinically -significant  abnormal laboratory test results may, in the opinion of the Investigator, 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant  abnormalities will be monitored by the Investigator until the parameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor Medical Monitor that monitoring is no longer necessary.  Laboratory abnormalities deemed not clinically -significant (NCS) by the Investigator should not be reported as AEs.  Similarly, 
laboratory abnormalities reported as AEs by the Investigator should not be deemed NCS on the laboratory sheet. 
The Investigator is responsible for reviewing and sig ning all laboratory reports .  The clinical 
laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values  and signatures . 
All platelet count results must be reviewed promptly (within 24 hours of receipt) by the Investigator or the designee to ensure that the count has not met the stopping rule and to determine whether the rate of decline is suggestive that the patient could be approaching the dose interru ption rule of 75,000/mm
3 as specified in Section 8.6.3. 
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered a n adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor as per Sections 9.3.3.1 and 9.4.1).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
58  All results of liver function tests must be reviewed promptly (within 24 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met the stopping rules per Section  8.6.1. 
All results of renal function tests must be reviewed promptly (within 24 hours of receipt) by the Investigator or the designee to ensure that the result has not met the stopping rules per Section  8.6.2. 
Any event meeting renal stopping rules criteria descr ibed in Section 8.6.2 is considered an 
adverse event of special interest and should be reported in an expedited fashion to the Sponsor as per Sections 9.3.3.1 and 9.4.1).  
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospitalized; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study 
• The condition that required the prescheduled or elective procedure or routinely scheduled 
treatment was present before and did not worsen or progress in the opinion of the Investigator between the patient ’s consent to participate in the study and the timin g of the 
procedure or treatment .  The condition is documented in the patient’s medical history. 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospital admission 
9.5.3 Dosing Errors  
Study Drug  (ISIS 681257 or placebo) errors should be documented as Protocol Deviations.  A 
brief description should be provided in the deviation, including whether the patient  was 
symptomatic (list symptoms) or asymptomatic, and the ev ent was accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of Study Drug  (ISIS 681257 or placebo) that exceeds protocol specifications and the patient  is 
symptomatic, then the symptom(s) should be documented as an AE  and be reported per 
Section  9.4. 
Should an overdose occur , the Investigator or designee should contact the Sponsor or designee 
within 24 hours. 
9.5.4 Contraception and Pregnancy 
Male and female patients  of childbearing potential must continue to use appropriate 
contraception with their partners, or refrain from sexual activity, as described in Section 6.3.1. 
If a patient  becomes pregnant or a pregnancy is suspected, or if a male patient makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately .  An Initial Pregnancy Form should be submitted to the Sponsor or 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
59  designee within 24 hours  of first learning of the occurrence of  pregnancy.  Follow-up 
information including delivery or termination is reported by designating as  ‘Follow-up’ on the 
Pregnancy Forms and reported within 24 hours of occurrence.  
Payment for all aspects of obstetrical care, child or related care will be the patient ’s 
responsibility. 
Female patient s:  If a suspected pregnancy occurs while on the study (including during the 
follow-up period ), a pregnancy test will be performed.  The patient  with a confirmed pregnancy 
will be immediately withdrawn from treatment with Study Drug.  However, the patient  will be 
encouraged to complete the Post- treatment Follow-up portion of the study to the extent that study 
procedures do not interfere with the pregnancy.  Regardless of continued study participation, the 
Investigator will assist the patient  in getting obstetrical care and the progress of the pregnancy 
will be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the pregnancy results in the birth of a child, the Study Center and 
Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth .  Follow-up will be performed to the ext ent permitted by the applicable regulations 
and privacy considerations. 
Male patient s:  The progress of the pregnancy of a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted  by the applicable regulations and 
privacy considerations. 
10. STATISTICAL CONSIDERATIONS  
The sections below indicate the overall structure and approach to the analysis of this study.  A 
detailed Statistical Analysis Plan (SAP) incorporating these sections  below will be prepared 
separately .  The SAP will outline all data handling conventions, including software, and specify 
additional statistical methods to be used for analysis.  
The study objectives are listed  in Section 1 . 
10.1 Study Endpoints, Subsets, and Covariates 
Efficacy and safety endpoints that will be evaluated after the last patient has completed the primary analysis time point are identified in the following sections. 
The primary efficacy and safety analysis time point is at Week 25 for patients who received 
every 4 -week  dosing (Cohorts A-C) and at Week 27 for patients who received weekly or 
biweekly dosing (Cohort s D and E).  For patients continuing treatment beyond the primary 
analysis time point additional supportive efficacy and safety analyses will be repeated at the completion of Study Drug  treatment. 
10.1.1 Primary Endpoint(s) 
The primary efficacy endpoint is the percent change in Lp(a) from baseline at the primary 
analysis time point achieved by ISIS 681257 compared to pooled placebo. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
60  Lp(a) levels will be analyzed from patient blood samples taken at specified time points 
throughout the study. 
10.1.2 Secondary Endpoints 
The secondary endpoints include the following parameters from baseline at the primary analysis 
time point for ISIS 681257 compared to placebo: 
• Percent change from baseline in LDL -C  
• Proportion of patients who achieve plasma Lp(a) ≤  50 mg/dL  (≤ 125 nmol/L) 
• Proportion of patients who achieve plasma Lp(a) ≤  30 mg/dL  (≤ 75 nmol/L) 
• Percent change from baseline in apoB  
• Percent change from baseline in OxPL -apo(a) 
• Percent change from baseline in OxPL -apoB 
10.1.3 Safety Endpoints 
The safety analysis will be performed using the following parameters: 
• AEs  
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)  
• Proportion of patients with platelet drop by severity, including platelet drop below lower 
limit of normal (LLN), platelet drop greater than 30% from Baseline, or any platelet drop meeting stopping rules.  
• Proportion of patients with liver adverse event s by severity, number of patients meeting 
liver stopping rules, and change in liver function tests by severity .   
• Proportion of patients with renal adverse e vents by severity, number of patients meeting 
renal stopping rules, and change in renal function tests by severity. 
• ECGs  
• Use of concomitant medications  
10.1.4 Dose Selection  
Dose selection for  the further development will be based on the following efficacy and safety 
considerations; more than 1 dose may meet these criteria.  An effective dose, or dose regimen, will be one that achieves clinically -meaningful  reduction in plasma Lp(a) levels.  Sa fety will be 
evaluated on the basis of incidence of expected and unexpected treatment -related SAEs and other 
specific safety considerations including the incidence of platelet reductions , and renal or hepatic 
injury.   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
61  10.2 Sample Size Considerations  
Based  upon prior clinical trial experience with ISIS 681257, it is estimated that the standard 
deviation of the percent change in Lp(a) is approximately 20%.  W ith 23 patients in each 
ISIS 681257 treatment group and 23 in placebo group there would be approximately 90% power 
to detect a 20% difference in percent change in Lp(a) levels between the ISIS 681257 treatment 
groups and placebo group at an alpha level of 0.05, assuming 30% reduction in the ISIS 681257 patients and 10% reduction in the placebo patients. 
Based upon prior clinical trial experience with Ionis  ASOs, a ssuming the incidence rate of 
platelet count below lower limit of normal (LLN) in placebo treated patients is 1.9 %, in the 
ISIS 681257 treated patients is 3.8%, twice the incidence rate observed i n placebo,  with 
45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to 
detect at least 1 event.  
Therefore, approximately 270 patients (54 patients per cohort, including 45 patients per cohort treated with ISIS 681257) will be randomized to ensure that both the safety and efficacy of ISIS 681257 will be adequately characterized in the study. 
10.3 Analysis Populations 
Full Analysis Set (FAS):  All patients who are  randomized, received at least 1 dose of Study 
Drug  (ISIS  681257 or placebo), and have a Baseline Lp(a) assessment .  The FAS represents the 
practically -feasible intent -to-treat (ITT) population as delineated in ICH Guideline E9.  This 
population will be used for the primary analysis of efficacy.   
Per Protocol Set ( PPS) :  Subset of the FAS who received within 6 months at least 5 monthly 
doses of Study Drug  for patients randomized in Cohorts A, B, and C or at least 20 weekly doses 
for patients randomized in Cohorts D and E, and who have no major protocol violations that could compromise the interpretation of efficacy.  Major violations will be determined prior to 
unblinding for statistical analysis .  This population will be used for supportive inferences 
concerning efficacy.  
Safety Set :  All patient s who are randomiz ed and receive at least 1 dose of Study Drug.  This 
population will be used for all safety analyses.   
PK Population:  All patients who are randomized and received at least 1 dose of Study Drug , and 
have sufficient data for the analysis of PK parameters .  This population will be used for analysis 
of PK data. 
10.4 Definition of Baseline  
Baseline for Lp(a), LDL-C, apoB, OxPL -apo(a), OxPL -apoB, and other lipid measurements  will 
be defined  the pre- dose measurement on Day 1 or closest to Day 1, prior to administration of 
Study Drug.  The baseline for other measurements  is defined as the last non- missing assessment 
prior to the first dose of Study Drug . 
10.5 Interim Analysis  
No interim efficacy analysis will be performed . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
62  10.6 Planned Methods of Analysis  
Summary tabulations will be provided for disposition, demographic, baseline, efficacy, and 
safety data as noted in the following sections.  Hypothesis testing will be used for the primary efficacy endpoint and select secondary efficacy endpoints. 
All eCRF data, lab data transfers, and any outcomes derived from the data will be provided in the 
patient data listings .  Patient data listings will be presented for all patients enrolled into the study .  
Descriptive summary statistics including n, mean, median, standard deviation, standard error, interquartile range (25th percentile, 75th percentile), and range (minimum, maximum) for continuous variables, and counts and percentages for categorical variables will be used to summarize most data .  Where appropriate, p -values will be reported.  All statistical tests will be 
conducted using 2- sided tests with 5% Type I error rate unless otherwise stated.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by 
treatment group.  The patient disposition will be summarized  by treatment group .  All patients 
enrolled will be included in a summary of patient disposition. 
10.6.2 Safety Analysis  
10.6.2.1 Adverse Events  
Treatment duration and amount of Study Drug  (ISIS 681257 or placebo) received will be 
summarized by treatment group .  Patient  incidence rates of all AE s will be tabulated by 
MedDRA system organ class, and by MedDRA preferred term .  Narratives of treatment -
emergent  deaths, serious and significant AE s, including early withdrawals due to AE s, will also 
be provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug , all 
treatment -emergent  serious AEs, and all treatment -emergent serious AEs potentially related to 
Study Drug  (ISIS  681257 or placebo) will be summarized. 
10.6.2.2 Clinical Laboratory Data 
Laboratory tests to ensure patient  safety including chemistry panel, complete blood count (CBC) 
with differential, coagulatio n panel, complement, etc., will be summarized by study visits for 
each treatment group .  These safety variables will also be presented as change and percent 
change from baseline over time after Study Drug  (ISIS  681257 or placebo) administration, as 
appropr iate.  In addition, the number of patients who experience abnormalities in clinical 
laboratory evaluations will be summarized by treatment group.  
10.6.2.3 Vital Signs and Examinations Vital sign and ECG measures will be tabulated by treatment group .   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
63  10.6.3 Efficacy Analysis  
10.6.3.1 Analysis of Primary Efficacy Endpoint 
The primary analysis of the primary endpoint will be the pairwise comparison of percent change 
from baseline to primary analysis time point in fasting Lp(a) between ISIS  681257 treatment 
groups and pooled placebo group in the FAS.  The data will be analyzed using an analysis of 
covariance (ANCOVA) model with the Baseline Lp(a)  as a covariate.  Missing data may be 
handled by LOCF or multiple imputation methods ( Schafer 1997; Schafer 1999 ). 
The primary efficacy analysis will take place after the last patient has completed the primary 
analysis time point, and the database has been locked,  
The following sensitivity analyses will be conducted : 
• The primary analysis will be repeated in the PPS  
• The primary efficacy endpoint will be analyzed using a Wilcoxon Rank Sum test on both 
FAS and PPS, and the treatment effect will be estimated using Ho dges-Lehmann 
estimator  
Additional sensitivity analyses may be conducted as appropriate; the details of these analyses 
will be outlined in the SAP.  
10.6.3.2 Analysis of Secondary Efficacy Endpoints 
• Percent change from baseline at  the primary analysis time point in fasting LDL -C will be 
compared between  each ISIS  681257 treatment groups and pooled placebo group usi ng 
an ANCOVA model with baseline as covariate  
• Proportion of patients who achieve ≤ 50 mg/dL ( ≤ 125 nmol/L) in fasting Lp(a) at the 
primary analysis time point will be compared between each  ISIS 681257 treatment group 
and pooled placebo group using a logistic regression model with Baseline Lp(a) as a 
covariate.  Proportion of patients who achieve ≤ 30 mg/dL  (≤ 75 nmol/L) in fasting Lp(a) 
at the primary analysis time  point will be analyzed similarly  
• Percent change from baseline at  the primary analysis t ime point in fasting apoB, 
OxPL -apo(a) and OxPL- apoB will be compared between  ISIS 681257 treatment groups 
and pooled placebo group using an ANCOVA model with baseline as covariate  
All analyses of secondary endpoints will be performed on the FAS as primary and PPS as supportive. 
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
For all patients, trough and post- treatment concentrations of  ISIS 681257 in plasma (a s total full 
length oligonucleotides, including fully conjugated, partially conjugated, and unconjugated 
ISIS 681257) will be determined and summarized by treatment with stratification by subject 
immunogenicity status  using descriptive statistics . 
In addition, non- compartmental PK  analysis of ISIS 681257 concentrations will be carried out on 
each indivi dual patient data set  in patients who received ISIS 681257 treatment, and the plasma 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
64  disposition half- life (t 1/2λz) associated with the apparent terminal elimination phase will be 
calculated, if appropriate, using available data at the End-of-T reatment and the post-t reatment 
follow-up period from the equation, t 1/2λz = 0.693 /λz, where λz is the rate constant associated with 
the apparent terminal elimination phase. 
For patients in the PK subgroup only, non- compartmental PK  analysis of ISIS 681257 will be 
carried out on each individual patient data set in patients who received ISIS 681257 treatment .  
The maximum observed drug concentration (C max) and the time taken to reach C max (Tmax) will 
be obtained directly from the concentration- time data .  Following single dosing (Day 1), area 
under the plasma concentration- time curve from time zero (pre -dose) to 24 hours after the dose 
(AUC 0-24hr) will be calculated using the linear trapezoidal rule .  Following multiple dosing, 
AUC 0-24hr and area under the plasma concentration -time curve during the time of each sampled 
dosing interval (tau,τ) at steady -state (AUC τ) will be calculated using the linear trapezoidal rule.  
Other PK  parameters, as appropriate, may be determined or calculated at  the discretion of the PK  
scientist.  Plasma PK  parameters will be summarized using descriptive statistics  with 
stratification by subject immunogenicity status .  Exposure-response relationships between 
selected PD  [e.g., Lp(a)]  and PK  measures (including b ut may  not be limited to plasma trough 
concentrations) may be explored (including with and without stratification by IM status)  in this 
study, or in a separate population PK analysis with all clinical studies combined . 
The immunogenicity (IM) of ISIS 681257 will be assessed before, during, and after treatment 
with Study Drug  (ISIS 681257 or placebo) .  The IM incidence (number) and incidence rate 
(percent) will be summarized at each evaluated study time point and at the patient level by treatment and dose, as the total number of and percent of evaluated patients with antibody negative, positive, and unknown status.  Study patients with positive anti-ISIS 681257 antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transien t’, or not 
determinable .  Potential relationships of immunogenicity with selected efficacy, safety, and PK  
measures may be evaluated.  
Additional details regarding the PK  and immunogenicity analysis will be described in the S AP. 
11. INVESTIGATOR’S R EGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential patient population, based on an English version provided by the Sponsor or designee. 
Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  or legally acceptable representative after adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of the study and before any  
protocol- specific screening procedures or any Study Drug  ISIS 681257 or placebo) are 
administered . 
Importantly, patients should be informed of the possibility and risks of a reduction in platelet 
count and other potential risks, in particular hepatic and renal  risks , and the importance of strict 
adherence to the monitoring program.  The patient  or legally acceptable representative must be 
given sufficient time to consider whether to participate in the study.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
65  The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by the patient  or a legally acceptable 
representative and by the person who conducted the informed consent discussion (not necessarily 
an Investigator).  The original signed informed consent form should be retained in the Study 
Master File and in any other locations required by institutional policy, and a copy of the signed consent form should be provided to the patient  or legally acceptable representative. 
11.2 Ethical Conduct of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October  2013 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory requirements will be strictly followed . 
11.3 Independent Ethics Committee  (IEC)/Institutional Review Board (IRB) 
A copy of the protocol, proposed informed consent form s, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor or designee before recruitment of patient s into the study and shipment of Study Drug.  A 
copy of the written approval of any other items/materials that must be approved by the Study Center  or IEC/IRB must also be received by the Sponsor or designee before recruitment of 
patient s into the study and shipment of Study Drug.  The Investigator’s Brochure must be 
submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to  and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should also notify the IEC/IRB of SAEs  occurring at the Study Center and other AE 
reports receiv ed from the Sponsor or designee, in accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study in accordance with local procedures .   
11.4 Patient  Confidentialit y 
The Investigator and Sponsor must ensure that the patient ’s confidentiality is maintained .  On the 
case report forms or other documents submitted to the Sponsor or designee , patient s should be 
identified by initials (if permitted by local law) and a patient  identification  number only.  
Documents that are not for submission to the Sponsor or designee ( e.g., signed informed consent 
forms) should be kept in strict confidence by the Investigator. 
In compliance with Federal and local regulations/ICH GCP Guidelines,  it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
66  12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1 Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee.  
Agreement from the Investigator must be obtained for all protocol amendments and amendments 
to the informed consent document.  The regulatory authority and IEC/IRB  must be informed of 
all amendments and give approval for any amendments likely to affect the safety of the patient s 
or the conduct of the trial.  The Investigator must send a copy of the approval letter from the 
IEC/IRB  to the Sponsor or designee.  
12.2 Study Termination 
The Sponsor or designee reserves the right to terminate the study .  The Investigator reserves the 
right to terminate their participation in the study , according to the terms of the site contract.  The  
Investigator/Sponsor or designee should notify the IEC/IRB  in writing of the trial’s completion 
or ET.  An Investigator who terminates participate is required to send a copy of the IEC/IRB 
notification to the Sponsor or designee. 
12.3 Study Documentation and Storage  
Source documents are original documents, data, and records from which the patient ’s case report 
form data are obtained .  These include but are not limited to hospital records, clinical and office 
charts, laboratory and pharmacy records, diaries , imaging , and correspondence.  In thi s study, 
eCRF  may not be used as source documents. 
The Investigator and S tudy Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by representatives from 
the Sponsor or designee and/or applicable r egulatory authorities .  Elements should include: 
• Patient  files containing completed case report forms, informed consents, and supporting 
copies of source documentation 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copies 
of pre -study documentation and all correspondence to and from the IEC/IRB  and the 
Sponsor or designee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug  Product 
Accountability Record, Return of Study Drug  Product for Destruction, final Study Drug  
product reconciliation, and all drug- related correspondence  
In addition, all original source documents supporting entries in the case report forms must be 
maintained and be readily available for the duration required by GCP or local regulatory requirements, whichever is longer. 
No study document should be destroyed without prior written agreement between the Sponsor or 
designee and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify the Sponsor or designee, in accordance with GCP . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
67  12.4 Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that patient  confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to patient  medical records and other study- related records 
needed to verify the entries on the case report forms.  Source dat a should be attributable, legible, 
contemporaneous, original, and accurate (ALCOA) and must meet the regulatory requirements for recordkeeping. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinical Quality Assurance Department (or designees).  Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study- related records will occur to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data received by  the Sponsor or designee.  During this review, patient data will be 
checked for consistency, omissions, and any apparent discrepancies.  In addition, the data will be reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be 
sent to the Study Center  for completion and return to Sponsor or designee . 
The Principal Investigator will sign and date the indicated places on the case report form .  These 
signatures will indicate that the Prin cipal Investigator inspected or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content in accordance with the general investigational plan . 
12.5 Language 
Case report forms must be comple ted in English .  Whenever possible, the trade name rather than 
the generic name for concomitant medications should be recorded and if possible, in English.  
Generic names are acceptable if the trade name is unknown .  Combination medications should be 
recor ded using their trade name in English if possible.  
All written information and other material to be used by patient s and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated and/or compensated for any study -
related illness/injury in accordance with the information provided in the Compensation for Inj ury 
section of the Informed Consent document. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
68  13. REFERENCES  
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Bennett CF . Pharmacological properties of 2ʹ -O-methoxyethyl -modified olig onucleotides . In: Crooke ST, editor . 
Antisense Drug Technology: Principles, Strategies and Applications, 2nd Edition . Boca Raton, FL . Taylor & Francis 
Group 2008; 365- 400. 
Bergmark C, Dewan A, Or soni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized 
phospholipids in human plasma . J Lipid Res 2008; 49: 2230- 2239.  
Bertoia ML, Pai JK, Lee J -H, et al. Oxidation -specific biomarkers and risk of peripheral artery disease. J Am Coll 
Cardiol 2013; 61(21): 2169- 2179.  
Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium . Genetic variants associated with Lp(a) 
lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518- 2528.  
Desai NR, Kohli P, Giugliano RP , et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin 
kexin type 9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LAPLACE -TIMI 57 Trial. Circ 2013; 128:  962-969. 
Dubé JB, Boffa MB, Hegele RA, Koschinsky ML . Lipoprotein(a): more interesting than ever after 50 years . Curr 
Opin Lipidol 2012; 23(2): 133 -140. 
Erqou S, Kaptog e S, Perry PL, et al; Emerging R isk Factors Collaboration . Lipoprotein(a) concentration and the risk 
of coronary heart disease, stroke, and nonvascular mortality . JAMA 2009; 302(4): 412- 423. 
Erqou S, Thompson A, Di Angelantonio E, et al. Apoliporotein(a) isoforms and the risk of vascular disease . JACC 
2010; 55(19): 2160- 2167.  
Frazer KA, Narla G, Zhang  JL, Rubin E . The apolipoprotein(a) gene is regulated by sex hormones and acute -phase 
inducers in YAC transgenic mice . Nat Gen 1995; 9: 424- 431. 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor- α phosphorothioate 2ʹ -O-(2-
meth oxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma 
lipoprotein (a) levels in humans. J Lipid Research 2016; 57: 340- 351. 
Guyton JR . Niacin in cardiovascular prevention: mechanisms, efficacy, and safety . Curr Opin Lipidol 2007; 18: 
415-420. 
Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulatio n in 
mice . J Pharmacol Exp Ther 2000; 292(2): 468- 479. 
Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to 
reduce high lipoprotein(a) levels and major adverse coronary events . Nat Clin Pract Cardiovasc Med 2009; 6(3): 
229-239. 
Kamstrup PR, Tybjaerg -Hansen A, Steffensen R, Nordestgaard BG . Genetically elevated lipoprotein(a) and 
increased risk of myocardial infarction . JAMA 2009; 301(22): 2331- 2339.  
Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein -associated phospholipase A2 
activity, and 10 -year cardiovascular outcomes: prospective results from the Bruneck study . Arterioscler Thromb 
Vasc Biol 2007; 27: 1788- 1795.  
Koschinsky ML and Marcovina SM . Structure -function relationships in apolipoprotein(a): insights into 
lipoprotein(a) assembly and pathogenicity . Curr Opin Lipidol 2004; 15(2): 167- 174. 
Kronenberg F and Utermann G . Lipoprotein(a): resurrected by genetics . J Intern Med 2013; 273: 6- 30. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
69  Leebmann J, Roeseler E, Julius U, et al; Pro(a)LiFe Study Group . Lipoprotein apheresis in patients with maximally 
tolerated lipid -lowering therapy, lipoprotein(a) -hyperlipoproteinemia, and progressive cardiovascular disease: 
Prospective observational multicenter study . Circ 2013; 128: 2567- 2576.  
Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and 
lipoprotein(a) . J Lipid Res 2013; 54: 2815- 2830.  
Li Y, Luke MM, Shiffman D, Devlin JJ . Genetic variants in the apolipoprotein(a) gene and coronary heart disease.  
Circ Cardiovasc Genet 2011; 4(5): 565- 573. 
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C -α expressi on. J Biol Chem 1999; 274: 1715- 1722.  
Merki E, Graham M, Taleb A,  et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) in 
transgenic mice. JACC 2011; 57(15): 1611- 1621.  
Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel . Lipoprotein(a) as 
a cardiovascular risk factor: current status . Euro Heart J 2010; 31: 2844- 2853.  
Parker K, Brunton L, Goodman LS, et al. Goodman & Gilman's the pharmacological basis of therapeutics . New 
York, NY. McGraw -Hill. 2006; ISBN 0- 07-142280- 142283.  
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10 -fold in mice . Nucleic Acids Res 2014; 42: 8796- 8807.  
Prakash TP, Yu J, Migawa MT, et al. Comprehensive structure -activity relationship of triantennary N-Acetyl 
galactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes . J Med Chem 2016 
Mar 24; 59(6): 2718- 2733.  
Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168- 186. 
Raal FJ, Honarpour  N, Blom  DJ, et al. Inhibition of PCSK9 with evolucomab in homozygous familial 
hypercho lesterolemia (TESLA Part B): a randomized, double blind, placebo controlled trial. Lancet 2015; 385: 
341-350. 
Rand ML, Sangrar W, Hancock MA, et al. Apoliprotein(a) enhances platelet responses to the thrombin receptor – activating peptide SFLLRN . Arterio T hromb Vasc Biol 1998; 18: 1393- 1399.  
Rosada A, Kassner U, Vogt A, et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 2014; 38: 135- 141. 
Safarova M. Specif ic lipoprotein(a) apheresis reduces atherosclerosis progression . 80th Congress of the European 
Atherosclerosis Society, Milan, Italy 28 May 2012.  
Schafer JL . Analysis of Incomplete Multivariate Data, New York: Chapman and Hall 1997.  
Schafer JL . Multiple im putation: a primer, Statistical Methods in Medical Research 1999; 8: 3 –15. 
Schulman S and Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medical products in non -surgical patients. J Thromb Haemost 2005; 3(4): 692- 694. 
Spence JD and Koschinsky M . Mechanisms of lipoprotein(a) pathogenicity . Arterioscler Thromb Vasc Biol 2012; 
32: 1550- 1551.  
Stockert RJ . The asialoglycoprotein receptor: relationships between structure, function, and expression . Physiol  Rev 
1995; 75: 591- 609. 
Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group . Genetic 
associations with valvular calcification and aortic stenosis . N Engl J Med 2013; 368(6): 503- 512. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
70  Thygesen K, Alpert JS, Jaffe AS , et al. Third universal definition of myocardial infarction.  Circ 2012;  126: 
2020- 2035.  
Tsimikas S, Mallat Z, Talmud PJ, et al.  Oxidation -specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal 
coronary events . J Am Coll Cardiol 2010; 56: 946- 955. 
Tsimikas S, Willeit P, Willeit J, et al. Oxidation -specific biomarkers, prospective 15 -year cardiovascular and stroke 
outco mes, and net reclassification of cardiovascular events . J Am Coll Cardiol 2012; 60: 2218- 2229.  
Tsimikas S, Duff GW, Berger PB, et al. Pro -inflammatory interleukin -1 genotypes potentiate the risk of coronary 
artery disease and cardiovascular events mediated  by oxidized phospholipids and lipoprotein(a) . J Am Coll Cardiol 
2014; 63: 1724- 1734.  
Yu RZ, Kim TW, Hong A, et al. Cross- species pharmacokinetic comparison from mouse to man of a second -
generation antisense oligonucleotide, ISIS 301012, targeting human ap olipoprotein B -100.  Drug Metab Dispos 
2007; 35: 460- 468.  
Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway Factor XI by antisense 
oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2 010; 116: 4684- 4692.  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
71   
  
 
  
 
14. APPENDICES  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5 
Protocol   30 May  2017  
 
72   
  
 
  
 
Appendix A  Schedule of Procedures 
 
Schedule of Procedures for Weekly and Every 2 -Week  Dosing Cohorts  
Schedule of Procedures for Every 4-Week Dosing Cohorts  
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
73  Appendix A  Schedule of Procedures  – Weekly and Every 2 -Week Dosing  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post L ast Dose 
Visit and Testing Window  +/- Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                      
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                     
Medical History c X                      
Vital Signs  X X  X X X X X X X   X X X X X X X X X X 
Physical Examination  X X  X  X  X  X    X  X  X X X X X 
Body Weight and Height  d X         X      X      X 
12- lead ECG (triplicate)  X X  X  X  X  X    X  X  X X X X X 
24-Hour Urine for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i X X X 
Genetic Testing   X  
Chemistry Panel j,k X EVERY 14 DAYS f X X X X   X X X X X X X X X X 
Hematology   j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh  Xh  
Platelet Function   X  X X X X X X X   X X X X X X X X X X 
Coagulation  X X        X             
Hepatitis B, C, HIV  X                      
Thyroid Panel  X                      
hsCRP   X        X         X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X X3 X1 X2 X  X    X X X X 
ISIS 681257 Antibodies   X  X X X    X         X   X 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
74  Appendix A  Schedule of Procedures – Weekly and Every 2 -Week  Dosing  Continued  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post L ast Dose 
Visit  and Testing  Window +/ - Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if applicable)  j, m X                      
Serum Pregnancy  Test m X X  X X X X X X    X X X X X X X X X X 
Archived Serum & Plasma 
Samples  j, n  X   X  X   X     X  X  X X X X 
PD Panel  j X X  X X X X X  X   X  X  X  X X X X 
Lipid Panel  j X X  X X X X X  X   X  X  X  X X X X 
Lp(a) Characterization   X   
Study Drug:  SC Injection   WEEKLY AND EVERY 2 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG  
(Week 1 through Week 53/Day 365)o    
Adverse Events  X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which i s the day of first Study Drug  dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in Appendix B under Extended Urinalysis should be  performed, including routine urinalysis, urine microscopy, UACR and UPCR. 
f Assessments and procedures to be conducted by either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 week s apart  during the t reatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then at Week 10 and Week 16 Follow -up visits .  
i Serum  Creatinine and Cys -C will be c ollected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone sample s at time 
points when a chemistry panel is not performed.  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
75  Appendix A  Schedule of Procedures – Weekly and Every 2 Week  Dosing Continued  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quantity not sufficient) a repeat blood  
specimen should be re -drawn as soon as possible (ideally within 7 days).   All platelet count results will be reviewed promptly (within 24 hours of receipt) by the 
Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor . 
l Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal . 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) and will be retained until completion of the final 
study report . 
o Patients will continue treatment in the study for 12 months, or until the last patient enrolled reaches 6 months of exposure.  When this  milestone  is met, all 
patients still on treatment will then enter a 16-week post -treatment follow -up period.  
 
Time (time is in reference t o Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8 hours post SC injection 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
76  Appendix A  Schedule of Procedures – Every 4-Week Dosing 
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post  Last D ose 
Visit and Testing Window  +/- Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                       
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                      
Medical History  c X                       
Vital Signs  X X  X X X X X X     X X X X X X X X X X 
Physical Examination  X X  X  X  X X      X  X  X X X X X 
Body Weight and Height  d X        X        X      X 
12- lead ECG (triplicate)  X X  X  X  X X      X  X  X X X X X 
24-hour Urine  for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i X X X 
Genetic Testing   X   
Chemistry Panel  j, k X EVERY 14 DAYS f X X X     X X X X X X X X X X 
Hematology  j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh Xh 
Platelet Function   X  X X X X X X     X X X X X X X X X X 
Coagulation  X X       X               
Hepatitis B, C, HIV  X                       
Thyroid Panel  X                       
hsCRP   X       X           X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X3 X1 X2 X X X  X    X X X X 
ISIS 681257 Antibodies   X  X X X   X           X   X 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
77  Appendix A  Schedule of Procedures – Every 4 -Week Dosing Continued  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post Last D ose 
Visit and Testing Window +/ - Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if 
applicable)  j, m X                       
Serum Pregnancy Test  m X X  X X X X X X     X X X X X X X X X X 
Archived Serum & Plasma  
Samples j, n  X   X  X  X     X  X  X  X X X X 
PD Panel  j X X  X X X X X X    X X  X  X  X X X X 
Lipid Panel  j X X  X X X X X X   X X X  X  X  X X X X 
Lp(a) Characterization   X   
Study Drug:  SC Injection   EVERY 4 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 through Week 49/Day 337)o    
Adverse Events  X X X X X X X X X X X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X X X X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which is the day of first Study Drug  dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in Appendix B under Extended Urinalysis should be performed, including routine urinalysis, urine microscopy, UACR and UPCR. 
f Assessments and procedures to be conducted by either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 weeks apart during the t reatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then at Week 10 and Week 16 Follow -up visits.  
i Serum  Creatinine and Cys -C will be c ollected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone sample s at time 
points when a chemistry panel is not performed.  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
78  Appendix A  Schedule of  Procedures – Every 4 -Week Dosing Continued  
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quantity not sufficient) a repeat blood 
specimen should be re- drawn as soon as possible (ideally within 7 days).   All platelet count results will be reviewed promptly (within 24 hours of receipt) by the 
Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor . 
l Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal . 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or  
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.)  and will be retained until completion of the final 
study report . 
o Patients will continue treatment in the study for 12 months, or until the last pati ent enrolled reaches 6 months of exposure.   When this milestone is  met, all 
patients still on treatment will then enter a 16-week post -treatment follow -up period.  
 
Time (time is in reference to Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8, hrs post SC injection  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
79   
 
 
  
 
 
Appendix B  L ist of L aboratory Analytes 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
80  Appendix B  List of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better characterize the profile of ISIS  681257 or other similar 
oligonucleotides. 
Clinical Chemistry 
Panel  
• Sodium 
• Potassium  
• Chloride  
• Bicarbonate  
• Total protein  
• Albumin  
• Calcium 
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Cholesterol  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect (unconjugated) 
bilirubin  
• ALT  
• AST  
• ALP  
• Creatinine kinase 
• GGT  
• Cys-C 
 Screening Tests  
• Hepatitis B surface 
antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG (women only)  
• TSH  
• Free T4  
• Free T3  
 
Coagulation  
• aPTT  
• PT 
• INR 
• Fibrinogen  
• Plasminogen  
 
PD Panel  
• Lp(a)  
• OxPL -apoB  
• OxPL -apo(a)  
 
Lipid Panel  
• Total Cholesterol  
• LDL cholesterol  
• HDL cholesterol  
• ApoB  
• Triglycerides  
• VLDL  Lp(a) Characterization  
• Apo(a) isoforms  
 
Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  (WBC)  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 681257 (total full 
length ASO) levels in plasma  
 
Immunogenicity  
• Anti-ISIS 681257 
antibodies  
 
Genetic Testing  
• LPA SNPs associated with elevated Lp(a)   
 Inflammatory 
• hs-CRP  
 
Extended Urinalysis 
• Routine  Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Blood 
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio  (UPCR) 
• A/C Ratio  (UACR) 
 
Renal Urine 
Biomarkers2 
• NGAL   
• NAG  
• KIM -1 
• Cys-C 
 
24 Hour Urine Test3 
• Creatinine clearance 
• Protein  
• Albumin  
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation purposes, stability assessments, metabolite assessments, or to assess other actions of ISIS  681257 with plasma 
constituents  
2 All samples will be collect ed, handled and stored under the conditions specified for  the assay s. Please refer to 
the study Laboratory Manual for details on the appropriate handling and storage methods for biomarker and 
other samples .   
3 To be performed during Screening upon confirmation of eligibility  
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
81   
 
  
 
  
Appendix C PK Sampling Schedule  
 
Sampling Schedule for Week ly and Every 2 -Week  Dosing Cohorts  
Sampling Schedule for Every 4-Week Dosing Cohorts  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
82  Appendix C  PK Sampling Schedule  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected prior to dosing, and at various times 
throughout the dosing and post-t reatment follow-up period  as noted in the tables below.  Plasma PK samples may also be used for 
profiling of drug binding proteins, bioanalytical method validation purposes, stability and metabolite assessments, immunogenicity 
testing (or possibly for purposes of immunogenicity assay development and/or validation), or to assess other actions of ISIS 681257 
with plasma constituents .  Extensive PK samples w ill be collected in PK subgroup only (10 subjects per cohort) (see tables below): 
Sampling Schedule for Weekly and Every 2 -Week  Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 183 184 185 197 253 365 *Post L ast Dose 
All 
Patients Pre-
dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group  
Only  Pre-dose, 1, 2, 4, & 8-hr
1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose, 1, 2, 4, & 8-hr
1 24-hr2 48-hr3 Pre-dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hrs  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
83  Appendix C  PK Sampling Schedule Continued  
Sampling Schedule for Every 4-Week Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 26 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 170 171 176 183 197 253 365 *Post L ast Dose  
All 
Patients Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose , NA NA NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group  
only Pre-dose
, 
1, 2, 4, and 8-hr
1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  
Pre-dose , 
1, 2, 4, 
and 8-hr
1 24-hr2 48-hr3 Anytime  Anytime  Pre-dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hours allowed  
2 24-hr from previous dose of Study Drug.  Window of (+/-) 4 hours allowed  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours allowed  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
84   
 
  
 
  
Appendix D  Grading Scale for Adverse Events Relating to 
Laboratory Abnormalities  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
85  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
The following grading recommendations for adverse events relating to lab test abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010. 
 
  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
86  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
87  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 5  
Protocol   30 May 2017  
 
88   
 
  
 
  
Appendix E  Additional Laboratory Tests for Patients with 
Platelet Count ˂  100,000/mm3 
   
ISIS 681257-CS6 CONFIDENTIAL Amendment 5 
Protocol   30 Ma y 2017 
 
89  Appendix E Laboratory Tests to Be Performed in the Event of a Platelet Count 
˂ 100,000/mm3 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes. 
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for review) 
Fibrinogen split products or D-dimer on fresh blood 
To Be Performed at Central Lab 
Citrated sample for platelets 
Coagulation panel (PT/INR, aPTT) 
CBC with re ticulocytes 
Fibrinogen 
Total globulins, total IgA, IgG and IgM 
Complement:  total C3 , total C4, Bb, C5a 
hsCRP 
von Willebrand factor (vWF) Antigen 
Helicobacter pylori 
Serology for: 
HBV, HCV, HIV (if not done recently for screening) 
Rubella 
CMV 
EBV 
Parvo B19 
Auto-antibody screen: 
Antiphospholipid 
Rheumatoid factor 
Anti-dsDNA 
Anti-thyroid 
To Be Performed at Specialty Lab(s) 
Antiplatelet antibodies and Anti-PF4 assay 
Anti-ASO antibody 
Platelet Antibody Bead Array (PABA) 
 
  
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 Collaborator: 
Akcea Therapeutics  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 
 
IONIS  PHARMACEUTICALS,  INC. 
 
ISIS 681257-CS6 
 
 
A Randomized, Double- blind, P lacebo-Controlled, D ose-Ranging 
Phase 2  Study of ISIS 681257 A dministered Subcutaneously to 
Patients with H yperlipoproteinemia(a) and Established 
Cardiovascular Disease ( CVD) 
 
Protocol  Amendment 4 – 5 January 2017 
 
 
EudraCT No:  2016-003373-18 
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
4  Protocol Signature Page 
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose- Ranging Phase 2 
Study of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment:  Amendment 4 
Date:  5 January 2017  
 
I hereby acknowledge that I have read and understand the attached clinical protocol , entitled “ A 
Randomized, Double-blind, Placebo-C ontrolled, Dose -Ranging Phase 2 Study of ISIS 681257 
Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD) ,” dated 5 January 2017, and agree to conduct the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENTS  ................................................................................................... 9  
PROTOCOL SYNOPSIS  ........................................................................................................... 10  
STUDY DESIGN AND TREATMENT SCHEMA  .................................................................. 16  
STUDY GLOSSARY .................................................................................................................. 17  
1. OBJECTIVES  ................................................................................................................. 21  
1.1 Primary Objective  ..........................................................................................................21  
1.2 Secondary Objective(s)  ..................................................................................................21  
2. BACKGROUND AND RATIO NALE  .......................................................................... 21  
2.1 Overview of Disease  ......................................................................................................21  
2.1.1  Lipoprotein (a) ........................................................................................................21  
2.1.2  Pathophysiology .....................................................................................................23  
2.1.3  Current Treatment Options .....................................................................................23  
2.2 Therapeutic Rationale  ....................................................................................................24  
2.3 ISIS 681257 ...................................................................................................................24  
2.3.1  Mechanism of Action  .............................................................................................24  
2.3.2  Chemistry  ...............................................................................................................25  
2.3.3  Preclinical Experience  ............................................................................................25  
2.3.4  Clinical Experience ................................................................................................26  
2.4 Rationale for Dose and Schedule of Administration .....................................................27  
3. EXPERIMENTAL PLAN .............................................................................................. 28  
3.1 Study Design  ..................................................................................................................28  
3.2 Number of Study Centers  ..............................................................................................29  
3.3 Number of Patients ........................................................................................................29  
3.4 Overall Study Duration and Follow-up .........................................................................29  
3.4.1  Screening  ................................................................................................................29  
3.4.2  Treatment  ................................................................................................................29  
3.4.3  Post- Treatment  .......................................................................................................29  
3.5 End-of-Study ..................................................................................................................29  
3.6 Data and Safety Monitoring Board ................................................................................30  
4. PATIENT ENROLLMENT ........................................................................................... 30  
4.1 Screening  .......................................................................................................................30  
4.2 Randomization ...............................................................................................................30  
4.3 Replacement of Patients  .................................................................................................31  
4.4 Unblinding of Treatment Assignment ...........................................................................31  
5. PATIENT ELIGIBILITY  .............................................................................................. 31  
5.1 Inclusion Criteria  ...........................................................................................................31  
5.2 Exclusion Criteria  ..........................................................................................................32  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
6  6. STUDY PROCEDURES  ................................................................................................ 34  
6.1 Study Schedule ..............................................................................................................34  
6.1.1  Screening  ................................................................................................................34  
6.1.2  Treatment Period  ....................................................................................................34  
6.1.3  Post- Treatment Period  ............................................................................................34  
6.2 Additional Study Assessments  .......................................................................................35  
6.2.1  Laboratory Assessments  .........................................................................................35  
6.2.2  Physical Exams and Vital Signs  .............................................................................36  
6.2.3  Electrocardiography  ...............................................................................................36  
6.2.4  PK Sampling  ...........................................................................................................36  
6.3 Restriction on the Lifestyle of Patients  ..........................................................................37  
6.3.1  Contraception Requirements ..................................................................................37  
6.3.2  Other Requirements  ................................................................................................38  
7. STUDY DRUG  ................................................................................................................ 38  
7.1 Study Drug Description  .................................................................................................38  
7.1.1  ISIS 681257 ............................................................................................................38  
7.1.2  Placebo  ...................................................................................................................38  
7.2 Packaging and Labeling  .................................................................................................38  
7.3 Study Drug Accountability ............................................................................................38  
8. TREATMENT OF PATIENTS ..................................................................................... 39  
8.1 Study Drug Administration  ............................................................................................39  
8.2 Other Protocol- Required Drugs  .....................................................................................40  
8.3 Other Protocol- Required Treatment Procedures  ............................................................40  
8.4 Treatment Precautions  ...................................................................................................40  
8.5 Safety Monitoring Rules ................................................................................................40  
8.5.1  Safety Monitoring Rules for Liver Chemistry Tests  ..............................................41  
8.5.2  Safety Monitoring for Renal Function ...................................................................42  
8.5.3  Safety Monitoring for Platelet Count Results  ........................................................43  
8.5.4  Safety Monitoring for Minor Bleeding Events .......................................................44  
8.5.5  Safety Monitoring for Constitutional Symptoms ...................................................44  
8.6 Stopping Rules ...............................................................................................................44  
8.6.1  Stopping Rules for Liver Chemistry Elevations .....................................................44  
8.6.2  Stopping Rules for Renal Function Test R esults  ....................................................45  
8.6.3  Stopping Rule for Platelet Count Results ...............................................................45  
8.7 Adjustment of Dose .......................................................................................................48  
8.8 Discontinuation of Study Drug ......................................................................................48  
8.8.1  Follow- up Visits for Early Termination from Treatment Period or from 
Post- Treatment Follow -up Period ..........................................................................48  
8.9 Withdrawal of Patients from the Study  ..........................................................................49  
8.10  Concomitant Therapy and Procedures ...........................................................................49  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
7  8.10.1  Concomitant Therapy .............................................................................................49  
8.10.2  Concomitant Procedures .........................................................................................50  
8.11  Treatment Compliance  ...................................................................................................50  
8.12  Safety Monitoring Compliance  ......................................................................................50  
9. SERIOUS AND NON- SERIOUS ADVERSE  EVENT REPORTING  ...................... 51  
9.1 Sponsor Review of Safety Information .........................................................................51  
9.2 Regulatory Requirements  ..............................................................................................51  
9.3 Definitions  .....................................................................................................................52  
9.3.1  Advers e Event  ........................................................................................................52  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................52  
9.3.3  Serious Adverse Event (SAE) ................................................................................52  
9.3.3.1  Adverse Events of Special Interest  ..................................................................53  
9.4 Monitoring and Recording Adverse Events ...................................................................53  
9.4.1  Serious Adverse Events/Adverse Events of Special Interest  .................................53  
9.4.2  Non-Serious Adverse Events ..................................................................................53  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................53  
9.4.3.1  Relationship to the Study Drug ........................................................................54  
9.4.3.2  Severity  ............................................................................................................54  
9.4.3.3  Action Taken with Study Drug ........................................................................54  
9.4.3.4  Treatment Given for Adverse Event  ................................................................55  
9.4.3.5  Outcome of the Adverse Event ........................................................................55  
9.5 Procedures for Handling Special Situations ..................................................................55  
9.5.1  Abnormalities of Laboratory Tests .........................................................................55  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Tre atments  ............56  
9.5.3  Dosing Errors .........................................................................................................56  
9.5.4  Contraception and Pregnancy .................................................................................57  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 57  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................57  
10.1.1  Primary Endpoint(s) ...............................................................................................58  
10.1.2  Secondary Endpoints ..............................................................................................58  
10.1.3  Safety Endpoints  .....................................................................................................58  
10.1.4  Dose Selection  ........................................................................................................59  
10.2  Sample Size Considerations ...........................................................................................59  
10.3  Analysis Populations ......................................................................................................59  
10.4  Definition of Baseline  ....................................................................................................60  
10.5  Interim Analysis  .............................................................................................................60  
10.6  Planned Methods of Analysis ........................................................................................60  
10.6.1  Demographic and Baseline Characteristics  ............................................................60  
10.6.2  Safety Analysis  .......................................................................................................60  
10.6.2.1  Adverse Events  ................................................................................................60  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
8  10.6.2.2  Clinical Laboratory Data ..................................................................................60  
10.6.2.3  Vital Signs and Examinations  ..........................................................................61  
10.6.3  Efficacy Analysis  ...................................................................................................61  
10.6.3.1  Analysis of Primary Efficacy Endpoint ...........................................................61  
10.6.3.2  Analysis of Secondary Efficacy Endpoints......................................................61  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................62  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. 62  
11.1  Informed Consent ..........................................................................................................62  
11.2  Ethical Conduct of the Study .........................................................................................63  
11.3  Independent Ethics Committee (IEC)/Institutional Review Board (IRB)  .....................63  
11.4  Patient Confidentiality  ...................................................................................................63  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ................................................ 64  
12.1  Protocol Amendments ....................................................................................................64  
12.2  Study Termination  .........................................................................................................64  
12.3  Study Documentation and Storage ................................................................................64  
12.4  Study Monitoring ...........................................................................................................65  
12.5  Language  ........................................................................................................................66  
12.6  Compensation for Injury ................................................................................................66  
13. REFERENCES  ................................................................................................................ 67  
14. APPENDICES  ................................................................................................................. 70  
Appendix A  Schedule of Procedures .....................................................................................71  
Appendix B  List of Laboratory Analytes  ..............................................................................78  
Appendix C  PK Sampling Schedule ......................................................................................80  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities .......83  
Appendix E  Additional Laboratory Tests for Patients with Platelet Count ˂ 100,000/mm3.87 
 
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 38 
Table 2  Study Drug Dosing Information  ........................................................................... 40 
Table 3  Actions in Patients with Low Platelet Count  ........................................................ 47 
 
TABLE OF FIGURES 
Page 
Figure 1  Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of 
apo(a) Covalently Bound to apoB..........................................................................22  
  
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
9  PROTOCOL AMENDMENTS 
 
Protocol Number:  ISIS 681257-CS6 
Protocol Title:  A Randomized, Double-blind, Plac ebo-Controlled, Dose-Ranging 
Phase 2 Study of ISIS 681257 Admi nistered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD) 
Amendment Number:  4 
Amendment Date:  5 January 2017 
 
The following table summarizes th e history and nature of amendm ents to the protocol of Study 
ISIS 681257-CS6.   
None of the antecedent versions of the study prot ocol has been enacted clinically and therefore 
no patients have been enrolled prior to issuance of Amendment 4. 
Protocol Version Date Rationale for Amendments 
Original Protocol  15 August 2016  
Amendment 1 6 October 2016 Regulatory advice on inclusion of more 
detailed description of processes for platelet monitoring, and more frequent 
monitoring of liver function. 
Amendment 2 29 November 2016 Regulatory advice on inclusion of 
biomarkers of renal damage and increased frequency of renal monitoring.  Addition of a 
DSMB. 
Amendment 3 30 December 2016 Adjustment of the frequency, and alert and 
intervention limits, for renal safety and adjustment of the frequency of liver safety 
testing.   
Amendment 4 5 January 2017 The study population was increased to 
270 patients (54 per cohort) to support a statistical assessment of risk of platelet 
reduction in this population.  In addition, the 
10 mg weekly treatment cohort has been 
modified to 20 mg every 2 weeks 
(biweekly). 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
10  PROTOCOL SYNOPSIS  
Protocol Title  A Randomized, Double -blind, Placebo-C ontrolled, Dose-R anging Phase 2 Study of 
ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and 
Established Cardiovascular Disease (CVD)   
Study Phase  2 
Indication  Patients with hyperlipoproteinemia(a) and established CVD . 
Investigational Drug  ISIS 681257 is a second generation 2ʹ -MOE modified, GalNAc 3–conjugated antisense 
oligonucleotide inhibitor of apolipoprotein (a) [ apo(a) ]. 
Primary Objective  To evaluate the safety , including tolerability , of ISIS 681257 and to assess the efficacy  of 
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels 
in patients with hyperlipoproteinemia(a) and established CVD.  
Secondary Objective(s)  To evaluate the efficacy of ISIS 681257 on plasma levels of low density lipoprotein 
cholesterol (LDL -C), apolipoprotein B 100 (apoB), oxidized phospholipids ( OxPL ) on 
apo(a)  [OxPL -apo(a)] , and OxPL  on apoB  (OxPL -apoB) . 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose 
regimens in patient s with hyperlipoproteinemia(a) and established CVD.  
Study Design  This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.  
Approximately 270 patients will be randomized in a 5:1 ratio to receive ISIS  6812 57 or 
placebo.  This number was chosen to provide statistical power for both efficacy and 
safety assessments.  Study Drug (ISIS  681257 or placebo) will be administered SC 
every week, every 2 weeks , or every 4 weeks, depending on cohort assignment, for up 
to 52 weekly doses, up to 26 every 2-week doses , or up to 13 every 4 -week doses.  
Minimum treatment duration is 6 months.  Maximum treatment duration is 12 months.  
The treatment portion of the study will be complete when the last enrolled patient reaches 6 months of exposure.  All patients will then enter a 16-week post -treatment 
follow -up period.  
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4-week dosing (Cohorts A -C) and at Week 27 for patients who received 
every 2 -week or weekly dosing (Cohorts D and E, respectively).  For patients continuing 
treatment beyond the primary analysis time point additional supportive efficacy and safety analyses will be repeated at the completion of Study Drug treatment.  
An independent Data and Safety Monitoring Board (DSMB) will be established to review 
safety, tolerability and efficacy (as needed) data collected on ISIS  681257 during this 
study, both individual events and aggregate data.   
Number of Subjects  Approximately 270 
Study Population  Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements  
2. Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent  
3. Clinical diagnosis of CVD defined as documented coronary artery disease, strok e, 
or peripheral artery disease  
4. Lp(a) plasma level ≥ 60 mg/dL  
5. Must be on standard- of-care preventative therapy for other than elevated Lp(a) 
CVD risk factors  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
11  PROTOCOL SYNOPSIS Continued  
Study Population  
Continued  Inclusion Criteria  
6. Patients on the following medications must be on a stable regimen for at least 
4 weeks prior to Screening and expected to remain on a stable regim en through the 
end of the post -treatment follow -up p eriod:  
a. Lipid lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing omega-3 fatty aci ds including OTC 
preparations)  
b. Antiplatelet drugs  
c. Testosterone, estrogens, progesterone, growth hormone or progestins  
7. Females:  must be non-pregnant and non -lactating and either;  
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy);  
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in 
females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and  FSH levels 
in the postmenopausal range for the laboratory involved);  
c. Abstinent* or,  
d. if engaged in sexual relations of child- bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to Section 6.3.1 ) from the time of signing 
the informed consent form until at least 16 weeks after the last dose of Study 
Drug  (ISIS 68 1257 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation methods), declaration of 
abstinence for the duration of a trial and withdrawal are not acceptable 
methods of contraception  
8. Males must be surgically sterile or, if engaged in sexual relations with a female of child-bearing potential, the patient must be using an acceptable contraceptive 
method (refer to Section 6.3.1) from the time of signing the informed consent form 
until at least 16 weeks after the last dose of ISIS 681257  
Exclusion Criteria  
1. Within 6 months of Screening:   acute coronary syndrome, major cardiac surgery , or 
stroke /transient ischemic attack   
2. Within 3 months of Screening:   coronary , carotid,  or peripheral arterial 
revascularization, major non- cardiac surgery, or lipoprotein apheresis   
3. Heart failure NYHA class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)  
5. History of acute kidney injury  within 12 months of S creening  
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day  1 
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis  C or chronic hepatitis B  
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been succes sfully treated  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
12  PROTOCOL SYNOPSIS Continued  
Study Population  
Continued  Exclusion Criteria  
10. Patients with a history of major bleed or high- risk of bleeding diathesis  
11. Recent history of, or  current drug or alcohol abuse  
12. Clinically -significant abnormalities in screening laboratory values that would render 
a patient unsuitable for inclusion, including the following:  
a. Urine protein/creatinine ratio (UPCR)  ≥ 0.25 mg/mg .  In the event of a UPCR 
above this threshold, eligibility may be confirmed by  a quantitative total urine 
protein measurement of ˂ 300 mg/24 -hr 
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.   In the event of a UACR 
above this threshold, eligibility may be confirmed by a quantitative total urine 
albumin measurement of ˂  150 mg/ 24-hr  
c. Estimated GFR  ˂ 60 mL/min as determined by the Chronic Kidney Disease-
Epidemiological Collaboration ( CKD-EPI) Equation for creatinine clearance  
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  
> 2.0 x ULN  
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s 
syndrome in which case total bilirubin must be ≤  3 mg/dL  
f. Alkaline phosphatase (ALP) > ULN  
g. Platelet count ˂  LLN 
13. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors  
14. Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half -lives of investigational agent, whichever is longer  
15. Treatment with any non-Ionis oligonucleotide (including small interfering ribonucleic 
acid [siRNA ]) at any time or prior treatment with an Ionis oligonucleotide or siRNA 
within 9 months of screening .  Patients that  have previously received only 1 dose of 
an Ionis oligonucleotide as part of a clinical study may be included as long as ≥ 4 month s has elapsed since dosing  
16. BMI > 40 kg/m
2  
17. Blood donation of 50-499 mL within 30 days of screening or of > 499 mL within 8 weeks of S creening  
18. Unwillingness to comply with study procedures, including follow -up, as specified by 
this protocol, or unwillingness to cooperate fully with the Investigator  
19. Have any other conditions, which, in the opinion of the Investigator or Sponsor 
would make the patient unsuitable for inclusion, or could interfere with the patient 
participating in or completing the Study  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
13  PROTOCOL SYNOPSIS Continued  
Treatment Groups  Patients will be randomized to 5 parallel cohorts:  
Cohort A (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort B (n = 54):  Patients will be randomized 5:1 to receive 40 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort C (n = 54):  Patients will be randomized 5:1 to receive 60 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses.  
Cohort D (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every 2 weeks for up to 26 doses.  
Cohort E (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every week for up to 52 doses.  
Cohort  Treatment  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 or placebo 
(Every 4 weeks)  ≤ 13 ≤ 260 mg  
B 40 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 or placebo  
(Every 4 weeks)  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 or placebo 
(Every 2 weeks)  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 or placebo  
(Every week) ≤ 52 ≤ 1040 mg  
 
Study Drug  Dosage 
and Administration  The Sponsor will provide ISIS 681257 in a concentration of 100 mg/mL and matching 
volume placebo:  
Cohort A:  20 mg every 4 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort B:  40 mg every 4 weeks ISIS 681257 or placebo (0.4 mL)  
Cohort C:  60 mg every 4 weeks ISIS 681257 or placebo (0.6 mL)  
Cohort D:  20 mg every 2 weeks ISIS 681257 or placebo (0.2 mL)  
Cohort E:  20 mg every week ISIS 681257 or placebo (0.2 mL)  
All doses will be given by SC injection.  Self -administration will be allowed after 
appropriate training of patient and/or caregiver.  
Rationale for Dose and 
Schedule Selection  The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given 
weekly that were found to be generally well -tolerated and to induce clinically -relevant 
reductions in Lp(a).  The range of dosing proposed for the present study will provide the 
equivalent drug exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and 
is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in 
mean reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% 
at steady -state.   
The highest dose selected for this study, 20 mg per week, is predicted to provide an 
approximately 85% reduction in Lp(a) at steady -state that is expected to be sufficient to 
bring almost all patients with hyperlipoproteinemia(a) into the normal range 
(Lp(a)  ≤ 30 mg/dL).  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
14  PROTOCOL SYNOPSIS Continued  
Rationale for Dose and 
Schedule Selection  
Continued  The present study will also evaluate safety and efficacy at different dosing frequencies:   every 4  weeks, every 2 weeks, and weekly.   Patients with 
hyperlipoproteinemia(a) will require chronic treatment and thus every 2 weeks or every 
4 weeks dosing regimens, if safe and well -tolerated, may provide advantages over 
weekly dosing in terms of convenien ce and compliance for patients.  Dosing regimens of 
20 mg every 2 weeks and 40 mg every 4 weeks will test if similar monthly exposure, at different frequencies of administration, will achieve similar safety and similar level of Lp(a) reduction since the reduction achieved by a given dose level is principally driven 
by total exposure, while individual dose levels and the related peak concentration (C
max) 
may influence tolerance and safety.  
Adjustment of Dose and/or Treatment 
Schedule  Dose adjustments, including dose interruptions, and/or decreasing the dose frequency 
may be allowed for safety or tolerability after consultation with the Sponsor Medical 
Monitor . 
Study Visit Schedule and Procedures  Detailed information regarding the study procedures are outlined in Section 6 , 
Appendices A  and C. 
All patients enrolled will be randomized to a minimum of 6 months of treatment in 1 of 
5 treatment cohorts.  On completion of the 6 months, patients may continue treatment 
within the same randomized cohort until the last enrolled patient reaches 6 months of exposure (for continuing safety assessments), with a maximal exposure period of 
12 months.   
The study for an individual patient will generally consist of the following periods:   
• An up to 4-week s creening period  
• An up to 52-week t reatment period during which Study Drug will be 
administered per assigned cohort by SC injection  
• A 16-week post -treatment follow -up p eriod  
Patients in Cohorts A through C will receive up to 13 SC doses of ISIS  681257 or 
placebo every 4 weeks.  Patients in Cohort D will receive up to 26 SC doses of ISIS 681257 or placebo every 2 weeks and patients in Cohort E will receive up to 52 SC 
doses of ISIS 681257 or placebo weekly .  Patients will return regularly for outpatient 
visits throughout the treatment and post -treatment follow -up periods accor ding to the 
Schedule of Procedures (Appendix A).   
Blood and urine samples will be collected regularly throughout the study for safety, 
efficacy, and PK analysis.  Appendix B  shows a list of analytes required for the study 
and Appendix C details the PK sample schedules.  
Safety and Tolerability Evaluations  Safety and tolerability assessments include:  adverse events, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs and use of concomitant medications.  Safety and tolerability results in patients dosed with ISIS 681257 will be 
compared with those dosed with placebo.  
Efficacy Evaluations  The primary analysis time point is at Week 25 for patients who received every 4-week 
dosing (Cohorts A -C) and at Week 27 for patients who received every 2 -week or weekly 
dosing (Cohorts  D and E) . 
The primary endpoint is the percent change in plasma Lp(a) from baseline at the primary 
analysis time point for ISIS 681257 treatment groups compared to placebo. 
The secondary endpoints comprise the effect of ISIS 681257 as compared to placebo at 
the primary analysis time point on the following:  
• Percent change from  baseline in LDL-C 
• Proportion of patients who achieve plasma Lp(a) ≤  50 mg/dL  
• Proportion of patients who achieve plasma Lp(a) ≤  30 mg/dL  
• Percent change from baseline in apoB  
• Percent change from baseline in OxPL-apo(a)  
• Percent change from baseline in OxPL -apoB  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
15  PROTOCOL SYNOPSIS Continued  
Pharmacokinetic 
Evaluations  Plasma samples will be taken from all patients for the measurement of ISIS 681257 
plasma trough levels  throu ghout treatment and during the p ost-treatment follow -up 
period .  In addition, in a subset of patients (approximately 12 patients per cohort), more 
frequent plasma samples will be taken following the first and D ay 169 (for Cohorts A , B, 
and C) or Day 183 (for Cohorts D and E)  dose to determine PK parameters.  Plasma 
sample collection time points are detailed in Appendi ces A and C. 
The plasma ISIS 681257 levels over time will be descriptively summarized by treatment 
with stratification by subject immunogenicity status .  Apparent terminal elimination half -
life will be calculated in patients who received ISIS 681257 treatment using a non-
compartmental method, if data permitted.  In addition, C max, Tmax, and AUC values will be 
calculated for the PK subgroup.  PK parameters will be descriptively summarized by treatment with stratificati on by subject immunogenicity status.  
Statistical Considerations  The primary efficacy analysis for the primary endpoint will be the pairwise comparison of 
percent change from baseline to the primary analysis time point in fasting Lp(a) between 
ISIS 681257 treated group s and placebo group in the Full Analysis Set.  
The data will be analyzed using an ANCOVA model with the baseline Lp(a) level as a covariate. 
Dose selection for the further development will be based on the following efficacy and safety considerations; more than 1 dose may meet these criteria.  An effective dose, or 
dose regimen, will be one that achieves a  clinically -meaningful 
reduction in plasma Lp(a) 
levels .  Safety will be evaluated on the basis of incidence of expected and unexpected 
treatme nt-related SAEs , and other specific safety considerations including the incidence 
of platelet reductions . 
Sample Size Considerations:  
Efficacy:  
Based upon prior clinical trial experience with ISIS  681257, it is estimated that the 
standard deviation of the percent change in Lp(a) is approximately 20%.  With 23 patients in each ISIS 681257 treatment group and 23 in placebo group there would 
be approximately 90% power to detect a 20% difference in percent change in Lp(a) 
levels between the ISIS 681257 treatmen
t groups and placebo group at an alpha level of 
0.05, assuming 30% reduction in the ISIS 681257 patients and 10% reduction in the 
placebo patients.  
Safety:  
Based upon prior clinical trial experience with ISIS  ASOs, assuming the incidence rate of 
platelet c ount below lower limit of normal (LLN) in placebo treated patients is 1.9%, in 
the ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, with 45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to detect at least 1 event.  
A total of approximately 270 patients (54 patients per cohort, including 45 patients per cohort treated with ISIS 681257) will be randomized to ensure that both the safety and efficacy of ISIS 681257 will be adequately characterized in the study.  
Sponsor/Collaborator  Ionis Pharmaceuticals/Akcea Therapeutics  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
16  STUDY DESIGN AND TREATMENT SCHEMA  
 
SCREENING PERIOD  
Weeks -4 to -1 
TREATMENT PERIOD  
Weeks 1 to 52*  
Dosing per assigned cohort:  
Cohorts A, B, and C:  Every 4 weeks  SC 
administration of 20, 40, or 60 mg ISIS 681257 or 
placebo  
Cohort D:  Every 2 weeks SC administration of 
20 mg ISIS 681257 or placebo  
Cohort E:  Every week SC administration of 20 mg 
ISIS 681257 or placebo  
Routine safety assessments :  PK and PD/efficacy 
assessments at specified time points  
*Treatment portion of the study will be complete 
when the last enrolled patient reaches 6 months of exposure.  
POST -TREATMENT 
EVALUATIONS  
Weeks 4, 10, and 16 after last dose of 
Study Drug  
3 clinica l visits for safety, efficacy,  
PK and PD assessments  
EARLY 
TERMINATION 
(ET) 
Follow Week 53 Schedule 
of Procedures at ET;  
Patient strongly 
encouraged to visit clinic 
for post -treatment 
assessments  
END- OF-STUDY 
PROCEDURES  
Early Termination or 3rd 
Follow -Up visit (16 Weeks 
after last dose of Study Drug)  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
17  STUDY GLOSSARY 
Abbreviation Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ALP  alkaline phosphatase 
ALT  alanine aminotransferase (SGPT)  
ANCOVA  analysis of covariance  
ANA  antinuclear antibody  
apo(a) apolipoprotein(a) 
apoB apolipoprotein B 
aPTT  activated partial thromboplastin time  
ASGPR  asialoglycoprotein receptor  
ASO antisense oligonucleotide 
AST  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time zero to 
time t 
βhCG  beta-subunit of human chorionic gonadotropin (pregnancy test) 
BP blood pressure 
BUN  blood urea nitrogen 
C centigrade  
C5a complement factor C5a (activated complement split product ) 
CAD coronary artery disease  
Cmax maximum concentration  
CBC  complete blood count 
CKD- EPI Chronic Kidney Disease –Epidemiological Collaboration  
CMV  cytomegalovirus 
CRF  case report form  
CRP  C-reactive protein  
CVD cardiovascular disease  
CT computed tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
18  STUDY GLOSSARY Continued  
Abbreviation Definition  
Cys C  Cystatin C  
dL deciliter  
DNA  phosphorothioate-modified oligodeoxynucleotides 
DSMB  Data and Safety Monitoring Board 
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
ET early termination  
FAS full analysis set  
FSH follicle -stimulating hormone 
GalNAc 3 triantennary N -acetyl galactosamine  
GCP  Good C linical P ractice  
GFR  glomerular filtration rate  
HAV  hepatitis A virus 
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV hepatitis C virus  
HIV human immunodeficiency virus 
hr, hrs hour(s) 
hsCRP  CRP measured by high sensitivity assay 
ICH International Conference on Harmonization 
IEC Independent Ethics Committee  
IgM immunoglobulin M 
IL-1β interleukin -1 beta 
INR international normalized ratio  
IRB Institutional Review Board  
ISIS 681257 antisense inhibitor of apolipoprotein (a) 
IV intravenous(ly) 
IXRS  interactive voice/internet response system  
KIM -1 kidney injury molecule 1 
kg kilogram 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
19  STUDY GLOSSARY Continued  
Abbreviation Definition  
L liter 
m2 square meter  
MCH  mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration 
MCV  mean corpuscular volume 
mg milligram 
MI myocardial infarction  
min minute  
mL milliliter  
mm millimeter  
mRNA messenger ribonucleic acid  
NAG  N-acetyl -β D-glucosaminidase  
NCS  not clinically -significant 
NGAL  neutrophil gelatinase- associated lipocalin  
NSAID  non-steroidal anti- inflammatory drug  
NYHA  New York Heart Association 
OxPL  oxidized phospholipids 
PAD peripheral arterial disease 
PBS phosphate buffered saline 
PCSK9  proprotein convertase subtilisin/kexin type 9 
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s) 
PLA 2 Lp(a) -associated Lp -phospholipase A 2 
PPS per protocol set 
PT prothrombin time 
RBC  red blood cells 
RNase H 1 an ubiquitous endonuclease that specifically hydrolyzes the RNA 
strand in RNA/DNA hybrids  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
siRNA small interfering ribonucleic acid  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
20  STUDY GLOSSARY Continued  
Abbreviation Definition  
SC subcutaneous(ly) 
Study Drug  ISIS 681257 or placebo 
SUSAR  suspected unexpected serious adverse reaction  
Tg transgenic 
Tmax time to maximal concentration  
UACR  urine albumin - creatinine ratio  
ULN  upper limit of normal 
UPCR  urine protein- creatinine ratio  
WBC  white blood cell 
WMA  World Medical Association  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
21  1. OBJECTIVES  
1.1 Primary Objective  
To evaluate the safety , including tolerability, of ISIS 681257 and to assess the efficacy of 
different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) levels in 
patients with hyperlipoproteinemia(a) and established cardiovascular disease ( CVD). 
1.2 Seconda ry Objective(s)  
To evaluate the efficacy  of ISIS 681257 on plasma levels of low density lipoprotein cholesterol  
(LDL-C), apolipoprotein B (apoB), oxidized phospholipids ( OxPL ) on apolipoprotein (a) 
[apo(a)] [ OxPL -apo(a) ] and OxPL  on apoB  (OxPL -apoB). 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose regimens in in patients with hyperlipoproteinemia(a) and established CVD. 
2. BACKGROUND AND RATIO NALE  
2.1 Overview of D isease  
2.1.1 Lipoprotein (a) 
Lipoprotein(a) [ Lp(a) ] is an atherogenic lipoprotein ( Figure 1, Koschinsky and Marcovina 2004) 
in which the apoB component of LDL is linked by a disulfide bond to apolipoprotein(a) [apo(a)], 
the distinct protein component of Lp(a) that is mainly responsible for its signature structural and functional properties ( Dubé et al. 2012; Kronenberg and Utermann  2013 ).  Lp(a) is now 
recognized as an independent, genetic, causal risk factor for coronary artery disease (CAD), stroke, peripheral arterial disease (PAD),  and calcific aortic stenosis ( Erquo et al. 2009; 
Nordestgaard et al. 2010; Thanassoulis et al. 2013 ). 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
22   
Figure 1 Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of apo(a) 
Covalently Bound to apoB 
Apo(a) contains 10 unique units of kringle IV repeats, of which KIV2 ar e present in variable copies (1 to  > 40) 
conferring structural heterogeneity to Lp(a).  Apo(a) also contains kringle V and an inactive protease -like (P) 
domain.  In this model, 4 KIV2 repeats are shown.  Lp(a) also contains OxPL in the lipid phase of apoB as 
well as covalently bound to apo(a).  
 
Plasma levels of Lp(a) vary substantially among individuals, and most of this variation reflects 
the effects of genetic variation in the LPA gene which encodes the apo(a) protein . 
A second contributor to plasma- level variability are LPA single nucleotide polymorphisms 
(SNPs) that can be associated with either higher or lower Lp(a) levels ( Clarke et al. 2009; 
Li et al. 2011 ).  Significant associations exist between 2 particular LPA variants, rs10455872 and 
rs3798220, increased Lp(a) levels, CVD, and aortic stenosis, with the CVD risk primarily 
mediated by Lp(a) plasma levels rather than an independent effect of the SNPs ( Clarke et al. 
2009; Li  et al. 2011). 
Lp(a) plasma levels are generally inversely associated with apo(a) size, and can vary by > 1,000-fold (0.1 to > 250 mg/dL or ˂  0.25 to > 625 nmol/L) between individuals ( Merk i et al.  
2011).  Despite this inter -individual variation, intra-individual Lp(a) levels are thought to be 
generally stable over time along a pre- set genetically determined levels without significant 
impact from dietary or environmental factors, mediating C VD risk throughout the patient’s 
lifetime.  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
23  2.1.2 Pathophysiology 
Lp(a) adheres to plaque sites and is retained in the artery wall  and has proatherogenic and 
pro-inflammatory properties due to its LDL and apo(a) components ( Spence and Koschinsky  
2012).  In addition, Lp(a) may be prothrombotic by inhibiting fibrinolysis because of its 
structural similarity  to plasminogen and its enhancement of platelet aggregation ( Rand et al.  
1998).  In vitro  studies have provided evidence for both of these pathogenic mechanisms, but 
in vivo  data are not definitive ( Dubé et al. 2012 ).  In humans, Lp(a) is the main lipoprotein 
carrier of OxPL, which may drive the risk associated with  Lp(a) (Bergmark et al. 2008; 
Leibundgut et al. 2013; Tsimikas et al. 2014).  In fact, OxPL measured on apoB (OxPL-apoB), 
which largely reflect the OxPL on Lp(a), have been shown to be a prognostic indicator for future 
CV events  (Tsimikas et al. 2010; Tsimikas et al. 2012; Tsimikas et al. 2014).  OxPL associated 
with Lp(a) can be subjected to degradation by the Lp(a)- associated Lp -phospholipase A 2 (PLA 2), 
implicating Lp(a) in novel proinflammatory and atherogenic pathways ( Kiechl et al. 2007). 
Hyperlipoproteinemia (a) in humans is  associated with increased risk of cardiac death, 
myocardial infar ction  (MI) , stroke, aortic stenosis, and peripheral arterial disease (PAD), 
particularly in subjects with small apo(a) isoforms ( Bennet t 2008; Erqou et al. 2009; Erqou et al.  
2010;  Bertoia  et al. 2013; Thanassoulis et al. 2013 ).  Although prospective, randomized, 
controlled outcomes studies have not been conducted, epidemiological, genome- wide association 
and Mendelian randomized controlled study data to date provide supporting evidence for a role of Lp(a) as a risk factor for CVD  (Kamstrup  et al. 2009).  For example, in the Copenhagen City 
Heart Studies of 42,000 subjects with a 15- year follow -up (Kamstrup  et al. 2009) using a 
Mendelian randomization approach, higher Lp(a) levels were related to risk of MI. 
2.1.3 Current Treatment  Options 
In 2010, the European Atherosclerosis Society (EAS) Consensus Panel recommended screening for elevated Lp(a) in people at moderate to high risk of CVD to reach a treatment goal of ˂ 50 mg/dL (125 nmol/L), after therapeutic management of LDL- C (Nordestgaard  et al. 2010).  
Approximately 20% of people are estimated to have plasma Lp(a) levels over 50 mg/dL 
(125 nmol/L) and approximately 0.3% to have levels over 175 mg/dL (438 nmol/L) .  There are 
no gender differences in Lp(a) concentrations but racial differences have been obs erved, with 
whites and Asians having lower levels while blacks and Hispanics generally have somewhat 
higher levels (Nordestgaard et al. 2010).  
Lifestyle and diet are  thought to have little impact on an individual’ s Lp(a) level .  Current 
treatment recommendations from the EAS Consensus Panel are limited to the use of 1 to 3 g of 
niacin (nicotinic acid) daily which could result in an up to 30% reduction in Lp(a).  However, niacin is associated with side effects (e.g., flushing) that reduce patient tolerability and 
compliance ( Parker et al. 2006; Guyton 2007). 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are neither indicated nor formally recommended for treatment of hyperlipoproteinemia(a) but have been reported to reduce Lp(a) levels by ~20%-35% in patients with hypercholesterolemia ( Desai et al . 2013; 
Raal et al . 2015).  
The other current option for patients with signif icantly elevated Lp(a) levels ( ≥ 60 mg/dL) is 
lipoprotein apheresis, either general lipoprotein apheresis ( Jaeger et al. 2009;   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
24  Leebmann et al. 2013; Rosada et al. 2014) or Lp(a)- specific apheresis ( Safarova 2012).  While 
very effective at acutely lowering  Lp(a) (acute and interval Lp(a) reductions of > 60% and 
> 30% respectively), this treatment option is expensive, burdensome for patients, and 
unavailable/not reimbursed in many countries and regions. 
2.2 T herapeutic Rationale 
Therapeutic modalities to reduce Lp(a) levels in humans are few, and there are no drugs 
currently available that specifically target Lp(a) alone.  Antisense oligonucleotides (ASOs) are emerging as viable therapeutic agents to treat disorders where overexpression of proteins is 
associated with a disease process .  Apo(a) is synthesized primarily in the liver , a target organ for  
ASOs, where it is subsequently covalently linked to the apoB-100 component of LDL to form 
the Lp(a) lipoprotein.  The goal of treatment with ISIS  681257 is to reduce the production of 
apo(a) in the liver and thus, the level of Lp(a) lipoprotein by using an ASO directed against the messenger ribonucleic acid (mRNA) of apo(a).  It has been hypothesized that a pharmacologic 
reduction in Lp(a) could slow down or reverse CVD  by reducing thrombotic, atherogenic, or 
inflammatory events in patients with elevated L p(a) levels ( Nordestgaard et al. 2010).  
Importantly, there is no evidence that lowering Lp(a) will result in adverse consequences in 
individuals, and there are no reports linking very low Lp(a) to any deleterious effects. 
2.3 ISIS  681257 
Please refer to the ISIS 681257 Investigator’s Brochure for more details on ISIS 681257 
mechanism of action, chemistry, pre- clinical and clinical experience.  The summary is provided 
below. 
2.3.1 Mechanism of Action  
ISIS 681257 is a second -generation ASO drug targeted to apo(a) that has been covalently bonded 
to triantennary N -acetyl galactosamine (GalNAc
3), a high-affinity ligand for the hepatocyte-
specific asialoglycoprotein receptor (ASGPR) to form an ASO -GalNAc 3 conjugate.  This 
GalNAc 3-conjugate approach results in en hanced ASO delivery to hepatocytes versus 
non-parenchymal cells and has increased ASO potency by approximately 10 -fold compared to 
unconjugated ASOs in mice ( Prakash et al. 2014). 
The ASO portion of ISIS 681257 is complementary to a region spanning the Exon 24-25 splice 
site at position 3901 of apo(a) transcript sequence (NM_005577.2) and binds to the mRNA by Watson and Crick base pairing.  The hybridization (binding) of ISIS 681257 to the cognate mRNA results in the Ribonuclease H1 (a non-specific endonucl ease that catalyzes the cleavage 
of RNA via hydrolytic mechanism RNase H1 -mediated degradation of the apo(a) mRNA, thus 
preventing production of the apo(a) protein).  Maximal antisense-mediated reduction of target mRNA levels is typically greater than 90% of control levels in sensitive tissues ( Zhang et al.  
2010).  Furthermore, reduction in target mRNA levels using this approach correlates directly 
with a subsequent reduction in target protein levels.  
ISIS 681257 does not have any complementary homology to plasminogen mRNA ( Graham et al . 
2016).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
25  2.3.2 Chemistry  
Chemically, ISIS 681257 is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by phosphorothioate and phosphodiester linkages (mixed backbone 
design).  The mixed backbone design reduces the total number of phosphorothioate linkages, 
which reduces non-specific interactions with proteins and further enhances potency of GalNAc 3 
conjugated ASOs. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2′ -O-(2-methoxyethyl) (2′ -MOE) -modified 
ribonucleotides.  These MOE -modified nucleotides confer (1) increased affinity for the target 
mRNA ( Altmann et al. 1996; McKay et al. 1999), (2) increased resistance to exonucleases and 
endonucleases (thereby increasing stability in tissue) ( Geary et al. 2003), and (3) amelioration of 
some of the high-dose toxicities, thereby resulting in an improved safety profile compared to first-generation antisense drugs containing phosphorothioate-modified oligodeoxynucleotides 
(DNA) ( Henry et al. 2000).  The third region, the central portion of the oligonucleotide, is 
composed of 10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and 
ISIS 681257 employs this chimeric structure to enable use of the ubiquitou s endonuclease that 
specifically hydrolyzes the RNA strand in RNA/DNA hybrids ( RNase H1 )-mechanism for 
antisense activity .  This is because while the 2′ -MOE modifica tion confers increased stability and 
affinity, it does not support RNase H1 -catalyzed cleavage of RNA hybridized to 2′ -MOE -
modified nucleotides ( McKay  et al. 1999).  The fourth region is composed of a triantennary 
cluster of GalNAc
3 sugars that is linked t o the 5ʹ end of ISIS 681257 via a phosphodiester 
linkage.  The GalNAc 3 cluster is a high affinity ligand for the ASGPR, a receptor expressed 
primarily on the surface of liver hepatocytes ( Stockert 1995).  The GalNAc 3 cluster enhances 
delivery of ISIS 681257 to liver hepatocytes over other cell types and enhances potency.  After 
internalization into cells, the GalNAc 3 cluster is metabolized to release “free ASO” inside the 
cell ( Prakash et al. 2014). 
2.3.3 Preclinical Experience  
The pharmacology of ISIS 681257 has been examined in apo(a) transgenic (Tg) mice which 
express the entire human apo(a) genomic sequence ( Frazer et al. 1995) and nonhuman primates. 
Administration of ISIS 681257, a human apo(a) antisense inhibitor, to mice containing the 
human apo(a) transgene produced dose-dependent reductions in human apo(a) liver mRNA and 
apo(a) plasma protein after 6 weeks of ASO administration at 0.3, 1, 3, and 10 mg/kg/wk. 
When ISIS 681257 was administered to normal chow fed cynomolgus monkeys for 4 weeks at 
the dose of 12 mg/kg/wk, it significantly reduced hepatic apo(a) mRNA by 90% relative to the 
cohort administered phosphate buffered saline (PBS).  As there is an 80% sequence conservation 
between apo(a) and plasminogen nucleotide sequences, plasminogen mRNA levels were also 
measured , and no change compared to the PBS cohort was observed. 
Findings from the chronic studies with ISIS 681257 (the 26- week mice  and 39-week monkey 
studies) were similar to those observed in the 4- and 6- week studies  and were not considered 
adverse.  The plasma and tissue concentrations observed for ISIS 681257 in  mice  and monkeys 
were generally similar to those observed for other unconjugated 20- mer 2 ʹ-MOE ASOs in this 
chemical class with and without GalNAc 3-conjugation.  However, the proportion of drug in 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
26  hepatocytes compare to nonparenchymal liver cells was greater for ISIS 68125 7, compared to the 
parent drug ISIS 494372 (without GalNAc 3-conjugation), which is the basis for increased 
potency of ISIS 681257 (unpublished re sults; Geary et al. 2003;  Yu et al. 2007; Prakash et al.  
2016).  
The most noteworth y safety fin ding in the chronic monkey study was  a marked platelet reduction  
that, occurred in 2 male monkeys in the high-dose group (20 mg/kg/wk) and 1 animal (1 female) 
in the mid -dose (10 mg/kg/wk) group beginning on Days 44-135, which led to the subsequent 
early termination  (ET) of these 3 animals .  An additional male monkey in the 10 mg/kg/wk dose 
group had a moderate decrease in platelets  that was successfully treated wi th steroid , and was 
terminated at the scheduled 6 -month interim sacrifice .  There were no platelet reductions or other 
toxicologically significant findings in monkeys treated with 2 mg/kg/wk for up to 39 weeks.  
There were no marked platelet reductions in mice at doses up to 70 mg/kg/wk for 26 weeks.  However, mice exposed to ISIS 681257 at doses of ≥ 10 mg/kg/wk for up to 26 weeks showed evidence of hepatobiliary effects in both sexes as indicated by increases in ALT (up to + 10.3x), 
AST (up to + 10.4x), and/or ALP (+ 2.5x).  
2.3.4 Clinical Experience  
Detailed information concerning the clinical studies conducted with ISIS 681257 can be found in 
the Investigator’s Brochure .  A summary of the study that has been conducted with ISIS 681257 
is included below. 
ISIS 681257- CS1 was a Phase 1 double-blind, placebo-controlled, dose- escalation study 
designed to assess the safety, tolerability, PK,  and pharmacodynamics (PD) of single and 
multiple doses of ISIS 681257 administered subcutaneously (SC)  to 45 healthy subj ects with 
Lp(a) ≥ the upper limit of normal  (ULN)  (30 mg/dL).  Twenty one (21) subjects received 10  to 
120 mg S C (10, 20, 40, 80, and 120 mg) as a single-dose, and 24 subjects received 10, 20, and 
40 mg a s multiple doses (6 doses in 21 days :  3 loading dos es during the first week on alternate 
days (Days 1, 3, and 5), and then once a week for the next 3 weeks (Days 8, 15, and 22). There were no serious adverse events  (SAEs) , or clinically -relevant  changes in laboratory 
assessments and a ll subjects completed the treatment and post- treatment follow -up periods. 
Constitutional symptoms such as fever, chills, increase in body temperature and arthralgias have 
been observed following parenteral administration of ASOs, primarily during the initial dosing period.  Following SC administration of ISIS 681257 constitutional symptoms  were observed  in 
4 of the 6 subjects  who received a single -dose of 120 mg.  The symptoms were mild in severity  
and resolved spontaneously with or without treatment with acetaminophen . 
Fluctuations in platelet counts to below the lower limit of normal were obse rved in 5 study 
subjects o n active drug and across doses.  These changes were not considered adverse or 
clinically -significant by the Investigator and did not appear to be dose rel ated.  
Two (2) mild AE s of redness at the site of injection  occurred 48 to 72 hours after administration 
in 1 subject who received ISIS  681257 in the 20 mg multiple-dose cohort.  Both AE s resolved by 
the time of the subject’s next visit. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
27  Following SC administration, ISIS  681257 was absorbed rapidly into the systemic circulation, 
with median time to maximum plasma concentrations (T max) ranging from 1 to 4 hours.  Similar 
Tmax values were observed at all dose levels .  Maximum observed plasma concentrations (C max) 
and AUC 0-24hr were dose-dependent over the studied SC dose range.  The mean peak (C max) and 
total exposure (AUC 0-24hr) increased proportionally with dose at dose levels ranging from 10 to 
40 mg, and greater than dose proportionally at dose levels ranging from 40 to 120 mg. 
After reaching C max, mean plasma concentrations of ISIS 681257 declined in a biphasic fashion 
over time, with an initial, relatively fast distribution phase that dominated the plasma clearance 
followed by a slower elimination ph ase.  Characterization of the terminal elimination phase 
yielded an apparent terminal elimination half -life of appr oximately 3  to 4 weeks over a dose 
range of 10  to 120 mg  (either single - or multiple -dose) , and appeared to be independent of dose.  
This res ult is consistent with the slow elimination of ISIS  681257 observed from monkey tissues, 
and the comparatively long elimination half -lives observed for this chemical class.  
Plasma trough concentrations (168 hours or 7 days from previous dose) monitored dur ing the 
treatment period in the multiple -dose cohorts increased with increasing dose, consistent with 
expectations (based on preclinical assessments and experience with other compounds of this chemical class) that trough plasma concentrations reflect expos ure in tissues.  Plasma trough 
concentrations did not increase greatly after the loading period ( Day 15 ), suggesting that 
accumulation in major tissues of distribution had approached  steady -state after the loading 
period. 
Overall, the human PK  of ISIS  681257 are consistent with the expected PK  for compounds 
within this chemical clas s. 
2.4 Rationale for Dose and Schedule of Administration 
The Phase 1 program evaluated ISIS 681257 doses of 10 mg, 20 mg, and 40 mg given weekly 
that were found to be general ly well -tolerated  and to induce clinically -relevant  reductions in 
Lp(a) . 
The range of dosing proposed for the present study will provide the equivalent drug exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and is predicted (based on modelling of PK/PD data obtained in Phase 1 study) to result in mean reductions from baseline in plasma 
Lp(a) ranging from approximately 60% to 85% at steady- state.  
The highest dose selected for this study, 20 mg per week, is predicted to provide an 
approximately 8 5% reduction in Lp(a) at steady- state that is expected to be sufficient to bring 
almost all patients with hyperlipoproteinemia(a) into the normal range (Lp(a) ≤ 30 mg/dL).  
The present study will also evaluate safety and efficacy at different dosing frequencies:   every 
4 weeks, every 2 weeks, and weekly.   Patients with hyperlipoproteinemia(a) will require chronic 
treatment and thus every 2 weeks or every 4 weeks dosing regimens, if safe and well- tolerated, 
may provide advantages over weekly dosing in terms of convenience and compliance for patients.   Dosing regimens of 20 mg every 2 weeks and 40 mg every 4 weeks will test if similar 
monthly exposure, at different frequencies of administration, will achieve similar safety and similar level of Lp(a) reduction s ince the reduction achieved by a given dose level is principally 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
28  driven by total exposure, while individual dose levels and the related peak concentration (C max) 
may influence tolerance and safety.  
3. EXPERIMENTAL PLAN 
3.1 Study Design 
This is a Phase 2, multicenter, randomized, double -blind, placebo-controlled, dose-ranging study.  
Approximately 270 patients will be randomized in a 5:1 ratio (225 ISIS 681257 and 45 placebo) 
to receive ISIS 681257 or placebo.  Study Drug (I SIS 681257 or placebo) will be administered 
SC every week, every 2 weeks (biweekly), or every 4 weeks, depending on cohort assignment, 
for up to 52 weekly doses, up to 26 every 2-week doses, or up to 13 every-4-week doses. 
The primary analysis time point  is at Week 25 for patients wh o received every 4-week dosing 
(Cohorts A-C) and at Week 27 for patients who received 2-week or weekly dosing (Cohorts D 
and E).  For patients continuing treatment beyon d the primary analysis time point additional 
supportive efficacy analysis (to evaluate whether th e treatment effect is maintained) and safety 
analysis (for the purpose of dose(s) selection) will be repeated at th e completion of Study Drug 
treatment. 
The treatment portion of the study will be comple te when the last enrolled patient reaches 
6 months of exposure.  All pa tients will then enter a 16-week post-treatment follow-up period. 
Patients ≥ 18 and ≤ 80 years old with elevated plasma Lp(a) levels ( ≥ 60 mg/dL ) and a clinical 
diagnosis of CVD are eligible for enrollment upon meeting the study specific eligibility criteria.  
Patients will be on standard-of-care  preventative therapy for other than elevated Lp(a) CVD risk 
factors as per current guidelines. 
Clinical diagnosis of CVD is defined as documented coronary artery disease (CAD), stroke, or 
peripheral artery disease (PAD) .  A diagnosis of CAD has to be documented by any of the 
following: 
• Angiographic evidence of ≥ 50% stenosis of 1 or more majo r epicardial coronary arteries 
• History of myocardial infarction documented by positive enzymes, and either symptoms of myocardial ischemia, or ECG changes ( Thygesen et al. 2012 ) 
• History of coronary revascularization 
• Evidence of cardiac ischemia on exercise testing, or imaging study 
Patients will be evaluated for study eligibility  during Screening, which takes place within 
4 weeks prior to Day 1 (the first day of Study Dr ug administration).  Patients who are determined 
to be eligible, based on screening assessments, will be enrolled in the study at Day 1 and randomly assigned to 1 of the 5 parallel dosing cohorts, with each cohort having a 5:1 ratio to 
receive ISIS 681257 or matching volume of placebo, respectively, by SC injection for up to 52 weeks. 
Following the End-of-Treatment, patients will  enter the 16-week post-treatment follow-up 
period. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
29  3.2 Number of Study Centers 
This is a multicenter, multinational study. 
3.3 Number of Patients 
Approximately 270 patients will be randomized in  this study, with approximately 54 patients 
assigned to each of the 5 treatment cohorts. 
3.4 Overall Study Duration and Follow-up 
The length of patients’ participation in the study may be up to 18 months (72 weeks), which 
includes a 4-week screening period, an up to 52-week treatment period with Study Drug 
(ISIS 681257 or placebo), and a 16-week post-treatment follow-up period.  The treatment portion of the study will be complete when the last en rolled patient reaches 6 months of exposure. 
Patients may be required to attend additional visits for monitoring of AEs or abnormal investigation results.  The frequency of add itional monitoring will be determined by the Study 
Medical Monitor in consultation with the Investigator. 
3.4.1 Screening 
Patient eligibility for the study will be de termined within 4 w eeks prior to study. 
3.4.2 Treatment For each patient minimum treatment duration is 6 months and maximum of 52 weeks.  
All patients enrolled will be randomized to a minimum of 6 months of treatment in 1 of 
5 treatment cohorts.  On completion of the 6 mont hs, patients may continue treatment within the 
same randomized cohort until the last enrolled patient reaches 6 months of exposure (for 
continuing safety assessments), with a maxima l exposure period of 12 months.  When this 
milestone is met, all patients will then enter a 16-week post-treatment follow-up period. 
Eligible patients will report to the Study Center for assessments at spec ified intervals throughout 
the 52-week treatment period as detaile d in the Schedule of Procedures in Appendix A .  During 
the Treatment, Study Drug (ISIS 681257 or placebo)  will be administered by SC injection once 
weekly, every 2 weeks, or every 4 weeks, depending on cohort assignment. 
3.4.3 Post-Treatment 
Patients when completed dosing will enter the 16-week post-treatment follow-up period and will 
return to the Study Center for 3 follow-up visits 4, 10, and 16 weeks after their last  injection of 
Study Drug as per Appendix A (Follow-up). 
The final study visit for each patient will be 16 weeks after the last dose of Study Drug. 
3.5 End-of-Study 
The End-of-Study is defined as  last patient, last visit.   
For individual patients, End-of -Study is defined as completio n of their last study visit. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
30  3.6 Data and Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) will be assembled to review safety, 
tolerability and efficacy (as needed) data collected on ISIS  681257 during this study.  The 
DSMB will be constituted to include expertise in medical specialties rele vant to the safety of 
antisense drugs (nephrology, hepatology, hematology and cardiology ).  Specialist members of 
the DSMB will be informed and consulted on all treatment -related SAEs  relevant to their 
experti se and all changes of relevant laboratory parameter s that trigger stopping rules 
(Section  8.6), within 48 hours of receipt of such results.  In addition, all accrued safety data 
relevant to each of medical area specialist will be forwarded monthly for review.  
The full DSMB review of all accumulated data will be performed quarterly.  Based on its 
ongoing assessment of the safety and tolerability of ISIS  681257, the DSMB will provide 
recommendations to the Sponsor for modifying, stopping or continuing the study as planned.  Details on the safety assessments, frequency of review, meeting schedules and controlled access 
to unblinded data are outlined in the DSMB Charter and/or Statistical Analysis Plan (SAP).  
4. PATIENT ENROL LMENT  
4.1 Screening  
Before patients  may be en rolled into the study, the Sponsor or designee requires a copy of the 
Study Center ’s written  independent ethics committee/institutional review board (IEC/IRB)  
approval of the protocol, informed consent form, and all other patient directed  information 
and/or recruitment material. 
Patients  or th eir legally acceptable representatives must sign the consent form  before any 
screening tests or assessments are performed .  At the time of consent, the patient  will be 
considered enrolled into the study and will be assigned  a unique screening number before any 
study procedures, including s creening procedures, are performed .  The screening number and 
patient  identification number must remain constant throughout the entire trial.  In the event the 
patient is re -consented and  re-screened the patient must be given a new screening number.  
Screening numbers and patient  identification numbers, once assigned, will not be re- used.  
4.2 Randomization 
Patients will be randomized  after all  screening  assessments have been completed and after the 
Investigator has verifi ed that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to randomization and assignment of a unique patient identification 
number. 
Using an Interactive Web -Response System (IXRS), eligible patients will be randomized 
in a 
1:1:1:1 :1 ratio  to 1 of the 5 parallel -dose cohorts (Cohorts A, B, C, D, or E).  Within each dose 
cohort, patients will be randomized in a 5:1 ratio to receive ISIS 681257 or matching volume of 
placebo, respectively.  
A permuted block schedule will be used.  The randomization schedule will be generated and held by an independent vendor. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
31  4.3 Replacement of Patients  
Patients  who withdraw from the study will not be replaced . 
4.4 Unblinding of Treatment Assignment  
The Sponsor and all patients , monitors, and Study C enter  personnel related to the study will be 
blinded throughout the study and until all patients have completed the study and the database has 
been locked .  However, if a patient  has suffered a SAE  (as defined in Section 9.3.3), and/or when 
knowledge of the treatment assignment will impact the clinical management of the patient , the 
Investigator will have the ability to unblind the treatment assignment for that  patient  using the 
IXRS .  The S ponsor will determine the point at which all treatment assignments will be 
unblinded.  The Sponsor or designee will be informed of the unblinding of a patient  within 
24 hours.  In addition, all SUSARs wil l be u nblinded by the Sponsor’s or designee’s Drug Safety 
and Quality Assurance personnel for the purpose of regulatory repor ting (see Section 9.2).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria at within 4 weeks of Study Day 1or at the time point specified in the individual eligibility criterion 
listed.  
5.1 Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements 
2. Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent 
3. Clinical diagnosis of CVD defined as documented coronary artery disease (CAD), stroke, 
or peripheral artery disease 
4. Lp(a) plasma level ≥  60 mg/dL  
5. Must be on standard-of- care preventative therapy for other than elevated Lp(a) CVD risk 
factors  
6. Patients on the following medications must be on a stable regimen for at least 4 w eeks 
prior to Screening and expected to remain on a stable regimen through the end of the post-t reatment follow-up period: 
a. lipid lowering drugs (statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 
[PCSK9s ] inhibitors, niacin, fibrates, fish oil or other products containing omega-3 
fatty acids including OTC preparations)  
b. a ntiplatelet drugs  
c. testosterone, estrogens, progesterone, growth hormone or progestins 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
32  7. Females:  must be non -pregnant and non- lactating and either : 
a. surgically  sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, 
bilateral oophorectomy) 
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females 
> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and  FSH levels in the postmenopausal range for 
the laboratory involved) 
c. Abstinent* or 
d. if engaged in sexual relations of child-bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to Secti on 6.3.1) from the time of signing the 
informed consent form until at least 16 weeks after the last dose of Study Drug  
(ISIS  681257 or placebo) 
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the 
preferred and usual life style of the patient .  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the 
duration of a trial and withdrawal are not acceptable methods of contraception 
8. Males must be surgically ster ile or, if engaged in sexual relations with a female of child -
bearing potential, the patient must be using an acceptable contraceptive method (refer to 
Section 6.3.1) fr om the time of signing the informed consent form until at least 16 weeks 
after the last  dose of ISIS 681257 
5.2 Exclusion Criteria  
1. Within 6 months of Screening :  acute coronary syndrome, m ajor cardiac surgery, or 
stroke /transient ischemic attach  
2. Within 3 months of Screening:  c oronary or peripheral arterial revascularization, major 
non-cardiac surgery , or lipoprotein apheresis  
3. Heart failure New York Heart Association ( NYHA) class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg) 
5.  History of acute kidney injury within 12 months of Screening  
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day 1 
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C 
or chro nic hepatitis B  
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ of the cervix that has been successfully treated  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
33  10. Patients with a history of major bleed or high-risk of bleeding diathesis  
11. Recent history of, or current drug or alcohol abuse 
12. Clinically -significant  abnormalities in screening laboratory values that would render a 
patient unsuitable for inclusion, including the following: 
a. Urine protein/creatinine ratio (UPCR) ≥ 0.25 mg/mg .  In the event of a UPCR  above 
this threshold, eligibility may be confirmed by a quantitative total urine protein 
measurement of ˂ 300 mg/24 -hr 
b. Urine albumin/creatinine ratio (UACR) ≥ 100 mg/g.  In the event of a UACR  above 
this threshold, eligibility may be confirmed by  a quantitative total urine albumin  
measurement of ˂ 150 mg/24-hr 
c. Estimated GFR  ˂ 60 mL/min (as determined by the Chronic Kidney Disease-
Epidemiological Collaboration ( CKD- EPI) Equation for creatinine clearance 
d. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN 
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in 
which case total bilirubin must be ≤  3 mg/dL  
f. Alkaline phosphatase (ALP)  > ULN  
g. Platele t count ˂  LLN  
13. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors 
14. Treatment with another investigational drug, biological agent, or device within 1 month 
of Screening, or 5 half-lives of investigational agent, whichever is longer 
15. Treatment with any non -Ionis oligonucleotide (including small interfering ribonucleic 
acid [ siRNA] ) at any time or prior treatment with an Ionis oligonucleotide or siRNA 
within 9 months of screening.  Patients that have previously received only 1 dose of an 
Ionis oligonucleotide as part of a clinical study may be included as long as ≥ 4 months 
has elapsed since dosing 
16. BMI > 40 kg/m2  
17. Blood donation of 50-499 mL within 30 days of Screening or of > 499 mL within 
8 weeks of S creening  
18. Unwillingness to comply with study procedures, including follow-up, as specified by this 
protocol, or unwillingness to cooperate fully with the Investigator 
19. Have any other conditions, which, in the opinion of the Investigator or Sponsor would 
make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the Study 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
34  6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, and C . 
6.1.1 Screening  
Written informed consent for the study will be obtained prior to the performance of any study-
related procedures including screening procedures .  A 4 -week period is provided for completing 
screening assessments and determining patient eligibility for the study .  Abnormal scre ening 
results may be re -tested once for determination of patient eligibility after consultation with the 
Sponsor Medical Monitor.  Patients may be re -screened 1 time in order to determine eligibility . 
During the s creening period, patients  will undergo a medical history and physical examination 
including vital signs, 12-lead electrocardiogram (ECG) and have blood and urine samples taken 
for clinical laboratory testing .  Patients  will be screened for HIV, hepatitis B , and hepatitis C.  
On co nfirmation of eligibility and prior to randomization, patients will also undergo a 24 hr urine 
collection for creatinine , albumin, and protein as a baseline assessment.  
6.1.2 Treatment Period  
During the t reatment period, patients will report to the study center for clinic visits .  Patients will 
receive 20 mg doses of Study Drug  administered by SC injection once every 4 weeks for up to 
52 weeks in Cohort A, 40 mg doses of Study Drug  administered by SC injection once every 
4 weeks for up to 52 weeks in Cohort B, 6 0 mg doses of Study Drug  administered by SC 
injection once every 4 weeks for up to 52 weeks in Cohort C, 20 mg doses of Study Drug  
administered by SC injection once every 2  week s for up to 52 weeks in Cohort D, or 2 0 mg 
doses of Study Drug ad ministered by SC injection once per week (weekly) for up to 52 weeks in 
Cohort E ( Section 8.1). 
Collection and measurement of vital signs, physical examination results, ECGs, clinical 
laboratory parameters ( Appendix B ), ISIS  681257 plasma concentrations, immunogenicity and 
biomarker samples , AEs  and concomitant medication/procedure information will be performed 
according to the Schedule of P rocedures in Appendix A. 
Extensive Pharmacokinetic (PK) Subgroup Only: 
Within each cohort, a subgroup of approximately 12 patients , who will consent to extensive PK 
sampling , will undergo additional PK sampling, in what is referred to as the PK Subgroup in this 
study.  Patients in this subgroup will have additional PK  samplin g time points in order to 
evaluate the plasma PK parameters of ISIS  681257.  Patients in this subgroup will have 
additional visits to the clinic during the t reatment p eriod in order to collect blood samples for PK 
assessment ( Appendix C ). 
6.1.3 Post-Treatment  Period  
Each patient will be followed for safety assessments for 16 weeks after the last dose of Study Drug.  During the post- treatment follow-up period, patients will return to the Study Center 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
35  for 3 outpatient visits at Week s 4, 10, and 16 after the last dose  of Study Drug for safety and 
clinical laboratory evaluations  and for blood sampling for PK ( Appendices A  and C ). 
6.2 Additional Study Assessments 
6.2.1 Laboratory Assessments  
Laboratory analyte samples will be collected throughout the study.  A list of these analytes is 
contained in Appendix B . 
Routine blood chemistry and urine samples (excl uding 24-hour urine collect ion) should be taken 
after fasting for at least 10 hours.  Any confirmatory  test, or test taken for safety reasons, may be 
taken at any time, irrespective of fasting status .  During preparation for fasting samples, the 
patient can drink water and they should ensure th at they consume sufficient water in order to not 
become dehydrated.  
If tests are uninterpretable (e.g., due to clum ping, hemolysis or quantity not sufficient) or 
missing, a repeat blood or urine specimen should be re-drawn as soon as po ssible (ideally within 
1 week). 
Hematology samples will be collected every 14 da ys.  Each time a hematology lab is drawn and 
sent to the central laboratory fo r analysis, an additional sample must be collected in parallel and 
analyzed locally.  In the event that both the central and local samples are unreportable (e.g., due 
to hemolyzed or clumped blood samples), patient dosing cannot continue until another sample is 
repeated and determined not to ha ve met a platelet stopping rule. 
If there is no reportable platelet  count within 14 days of the last  platelet count, the Investigator 
will contact the patient to hold dosing until a ne w platelet count is obtained and reviewed. 
Blood and urine samples for renal function testing will also be collected every 14 days and sent 
to the central laboratory for analysis, per Section 8.5.2.  If there are no test results available 
within 14 days of the last set of results for para meters considered critical to patient safety, the 
Investigator will contact the patient to hold dosin g until a new test set is obtained and reviewed. 
Liver function testing will also be collected ever y 14 days and sent to the central laboratory for 
analysis for the first 3 mont hs of the study treatment, and monthly thereafter during the 
Treatment Period per Section 8.5.1.   
All lab samples sent to the central laboratory are received on the next day and processed.  Lab 
Alerts issued as per protocol safety monitoring requirements or  stopping rules will indicate the 
applicable protocol section to facilitate review  and will be immediately and simultaneously sent 
by email to the Investigator, the Sponsor a nd the CRO Medical Monitors, the Sponsor Drug 
Safety Physician, and the Clinical Trial Manager (CTM), and should be received by them within 
2 days from sample collection.  Hematology results from the site’s local la boratories are received 
by the study center staff on the day of sample collection, and should be entered as soon as 
possible into the eCRF to inform the Sponsor and CRO study monitoring teams. 
All platelet count results must  be reviewed promptly (wit hin 48 hours of receipt) by the 
Investigator, or designee, to ensu re that the count has not met th e stopping rule and to determine 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
36  whether the rate of decline is suggestive that the patient could be approaching the dose 
interruption rule of 75,000/mm3 as specified in Section 8.6.3.  Any case of a platelet count 
reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is c onsidered an adverse event of 
special interest and must be reported in an  expedited fashion to the Sponsor as per 
Sections 9.3.3.1  and 9.4.1. 
All liver and renal function tests must also be reviewed promptly (withi n 48 hours of receipt) by 
the Investigator, or designee, to ensure th at the result has not met the stopping rule. 
All lab alerts received, including those rela ted to platelet, liver, or renal function 
monitoring/stopping rules, are also reviewed promptly  by the Sponsor and the CRO Medical 
Monitors who will agree on actions to be taken.  Within 24 hours of receiving an actionable lab 
alert the CRO Medical Monitor will communicate in structions to the Inve stigator and the study 
personnel by emailing them the Safety Surve illance Form that needs to be signed by the 
Investigator/study personnel and promptly return ed to the Sponsor and CRO Medical Monitor.  
In urgent cases, such as platelets results below 50,000/mm3, or liver or renal test results reaching 
a critical stopping rule the Investigat or must also be contacted by phone.  
Further information on safety monitoring and actions  to be taken by the Study Investigator in the 
event of reduced platelet count are provided in Sections 8.5.3 and 8.6.3. 
6.2.2 Physical Exams and Vital Signs 
Physical exams and vital signs wi ll be performed as indicated in the Schedule of Procedures 
(Appendix A ).  Vital signs should include weight, bl ood pressure (BP), pulse rate, respiratory 
rate and body temperature.  BP and pulse rate w ill be recorded after the patient has been in a 
sitting position for at least 5 minutes.  BP should always be measured on the same arm 
(preferentially on the left arm).  Height will be measured at Screening. 
6.2.3 Electrocardiography  
Electrocardiography (ECG) will be conducted at Sc reening, Day 1, (prior to the first dose of 
Study Drug), and again during the treatment period as follows per dosing cohort: 
• Cohorts A, B, and C at Weeks 5, 13, 21, 25, 33, 41, 49, and 53  
• Cohorts D and E at Weeks 5, 13, 21, 27, 33, 41, 49, and 53 
In all cohorts, ECGs will be conducted during th e post-treatment follow-up period at 4, 10, and 
16 weeks after the last dose of Study Drug. 
ECGs will be recorded after the patient has been resting in a supine position for at least 
5 minutes.  ECGs will be performed in triplicate. 
6.2.4 PK Sampling 
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected 
prior to dosing on Day 1 and at various times  throughout the treatment and post-treatment 
follow-up periods as noted in the tables in Appendix C . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
37  Within each cohort, patients assigned to the PK Subgroup will have additional PK  sampling time 
points and additional visits to the clinic during the t reatment p eriod in order to collect blood 
samples for PK assessment ( Appendix C ). 
6.3 Restriction on the Lifestyle of Patient s 
6.3.1 Contraception Requirements  
All male patient s and women  of childbearing potential must refrain from sperm/egg donation and 
either be abstinent† or pr actice effective contraception from the time of signing the informed 
consent form until at least 16 weeks  after their last dose of study treatment .   
Male patient s engaged in sexual relations with a female of child -bearing potential must a lso 
encourage their female partner to use effective contraception from the time of signing the 
informed consent until 16 weeks  after the patient ’s last dose of study treatment.  
For the purposes of this study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
• Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patient s: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
Follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository 
• Male patient s with partners that are pregnant must use condoms as contraception to 
ensure that the fetus i s not exposed to the Study Drug 
For female patient s and female partners of male patient s: 
• Using 1 or more of the following acceptable methods of contraception:  surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception , intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom * with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository  
†Note: Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the 
duration of a trial and withdrawal are not acceptable methods of contraception. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
38  *Note : A female condom and a male condom should not be used together as friction 
between the 2 can result in either or both product s failing . 
6.3.2 Other Requirements  
All patients will be required to fast for at le ast 10 hours before visits requiring fasted blood 
sampling.  
7. STUDY DRUG  
7.1 Study Drug  Description  
Study Drug ( ISIS 681257 or Placebo)  characteristics are listed in  Table 1.  
Study Drug ( ISIS 681257 or Placebo)  will be provided as 0.8 mL deliverable volume in 2 mL 
stoppered and sealed glass vials as a sterile solution .   
The Study Drug  is clear to slightly yellow in color, it is for single use , contains no preservatives 
and must be stored between 2 to 8 °Celsiu s and be protected from light. 
7.1.1 ISIS  681257 
ISIS 681257 vials contains 100 mg/mL ISIS 681257 in Water for Injection.  Additionally, 
sodium phosphate buffer and sodium chloride are added to control the measure of the acidity or 
basicity of the  solution (pH) and tonicity, respectively.  The target pH is 7.4. 
7.1.2 Placebo  
Placebo vials contain 0.9% sodium chloride in Water for Injection.  1.6 µg/mL riboflavin is 
added to ensure color matching of placebo vials to ISIS 681257 vials.  
Table 1 Study Drug  Characteristics  
Study Drug  ISIS 681257  Placebo  
Strength 100 mg/ mL  Not Applicable  
Volume/Formulation  0.8 mL solution per 
2.0 mL vial  0.8 mL solution per  
2.0 mL vial  
Route of Administration  SC SC 
SC = subcutaneous  
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug  (ISIS 681257 or placebo) 
labeled in accordance with specific country regulatory requirements . 
7.3 Study Drug  Accountability  
The study staff is required to document the receipt, dispensing, and return  of Study Drug  
(ISIS 681257 or placebo) supplies provided by the Sponsor.  The patient must return all used and 
unused Study Drug  to the Study Center for accountability .  The Study Center must return all 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4
Protocol 5 January 2017
 
39  used and unused Study Drug to the Sponsor or de signee for destruction.  All used syringes must 
be disposed of as per the site’s hazardous waste destruction policy. 
8. TREATMENT OF PATIENTS 
8.1 Study Drug Administration 
ISIS 681257 will be administered to patie nts by Study Center staff as follows: 
Cohort A: a single SC dose of 20 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort B: a single SC dose of 40 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort C: a single SC dose of 60 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort D: a single SC dose of 20 mg every 2 weeks for up to 52 weeks and a maximum of 
26 doses 
Cohort E: a single SC dose of 20 mg every week (weekly) for up to 52 weeks and a 
maximum of 52 doses 
Self-administration will be allowed after appr opriate training of patie nt and/or caregiver. 
Patients in Cohorts A, B, and C should receive 1 dose every 4 weeks, patients in Cohort D 
should receive 1 dose every 2 weeks and Cohort E should receive 1 dose per week with weeks 
always defined relative to Study Day 1.  For exam ple if a patient receiv es the first dose on a 
Monday, subsequent doses should be given on Mondays according to the respective dosing 
schedule, if possible.  If a patient misses an injection, or if dosing on the usual day is not 
possible, the patient can reschedu le the injection provided that 2 doses are administered at least 
2 days apart. 
Every effort should be made to ensure the prev ious dose is given 7 days prior to a scheduled 
clinic visit. Please refer to the Study Drug Ma nual provided by the Sponsor or  designee for more detailed 
instructions for Study Drug (ISIS 681257 or pl acebo) preparation and administration. 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
40  Table 2 Study Drug  Dosing Information 
Cohort  Treatment  Volume to Administer/Dose  # Doses  Total ISIS 681257  
A 20 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.2 mL  ≤ 13 ≤ 260 mg 
B 40 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.4 mL  ≤ 13 ≤ 520 mg  
C 60 mg ISIS 681257 
or placebo  
(Every 4 weeks)  0.6 mL  ≤ 13 ≤ 780 mg  
D 20 mg ISIS 681257 
or placebo  
(Every 2 weeks)  0.2 mL  ≤ 26 ≤ 520 mg  
E 20 mg ISIS 681257 
or placebo  
(Every week) 0.2 mL  ≤ 52 ≤ 1040 mg  
 
8.2 Other Protocol -Required Drugs  
No other Study Drug  treatments  are required by the protocol. 
8.3 Other Protocol -Required Treatment Procedures  
No other treatment procedures are required by the protocol. 8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator ” section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of the pre- dose test 
closest to Day 1 and the Day 1  value itself . 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen based on preclinical and clinical 
observations. 
In case of discrepancy  between the test results from 2 sources, such as between the central and 
local lab, safety -mandated action must be initiated based on the more critical ( lower or highe r, as 
relevant) of the 2 values.  
Confirmation Guidance :  At any time during the study (treatment or post-t reatment follow-up 
periods), the clinical laboratory results meeting any of the safety monitoring criteria presented 
below must be confirmed by perfor ming measurements (ideally in the same laboratory that 
performed the initial measurement) on new specimens prior to administering the next dose of 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
41  Study Drug  (ISIS 681257 or placebo).   All new specimen collections should take place as soon 
as possible (ide ally within 3 days of the initial collection) .  
In addition, as described in Section 6.2.1 hematology lab s should be sent in parallel to the central 
and local laboratory for analysis. 
Stopping Rule Guidance:  The Investigator may interrupt or permanently discontinue study 
treatment for any medical reason including changes in clinical laboratory results.   
In the event of an initial clinical laboratory result that meets a stopping criterion, patients must 
not be re -dosed until a confirmatory test result has been reviewed by the Study Medical Monitor.  
If any of the stopping criteria described below (refer to Sections 8.6.1 to 8.6.3) are met and are confirmed, the patient will be permanently discontinued from furt her treatment with Study Drug 
(ISIS 681257 or placebo), evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post- treatment 
evaluation portion of the study.  In general, patients who do not meet the stopping rules based upon retest may continue dosing.  However, the Investigator and the Study Medical Monitor (or appropriately qualified designee) should confer as to whether additional close monitoring of the 
patient is appropriate. 
Additional Guidance:  If possible, a PK sample should be collected as soon as possible after an 
SAE has occurred (preferably within 2 weeks).  In addition, if a patient is asked to return to the clinic for additional evaluations due to an AE, then a PK sample should be taken at the time of 
the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Ev aluation,” issued by the U.S.  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline, please refer to 
guidance in Section 8.5 ab ove. 
All patients will have liver chemistry  tests monitored every 2 weeks for the first 3 months of the 
study treatment, and monthly thereafter  during the Treatment Period . 
In the event of appearance of symptoms or signs of hepatic injury (jaundice, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash,  abnormal bleeding or bruising, or 
eosinophi lia > ULN ) liver  enzymes and bilirubin should be tested as soon as possible.  Testing at 
a lab that is local to the patient is permissible for this purpose.  
In the event of an ALT or AST measurement that is > 3 x ULN (or the greater of 2 x baseline value or 3 x ULN if the baseline value was > ULN) at any time during the s tudy ( treatment or 
post-t reatment period), the initial measurement(s) should be confirmed as described in 
Section  8.5. 
Patients  with confirmed ALT or AST levels > 3 x ULN should have their liver chemistry tests 
(ALT, AST, ALP, international normalized ratio [ INR] and total bi lirubin) retested at least once 
weekly until ALT and AST levels become ≤ 1.2 x ULN . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
42  All results of liver function tests  must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the result  has not met the stopping rule s per 
Section  8.6.1. 
Further Investigation into Liver Chemistry Elevations :  For patients  with confirmed ALT or AST 
levels > 3 x ULN , the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases 
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environmental chemical agents and travel 
4. Serology for viral hepatitis (hepatitis A virus [ HAV] immunoglobulin M [ IgM], hepatitis 
B sur face antigen [ HBsAg ], hepatitis C virus [ HCV ] antibody, Cytomegalovirus [ CMV ] 
IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor and t he study DSMB.  Repetition of the above evaluations should be 
considered if a patient’s ALT and/or AST levels reach 5 x ULN . 
All routine liver function test results will be reviewed on an ongoing basis at the weekly s afety 
review by the  Medical Monitor.  
All lab alerts for abnormal liver function tests must be promptly (within 48 hours of receipt) 
reviewed by the Investigator and Medical Monitors. 
Lab alerts for abnormal liver chemistry  tests will be issued for:  1) ALT or AST >  3 x ULN ; 
2) ALT or AST >  2 x baseline; 3) total bilirubin >  ULN; 4)  ALP  > ULN.  These alert levels are 
set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the 
FDA Guidance referenced in Section 8.5.1. 
8.5.2 Safety Monitoring for Renal Function  
All patients will have renal function tests monitored every 2 weeks throughout the study.  
In the event of appearance of symptoms or signs consistent with renal dysfunction such as 
hematuria, polyuria, anuria, flank pain, new-onset hypertension, nausea and/or anorexia, renal function should be tested as soon as possibl e.  Testing at a lab that is local to the patient is 
permissible for this purpose. 
During the course of the study, urinary surveillance will include urinalysis to include urine 
albumin/creatinine ratio ( UACR ), urine protein/creatinine ratio ( UPCR ) and urinary red blood 
cells ( RBCs ), as well as  serum creatinine and cystatin -C to estimate glomerular filtration rate 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
43  (eGFR ), which will be monitored every 2 weeks.  In addition, biomarkers of acute renal injury 
will also be measured every 2 weeks ( Appendix B ).  
The assessment of serum creatinine, cystatin -C, and urinalysis more frequently than every 
2 weeks will be guided by consultation with a local nephrologist.  Any decision taken by the 
Investigator to discontinue study medication will be made taking into account all available and relevant data.   In addition, the decision to discontinue Study Drug  may also be based on lesser 
changes in these parameters observed in isolation or in association with other renal -related 
abnormalities.  Any decision taken t o restart study medication will be made in consultation with 
the Study Medical Monitor taking into account all available and relevant data.  
All renal function test results will be reviewed on an ongoing basis at the weekly safety review 
by the Medical Mon itor. 
All results of renal function tests  must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the result  has not met the stopping rule s per 
Section  8.6.2. 
Lab alerts for abnormal renal tests will be issued for:  C reatinine clearance (by CKD -EPI 
formula) decrease from baseline > 25%, u rine albumin/creatinine  ratio  (UACR)  > 250 mg/ g, 
urine protein/creatinine ratio (UPCR)  > 0.5 mg/mg , or an increase in serum cr eatinine from 
baseline > 0.3 mg/dL ). 
These alert levels are set to anticipate and prevent the risk of a medically significant change in renal function while receiving  Study D rug. 
In the event of a confirmed (as described in Section 8.5) laboratory result meeting one or more of 
the above criteria , dosing with the Study Drug  should be interrupted and the Study Medical 
Monitor informed.  In addition, the following supplemental renal tests should be immediately 
obtained:  
Serum creatinine, urine culture, 24- hour urine sample for creatinine clearance, urine 
albumin  and urine protein, urine microscopy sample with inspection of sediment. 
The Investigator should also review the patient’s concomitant medications for potentially 
nephrotoxic agents, and, with the results of these evaluations, review any decision to continue or discontinue the patient in c onsultation with the Study Medical Monitor and the medical area 
specialist consultant of the DSMB . 
8.5.3 Safety Monitoring for Platelet Count Results  
All patients will have platelet counts monitored every 2 weeks for the duration of the study and must not receive S tudy Drug without an interpretable platelet count result in the prior 2 weeks.  
In addition, platelet function will be evaluated by aggregometry, using an approved point-of- care 
diagnostic device,  in all patients at each study site visit, with additional functional testing being 
performed at selected study centers .  
As described in Section 6.2.1, a ll platelet count results must be reviewed promptly (within 
48 hours of receipt) by the Investigator or the designee to ensure that the count has not met the 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
44  stopping rule and to determine whether the rate of decline is suggestive that the patient could be 
approaching the dose interruption rule of 75,000/mm3 as specified in Section 8.6.3.   
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered a n adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor.  
Lab alerts related to platelet monitoring/stopping rules are issued when :  1) platelet counts are 
< 140,000 mm3; 2) when platelet count is ≥ 30% decreased from baseline, or 3) when the 
hematology sample is unreportable.  All these lab alert s, are reviewed promptly by the Medical 
Monitor and instructions are communicated to the Investigator and the study personnel within 
24 hours of receiving a n actionable lab alert  as described in Section 6.2.1. 
Actions to be taken in the event of reduced platelet count are shown in Table 3 in Section 8.6.3. 
In the event of a platelet count ˂  100,000/mm3 the laboratory tests outlined in Appendix D , 
should be performed as soon as possible.  Additional lab tests will be determined by the Sponsor 
Medical Monitor or designee in consultation with the Investigator. 
8.5.4 Safety Monitoring for Minor Bleeding Events 
Patients will be instructed to promptly report any signs or symptoms of bleeding.  Minor 
bleeding events are those that do not fulf ill the criteria for major bleeding or clinically -relevant, 
non-major bleeding events (which are defined in Section 8.6.3), for example excess bruising, petechiae, or gingival bleeding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation parameters activated partial thromboplastin time (aPTT), prothrombin time (PT), INR , hepatic 
enzymes, bilirubin and platelet count should be performed. 
8.5.5 Safety Monitoring for Constitutional Symptoms  
Patients will be instructed to promptly report any signs o r symptoms of fever, constitutional 
symptoms , rash, arthralgia or joint swelling that may arise during the study and the Investigator 
should closely evaluate all potential causes, including concomitant illness.  Patients who  
experience persistent symptoms should be discussed with the Sponsor Medical Monitor or 
designee to determine whether additional monitoring or laboratory tests are required. 
8.6 Stopping Rules  
For the purposes of stopping rules, Baseline is defined as the average of Day 1 pre-dose 
assessment and the last measurement prior to Day 1.  
8.6.1 Stopping Rules for Liver Chemistry Elevations  
In the event of confirmed laboratory results meeting any of the followi ng criteria, dosing of a 
patient with Study Drug  will be stopped permanently: 
1. ALT or AST > 8 x ULN , which is confirmed 
2. ALT or AST >  5 x ULN , which is confirmed and persists for ≥ 2 weeks  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
45  3. ALT or AST >  3 x ULN (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), which is confirmed and total bilirubin >  2 x ULN  or INR > 1.5  
4. ALT or AST >  3 x ULN  (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), which is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of  fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (> ULN ) felt by the Investigator to be 
potentially related to hepatic inflammation  
8.6.2 Stopping Rules for Renal Function Test Results  
In the event of an estimated creatinine clearance ( by CKD -EPI formula) meeting any of the 
following criteria, or any change in renal biomarkers deemed by the nephrologist on the DSMB 
to require further evaluat ion, a serum creatinine and 24 -hour urine sample for creatinine 
clearance and protein should be obtained: 
1. CKD- EPI decrease of > 40% from B aseline  
2. CKD- EPI v alue < 45 mL/min/1.73 m2 
Dosing of a patient with Study Drug (ISIS 681257 or placebo) will be stopped permanently  if 
24-hour urine testing confirms any of the following values in the absence of an alternative 
explanation : 
1. Urine protein is > 1.0 g 
2. Creatinine clearance decrease of > 40% from baseline 
3. C reatinine clearance < 45  mL/min/1.73 m2 
Irrespective of whether the stopping rule is confirmed or not, the follow-up schedule and 
frequency of renal function monitoring after the initial event will be determined by the Study Medical Monitor in consultation with the Investigator and the medical a rea specialist  on the 
DSMB .  The Investigator should consider consulting a local nephrolog ist for any change of renal 
function that presents a concern.  If a renal biopsy is performed, a sample specimen should be made available for examination by an independent renal pathologist who has been engaged by 
the Sponsor to review such specimens.  
8.6.3 Stopping Rule for Platelet Count Results  
Stopping Rules for Platelet Count Results 
Actions to be taken in the event of a low platelet count are summarized in Table 3 below. 
In the event of any platelet count less than 50,000/mm
3, or a platelet count less than 75,000/mm3 
that occurs while the patient is already on reduced dose, dosing of the patient with Study Drug  
will be stopped permanently (Table 3) .  Platelet count will be monitored daily until 2 successive 
values show improvement then monitored every 2- 3 days until platelet count is stable.  
Administration of  steroids is recommended for patients whose platelet count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by administration of high dose 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
46  steroids.  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2 -4 weeks for 1 -4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2 -4 weeks then taper; or methylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone ). 
In the event of a platelet count ˂  75,000/mm3 and > 50,000/mm3, and in the absence of major 
bleeding or clinically -relevant non- major bleeding (defined below; Schulman et al. 2005), dosing 
of a patient with Study Drug should be suspended temporarily until the platelet count has 
recovered to  > 100,000/mm3.  If dosing is continued it must be at a reduced dos e as shown in 
Table 3 .  The suitability of the patient for continued dosing will be determined by the 
Investigator in consultation with the Study Medical Monitor and will be based on factors such as the original rate of decline in the patient’s platelet count, whether any bleeding events were experienced by the patient, and the speed of recovery of platelet count after interruption  of 
dosing. 
If, after reintroduction of Study Drug, the platelet count again falls below 75,000/mm
3, then 
dosing of the patient with Study Drug  will be stopped permanently.  
Once a patient commences weekly monitoring this frequency of monitoring should continue 
irrespective of whether the platelet count rises into the normal range. 
Any unreportable platelet count result must be rechecked and determined not to have met a 
stopping rule before dosing can continue. 
Definition of Major Bleeding Events (Schulman et al. 2005):  
• Fatal bleeding, and/or  
• Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 24 hours, or leading to transfusion of 2 or more units of whole or red cells 
Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman et al. 2005): 
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting > 24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epitasis, gingival bleeding, hemoptysis, hematemesis  
6. Bleedin g after venipuncture for > 5 minutes  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
47  Table 3 Actions in Patients with Low Platelet Count  
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every week * 
75K-100K/mm3 Permanently reduce as follows:  
For Cohort A:  reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks   
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week s 
For Cohort E:  reduce to 10 mg every week  Closer observation  
Monitor every week * 
50K-75K/mm3 Pause dosing  
When platelet count returns to >  100K/mm3 restart 
dosing as follows  only if approved by Sponsor 
Medical Monitor : 
For Cohort A:   reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks  
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week  
For Cohort E :  reduce to 10 mg every week  
or 
Permanently discontinue Study Drug i f it occurs 
while on already reduced dose  Closer observation  
Monitor every 2-3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/ non-
steroidal anti-inflammatory 
drug ( NSAIDS )/ anticoagulant 
medication  
25K-50K/mm3 Permanently discontinue Study Drug  Closer observation: 
Monitor daily until 
2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet 
agents/NSAIDS/anticoagulant medication while platelet 
count ˂ 50K/mm3 if possible 
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 
2 successive values show 
improvement then monitor every 2 -3 days until platelet 
count stable  
Steroids recommended**  
Consider need for hospitalization and referral to 
hematologist  
Discontinue antiplatelet agents/NSAIDS/anticoagulant 
medication while platelet 
count ˂ 50K/mm
3 if possible 
* Once a patient commences weekly monitoring this frequency of monitoring should continue irrespective of 
whether the platelet count rises into the normal range. 
** Recovery in platelet count may be accelerated by administration of high dose steroids .  Treatment guidelines for 
immune thrombocytopenia ( Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days ever y 
2-4 weeks for 1- 4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require continuation with oral steroids after methyl prednisolone) . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
48  8.7 Adjustment of Dose  
Dose frequency adjustments for platelet count reduction must be made in accordance with 
Section 8.6.3 and Table 3  (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.   
Patients may have their dose interrupted in response to AEs after consultation with Study 
Medical Monitor. 
8.8 Discontinuation of Study Drug  
A patient  must permanently discontinue study treatment for any of the following: 
• The patient  becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patient  withdraws consent  
• The patient  experiences an AE  that necessitates permanent discontinuation of Study Drug  
• The patient  develops laboratory test abnormalities that meet any of  the stopping rules 
listed in  Sections  8.6.1 to 8.6.3 
• When a platelet count  of less than 50,000/mm
3, or a platelet count less than 75,000/mm3 
while the patient is on a reduced dose. 
The reason for discontinuation of Study Drug  must be recorded in the electronic Case Report 
Form (eCRF) and source documentation. 
8.8.1 Follow- up Visits for Early Termination from Treatment  Period  or from 
Post-Treatment Follow -up Period 
Any patient who discont inues early from the t reatment p eriod or from post-t reatment follow-up 
period  should be followed as per the platelet monitoring rules shown in Table 3 , Section 8.6.3 for 
the first 6 weeks after discontinuing Study Drug .  Following this period, if the platelet count is 
stable (at least 3  consecutive values that are stable as determined by the Sponsor M edical 
Monitor and > 100,000/mm3), the next platelet count should be taken within at least 6  weeks so 
that patients are monitored for at least 12 weeks after discontinuing Study Drug. 
Following 6 weeks of Study Drug  discontinuation, patients should be strongly encouraged to 
attend planned Study Center visits (including End-of- Treatment Week 53 visit and final 
Post-T reatment Follow -up visit 16 weeks after their last dose of Study Drug ) to collect the study 
assessments in accordance with the S chedule of Procedures in Appendix A . 
If the patient declines or is unable to partici pate in the above, an  ET visit ( Week  53 visit 
assessments) should be performed at the time of withdrawal, at a minimum, and ideally within 
2 weeks from the last dose of Study Drug. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
49  8.9 Withdrawal of Patient s from t he Study  
Patient s must be withdrawn from the study for any of the following:  
• Withdrawal of consent 
• The patient  is unwilling or unable to comply with the protocol 
• The patient  permanently discontinues Study Drug  (see Section 8.8)   
• The patient  meets any of the Exclusion C riteria (see Section 5.2) after enrolling in the 
study that in the opinion of the Investigator represents a safety risk to the patient   
Other r easons for withdrawal of patient s from the study might include:  
• At the discretion of the Investigator for medical reasons  
• At the discretion of the Investigator or Sponsor for noncompliance 
• Significant protocol deviation  
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal .  All information, including the reason for withdrawal from study, must be 
recorded in the eCRF . 
Any patient  who withdraws consent to participate in the study will be removed from further 
treatment and study observation immediately upon the date of request.  These patient s should be 
encouraged to complete the ET study procedures and observations at the time of withdrawal 
(Appendix A ). 
For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  ET study procedures and observations at the time of withdrawal ( see 
Appendix A). 
8.10 Concomitant Therapy  and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the patient ’s 
eCRF .  AE s related to administration of these therapies or procedures must also be documented 
on the appropriate eCRF . 
8.10.1 Concomitant Therapy 
A concomitant therapy is any non-protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered  from  the time 
the patient has signed the informed consent at screening to the end of the post -treatment  follow-
up period . 
Allowed Concomitant Therapy 
Use of the following is allowed only if the patient has been on a stable regimen for at least 
4 weeks prior to screening and is planned to remain on a stable regimen through the end of the 
post-t reatment follow-up period:  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
50  • Lipid lowering drugs ( statins, ezetimibe,  PCSK9 inhibitors, niacin, fibrates, fish oil, other 
products containing omega-3 fatty acids (including OTC preparations) 
• Anti- platelet therapies  
• Testosterone, estrogens, progesterone, growth hormone, or progestins. 
Disallowed Concomitant Therapy 
Use of the following is disallowed: 
• Warfarin, direct thrombin inhibitors or Factor Xa inhibitors 
• Other experimental agents during the study including investigational drug, biological 
agent, or device within 1 month of Screening, or 5 half- lives of investigational agent, 
whichever is longer.  T his includes marketed agents at experimental dosages  
• Treatment with any non -Ionis oli gonucleotide (including siRNA) at any time or prior 
treatment with an Ionis oligonucleotide or siRNA within 9 months of screening.  Patients 
that have previously received only 1 dose of an Ionis oligonucleotide as part of a clinical 
study may be included a s long as ≥ 4 months has elapsed since dosing 
• Lipoprotein apheresis  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy . 
8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between  
screening and the end of the post-t reatment  follow-up period . 
8.11 Treatment Compliance  
Compliance with treatment dosing is to be monitored and documented by the Study Center staff 
and recorded in the eCRF .   
Patients or Study Center Staff will record treatment administered in a dosing diary that w ill be 
reviewed by Study Center staff and  entered into the eCRF . 
8.12 Safety Monitoring Compliance 
Compliance with  safety monitoring requirements and treatment stopping rules must be 
documented by the Study Center staff.   
Patients and the Study Investigators are required to adhere to a strict program of monitoring of 
platelet count, and liver and renal function as described in Section 6.2.1, Sections  8.5.1- 8.5.3, 
and Sections 8.6.1- 8.6.3. 
Patients will be required to have platelet counts every 2 weeks for the duration of the study and 
must not receive S tudy Drug without an interpretable platelet count result in the prior 2 weeks, in 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
51  which case the Investigator must contact the patient to hold dosing until a new platelet count is 
obtained and reviewed, and will document this contact.  
Patients will also be required to have renal function testing and assessment of biomarkers of 
renal damage every 2 weeks, and must not r eceive Study Drug if there are no test results for 
parameters considered critical to patient safety available within the prior 2 weeks.  In such a case, the Investigator must contact the patient to hold dosing until these or new tests are obtained 
and revi ewed.  
Adherence to the program will be closely monitored by the Sponsor , and patients and trial sites 
that are unable or unwilling to comply with this important risk mitigation program will be 
discontinued from the study.  
Patients should be informed of the possibility and risks of a reduction in platelet count, and of 
potential hepatic and renal risks,  and the importance of adherence to the monitoring program.  
Any case of a platelet count reduction to levels below 50,000/mm
3 (Grade 3 or Grade 4) is 
considered an adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor. 
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING   
9.1 Sponsor Review of Safety Information 
Safety informatio n will be collected, reviewed, and evaluated  by the Sponsor or designee in 
accordance with the Safety Management P lan throughout the conduct of the clinical trial. 
9.2 Regulatory Requirements  
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators of suspected unexpected serious adverse reactions (SUSARs) per the International 
Conference on Harmonization (ICH) guidelines E2A and ICH E6.  Country- specific regulatory 
requirements will be followed in accordance with local country regulations and guideli nes. 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations. 
In addition to the Investigator’s assessment of relatedness, the Sponsor or designee  will evaluate 
the available information and perform an independent assessment of relatedness.  While the 
Sponsor may upgrade an Investigator’s decision it is not permissible to downgrade the Investigator’s opinion for the purposes of determining whether the SAE meets the definition of a 
SUSAR.  
Appropriate personnel at the Sponsor or designee will unblind SUSARs for the purpose of 
regulatory reporting.  The Sponsor or designee will submit SUSARs to Regulatory Agencies in 
blinded or unblinded fashion according to local law.   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
52  9.3 Defin itions  
9.3.1 Adverse Event  
An adverse event  is any unfavorable and unintended sign ( including a clinically -significant  
abnormal laboratory finding, for example ), symptom, or disease temporally associated with the 
study or use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any AE caused by the Study Drug . 
A suspected adverse reaction  is any AE  for which there is a reasonable possibility that the drug 
caused the AE .  A suspected adverse reaction implies a lesser degree of certainty about causality 
than an adverse reaction.  
9.3.3 Serious Adverse Event (SAE)  
A SAE  is any AE  that in the view of eit her the Investigator or Sponsor, meets any of the 
following criteria:  
• Results in death  
• Is life threatening,  that is, poses an immediate risk of death at the time of the event  
• An AE  or suspected adverse reaction is considered “life-threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the patient  at immediate risk of 
death .  It does not include an AE  or suspected adverse reaction that , had it occurred in a 
more severe form, might have caused death 
• Requires inpatient hospitalization or prolongation of existing hospitalization  
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions 
• Results in a congenital anomaly or birth defect in the offspring of the patient (whether the patient  is male or female)  
• Important medical events  that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered serious when, based upon appropriate medical judgment, they may jeopar dize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization , or the development of drug dependency or drug abuse 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
53  9.3.3.1 Adverse Events of Special Interest  
For the purpose of this study severe reductions in platelet count < 50,000 mm3 are considered  as 
AE of special interest  and should be subject to expediting reporting to the Sponsor following the 
same requirements as for SAE reporting (Section 9.4.1). 
9.4 Monitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre-existing condition worsened.  The Investi gator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.1 Serious Adverse Events/Adverse Events of Special Interest  
In the interest of patient  safety, and in order to fulfill regulatory requirements , all SAEs and AEs 
of special interest (regardless of their relationship to Study Drug ) should be reported to the 
Sponsor  or designee within 24 hours of the Study Center’s first knowledge of the  event .  The 
collection of SAEs will begin after the patient  signs the informed consent form and stop at the 
end of the patient ’s follow-up period .  When  the Investigator is reporting by telephone, it is 
important to speak to someone in person versus leaving a message.  An  Initial Serious Adv erse 
Event Form should be completed and a copy should be emailed or faxed to the Sponsor or 
designee.  The contact information  for reporting SAEs is as follows:  
Attention:    
Email:    
Fax:    
Detailed information should be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be followed until resolution  during the study period.  SAEs that remain ongoing past th e patient ’s last 
protocol-specified follow-up visit will be evaluated by the Investigator and Sponsor.  If the 
Investigator and Sponsor agree the patient ’s condition is unlikely to resolve, the Investigator and 
Sponsor will deter mine the follow -up requirem ent. 
All SAEs considered treatment- related , as defined in Section 9.4.3.1, w ill be reported by the 
Sponsor to the DSMB as described in Section 3.6.  
9.4.2 Non-Serious Adverse Events  
The recording of non- serious AEs will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow-up period .  The Investigator will monitor each  
patient  closely and record all observed or volunteered AEs on the Adverse Event Case Report 
Form.  
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opinion of the following should be documented on the Adverse Event Case 
Report Form: 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
54  9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug  (ISIS  681257 or placebo) is characterized by 1 of the 
following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug , e.g., 
confirmation by positive re- challenge test  
• Possible:   The event cannot be explained by the patient’s medical  condition, conc omitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug  (ISIS 681257 or placebo) administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions.  For reporting purposes, 
Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by the patient’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug  
9.4.3.2 Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is eas ily tolerated by the subject and does not affect the subject’s usual 
daily activities  
• Moderate:   The event causes the subject more discomfort and interrupts the subject’s 
usual daily activities  
• Severe:  The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3). 
9.4.3.3 Action Taken with Study Drug  
Action taken with Study Drug  (ISIS 681257 or placebo) due to the event is characterized by 1 of 
the following. 
• None:  No changes were made to Study Drug  (ISIS 681257 or placebo) administration 
and dose 
• Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the same dose  
• Temporarily Interrupted, Restarted Reduced Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the next lower dose  
• Permanently Discontinued:   Study Drug  was discontinued and not restarte d 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
55  9.4.3.4 Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for an  AE should be recorded on the 
Adverse Event Case Report Form .  Treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  eCRF , as appropriate. 
9.4.3.5 Outcome of the Adverse Event  
If the event is a non -serious AE , then t he event’s outcome is characterized by 1 of the following: 
• Ongoing:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity (if applicab le):  AE severity changed  
If the event is an SAE , then the event’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious eCRF  (the 
SAE resolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely fr om the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be entered as the SAE resolution date) 
9.5 Procedures for Handling Special Situations  
9.5.1 Abnormalities of Laboratory Tests 
Clinically -significant  abnormal laboratory test results may, in the opinion of the Investigator, 
constitute or be associated with an AE .  Examples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the underlying diagnosis should be listed in preference to  abnormal laboratory values as AEs.  
Clinically -significant  abnormalities  will be monitored by the Investigator until the parameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor Medical Monitor that monitoring is no longer necessary.  Laboratory abnormalities deemed not clinically -significant (NCS) by the Investigator should not be reported as AEs.  Similarly, 
laboratory abnormalities reported as AEs by the Investigator should not be deemed NCS on the 
laboratory sheet. 
The Investigator is responsible for reviewing and signing all laboratory reports.  The clinical 
laboratory reports will serve as source documents and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory values  and signatures . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
56  All platelet count results must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the count has not met the stopping rule and to determine whether the rate of decline is suggestive that the patient could be approaching the dose 
interruption rule of 75,000/mm
3 as specified in Section 8.6.3. 
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered a n adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor as per Sections 9.3.3.1 and 9.4.1).  
All results of liver function tests must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met the stopping rules per 
Section  8.6.1. 
All results of renal f unction tests must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the result has not met the stopping rules per Section  8.6.2. 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments  
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered an SAE, even if the patient is hospitalized; the Study Center  must document all of the following:  
• The prescheduled or elective procedure or routinely scheduled treatment was scheduled 
(or was on a waiting list to be scheduled) prior to obtaining the patient ’s consent to 
participate in the study 
• The condition that required the prescheduled or elective procedure or routinely scheduled treatment was present before and did not worsen or progress in the opinion of the 
Investigator between the patient ’s consent to participate in the study and the timin g of the 
procedure or treatment .  The condition is documented in the patient’s medical history. 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole reason for the intervention or hospital admission 
9.5.3 Dosing Errors  
Study Drug  (ISIS 681257 or placebo) errors should be documented as Protocol Deviations.  A 
brief description should be provided in the deviation, including whether the patient  was 
symptomatic (list symptoms) or asymptomatic, and the ev ent was accidental or intentional.  
Dosing details should be captured on the Dosing Case Report Form .  If the patient  takes a dose 
of Study Drug  (ISIS 681257 or placebo) that exceeds protocol specifications and the patient  is 
symptomatic, then the symptom(s) should be documented as an AE  and be reported per 
Section  9.4. 
Should an overdose occur , the Investigator or designee should contact the Sponsor or designee 
within 24 hours. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
57  9.5.4 Contraception and Pregnancy 
Male and female patients  of childbearing potential must continue to use appropriate 
contraception with their partners, or refrain from sexual activity, as described in Secti on 6.3.1. 
If a patient  becomes pregnant or a pregnancy is suspected, or if a male patient makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately .  An Initial Pregnancy Form should be submitted to the Sponsor or 
designee within 24 hours  of first learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported by designating as  ‘Follow-up’ on the 
Pregnancy F orms and reported within 24 hours of occurrence.  
Payment for all aspects of obstetrical care, child or related care will be the patient ’s 
responsibility. 
Female patient s:  If a suspected pregnancy occurs while on the study (including during the 
follow-up period ), a pregnancy test will be performed.  The patient  with a confirmed pregnancy 
will be immediately withdrawn from treatment with Study Drug.  However, the patient  will be 
encouraged to complete the Post- treatment Follow-up portion of the study to the extent that study 
procedures do not interfere with the pregnancy.  Regardless of continued study participation, the Investigator will assist the patient  in getting obstetrical care and the progress of the pregnancy 
will be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the pregnancy results in the birth of a child, the Study Center and 
Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth .  Follow-up will be performed to the extent permitted by the applicable regulations 
and privacy considerations. 
Male patient s:  The progress of the pregnancy of a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth .  Follow- up will be performed to the extent permitted by the applicable regulations and 
privacy considerations. 
10. STATISTICAL CONSIDERATIONS  
The sections below indicate the overall structure and approach to the analysis of this study.  A 
detailed Statistical Anal ysis Plan (SAP) incorporating these sections below will be prepared 
separately .  The SAP will outline all data handling conventions, including software, and specify 
additional statistical methods to be used for analysis.  
The study objectives are listed  in Section 1 . 
10.1 Study Endpoints, Subsets, and Covariates  
Efficacy and safety endpoints that will be evaluated are identified in the following sections . 
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4 -week  dosing (Cohorts A-C) and at Week 27 for patients who received weekly or 
biweekly dosing (Cohort s D and E).  For patients continuing treatment beyond the primary 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
58  analysis time point additional supportive efficacy and safety analyses will be repeated at the 
completion of Study Drug  treatment. 
10.1.1 Primary Endpoint(s) 
The primary efficacy endpoint is the percent change in Lp(a) from baseline at the primary 
analysis time point achieved by ISIS 681257 compared to pooled placebo. 
Lp(a) levels will be analyzed from patient blood samples taken at specified time points 
throughout the study. 
10.1.2 Secondary Endpoints 
The secondary endpoints include the following parameters from baseline at the primary analysis 
time point for ISIS 681257 compared to placebo: 
• Percent change from baseline in LDL -C  
• Proportion of patients who achieve plasma Lp(a) ≤  50 mg/dL  
• Proportion of patients who achieve plasma Lp(a) ≤  30 mg/dL  
• Percent change from baseline in apoB  
• Percent change from baseline in OxPL -apo(a) 
• Percent change from baseline in OxPL -apoB 
10.1.3 Safety Endpoints 
The safety analysis will be performed using the following parameters : 
• AEs  
• Vital signs and weight  
• Physical examinations  
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis) 
• Proportion of patients with platelet drop by severity, including platelet drop below lower 
limit of normal (LLN), platelet drop greater than 30% from Baseline, or any platelet drop 
meeting stopping rules.  
• Proportion of patients with liver adverse event s by severity, number of patients meeting 
liver stopping rules, and change in liver function tests  by severity .   
• Proportion of patients with renal events by severity, number of patients meeting renal stopping rules, and change in renal function tests by severity . 
• ECGs  
• Use of concomitant medications  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
59  10.1.4 Dose Selection  
Dose selection for the further development will be based on the following efficacy and safety 
considerations; more than 1 dose may meet these criteria.  An effectiv e dose, or dose regimen, 
will be one that achieves clinically -meaningful  reduction in plasma Lp(a) levels.  Safety will be 
evaluated on the basis of incidence of expected and unexpected treatment -related SAEs and other 
specific safety considerations including the incidence of platelet reductions , and renal or hepatic 
injury.   
10.2 Sample Size Considerations  
Based upon prior clinical trial experience with ISIS 681257, it is estimated that the standard deviation of the percent change in Lp(a) is approximately 20%.  W ith 23 patients in each 
ISIS 681257 treatment group and 23 in placebo group there would be approximately 90% power 
to detect a 20% difference in percent change in Lp(a) levels between the ISIS 681257 trea tment 
groups and placebo group at an alpha level of 0.05, assuming 30% reduction in the ISIS 681257 
patients and 10% reduction in the placebo patients. 
Based upon prior clinical trial experience with Ionis  ASOs, a ssuming the incidence rate of 
platelet coun t below lower limit of normal (LLN) in placebo treated patients is 1.9 %, in the 
ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, with 
45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to 
detect at least 1 event.  
Therefore, approximately 270 patients (54 patients per cohort, including 45 patients per cohort 
treated with ISIS 681257) will be randomized to ensure that both the safety and efficacy of 
ISIS 681257 will be adequately characte rized in the study. 
10.3 Analysis Populations 
Full Analysis Set (FAS):  All patients who are  randomized, received at least 1 dose of Study 
Drug  (ISIS  681257 or placebo), and have a Baseline Lp(a) assessment.  The FAS represents the 
practically -feasible intent- to-treat (ITT) population as delineated in ICH Guideline E9.  This 
population will be used for the primary analysis of efficacy.   
Per Protocol Set (PPS) :  Subset of the FAS who received within 6 months at least 5 monthly 
doses of Study Drug  for pat ients randomized in Cohorts A, B, and C or at least 20 weekly doses 
for patients randomized in Cohorts D and E, and who have no major protocol violations that 
could compromise the interpretation of efficacy.  Major violations will be determined prior to 
unblinding for statistical analysis .  This population will be used for supportive inferences 
concerning efficacy.  
Safety Set :  All patients who are randomized and receive at least 1 dose of Study Drug.  This 
population will be used for all safety analyses.   
PK Population:  All patients who are randomized and received at least 1 dose of Study Drug , and 
have sufficient data for the analysis of PK parameters .  This population will be used for analysis 
of PK data. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
60  10.4 Definition of Baseline  
Baseline for Lp(a), LDL-C, apoB, OxPL -apo(a), OxPL -apoB, and other lipid measurements  will 
be defined  the pre- dose measurement on Day 1 or closest to Day 1, prior to administration of 
Study Drug.  The baseline for other measurements  is defined as the last non- missing assessme nt 
prior to the first dose of Study Drug . 
10.5 Interim Analysis  
No interim efficacy analysis will be performed . 
10.6 Planned Methods of Analysis  
Summary tabulations will be provided for disposition, demographic, baseline, efficacy, and 
safety data as noted  in the following sections.  Hypothesis testing will be used for the primary 
efficacy endpoint and select secondary efficacy endpoints. 
All eCRF data, lab data transfers, and any outcomes derived from the data will be provided in the 
patient data listings .  Patient data listings will be presented for all patients enrolled into the study .  
Descriptive summary statistics including n, mean, median, standard deviation, standard error, interquartile range (25th percentile, 75th percentile), and range (minimum, m aximum) for 
continuous variables, and counts and percentages for categorical variables will be used to summarize most data .  Where appropriate, p -values will be reported.  All statistical tests will be 
conducted using 2- sided tests with 5% Type I error rate unless otherwise stated.  
10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by 
treatment group.  The patient disposition will be summarized  by treatment group .  All patients 
enrolled will be included in a summary of patient disposition. 
10.6.2 Safety Analysis  
10.6.2.1 Adverse Events  
Treatment duration and amount of Study Drug  (ISIS 681257 or placebo) received will be 
summarized by treatment group .  Patient  incidence rates of all AE s will be tabulated by 
MedDRA system organ class, and by MedDRA preferred term .  Narratives of treatment -
emergent  deaths, serious and significant AE s, including early withdrawals due to AE s, will also 
be provided. 
All treatment -emergent  AEs, all treatment -emergent  AEs potentially related to Study Drug , all 
treatment -emergent  serious AEs, and all treatment -emergent  serious AEs potentially related to 
Study Drug  (ISIS  681257 or placebo) will be summarized. 
10.6.2.2 Clinical Laboratory Data  
Laboratory tests to ensure patient  safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, complement, etc., will be summarized by study visits for 
each treatment group .  These safety variables will also be presented as change and percent 
change from baseline over time after Study Drug  (ISIS  681257 or placebo) administration, as 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
61  appropriate.  In addition, the number of patients who experience abnormalities in clinical 
laboratory evaluations will b e summarized  by treatment group. 
10.6.2.3 Vital Signs and Examinations 
Vital sign and ECG measures will be tabulated by treatment group .   
10.6.3 Efficacy Analysis  
10.6.3.1 Analysis of Primary Efficacy Endpoint 
The primary analysis of the primary endpoint will be the pairwise comparison of percent change 
from baseline to primary analysis time point in fasting Lp(a) between ISIS  681257 treatment 
groups and pooled placebo group in the FAS.  The data will be analyzed using an analysis of 
covariance (ANCOVA) model with the Baseline Lp(a)  as a covariate.  Missing data may be 
handled by LOCF or multiple imputation methods ( Schafer 1997; Schafer 1999 ). 
The primary efficacy analysis will take place after the last patient has completed the primary analysis time point and at least 50% of randomized patients have completed Week 52 visits, and 
the database has been locked,  
The following sensitivity analyses will be conducted : 
• The primary analysis will be repeated in the PPS  
• The primary efficacy endpoint will be analyzed using a Wilcoxon Rank Sum test on both 
FAS and PPS, and the treatment effect will be estimated using Ho dges-Lehmann 
estimator  
Additional sensitivity analyses may be conducted as appropriate; the details of these analyses 
will be outlined in the SAP.  
10.6.3.2 Analysis of Secondary Efficacy Endpoints 
• Percent change from baseline at  the primary analysis time point in fasting LDL -C will be 
compared between  each ISIS  681257 treatment groups  and pooled placebo group using 
an ANCOVA model with baseline as covariate  
• Proportion of patients who achieve ≤ 50 mg/dL in fasting Lp(a) at the primary analysis 
time point will be compared between each  ISIS 681257 treatment group and pooled 
placebo group using a  logistic regression model with Baseline Lp(a) as a covariate.  
Proportion of patients who achieve ≤ 30 mg/dL in fasting Lp(a) at the primary analysis 
time point will be analyzed similarly  
• Percent change from baseline at  the primary analysis t ime point in fasting apoB, 
OxPL -apo(a) and OxPL- apoB will be compared between  ISIS 681257 treatment groups 
and pooled placebo group using an ANCOVA model with baseline as covariate  
All analyses of secondary endpoints will be performed on the FAS as primary and PPS as supportive. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
62  10.6.4 Pharmacokinetic and Immunogenicity Analysis  
For all patients, trough and post- treatment concentrations of  ISIS 681257 in plasma (a s total full 
length oligonucleotides, including fully conjugated, partially conjugated, and unconjugated 
ISIS 681257) will be determined and summarized by treatment with stratification by subject 
immunogenicity status  using descriptive statistics . 
In addition, non- compartmental PK  analysis of ISIS 681257 concentrations will be carried out on 
each individual patient data set  in patients who received ISIS 681257 treatment, and the plasma 
disposition half- life (t 1/2λz) associated with the apparent terminal elimination phase will be 
calculated, if appropriate, using available data at the End-of-T reatment and the post-t reatment 
follow-up period from the equation, t 1/2λz = 0.693 /λz, where λz is the rate constant associated with 
the apparent terminal elimination phase. 
For patients in the PK subgroup only, non- compartmental PK  analysis of ISIS 681257 will be 
carried out on each individual patient data set in patients who received ISIS 681257 treatment .  
The maximum observed drug concentration (C max) and the time taken to reach C max (Tmax) will 
be obtained directly from the concentration- time data .  Following single dosing (Day 1), area 
under the plasma concentration- time curve from time zero (pre -dose) to 24 hours after the dose 
(AUC 0-24hr) will be calculated using the linear trapezoidal rule .  Following multiple dosing, 
AUC 0-24hr and area under the plasma concentration -time curve during the time of each sampled 
dosing interval (tau,τ)  at steady -state (AUC τ) will be calculated using the linear trapezoidal rule.  
Other PK  parameters, as appropriate, may be determined or calculated at the discretion of the PK  
scientist.  Plasma PK  parameters will be summarized using descriptive statistics  with 
stratification by subject immunogenicity status .  Exposure-response relationships between 
selected PD  [e.g., Lp(a)]  and PK  measures (including but may  not be limited to plasma trough 
concentrations) may be explored (including with and without stratifi cation by IM status)  in this 
study, or in a separate population PK analysis with all clinical studies combined . 
The immunogenicity (IM) of ISIS 681257 will be assessed before, during, and after treatment 
with Study Drug  (ISIS 681257 or placebo) .  The IM incidence (number) and incidence rate 
(percent) will be summarized at each evaluated study time point and at the patient level by treatment and dose, as the total number of and percent of evaluated patients with antibody negative, positive, and unknown status.  Study patients with positive anti-ISIS 681257 antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or not determinable .  Potential relationships of immunogenicity with selected efficacy, safety, and PK 
measures may be evaluated.  
Additional details regarding the PK  and immunogenicity analysis will be described in the S AP. 
11. INVESTIGATOR’S R EGULATORY OBLIGATIONS  
11.1 Informed Consent  
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English version provided by the Sponsor or designee. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
63  Before a patient ’s participation in the trial, the  Investigator is responsible for obtaining written 
informed consent from the patient  or lega lly acceptable representative after adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of the study and before any 
protocol- specific screening procedures or any Study Drug  ISIS 681257 or placebo) are 
administered . 
Import antly,  patients should be informed of the possibility and risks of a reduction in platelet 
count and other potential risks, in particular hepatic and renal  risks , and the importance of strict 
adherence to the monitoring program.  The patient  or legally acceptable representative must be 
given sufficient time to consider whether to participate in the study.  
The acquisition of informed consent and the patient ’s agreement or refusal to notify his/her 
primary care physician  should be documented in the patient’s medical records and the informed 
consent form should be signed and personally dated by the patient  or a legally acceptable 
representative and by the person who conducted the informed consent discussion (not necessarily 
an Investigator).  The  original signed informed consent form should be retained in the Study 
Master File and in any other locations required by institutional policy, and a copy of the signed 
consent form should be provided to the patient  or legally acceptable representative. 
11.2 Ethical Conduct of the Study  
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated 
October  2013 the applicable regulations and guidelines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and other applicable regulatory 
requirements will be strictly followed . 
11.3 Independent Ethics Committee  (IEC)/Institutional Review Board (IRB) 
A copy of the protocol, proposed informed consent form s, other written patient  information, and 
any proposed advertising material must be submitted to the IEC/IRB  for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received b y the 
Sponsor or designee before recruitment of patient s into the study and shipment of Study Drug.  A 
copy of the written approval of any other items/materials that must be approved by the Study 
Center or IEC/IRB must also be received by the Sponsor or designee before recruitment of 
patient s into the study and shipment of Study Drug.  The Investigator’s Brochure must be 
submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to and, where necessary, obtain approval from the IEC/IRB , for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should also notify the IEC/IRB of SAEs  occurring at the Study Center and other AE 
reports received from the Sponsor or designee, in accordance with local procedures.  
The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study in accordance with local procedures .   
11.4 Patient  Confidentiality  
The Investigator and Sponsor must ensure that the patient ’s confidentiality is maintained .  On the 
case report forms or other documents submitted to the Sponsor or designee , patient s should be 
identified by initials (if permitted by local law) and a patient  identification  number only.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
64  Documents that are not for submission to the Sponsor or designee ( e.g., signed informed consent 
forms) should be kept in strict confidence by the Investigator. 
In compliance with Federal and local regulations/ICH GCP Guidelines,  it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1 Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee.  Agreement from the Investigator must be obtained for all protocol amendments and amendments 
to the informed consent document.  The regulatory authority and IEC/IRB  must be informed of 
all amendments and give approval for any amendments likely to affect the safety of the patient s 
or the conduct of the trial.  The Investigator must send a copy of the approval letter from the 
IEC/IRB  to the Sponsor or designee.  
12.2 Study Termination 
The Sponsor or designee reserves the right  to terminate the study .  The Investigator reserves the 
right to terminate their participation in the study , according to the terms of the site contract.  The  
Investigator/Sponsor or designee should notify the IEC/IRB  in writing of the trial’s completion 
or ET.  An Investigator who terminates participate is required to send a copy of the IEC/IRB 
notification to the Sponsor or designee. 
12.3 Study Documentation and Storage  
Source documents are original documents, data, and records from which the patient ’s case report 
form data are obtained .  These include but are not limited to hospital records, clinical and office 
charts, laboratory and pharmacy records, diaries , imaging , and correspondence.  In this study, 
eCRF  may not be used as source documents. 
The Inves tigator and S tudy Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by representatives from 
the Sponsor or designee and/or applicable r egulatory authorities .  Elements should include: 
• Patient  files containing completed case report forms, informed consents, and supporting 
copies of source documentation 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copies 
of pre -study documentation and all correspondence to and from the IEC/IRB  and the 
Sponsor or designee  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
65  • If drug supplies are maintained at the Study Center, proof of receipt, Study Drug  Product 
Accountability Record, Return of Study Drug  Product for Destruction, final Study Drug  
product reconciliation, and all drug- related correspondence  
In addition, all original source documents supporting entries in the case report forms must be 
maintained and be readily available for the duration required by GCP or local regulatory 
requirements, whichever is longer. 
No study document should be destroyed without prior written agreement between the Sponsor or 
designee and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify the Sponsor or designee, in 
accordance with GCP . 
12.4 Study M onitoring 
The Sponsor representative and regulatory authority inspectors are responsible for contacting and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that 
patient  confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to patient  medical records and other study- related records 
needed to verify the entries on the case report forms.  Source dat a should be attributable, legible, 
contemporaneous, original, and accurate (ALCOA) and must meet the regulatory requirements 
for recordkeeping. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinical Quality Assurance Department (or designees).  Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study- related records will occur to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data received by  the Sponsor or designee.  During this review, patient data will be 
checked for consistency, omissions, and any apparent discrepancies .  In addition, the data will be 
reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the clinical data management review process, data queries and/or Study Center  notifications will be 
sent to the Study Center  for c ompletion and return to Sponsor or designee . 
The Principal Investigator will sign and date the indicated places on the case report form .  These 
signatures will indicate that the Principal Investigator inspected or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content in 
accordance with the general investigational plan . 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
66  12.5 Language 
Case report forms must be completed in  English .  Whenever possible, the trade name rather than 
the generic name for concomitant medications should be recorded and if possible, in English.  
Generic names are acceptable if the trade name is unknown .  Combination medications should be 
recorded us ing their trade name in English if possible.  
All written information and other material to be used by patient s and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropri ate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated and/or compensated for any study -
related illness/injury in accordance with the information provided in the Compensation for Injury 
section of the Informed Consent document. 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
67  13. REFERENCES  
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Bennett CF . Pharmacological properties of 2ʹ -O-methoxyethyl -modified olig onucleotides . In: Crooke ST, editor . 
Antisense Drug Techno logy: Principles, Strategies and Applications, 2nd Edition . Boca Raton, FL . Taylor & Francis 
Group 2008; 365- 400. 
Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized 
phospholipids in human plasma . J Lipid Res 2008; 49: 2230- 2239.  
Bertoia ML, Pai JK, Lee J -H, et al. Oxidation -specific biomarkers and risk of peripheral artery disease. J Am Coll 
Cardiol 2013; 61(21): 2169- 2179.  
Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium . Genetic variants associated with Lp(a) 
lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518- 2528.  
Desai NR, Kohli P, Giugliano RP , et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin 
kexin type 9, significantly reduces lipopro tein (a) in hypercholesterolemic patients receiving statin therapy: an 
analysis from the LAPLACE -TIMI 57 Trial. Circ 2013; 128:  962-969. 
Dubé JB, Boffa MB, Hegele RA, Koschinsky ML . Lipoprotein(a): more interesting than ever after 50 years . Curr 
Opin Lipid ol 2012; 23(2): 133 -140. 
Erqou S, Kaptog e S, Perry PL, et al; Emerging R isk Factors Collaboration . Lipoprotein(a) concentration and the risk 
of coronary heart disease, stroke, and nonvascular mortality . JAMA 2009; 302(4): 412- 423. 
Erqou S, Thompson A, Di Angelantonio E, et al. Apoliporotein(a) isoforms and the risk of vascular disease . JACC 
2010; 55(19): 2160- 2167.  
Frazer KA, Narla G, Zhang JL, Rubin E . The apolipoprotein(a) gene is regulated by sex hormones and acute -phase 
inducers  in YAC transgenic mice . Nat Gen 1995; 9: 424- 431. 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma 
lipoprotein (a) levels in humans. J Lipid Research 2016; 57: 340- 351. 
Guyton JR . Niacin in cardiovascular prevention: mechanisms, efficacy, and safety . Curr Opin Lipidol 2007; 18: 
415-420. 
Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292(2): 468- 479. 
Jaeger BR, Richter Y, Nagel D, et al . Longitudinal cohort study on the effectiveness of lipid apheresis treatment to 
reduce high lipoprotein(a) levels and major adverse coronary events . Nat Clin Pract Cardiovasc Med 2009; 6(3): 
229-239. 
Kamstrup PR, Tybjaerg -Hansen A, Steffensen R, Nordestga ard BG . Genetically elevated lipoprotein(a) and 
increased risk of myocardial infarction . JAMA 2009; 301(22): 2331- 2339.  
Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein -associated phospholipase A2 
activity, and 10 -year cardiovascular outcomes: prospective results from the Bruneck study . Arterioscler Thromb 
Vasc Biol 2007; 27: 1788- 1795.  
Koschinsky ML and Marcovina SM . Structure -function relationships in apolipoprotein(a): insights into 
lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004; 15(2): 167- 174. 
Kronenberg F and Utermann G . Lipoprotein(a): resurrected by genetics . J Intern Med 2013; 273: 6- 30. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
68  Leebmann J, Roeseler E, Julius U, et al; Pro(a)LiFe Study Group . Lipoprotein apheresis in patients with ma ximally 
tolerated lipid -lowering therapy, lipoprotein(a) -hyperlipoproteinemia, and progressive cardiovascular disease: 
Prospective observational multicenter study . Circ 2013; 128: 2567- 2576.  
Leibundgut G, Scipione C, Yin H, et al. Determinants of binding o f oxidized phospholipids on apolipoprotein(a) and 
lipoprotein(a) . J Lipid Res 2013; 54: 2815- 2830.  
Li Y, Luke MM, Shiffman D, Devlin JJ . Genetic variants in the apolipoprotein(a) gene and coronary heart disease.  
Circ Cardiovasc Genet 2011; 4(5): 565- 573. 
McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem 1999; 274: 1715- 1722.  
Merki E, Graham M, Taleb A,  et al. Antisense oligonuc leotide lowers plasma levels of apolipoprotein (a) in 
transgenic mice. JACC 2011; 57(15): 1611- 1621.  
Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel . Lipoprotein(a) as 
a cardiovascular risk factor: current status . Euro Heart J 2010; 31: 2844- 2853.  
Parker K, Brunton L, Goodman LS, et al. Goodman & Gilman's the pharmacological basis of therapeutics . New 
York, NY. McGraw -Hill. 2006; ISBN 0- 07-142280- 142283.  
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of ant isense oligonucleotides to hepatocytes using 
triantennary N-acetyl galactosamine improves potency 10 -fold in mice . Nucleic Acids Res 2014; 42: 8796- 8807.  
Prakash TP, Yu J, Migawa MT, et al. Comprehensive structure -activity relationship of triantennary N-Acetyl 
galactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes . J Med Chem 2016 
Mar 24; 59(6): 2718- 2733.  
Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary imm une thrombocytopenia. Blood 2010; 115: 168- 186. 
Raal FJ, Honarpour  N, Blom  DJ, et al. Inhibition of PCSK9 with evolucomab in homozygous familial 
hypercholesterolemia (TESLA Part B): a randomized, double blind, placebo controlled trial. Lancet 2015; 385: 341-350. 
Rand ML, Sangrar W, Hancock MA, et al. Apoliprotein(a) enhances platelet responses to the thrombin receptor – activating peptide SFLLRN . Arterio Thromb Vasc Biol 1998; 18: 1393- 1399.  
Rosada A, Kassner U, Vogt A, et al. Does regular lipid apheresis i n patients with isolated elevated lipoprotein(a) 
levels reduce the incidence of cardiovascular events? Artif Organs 2014; 38: 135 -141. 
Safarova M . Specific lipoprotein(a) apheresis reduces atherosclerosis progression . 80th Congress of the European 
Atherosc lerosis Society, Milan, Italy 28 May 2012.  
Schafer JL . Analysis of Incomplete Multivariate Data, New York: Chapman and Hall 1997. 
Schafer JL . Multiple imputation: a primer, Statistical Methods in Medical Research 1999; 8: 3 –15. 
Schulman S and Kearon C; Sub committee on Control of Anticoagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medical products in non -surgical p atients. J Thromb Haemost 2005; 3(4): 692- 694. 
Spence JD and Koschinsky M . Mechanisms of lipoprotein(a) pathogenicity . Arterioscler Thromb Vasc Biol 2012; 
32: 1550- 1551.  
Stockert RJ . The asialoglycoprotein receptor: relationships between structure, function, and expression . Physiol  Rev 
1995; 75: 591- 609. 
Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group . Genetic 
associations with valvular calcification and aortic stenosis . N Engl J Med 2013; 368(6): 503- 512. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
69  Thygesen K, Alpert JS, Jaffe AS , et al. Third universal definition of myocardial infarction.  Circ 2012;  126: 
2020- 2035.  
Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation -specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal 
coronary events . J Am Coll Cardiol 2010; 56: 946- 955. 
Tsimikas S, Willeit P, Willeit J, et al. Oxidation -specific biomarkers, prospective 15 -year cardiovascular and stroke 
outcomes, and net reclassification of cardiovascular events . J Am Coll Cardiol 2012; 60: 2218- 2229.  
Tsimikas S, Duff GW, Berger PB, et al. Pro -inflammatory interleukin -1 genotypes potentiate the risk of coronary 
artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a) . J Am Coll Cardiol 
2014; 63: 1724- 1734.  
Yu RZ, Kim TW, Hong A, et al. Cross- species pharmacokinetic comparison from mouse to man of a second -
generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B -100.  Drug Metab Dispos 
2007; 35: 460- 468.  
Zhang H, Löwenberg EC, Crosby JR, et a l. Inhibition of the intrinsic coagulation pathway Factor XI by antisense 
oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684- 4692.  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
70   
  
 
  
 
14. APPENDICES  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January  2017  
 
71   
  
 
  
 
Appendix A  Schedule of Procedures 
 
Schedule of Procedures for Weekly and Every 2 -Week  Dosing Cohorts  
Schedule of Procedures for Every 4-Week Dosing Cohorts  
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
72  Appendix A  Schedule of Procedures  – Weekly and Every 2 -Week  Dosing  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post L ast Dose 
Visit Window  +/- Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                      
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                     
Medical History  c X                      
Vital Signs  X X  X X X X X X X   X X X X X X X X X X 
Physical Examination  X X  X  X  X  X    X  X  X X X X X 
Body Weight and Height  d X         X      X      X 
12- lead ECG (triplicate)  X X  X  X  X  X    X  X  X X X X X 
24-Hour Urine for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i X X X 
Genetic Testing   X  
Chemistry Panel j,k X EVERY 14 DAYS f X X X X   X X X X X X X X X X 
Hematology   j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh  Xh  
Platelet Function   X  X X X X X X X   X X X X X X X X X X 
Coagulation  X X        X             
Hepatitis B, C, HIV  X                      
Thyroid Panel  X                      
hsCRP   X        X         X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X X3 X1 X2 X  X    X X X X 
ISIS 681257 Antibodies   X  X X X    X         X   X 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
73  Appendix A  Schedule of Procedures – Weekly and Every 2 -Week  Dosing  Continued  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 183 184a 185a 197 225 253 281 309 337 365 *Post L ast Dose 
Visit Window +/ - Days  0 -3b 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if 
applicable)  j, m X                      
Serum Pregnancy Test  m X X   X  X  X      X  X  X X X X 
Archived Serum & Plasma Samples  j, n  X   X  X   X     X  X  X X X X 
PD Panel j X X  X X X X X  X   X  X  X  X X X X 
Lipid Panel j X X  X X X X X  X   X  X  X  X X X X 
Lp(a) Characterization   X   
Study Drug:  SC Injection   WEEKLY AND EVERY 2 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG  
(Week 1 through Week 53/Day 365)o    
Adverse Events  X X X X X X X X  X X X X X X X X X X X X X 
Concomitant Medication  X X X X X X X X  X X X X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which is the day of first Study Drug dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in Appendix B under Extended Urinalysis should be performed, including routine urinalysis, urine microscopy, UACR and UPCR. 
f Assessments and procedures to be conducted by  either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 week s apart  during the t reatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function 
(Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then every 6 weeks .  
i Serum  Creatinine and Cys -C will be c ollected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone sample s at time 
points when a chemistry panel is not performed.  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
74  Appendix A  Schedule of Procedures – Weekly and Every 2 Week  Dosing Continued  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
k If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quantity not sufficient) a repeat blood  
specimen should be re- drawn as soon as possible (ideally within 7 days).   All platelet count results will be reviewed promptly (within 48 hours of receipt) by the 
Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor . 
l Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically sterile or post -menopausal. 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measure ment of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of 
ISIS 681257. 
o Patients will continue treatment in the study until the last patient enrolled reaches 6 months of exposure, and 50% of the enrolled patients have received 
Study  Drug for 52 weeks.  When both of these milestones are met, all patients will then enter a 16 -week post -treatment follow -up period.  
 
Time (time is in reference to Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8 hours post SC injection 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
75  Appendix A  Schedule of Procedures – Every 4-Week Dosing 
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post  Last D ose 
Visit Window  +/- Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
Informed Consent  X                       
Outpatient Visit  X X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria  X X                      
Medical History  c X                       
Vital Signs  X X  X X X X X X     X X X X X X X X X X 
Physical Examination  X X  X  X  X X      X  X  X X X X X 
Body Weight and Height  d X        X        X      X 
12- lead ECG (triplicate)  X X  X  X  X X      X  X  X X X X X 
24-hour Urine  for Creatinine 
Clearance and Protein  X     
Extended Urinalysis  e X EXTENDED URINALYSIS PERFORMED EVERY 14 DAYS e, f X X X 
Renal Biomarkers g X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS f, g Xh Xh Xh 
Serum Creatinine and Cys -C i, j  SERUM CREATININE and Cys -C PERFORMED EVERY 14 DAYS f, i    
Genetic Testing   X   
Chemistry Panel  j, k X EVERY 14 DAYS  f X X X     X X X X X X X X X X 
Hematology  j, k X HEMATOLOGY PERFORMED EVERY 14 DAYS  f, k Xh Xh Xh 
Platelet Function   X  X X X X X X     X X X X X X X X X X 
Coagulation  X X       X               
Hepatitis B, C, HIV  X                       
Thyroid Panel  X                       
hsCRP   X 
      X  
         X   X 
Plasma PK - ISIS 681257  l  X3 X1 X X X X X X3 X1 X2 X X X  X    X X X X 
ISIS 681257 Antibodies   X  X X X   X           X   X 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
76  Appendix A  Schedule of Procedures – Every 4 -Week Dosing Continued  
 Screen  Treatment Period  Follow -up Period  
Study Week  -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET  4* 10* 16* 
Study Day  -28 to -1 1 2a 29 57 85 113 141 169 170a 171a 176a 183a 197 225 253 281 309 337 365 *Post Last D ose 
Visit Window +/- Days  0 -3b 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if 
applicable)  j, m X                       
Serum Pregnancy Test  m X X  X X X X X X     X X X X X X X X X X 
Archived Serum & Plasma  
Samples j, n  X   X  X  X     X  X  X  X X X X 
PD Panel j X X  X X X X X X    X X  X  X  X X X X 
Lipid Panel j X X  X X X X X X   X X X  X  X  X X X X 
Lp(a) Characterization   X   
Study Drug:  SC Injection   EVERY 4 -WEEK SUBCUTANEOUS ADMINISTRATION OF STUDY DRUG (Week 1 through Week 49/Day 337)o    
Adverse Events  X X X X X X X X X X X   X X X X X X X X X X 
Concomitant Medication  X X X X X X X X X X X   X X X X X X X X X X 
All procedures and study samples are to be done pre-dose at respective visits, unless specified  
a Visit only required for patients in PK subgroup.  
b Day 1/Baseline assessments can be performed up to 3 days ( -3 days) prior to the actual Day 1 visit, which is the day of first Study Drug dose . 
c Patient charts will be reviewed in order to collect disease associated medical history data such as CVD history . 
d Height only required at Screening. 
e All tests listed in Appendix B under Extended Urinalysis should be performed, including routine urinalysis, urine microscopy, UACR and UPCR. 
f Assessments and procedures to be conducted by either a home healthcare service or the Study Center .  Patient Study Center visits must be no more than 
4 weeks apart during the t reatment period. 
g Urine samples for renal biomarkers will be collected.  Sample analysis will be conducted in accordance with Safety Monitoring for Renal Function (Section 8.5.2). 
h During follow -up period, hematology sampling for platelet values and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then every 6 weeks . 
i Serum  Creatinine and Cys -C will be c ollected as a part of chemistry panel at visits when chemistry panel is performed, or as stand- alone sample s at time 
points when a chemistry panel is not performed.  
j Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours, unless tests are repeated for safety reasons . 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
77  Appendix A  Schedule of Procedures – Every 4 -Week Dosing Continued  
k If the platelet value, serum  creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quantity not sufficient) a repeat blood 
specimen should be re- drawn as soon as possible (ideally within 7 days).   All platelet count results will be reviewed promptly (within 48 hours of receipt) by the 
Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor . 
l Refer to Appendix C  for PK Sampling schedule.  
m Women who are not surgically st erile or post -menopausal. 
n Serum and plasma samples will be collected and stored for follow -up exploration of laboratory findings and/or AEs (e.g., measurement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, measurement of antibodies, etc.) in this or subsequent clinical studies of 
ISIS 681257. 
o Patients will continue treatment in the study until the last patient enrolled reaches 6 months of exposure, and 50% of the enrolled patients have received Study  Drug for 52 weeks.   When both of these milestones are met, all patients will then enter a 16 -week post -treatment follow -up period.  
 
Time (time is in reference to Study Drug  administration):  
1 24-hr  from previous dose of Study Drug  
2 48-hr  from previous dose of Study Drug  
3 Pre-dose, 1, 2, 4, 8, hrs post SC injection  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
78   
  
  
 
 
Appendix B  L ist of L aboratory Analytes 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
79  Appendix B  List of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better characterize the profile of ISIS  681257 or other similar 
oligonucleotides. 
Clinical Chemistry 
Panel  
• Sodium  
• Potassium  
• Chloride  
• Bicarbonate  
• Total  protein  
• Albumin  
• Calcium  
• Magnesium  
• Phosphorus  
• Glucose  
• BUN 
• Creatinine  
• Cholesterol  
• Uric Acid  
• Total bilirubin  
• Direct (conjugated) 
bilirubin  
• Indirect 
(unconjugated) 
bilirubin  
• ALT  
• AST  
• ALP  
• Creatinine kinase 
• GGT  
• Cys-C 
 Screening Tests  
• Hepatitis B surface antigen  
• Hepatitis C antibody  
• HIV antibody  
• FSH (women only)  
• Serum βhCG (women only)  
• TSH  
• Free T4  
• Free T3  
 
Coagulation  
• Fibrinogen  
• Plasminogen  
 
PD Panel  
• Lp(a)  
• OxPL -apoB  
• OxPL -apo(a)  
 
Lipid Panel  
• Total Cholesterol  
• LDL cholesterol  
• HDL cholesterol  
• ApoB  
• Triglycerides  
• VLDL  Lp(a) Characterization  
• Apo(a) isoforms  
 
Hematology  
• Red blood cells  
• Hemoglobin  
• Hematocrit  
• MCV, MCH, MCHC 
• Platelets  
• White blood cells  (WBC)  
• WBC Differential (% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Pharmacokinetics1 
• ISIS 681257 (total full 
length ASO) levels in 
plasma  
 
Immunogenicity  
• Anti-ISIS 681257 
antibodies  
 
Genetic Testing  
• LPA SNPs associated with elevated Lp(a)   
 Inflammatory 
• hs-CRP  
 
Extended Urinalysis 
• Routine Urinalysis  
- Color  
- Appearance  
- Specific gravity  
- pH 
- Protein  
- Blood 
- Glucose  
- Ketones  
- Bilirubin  
- Urobilinogen  
- Leukocyte esterase  
- Nitrate  
• Microscopic examination  
• P/C Ratio  (UPCR) 
• A/C Ratio  (UACR) 
 
Renal Urine 
Biomarkers2 
• NGAL   
• NAG  
• KIM -1 
• Cys-C 
 
24 Hour Urine Test3 
• Creatinine clearance 
• Protein  
• Albumin  
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabolite assessments, or to assess other actions of ISIS  681257 with plasma 
constituents  
2 All samples will be collect ed, handled and stored under the conditions specified for  the assay s. Please refer to 
the study Laboratory Manual for details on the appropriate handling and storage methods for biomarker and 
other samples .   
3 To be performed during Screening upon confirmation of eligibility  
 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4 
Protocol   5 January 2017 
 
80   
  
 
  
 
Appendix C PK Sampling Schedule 
 
Sampling Schedule for Weekly and Every 2-Week Dosing Cohorts 
Sampling Schedule for Every 4-Week Dosing Cohorts 
 
 
ISIS 681257-CS6 CONFIDENTIAL Amendment 4 
Protocol   5 January 2017 
 
81  Appendix C PK Sampling Schedule  
Blood samples for the determination of plasma ISIS 681257 concentr ations will be collected prior to dosing, and at various times 
throughout the dosing and post-treatment follow-up period as noted in the tables  below.  Plasma PK samples may also be used for  
profiling of drug binding pr oteins, bioanalytical method valid ation purposes, stability and me tabolite assessments, immunogenic ity 
testing (or possibly for purposes of immunogeni city assay development and/or validation) , or to assess other actions of ISIS 68 1257 
with plasma constituents.  Extensive PK samples will be collected in PK subgroup only (10 subjects per cohort) (see tables belo w): 
Sampling Schedule for Weekly and Every 2-Week Dosing Cohorts 
 Treatment Period Follow-up Period 
Study 
Week 1 1 5 9 13 17 21 25 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 183 184 185 197 253 365 *Post Last Dose 
All 
Patients Pre-
dose NA Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose NA NA NA Pre-dose Pre-dose Anytime Anytime Anytime 
PK Sub-
group 
Only Pre-
dose, 
1, 2, 4, 
& 8-hr1 24-hr2 Pre-
dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-dose Pre-
dose, 
1, 2, 4, 
& 8-hr
1 24-hr248-hr3 Pre-
dose Pre-dose Pre-dose Anytime Anytime Anytime 
1 Window of (-) 2 hrs 
2 24-hr from previous dose of Study Drug.  Window of (+/-) 4 hours 
3 48-hr from previous dose of Study Drug.  Window of (+/-) 6 hours 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
82  Appendix C  PK Sampling Schedule Continued  
Sampling Schedule for Every 4-Week Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 26 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 170 171 176 183 197 253 365 *Post L ast Dose  
All 
Patients Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose , NA NA NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group 
only Pre-
dose , 
1, 2, 4, and 
8-hr
1 24-hr2 Pre-
dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  
Pre-
dose , 
1, 2, 4, 
and 
8-hr1 24-hr2 48-hr3 Anytime  Anytime  Pre-
dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hours allowed  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours allowed  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours allowed  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
83   
 
  
 
  
Appendix D  Grading Scale for Adverse Events Relating to 
Laboratory Abnormalities  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
84  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
The following grading recommendations for adverse events relating to lab test abnormalities are 
based upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010. 
 
       
 
             
          
                   
       
            
            
   
                   
                    
      
          
                     
    
        
            
    
 
      
         
      
               
        
             
 
       
 
            
 
              
       
 
            
 
             
                                 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
85  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
      
                                 
       
             
        
             
          
            
              
              
                
                            
         
      
     
        
 
       
       
 
        
      
               
              
               
     
         
             
    
           
   
        
       
      
        
       
            
             
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
86  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
     
 
 
                     
          
   
       
                     
 
                   
      
                     
      
                  
                 
    
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
87   
 
  
 
  
Appendix E  Additional Laboratory Tests for Patients with  
Platelet Count ˂  100,000/mm3 
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 4  
Protocol   5 January 2017  
 
88  Appendix E  Laboratory Tests to Be Performed in the Event of a Platelet Count 
˂ 100,000/mm3 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Fibrinogen  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
von Willebrand factor (vWF) Antigen  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Helicobacter pylori  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
Platelet Antibody Bead Array (PABA) 
 
  
 
 
 
Sponsor:  
Ionis Pharmaceuticals, Inc.  
2855 Gazelle Court 
Carlsbad, CA  92010 Collaborator: 
Akcea Therapeutics  
55 Cambridge Parkway, Suite 100 
Cambridge, MA  02142 
 
IONIS  PHARMACEUTICALS,  INC. 
 
ISIS  681257-CS6 
 
 
A Randomized, Double- blind, P lacebo-Controlled, D ose-Ranging 
Phase 2  Study of ISIS 681257 A dministered Subcutaneously to 
Patients with H yperlipoproteinemia(a) and Established 
Cardiovascular Disease ( CVD) 
 
Protocol  Amendment 3 – 9 December  2016 
 
 
EudraCT No:   2016-003373-18 
 

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
4  Protocol Signature Page 
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose- Ranging Phase 2 
Study of ISIS 681257 Administered Subcutaneously to Patients with 
Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)  
Amendment:  Amendment 3 
Date:  9 December  2016  
 
I hereby acknowledge that I have read and understand the attached clinical protocol , entitled “ A 
Randomized, Double-blind, Placebo-C ontrolled, Dose -Ranging Phase 2 Study of ISIS 681257 
Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD) ,” dated 9 December  2016, and agree to conduct the study as 
described herein.  
I agree to comply with the International Conference on Harmonization  Tripartite Guideline o n 
Good Clinical Practice (E6).  
I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Ionis Pharmaceuticals, Inc.   
 
 
   
Investigator’s Signature  
   
Investigator’s Name (please print)   Date (DD Month YYYY)  
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
5  TABLE OF CONTENTS  
Page 
PROTOCOL AMENDMENT ...................................................................................................... 9  
PROTOCOL SYNOPSIS  ........................................................................................................... 10  
STUDY DESIGN AND TREATMENT  SCHEMA  .................................................................. 16  
STUDY GLOSSARY .................................................................................................................. 17  
1. OBJECTIVES  ................................................................................................................. 21  
1.1 Primary Objective  ..........................................................................................................21  
1.2 Secondary Objective(s)  ..................................................................................................21  
2. BACKGROUND AND RATIO NALE  .......................................................................... 21  
2.1 Overview of Disease  ......................................................................................................21  
2.1.1  Lipoprotein (a) ........................................................................................................21  
2.1.2  Pathophysiology .....................................................................................................23  
2.1.3  Current Treatment Options .....................................................................................23  
2.2 Therapeutic Rationale  ....................................................................................................24  
2.3 ISIS 681257 ...................................................................................................................24  
2.3.1  Mechanism of Action  .............................................................................................24  
2.3.2  Chemistry  ...............................................................................................................25  
2.3.3  Preclinical Experience  ............................................................................................25  
2.3.4  Clinical Experience ................................................................................................26  
2.4 Rationale for Dose and Schedule of Administration .....................................................27  
3. EXPERIMENTAL PLAN .............................................................................................. 28  
3.1 Study Design  ..................................................................................................................28  
3.2 Number of Study Centers ..............................................................................................29  
3.3 Number of Patients ........................................................................................................29  
3.4 Overall Study Duration and Follow-up .........................................................................29  
3.4.1  Screening  ................................................................................................................29  
3.4.2  Treatment  ................................................................................................................29  
3.4.3  Post- Treatment  .......................................................................................................29  
3.5 End-of-Study ..................................................................................................................29  
3.6 Data and Safety Monitoring Board ................................................................................30  
4. PATIENT ENROLLMENT ........................................................................................... 30  
4.1 Screening  .......................................................................................................................30  
4.2 Randomization ...............................................................................................................30  
4.3 Replacement of Patients  .................................................................................................31  
4.4 Unblinding of Treatment Assignment ...........................................................................31  
5. PATIENT ELIGIBILITY  .............................................................................................. 31  
5.1 Inclusion Criteria  ...........................................................................................................31  
5.2 Exclusion Criteria  ..........................................................................................................32  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
6  6. STUDY PROCEDURES  ................................................................................................ 33  
6.1 Study Schedule ..............................................................................................................33  
6.1.1  Screening  ................................................................................................................33  
6.1.2  Treatment Period  ....................................................................................................34  
6.1.3  Post- Treatment Period  ............................................................................................34  
6.2 Additional Study Assessments  .......................................................................................34  
6.2.1  Laboratory Assessments  .........................................................................................34  
6.2.2  Physical Exams and Vital Signs  .............................................................................36  
6.2.3  Electrocardiography  ...............................................................................................36  
6.2.4  PK Sampling  ...........................................................................................................36  
6.3 Restriction on the Lifestyle of Patients  ..........................................................................36  
6.3.1  Contraception Requirements ..................................................................................36  
6.3.2  Other Requirements  ................................................................................................37  
7. STUDY DRUG  ................................................................................................................ 37  
7.1 Study Drug Descr iption  .................................................................................................37  
7.1.1  ISIS 681257 ............................................................................................................38  
7.1.2  Placebo  ...................................................................................................................38  
7.2 Packaging and Labeling  .................................................................................................38  
7.3 Study Drug Accountability ............................................................................................38  
8. TREATMENT OF PATIENTS ..................................................................................... 38  
8.1 Study Drug Administration  ............................................................................................38  
8.2 Other Protocol- Required Drugs  .....................................................................................39  
8.3 Other Protocol- Required Treatment Procedures  ............................................................39  
8.4 Treatment Precautions  ...................................................................................................40  
8.5 Safety Monitoring Rules ................................................................................................40  
8.5.1  Safety Monitoring Rules for Liver Chemistry Tests  ..............................................40  
8.5.2  Safety Monitoring for Renal Function ...................................................................42  
8.5.3  Safety Monitoring for Platelet Count Results  ........................................................43  
8.5.4  Safety Monitoring for Minor Bleeding Events .......................................................43  
8.5.5  Safety Monitoring for Constitutional Symptoms  ...................................................43  
8.6 Stopping Rules ...............................................................................................................44  
8.6.1  Stopping Rules for Liver Chemistry Elevations .....................................................44  
8.6.2  Stopping Rules for Renal Function Test Results  ....................................................44  
8.6.3  Stopping Rule for Platelet Count Results ...............................................................45  
8.7 Adjustment of Dose .......................................................................................................47  
8.8 Discontinuation of Study Drug ......................................................................................47  
8.8.1  Follow- up Visits for Early Termination from Treatment Period or from 
Post- Treatment Follow -up Period ..........................................................................48  
8.9 Withdrawal  of Patients from the Study  ..........................................................................48  
8.10  Concomitant Therapy and Procedures ...........................................................................49  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
7  8.10.1  Concomitant Therapy .............................................................................................49  
8.10.2  Concomitant Procedures  .........................................................................................50  
8.11  Treatment Compliance  ...................................................................................................50  
8.12  Safety Monitoring Compliance  ......................................................................................50  
9. SERIOUS AND NON- SERIOUS ADVERSE EVENT REPORTING  ...................... 50  
9.1 Sponsor Review of Safety Information .........................................................................50  
9.2 Regulatory Requirements  ..............................................................................................50  
9.3 Definitions  .....................................................................................................................51  
9.3.1  Adverse Event  ........................................................................................................51  
9.3.2  Adverse Reaction and Suspected Adverse Reaction  ..............................................51  
9.3.3  Serious Adverse Event (SAE) ................................................................................51  
9.3.3.1  Adverse Events of Special Interest  ..................................................................52  
9.4 Monitoring and Recording Adverse Events ...................................................................52  
9.4.1  Serious Adverse Events/Adverse Events of Special Interest  .................................52  
9.4.2  Non-Serious Adverse Events ..................................................................................53  
9.4.3  Evaluation of Adverse Events (Serious and Non-Serious) ....................................53  
9.4.3.1  Relationship to the St udy Drug  ........................................................................53  
9.4.3.2  Severity  ............................................................................................................53  
9.4.3.3  Action Taken with Study Drug ........................................................................54  
9.4.3.4  Treatment Given for Adverse Event  ................................................................54  
9.4.3.5  Outcome of the Adverse Event ........................................................................54  
9.5 Procedures for Handling Special Situations ..................................................................55  
9.5.1  Abnormalities of Laboratory Tests .........................................................................55  
9.5.2  Prescheduled or Elective Procedures or Routinely Scheduled Treatments  ............55  
9.5.3  Dosing Errors .........................................................................................................56  
9.5.4  Contraception and Pregnancy .................................................................................56  
10. STATISTICAL CONSIDERATIONS  .......................................................................... 57  
10.1  Study Endpoints, Subsets, and Covariates .....................................................................57  
10.1.1  Primary Endpoint(s) ...............................................................................................57  
10.1.2  Secondary Endpoints ..............................................................................................57  
10.1.3  Safety Endpoints  .....................................................................................................57  
10.1.4  Dose Selection  ........................................................................................................58  
10.2  Sample Size C onsiderations ...........................................................................................58  
10.3  Analysis Populations ......................................................................................................58  
10.4  Definition of Baseline  ....................................................................................................59  
10.5  Interim Analysis  .............................................................................................................59  
10.6  Planned Methods of Analysis ........................................................................................59  
10.6.1  Demographic and Baseline Characteristics  ............................................................59  
10.6.2  Safety Analysis  .......................................................................................................59  
10.6.2.1  Adverse Events  ................................................................................................59  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
8  10.6.2.2  Clinical Laboratory Data ..................................................................................60  
10.6.2.3  Vital Signs and Examinations  ..........................................................................60  
10.6.3  Efficacy Analysis  ...................................................................................................60  
10.6.3.1  Analysis of Primary Efficacy Endpoint ...........................................................60  
10.6.3.2  Analysis of Secondary Efficacy Endpoints......................................................60  
10.6.4  Pharmacokinetic and Immunogenicity Analysis ....................................................61  
11. INVESTIGATOR’S REGULATORY OBLIGATIONS  ............................................. 62  
11.1  Informed Consent ..........................................................................................................62  
11.2  Ethical Conduct of the Study .........................................................................................62  
11.3  Independent Ethics Committee (IEC)/Institutional Review Board (IRB)  .....................62  
11.4  Patient Confidentiality  ...................................................................................................63  
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  ................................................ 63  
12.1  Protocol Amendments ....................................................................................................63  
12.2  Study Termination  .........................................................................................................63  
12.3  Study Documentation and Storage ................................................................................63  
12.4  Study Monitoring ...........................................................................................................64  
12.5  Language  ........................................................................................................................65  
12.6  Compensation for Injury ................................................................................................65  
13. REFERENCES  ................................................................................................................ 66  
14. APPENDICES  ................................................................................................................. 69  
Appendix A  Schedule of Procedures ....................................................................................70  
Appendix B  List of Laboratory Analytes  .............................................................................77  
Appendix C  PK Sampling Schedule ....................................................................................79  
Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities......83  
Appendix E  Additional Laboratory Tests for Patients with Platelet Count ˂ 100,000/mm387 
 
 
TABLE OF TABLES 
Page 
Table 1  Study Drug Characteristics  ................................................................................... 38 
Table 2  Study Drug Dosing Information  ........................................................................... 39 
Table 3  Actions in Patients with Low Platelet Count  ........................................................ 46 
 
TABLE OF FIGURES 
Page 
Figure 1  Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of 
apo(a) Covalently Bound to apoB..........................................................................22   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
9  PROTOCOL AMENDMENT  
 
Protocol Number:  ISIS 681257- CS6 
Protocol Title:  A Ran domized, Double-blind, Placebo-Controlled, Dose- Ranging 
Phase 2 Study of ISIS 681257 Administered Subcutaneously to 
Patients with Hyperlipoproteinemia(a) and Established 
Cardiovascular Disease (CVD)  
Amendment Number:  3 
Amendment Date:  9 December  2016 
 
The following table summarizes the history of amendments to the protocol of Study 
ISIS 681257- CS6.  None of the antecedent versions of the study protocol has been enacted 
clinically and therefore no patients have been enrolled prior to issuance of Amendment 3. 
Protocol Version  Date  Rationale for Amendments  
Original Protocol  15 August 2016   
Amendment 1 6 October 2016  Regulatory advice on inclusion of more 
detailed description of processes for platelet monitoring, and more frequent 
monitoring of liver function.  
Amendment 2  29 November 2016  Regulatory advice on inclusion of 
biomarkers of renal damage and increased 
frequency of renal monitoring.  
Amendment 3  9 December 2016  The study population was increased to 270 patients (54 per cohort) to support a 
statistical assessment of risk of platelet 
reduction in this population.  In addition, the 
treatment c ohorts have been modified to 
reflect both potential doses and dose 
regimens.  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
10  PROTOCOL SYNOPSIS  
Protocol Title  A Randomized, Double -blind, Placebo-C ontrolled, Dose-R anging Phase 2 Study of 
ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and 
Established Cardiovascular Disease (CVD)   
Study Phase  2 
Indication  Patients with hyperlipoproteinemia(a) and established CVD . 
Investigational Drug  ISIS 681257 is a second generation 2ʹ -MOE modified, GalNAc 3–conjugated antisense 
oligonucleotide inhibitor of apolipoprotein (a) [ apo(a) ]. 
Primary Objective  To evaluate the safety , including tolerability , of ISIS 681257 and to assess the efficacy  
and safety of different doses and dosing regimens of ISIS 681257 for reduction of 
plasma Lp(a) levels in patients with hyperlipoproteinemia(a) and established CVD.  
Secondary Objective(s)  To evaluate the efficacy of ISIS 681257 on plasma levels of low density lipoprotein 
cholesterol (LDL -C), apolipoprotein B 100 (apoB), oxidized phospholipids ( OxPL ) on 
apo(a)  [OxPL -apo(a)] , and OxPL  on apoB  (OxPL -apoB) . 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose 
regimens in patient s with hyperlipoproteinemia(a) and established CVD.  
Study Des ign This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study .  
Approximately 270 patients will be randomiz ed in a 5:1 ratio to receive ISIS  681257 or 
placebo.  This number was chosen to provide statistical power for both efficacy and 
safety assessments.  Study Drug  (ISIS 681257 or placebo) will be administered SC 
every week, every 2 weeks  or every 4 weeks, depending on cohort assignment, for up to 
52 weekly doses , up to 26 every 2 -week doses  or up to 13  every 4-week doses .  
Minimum treatment duration is 6 months.   Maximum treatment duration is 12 months.  
The treatment portion of the study will be complete when the last enrolled patient 
reaches 6 months of exposure .  All patients will then enter a 16-week post-treatment 
follow -up p eriod . 
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4-week  dosing (Cohorts A -C) and at Week 27 for patients who received 
every 2 -week or weekly dosing (Cohort s D and E , respectively ).  For patients continuing 
treatment beyond the primary analysis time point additional supportive efficacy and safety analyses will be repeated at the completion of Study Drug treatment . 
An independent Data and Safety Monitoring Board (DSMB) will be established to review 
safety, tolerability and efficacy (as needed) data collected on ISIS  681257 during this 
study , both individual events and aggregate data.   
Number of Subjects  Approximately 270 
Study Population  Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements  
2. Males or females aged ≥ 18 and ≤ 80 years old at the time of informed consent  
3. Clinical diagnosis of CVD defined as documented coronary artery disease, strok e, 
or peripheral artery disease  
4. Lp(a) plasma level ≥ 60 mg/dL  
5. Must be on standard- of-care preventative therapy for other than elevated Lp(a) 
CVD risk  factors  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
11  PROTOCOL SYNOPSIS Continued  
Study Population  
Continued  Inclusion Criteria  
6. Patients on the following medications must be on a stable regimen for at least 
4 weeks prior to Screening and expected to remain on a stable regim en through the 
end of  the p ost-treatment follow -up p eriod:  
a. Lipid lowering drugs (statins, ezetimibe, PCSK9 inhibitors, niacin, fibrates, fish oil or other products containing omega-3 fatty aci ds (including OTC 
preparations)  
b. Antiplatelet drugs  
c. Testosterone, estrogens, progesterone, growth hormone or progestins  
7. Females:  must be non-pregnant and non -lactating and either;  
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy);  
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in 
females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and  FSH levels 
in the postmenopausal range for the laboratory involved);  
c. Abstinent* or,  
d. if engaged in sexual relations of child- bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to Section 6.3.1 ) from the time of signing 
the informed consent form until at least 16 weeks after the last dose of  Study 
Drug  (ISIS 681257 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with 
the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., 
calendar, ovulation, symptothermal, post -ovulation method s), declaration of 
abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception  
8. Males must be surgically sterile or, if engaged in sexual relations with a female of 
child-bearing potential, the patient must be using an acceptable contraceptive 
method (refer to Section 6.3.1) from the time of signing the informed consent form 
until at least 16 weeks after the last dose of ISIS 681257  
Exclusion Criteria  
1. Within 6 months of Screening:   acute coronary syndrome, major cardiac surgery , or 
stroke /transient ischemic attack   
2. Within 3 months of Screening:   coronary , carotid,  or peripheral arterial 
revascularization, major non- cardiac surgery, or lipoprotein apheresis   
3. Heart failure NYHA class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg)  
5. History of acute kidney injury  within 12 months of S creening  
6. Uncontrolled hyper or hypothyroidism  
7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1 
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis  C or chronic hepatitis B  
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ  of the cervix that has been successfully treated  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
12  PROTOCOL SYNOPSIS  Continued  
Study Population  
Continued  Exclusion Criteria  
10. Patients with a history of major bleed or high- risk of bleeding diathesis  
11. Recent history of, or  current drug or alcohol abuse  
12. Clinically -significant abnormalities in screening laboratory values that would render 
a patient unsuitable for inclusion, including the following:  
a. Urine protein/creatinine (P/C) ratio ≥ 0.25 mg/mg.  In the event of a P/C ratio 
above this threshold, eligibility may be confirmed by a quantitative total urine 
protein measurement of ˂ 500 mg/24 -hr 
b. Positive test (including trace) for blood upon urinalysis .  In the event of a 
positive test, eligibility may be confirmed with a urine microscopy showing ≤ 5 red blood cells (RBCs) per high power field  
c. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >  2.0 x 
ULN 
d. Estimated GFR  ˂ 60 mL/min (as determined by the Cockcroft -Gault Equation 
for creatinine clearance)  
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s 
syndrome in which case total bilirubin must be ≤  3 mg/dL  
f. Alkaline phosphatase (ALP) > ULN  
g. Platelet count ˂  LLN 
13. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors  
14. Treatment with another investigational drug, biological agent, or device within 
1 month of Screening, or 5 half -lives of investigational agent, whichever is longer  
15. Treatment with any non-Ionis oligonucleotide (including small interfering ribonucleic 
acid [ siRNA ]) at any time or prior treatment with an Ionis oligonucleoti de or siRNA 
within 9 months of S creening.  Patients that  have previously received only 1 d ose of 
an Ionis oligonucleotide as part of a clinical study may be included as long as ≥ 4 months has elapsed since dosing  
16. BMI > 40 kg/m2  
17. Blood donation of 50-499 mL within 30 days of Screening or of > 499 mL within 8 weeks of S creening  
18. Unwillingness to comply with study procedures, including follow -up, as specified by 
this protocol, or unwillingness to cooperate fully with the Investigator  
19. Have any other conditions, which, in the opinion of the Investigator or Sponsor 
would make the patient unsuitable for inclusion, or could interfere with the patient 
participating in or completing the Study  
  
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
13  PROTOCOL SYNOPSIS Continued 
Treatment Groups Patients will be randomized to 5 parallel cohorts: 
Cohort A (n = 54): Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses. 
Cohort B (n = 54):  Patients will be randomized 5:1 to receive 40 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses. 
Cohort C (n = 54):  Patients will be randomized 5:1 to receive 60 mg ISIS 681257 
or placebo SC once every 4 weeks for up to 13 doses. 
Cohort D (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every 2 weeks for up to 26 doses. 
Cohort E (n = 54):  Patients will be randomized 5:1 to receive 20 mg ISIS 681257 
or placebo SC every week for up to 52 doses. 
Cohort Treatment # Doses Total ISIS 681257 
A 20 mg ISIS 681257 or placebo 
(Every 4 weeks) ≤ 13 ≤ 260 mg 
B 40 mg ISIS 681257 or placebo
(Every 4 weeks) ≤ 13 ≤ 520 mg 
C 60 mg ISIS 681257 or placebo 
(Every 4 weeks) ≤ 13 ≤ 780 mg 
D 20 mg ISIS 681257 or placebo
(Every 2 weeks) ≤ 26 ≤ 520 mg 
E 20 mg ISIS 681257 or placebo
(Every week) ≤ 52 ≤ 1040 mg 
 
Study Drug Dosage 
and Administration The Sponsor will provide ISIS 681257 in a concentration of 100 mg/mL and matching 
volume placebo: 
Cohort A:  20 mg every 4 weeks ISIS 681257 or placebo (0.2 mL) 
Cohort B:  40 mg every 4 weeks ISIS 681257 or placebo (0.4 mL) 
Cohort C:  60 mg every 4 weeks ISIS 681257 or placebo (0.6 mL) 
Cohort D:  20 mg every 2 weeks ISIS 681257 or placebo (0.20 mL) 
Cohort E:  20 mg every week ISIS 681257 or placebo (0.20 mL) 
All doses will be given by SC injection.  Self-administration will be allowed after 
appropriate training of patient and/or caregiver. 
Rationale for Dose and 
Schedule Selection The Phase 1 study, ISIS 681257-CS1, ev aluated 3 multiple-dose cohorts of 
ISIS 681257, 10 mg, 20 mg, and 40 mg.  Subjects were randomized (8:2 active:placebo) 
to receive ISIS 681257 for a total of 6 doses administered by SC injection:  3 doses 
during the first week and then once a week fo r the next 3 weeks.  These doses at this 
frequency of administration were found to be generally well-tolerated and to induce clinically-relevant reductions in LP(a). 
The range of dosing proposed for the pres ent study will provide the equivalent drug 
exposure of 5 mg, 10 mg, 15 mg, and 20 mg administered weekly, and is predicted 
(based on modelling of PK/PD data obtained in Phase 1 study) to result in mean 
reductions from baseline in plasma Lp(a) ranging from approximately 60% to 85% at 
steady-state.  
The highest dose selected for this study, 20 mg per week, is predicted to provide an 
approximately 85% reduction in Lp(a) at steady-s tate that is expected to be sufficient to 
bring almost all patients with hyperlipoproteinemia(a) into the normal range (Lp(a) 
≤ 30 mg/dL). 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
14  PROTOCOL SYNOPSIS Continued 
Rationale for Dose and 
Schedule Selection Continued The present study will also evaluate safety and efficacy at different dosing frequencies:  
every 4 weeks, every 2 weeks, and weekly.  Patients with hyperlipoproteinemia(a) will 
require chronic treatment and t hus every 2 weeks or every 4 weeks dosing regimens, if 
safe and well-tolerated, may provide advantages over weekly dosing in terms of convenience and compliance for patients.  Do sing regimens of 20 mg every 2 weeks and 
40 mg every 4 weeks will test if similar mont hly exposure, at different frequencies of 
administration, will achieve similar safety and similar level of Lp(a) reduction since the 
reduction achieved by a given dose level is principally driven by total exposure, while 
individual dose levels and the related peak concentration (C
max) may influence tolerance 
and safety. 
Adjustment of Dose 
and/or Treatment 
Schedule Dose adjustments, including dose interr uptions, and/or decreasing the dose may be 
allowed for safety or tolerability after consultation with the Sponsor Medical Monitor. 
Study Visit Schedule 
and Procedures  Detailed information regarding the study procedures are outlined in Section 6 , 
Appendices A  and C. 
All patients enrolled will be randomized to a mini mum of 6 months of treatment in 1 of 
5 treatment cohorts.  On completion of t he 6 months, patients ma y continue treatment 
within the same randomized cohort until the last enrolled patient reaches 6 months of 
exposure (for continuing safety assessment s), with a maximal exposure period of 12 
months. 
The study for an individual patient will generally consist of the following periods: An up to 4-week screening period 
An up to 52-week treatment period during which Study Drug will be administered per 
assigned cohort by SC injection 
A 16-week post-treatment follow-up period Patients in Cohorts A through C will receive up to 13 SC doses of ISIS 681257 or 
placebo every 4 weeks.  Patients in Cohort D will receive up to 26 SC doses of 
ISIS 681257 or placebo every 2 weeks and patients in Cohort E will receive up to 
52 weekly SC doses of ISIS 681257 or placebo.  Patients will return regularly for 
outpatient visits throughout th e treatment and post-treatment  follow-up periods according 
to the Schedule of Procedures (Appendix A). 
Blood and urine samples will be collected regularly throughout the study for safety, 
efficacy, and PK analysis.  Appendix B  shows a list of analytes required for the study 
and Appendix C details the PK sample schedules. 
Safety and Tolerability 
Evaluations Safety and tolerability assessments include:  adverse events, vital signs and weight, 
physical examinations, clinical laboratory tests, ECGs and use of concomitant 
medications.  Safety and tolerability results,  including results of laboratory tests related 
to the monitoring rules for platelets, liver and renal functions, in patients dosed with ISIS 681257 will be compared with those dosed with placebo. 
Efficacy Evaluations The primary analysis time point is at Week 25 for patients who received every 4-week 
dosing (Cohorts A-C) and at Week 27 for pati ents who received every 2-week or weekly 
dosing (Cohorts D and E, respectively). 
The primary endpoint is the percent change in plasma Lp(a) from baseline at the primary 
analysis time point for ISIS 681257 treatment groups compared to placebo. The secondary endpoints comprise the effect of  ISIS 681257 as compared to placebo at 
the primary analysis time point on the following: 
• Percent change from baseline in LDL-C  
• Proportion of patients who achieve plasma Lp(a) ≤ 50 mg/dL 
• Proportion of patients who achieve plasma Lp(a) ≤ 30 mg/dL, 
• Percent change from baseline in apoB • Percent change from baseline in OxPL-apo(a) • Percent change from baseline in OxPL-apoB 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
15  PROTOCOL SYNOPSIS Continued 
Pharmacokinetic 
Evaluations Plasma samples will be taken from all pat ients for the measurement of ISIS 681257 
plasma trough levels throughout treatment and during the post-treatment follow-up 
period.  In addition, in a subset of patient s (approximately 12 patients per cohort), more 
frequent plasma samples will be taken following the Day 1 and Day 169 doses (for Cohorts A, B, and C) or following the Day 1 and Day 183 doses (for Cohorts D and E) to 
determine PK parameters.  Plasma sample collection time points are detailed in Appendices A  and C. 
The plasma ISIS 681257 levels over time will be descriptively summarized by treatment with stratification by subject immunogenicity status.  Apparent terminal elimination half-
life will be calculated in patients who received ISIS 681257 treatment using a non-compartmental method, if data permitted.  In addition, C
max, Tmax, and AUC values will be 
calculated for the PK subgroup.  PK parameters will be descriptively summarized by treatment with stratification by subject immunogenicity status. 
Statistical 
Considerations The primary efficacy analysis for the primar y endpoint will be the pairwise comparison of 
percent change from baseline to the primary a nalysis time point in fasting Lp(a) between 
ISIS 681257 treated groups and placebo group in the Full Analysis Set. 
The data will be analyzed using an ANCOVA model with the baseline Lp(a) level as a 
covariate. 
Dose selection for the further development will be based on the following efficacy and 
safety considerations; more than 1 dose may m eet these criteria.  An effective dose, or 
dose regimen, will be one that achieves a clinically-meaningful reduction in plasma Lp(a) 
levels.  Safety will be evaluated on the basis of incidence of expected and unexpected 
treatment-related SAEs, and other s pecific safety considerations including the incidence 
of platelet reductions. 
Sample Size Considerations: 
Efficacy: 
Based upon prior clinical trial experience with ISIS 681257, it is estimated that the 
standard deviation of the percent change in Lp(a) is approximately 20%.  With 
23 patients in each ISIS 681257 treatment group and 23 in placebo group there would 
be approximately 90% power to detect a 20% difference in percent change in Lp(a) 
levels between the ISIS 681257 treatment groups  and placebo group at an alpha level of 
0.05, assuming 30% reduction in the IS IS 681257 patients and 10% reduction in the 
placebo patients. 
Safety: 
Based upon prior clinical trial experience with ISIS ASOs, assuming the incidence rate of 
platelet count below lower limit of normal (LLN) in placebo treated patients is 1.9%, in 
the ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, 
with 45 patients in each ISIS 681257 treatm ent group, there would be approximately 
80% power to detect at least 1 event. 
A total of approximately 270 patients (54 pa tients per cohort, including 45 patients per 
cohort treated with ISIS 681257) will be randomized to ensure that both the safety and 
efficacy of ISIS 681257 will be adequately characterized in the study. 
Sponsor/Collaborator Ionis Pharmaceutical s/Akcea Therapeutics 
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
16  STUDY DESIGN AND TREATMENT SCHEMA  
 
 
SCREENING PERIOD  
Weeks -4 to -1 
TREATMENT PERIOD  
Weeks 1 to 52* 
Dosing per assigned cohort:  
Cohorts A, B , and C :  Every 4 weeks SC 
administration of 20, 40, or 60 mg ISIS 681257 or 
placebo  
Cohort D :  Every 2 weeks SC administration of 
20 mg ISIS 681257 or placebo  
Cohort E :  Every week SC administration of 20 mg 
ISIS 681257 or placebo  
Routine safety assessments.  PK and PD/ef ficacy 
assessments at specified time points  
*Treatment portion of the study will be complete 
when the last enrolled patient reaches 6 months 
of exposure. 
POST -TREATMENT 
EVALUATIONS  
Weeks 4, 10, and 16 after last dose of 
Study Drug  
3 clinical visits for s afety, efficacy,  
PK and PD assessments  
EARLY 
TERMINATION 
(ET) 
Follow Week 53 Schedule 
of Procedures at ET;  
Patient strongly 
encouraged to visit clinic 
for post -treatment 
assessments  
END- OF-STUDY 
PROCEDURES  
Early T ermination or 3rd 
Follow -Up visit (16 Weeks 
after last dose of Study Drug)  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
17  STUDY GLOSSARY 
Abbreviation Definition  
2′-MOE  2′-O-(2-methoxyethyl)  
AE adverse event  
ALP  alkaline phosphatase 
ALT  alanine aminotransferase (SGPT)  
ANCOVA  analysis of covariance  
ANA  antinuclear antibody  
apo(a) apolipoprotein(a) 
apoB apolipoprotein B 
aPTT  activated partial thromboplastin time  
ASGPR  asialoglycoprotein receptor  
ASO antisense oligonucleotide 
AST  aspartate aminotransferase (SGOT)  
AUC  area under the curve  
AUC t area under the plasma concentration -time curve from time zero to 
time t 
βhCG  beta-subunit of human chorionic gonadotropin (pregnancy test) 
BP blood pressure 
BUN  blood urea nitrogen 
C centigrade  
C5a complement factor C5a (activated complement split product) 
CAD coronary artery disease  
Cmax maximum concentration  
CBC  complete blood count 
CMV  cytomegalovirus 
CRF  case report form  
CRP  C-reactive protein  
CVD cardiovascular disease  
CT computed tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
dL deciliter  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
18  STUDY GLOSSARY Continued  
Abbreviation Definition  
DNA  phosphorothioate-modified oligodeoxynucleotides 
DSMB  Data and Safety Monitoring Board 
CKD- EPI Chronic Kidney Disease –Epidemiological Collaboration  
Cys C  Cystatin C  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
ET early termination  
FAS full analysis set  
FSH follicle -stimulating hormone 
GalNAc 3 triantennary N -acetyl galactosamine  
GCP  Good C linical P ractice  
GFR  glomerular  filtration rate  
HAV  hepatitis A virus  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV hepatitis C virus  
HIV human immunodeficiency virus 
hr, hrs hour(s) 
hsCRP  CRP measured by high sensitivity assay 
ICH International Conference on Harmonization  
IEC Independent Ethics Committee 
IgM immunoglobulin M 
IL-1β interleukin -1 beta 
INR international normalized ratio  
IRB Institutional Review Board  
ISIS 681257 antisense inhibitor of apolipoprotein (a) 
IV intravenous(ly) 
IXRS  interactive voice/internet response system 
KIM -1 kidney injury molecule 1 
kg kilogram 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
19  STUDY GLOSSARY Continued  
Abbreviation Definition  
L Liter 
LLN  lower limit of normal 
m2 square meter  
MCH  mean corpuscular hemoglobin 
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume 
mg milligram 
MI myocardial infarction  
min minute  
mL milliliter  
mm millimeter  
mRNA messenger ribonucleic acid  
NAG  N-acetyl -β D-glucosaminidase  
NCS  not clinically -significant 
NGAL  neutrophil gelatinase- associated lipocalin  
NSAID  non-steroidal anti- inflammatory drug  
NYHA  New York Heart Association  
OxPL  oxidized phospholipids 
PAD peripheral arterial disease 
PBS phosphate buffered saline 
PCSK9  proprotein convertase subtilisin/kexin type 9 
pH measure of the acidity or basicity of a solution  
PK pharmacokinetic(s) 
PLA 2 Lp(a) -associated Lp -phospholipase A 2 
PPS per protocol set 
PT prothrombin time 
RBC  red blood cells 
RNase H 1 an ubiquitous endonuclease that specifically hydrolyzes the RNA 
strand in RNA/DNA hybrids  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
20  STUDY GLOSSARY Continued  
Abbreviation Definition  
siRNA small interfering ribonucleic acid  
SC subcutaneous(ly) 
Study Drug  ISIS 681257 or placebo 
SUSAR  suspected unexpected serious adverse reaction  
Tg transgenic 
Tmax time to maximal concentratio n 
UACR  urine albumin - creatinine ratio  
ULN  upper limit of normal 
UPCR  urine protein- creatinine ratio  
WBC  white blood cell 
WMA  World Medical Association  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
21  1. OBJECTIVES  
1.1 Primary Objective  
To evaluate the safety , including tolerability, of ISIS 681257 and to assess the efficacy and 
safety of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lp(a) 
levels in patients with hyperlipoproteinemia(a) and established cardiovascular disease ( CVD). 
1.2 Secondary Objective(s)  
To evaluate the efficacy  of ISIS 681257 on plasma levels of low density lipoprotein cholesterol  
(LDL-C), apolipoprotein B (apoB), oxidized phospholipids ( OxPL ) on apolipoprotein (a) 
[apo(a)] [ OxPL -apo(a) ] and OxPL  on apoB  (OxPL -apoB). 
To evaluate pharmacokinetics (PK) of ISIS 681257 across different doses and dose regimens in in patients with hyperlipoproteinemia(a) and established CVD. 
2. BACKGROUND AND RATIONALE  
2.1 Overview of D isease  
2.1.1 Lipoprotein (a) 
Lipoprotein(a) [ Lp(a) ] is an atherogenic lipoprotein ( Figure 1, Koschinsky and Marcovina 2004) 
in which the apoB component of LDL is linked by a disulfide bond to apolipoprotein(a) [apo(a)], 
the distinct protein component of Lp(a) that is mainly responsible for its signature structural and functional properties ( Dubé et al. 2012; Kronenberg and Ute rmann  2013 ).  Lp(a) is now 
recognized as an independent, genetic, causal risk factor for coronary artery disease (CAD), stroke, peripheral arterial disease (PAD),  and calcific aortic stenosis ( Erquo et al. 2009; 
Nordestgaard et al. 2010; Thanassoulis et al . 2013 ). 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
22   
Figure 1 Schematic Representation of the Lp(a) Particle.  Lp(a) is Composed of apo(a) 
Covalently Bound to apoB 
Apo(a) contains 10 unique units of kringle IV repeats, of which KIV2 ar e present in variable copies (1 to  > 40) 
conferring structural heterogeneity to Lp(a).  Apo(a) also contains kringle V and an inactive protease- like (P) 
domain.  In this model, 4 KIV2 repeats are shown.  Lp(a) also contains OxPL in the lipid phase of apoB as 
well as covalently bound to apo(a).  
 
Plasma levels of Lp(a) vary substantially among individuals, and most of this variation reflects 
the effects of genetic variation in the LPA gene which encodes the apo(a) protein . 
A second contributor to plasma- level variability are LPA single nucleotide polymorphisms 
(SNPs) that can be associated with either higher or lower Lp(a) levels ( Clarke et al. 2009; 
Li et al. 2011 ).  Significant associations exist between 2 particular LPA variants, rs10455872 and 
rs3798220, increased Lp(a) levels, CVD, and aort ic stenosis, with the CVD risk primarily 
mediated by Lp(a) plasma levels rather than an independent effect of the SNPs (Clarke et al. 
2009; Li  et al. 2011). 
Lp(a) plasma levels are generally inversely associated with apo(a) size, and can vary by 
> 1,000- fold (0.1 to > 250 mg/dL or ˂  0.25 to > 625 nmol/L) between individuals ( Merki et al. 
2011).  Despite this inter -individual variation, intra-individual Lp(a) levels are thought to be 
generally stable over time along a pre- set genetically determined levels without significant 
impact from dietary or environmental factors, mediating CVD risk throughout the patient’s 
lifetime.  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
23  2.1.2 Pathophysiology 
Lp(a) adheres to plaque sites and is retained in the artery wall  and has proatherogenic and 
pro-inflammatory prope rties due to its LDL and apo(a) components ( Spence and Koschinsky  
2012).  In addition, Lp(a) may be prothrombotic by inhibiting fibrinolysis because of its 
structural similarity  to plasminogen and its enhancement of platelet aggregation ( Rand et al.  
1998).  In vitro  studies have provided evidence for both of these pathogenic mechanisms, but 
in vivo  data are not definitive ( Dubé et al. 2012 ).  In humans, Lp(a) is the main lipoprotein 
carrier of OxPL, which may drive the risk associated with  Lp(a) (Bergmark et al. 2008; 
Leibundgut et al. 2013; Tsimikas et al. 2014).  In fact, OxPL measured on apoB (OxPL-apoB), 
which largely reflect the OxPL on Lp(a), have been shown to be a prognostic indicator for future 
CV events  (Tsimikas et al. 2010; Tsimikas et al. 2012; Tsimikas et al. 2014).  OxPL associated 
with Lp(a) can be subjected to degradation by the Lp(a)- associated Lp -phospholipase A 2 (PLA 2), 
implicating Lp(a) in novel proinflammatory and atherogenic pathways ( Kiechl et al. 2007). 
Hyperlipoproteinemia (a) in hum ans is  associated with increased risk of cardiac death, 
myocardial infarction  (MI) , stroke, aortic stenosis, and peripheral arterial disease (PAD), 
particularly in subjects with small apo(a) isoforms ( Bennet t 2008; Erqou et al. 2009; Erqou et al.  
2010;  Bertoia  et al. 2013; Thanassoulis et al. 2013 ).  Although prospective, randomized, 
controlled outcomes studies have not been conducted, epidemiological, genome- wide association 
and Mendelian randomized controlled study data to date provide supporting evide nce for a role 
of Lp(a) as a risk factor for CVD  (Kamstrup  et al. 2009).  For example, in the Copenhagen City 
Heart Studies of 42,000 subjects with a 15- year follow -up (Kamstrup  et al. 2009) using a 
Mendelian randomization approach, higher Lp(a) levels were related to risk of MI. 
2.1.3 Current Treatment  Options 
In 2010, the European Atherosclerosis Society (EAS) Consensus Panel recommended screening for elevated Lp(a) in people at moderate to high risk of CVD to reach a treatment goal of ˂ 50 mg/dL (125 nmol/L), after therapeutic management of LDL -C (Nordestgaard  et al. 2010).  
Approximately 20% of people are estimated to have plasma Lp(a) levels over 50 mg/dL 
(125 nmol/L) and approximately 0.3% to have levels over 175 mg/dL (438 nmol/L) .  There are 
no gender differences in Lp(a) concentrations but racial differences have been observed, with whites and Asians having lower levels while blacks and Hispanics generally have somewhat 
higher levels (Nordestgaard et al. 2010).  
Lifestyle and diet are  thought to have little impact on an individual’ s Lp(a) level .  Current 
treatment recommendations from the EAS Consensus Panel are limited to the use of 1 to 3 g of 
niacin (nicotinic acid) daily which could result in an up to 30% reduction in Lp(a).  Howev er, 
niacin is associated with side effects (e.g., flushing) that reduce patient tolerability and 
compliance ( Parker et al. 2006; Guyton 2007). 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are neither indicated nor formally recommended f or treatment of hyperlipoproteinemia(a) but have been reported to 
reduce Lp(a) levels by ~20%-35% in patients with hypercholesterolemia ( Desai et al . 2013; 
Raal et al . 2015).  
The other current option for patients with signif icantly elevated Lp(a) levels ( ≥ 60 mg/dL) is 
lipoprotein apheresis, either general lipoprotein apheresis ( Jaeger et al. 2009;   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
24  Leebmann et al. 2013; Rosada et al. 2014) or Lp(a)- specific apheresis ( Safarova 2012).  While 
very effective at acutely lowering  Lp(a) (acute and interval Lp(a) reductions of > 60% and 
> 30% respectively), this treatment option is expensive, burdensome for patients, and 
unavailable/not reimbursed in many countries and regions. 
2.2 T herapeutic Rationale 
Therapeutic modalities to reduce Lp(a) levels in humans are f ew, and there are no drugs 
currently available that specifically target Lp(a) alone.  Antisense oligonucleotides (ASOs) are 
emerging as viable therapeutic agents to treat disorders where overexpression of proteins is 
associated with a disease process .  Apo(a) is synthesized primarily in the liver , a target organ for 
ASOs, where it is subsequently covalently linked to the apoB-100 component of LDL to form 
the Lp(a) lipoprotein.  The goal of treatment with ISIS  681257 is to reduce the production of 
apo(a) in the liver and thus, the level of Lp(a) lipoprotein by using an ASO directed against the messenger ribonucleic acid (mRNA) of apo(a).  It has been hypothesized that a pharmacologic 
reduction in Lp(a) could slow down or reverse CVD  by reducing thrombotic, atherogenic, or 
inflammatory events in patients with elevated Lp(a) levels ( Nordestgaard et al. 2010).  
Importantly, there is no evidence that lowering Lp(a) will result in adverse consequences in 
individuals, and there are no reports linking very low Lp(a ) to any deleterious effects.  
2.3 ISIS  681257 
Please refer to the ISIS 681257 Investigator’s Brochure for more details on ISIS 681257 
mechanism of action, chemistry, pre- clinical and clinical experience.  The summary is provided 
below. 
2.3.1 Mechanism of Action  
ISIS 681257 is a second -generation ASO drug targeted to apo(a), that has been covalently 
bonded to triantennary N -acetyl galactosamine (GalNAc
3), a high- affinity ligand for the 
hepatocyte- specific asialoglycoprotein receptor (ASGPR) to form an ASO -GalNAc 3 conjugate.  
This GalNAc 3-conjugate approach results in enhanced ASO delivery to hepatocytes versus 
non-parenchymal cells and has increased ASO potency by approximately 10 -fold compared to 
unconjugated ASOs in mice ( Prakash et al. 2014). 
The ASO portion of ISIS 681257 is complementary to a region spanning the Exon 24-25 splice 
site at position 3901 of apo(a) transcript sequence (NM_005577.2) and binds to the mRNA by Watson and Crick base pairing.  The hybridization (binding) of ISIS 681257 to the cognate mRNA results in the Ribonuclease H1 (a non- specific endonuclease that catalyzes the cleavage 
of RNA via hydrolytic mechanism RNase H1 -mediated degradation of the apo(a) mRNA, thus 
preventing production of the apo(a) protein).  Maximal antis ense-mediated reduction of target 
mRNA levels is typically greater than 90% of control levels in sensitive tissues ( Zhang et al.  
2010).  Furthermore, reduction in target mRNA levels using this approach correlates directly 
with a subsequent reduction in target protein levels.  
ISIS 681257 does not have any complementary homology to plasminogen mRNA ( Graham et al . 
2016).  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
25  2.3.2 Chemistry  
Chemically, ISIS 681257 is a synthetic oligomer of 20 nucleotides (i.e., a 20- mer) that are 
connected sequentially by phosphorothioate and phosphodiester linkages (mixed backbone 
design).  The mixed backbone design reduces the total number of phosphorothioate linkages, which reduces non-specific interactions with proteins and further enhances potency of GalNAc
3 
conjugated ASOs. 
Structurally, the oligonucleotide has 4 regions.  Two (2) of them, the 5 nucleotides at the 5′ end 
and the 5 nucleotides at the 3′ end, are composed of 2′ -O-(2-methoxyethyl) (2′ -MOE) -modified 
ribonucleotides.  These MOE -modified nucleotides confer (1) increased affinity for the target 
mRNA ( Altmann et al. 1996; McKay et al. 1999), (2) increased resistance to exonucleases and 
endonucleases (thereby increasing stability in tissue) ( Geary et al. 2003), and (3) amelioration of 
some of the high- dose toxicities, thereby resulting in an improved safety profile compared to 
first-generation antisense drugs containing phosphorothioate-modified oligodeoxynucleotides 
(DNA) ( Henry et al. 2000).  The third region, the central portion of the oligonucleotide, is 
composed of 10 oligodeoxynucleotides.  This chimeric design is called a MOE -Gapmer, and 
ISIS 681257 employs this chimeric structure to enable use of the ubiquitou s endonuclease that 
specifically hydrolyzes the RNA strand in RNA/DNA hybrids ( RNase H1 )-mechanism fo r 
antisense activity .  This is because while the 2′ -MOE modification confers increased stability and 
affinity, it does not support RNase H1 -catalyzed cleavage of RNA hybridized to 2′ -MOE -
modified nucleotides ( McKay  et al. 1999).  The fourth region is composed of a triantennary 
cluster of GalNAc 3 sugars that is linked to the 5ʹ end of ISIS 681257 via a phosphodiester 
linkage.  The GalNAc 3 cluster is a high affinity ligand for the ASGPR, a receptor expressed 
primarily on the surface of liver hepatocytes ( Stockert 1995).  The GalNAc 3 cluster enhances 
delivery of ISIS 681257 to liver hepatocytes over other cell types and enhances potency.  After 
internalization into cells, the GalNAc3 cluster is metabolized to release “free ASO” inside the 
cell ( Prakash et al. 2014). 
2.3.3 Preclinical Experience  
The pharmacology of ISIS 681257 has been examined in apo(a) transgenic (Tg) mice which express the entire human apo(a) genomic sequence ( Frazer et al. 1995) and nonhuman primates. 
Administration of ISIS 681257, a human apo(a) antisense inhibitor, to mice containing the 
human apo(a) transgene produced dose-dependent reductions in human apo(a) liver mRNA and 
apo(a) plasma protein after 6 weeks of ASO administration at 0.3, 1, 3, and 10 mg/kg/wk. 
When ISIS 681257 was admi nistered to normal chow fed cynomolgus monkeys for 4 weeks at 
the dose of 12 mg/kg/wk, it significantly reduced hepatic apo(a) mRNA by 90% relative to the 
cohort administered phosphate buffered saline (PBS).  As there is an 80% sequence conservation between apo(a) and plasminogen nucleotide sequences, plasminogen mRNA levels were also 
measured , and no change compared to the PBS cohort was observed. 
Findings from the chronic toxicology studies with ISIS 681257 (the 26- week mice an d 39- week  
monkey studies) were similar to those observed in the 4- and 6- week studies  and were not 
considered adverse .  The plasma and tissue concentrations observed for ISIS 681257 in  mice  and 
monkeys were generally similar to those observed for other unconjugated 20- mer 2 ʹ-MOE ASOs 
in this chemical class with and without GalNAc
3-conjugation.  However, the proportion of drug 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
26  in hepatocytes compare to nonparenchymal liver cells was greater for ISIS 681257, compared to 
the parent drug ISIS 494372 (without GalNAc 3-conjugation), which is the basis for increased 
potency of ISIS 681257 (unpublished results; Geary et al. 2003;  Yu et al. 2007; Prakash et al.  
2016).  
The most noteworth y safety fin ding in the chronic monkey study was  a marked platelet reduction  
that occurred in 2 male monkeys in the high-dose group (20 mg/kg/wk) and 1 female animal in 
the mid -dose (10 mg/kg/wk) group beginning on Days 44-135, which led to the subsequent early 
termination  (ET)  of these 3 animals.  An additional male monkey in the 10 mg/kg/wk dose group 
had a moderate decrease in platelets  that was successfully treated with steroid s, and was 
terminated at the scheduled 6 -month interim sacrifice .  There were no platelet reductions or other 
toxicologically significant findings in monkeys treated with 2 mg/kg/wk for up to 39 weeks.  There were no marked platelet reductions in mice at doses up to 70 mg/kg/wk for 26 weeks.  However, mice exposed to ISIS 681257 at doses of ≥ 10 mg/kg/wk for up to 26 weeks showed evidence of adverse hepatobilia ry effects in both sexes as indicated by increases in ALT (up to 
+ 10.3x), AST (up to + 10.4x), and/or ALP (+ 2.5x).  
Detailed information concerning the pre clinical pharmacology and toxicology studies conducted 
with ISIS 681257 can be found in the Investigator’s Brochure. 
2.3.4 Clinical Experience  
To date, ISIS 681257 has been studied in a single Phase 1 clinical trial of 45 healthy subjects.  
ISIS 681257- CS1 was a Phase 1 double-blind, placebo-controlled, dose- escalation study 
designed to assess the safet y, tolerability, PK,  and pharmacodynamics (PD) of single and 
multiple doses of ISIS 681257 administered subcutaneously (SC)  to 45 healthy subjects with 
Lp(a) ≥ the upper limit of normal  (ULN)  (30 mg/dL).  Twenty one (21) subjects received 10  to 
120 mg S C (10, 20, 40, 80, and 120 mg) as a single-dose, and 24 subjects received 10, 20, and 
40 mg a s multiple doses (6 doses in 22 days :  3 loading doses during the first week on alternate 
days [Days 1, 3, and 5], and then once a week for the next 3 weeks [ Days 8,  15, and 22]). 
There were no serious adverse events  (SAEs) , or clinically -relevant  changes in laboratory 
assessments and a ll subjects completed the treatment and post- treatment follow -up periods. 
Constitutional symptoms such as fever, chills, increase in body temperature and arthralgias have been observed following parenteral administration of ASOs, primarily during the initial dosing period.  Following SC administration of ISIS 681257 constitutional symptoms  were observed  in 
4 of the 6 subjects  who received a single -dose of 120 mg.  The symptoms were mild in severity  
and resolved spontaneously with or without treatment with acetaminophen . 
Fluctuations in platelet counts to below the lower limit of normal were obse rved in 5 study 
subjects on acti ve drug and across doses.  These changes were not considered adverse or 
clinically -significant by the Investigator and did not appear to be dose related. 
Two (2) mild AE s of redness at the site of injection  occurred 48 to 72 hours after administration 
in 1 subject who received ISIS  681257 in the 20 mg multiple-dose cohort.  Both AE s resolved by 
the time of the subject’s next visit. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
27  Following SC administration, ISIS 681257 was absorb ed rapidly into the systemic circulation, 
with median time to maximum plasma concentrations (T max) ranging from 1 to 4 hours.  Similar 
Tmax values were observed at all dose levels.  Maximum observed plasma concentrations (C max) 
and AUC 0-24hr were dose-dependent over the studied SC dose range.  The mean peak (C max) and 
total exposure (AUC 0-24hr) increased proportionally with dose at  dose levels ranging from 10 to 
40 mg, and greater than dose proportionally at dose levels ranging from 40 to 120 mg. 
After reaching C max, mean plasma concentrations of ISIS  681257 declined in a biphasic fashion 
over time, with an initial, relatively fast distri bution phase that dominate d the plasma clearance 
followed by a slower elimination phase.  Charac terization of the terminal elimination phase 
yielded an apparent terminal elimination half-life of approxi mately 3 to 4 weeks over a dose 
range of 10 to 120 mg (either single- or multiple-dose), and appeared to be independent of dose.  
This result is consistent with  the slow elimination of ISIS  681257 observed from monkey tissues, 
and the comparatively long elimination half- lives observed for this chemical class. 
Plasma trough concentrations ( 168 hours or 7 days from previous dose) monitored during the 
treatment period in the multiple- dose cohorts increased with increasing dose, consistent with 
expectations (based on preclinical assessments and experience with other compounds of this chemical class) that trough plasma concentratio ns reflect exposure in tissues.  Plasma trough 
concentrations did not increase greatly af ter the loading period (D ay 15), suggesting that 
accumulation in major tissues of distribution ha d approached steady-state after the loading 
period. 
Overall, the human PK of IS IS 681257 are consistent with th e expected PK for compounds 
within this chemical class. 
Detailed information concerning the Phase 1 clinical study conducted with ISIS 681257 can be 
found in the Investigator’s Br ochure and recent publication (Viney et al. 2016 ).   
2.4 Rationale for Dose and Schedule of Administration 
The Phase 1 study, ISIS 681257-CS1, evaluated 3 multiple-dose cohorts of ISIS 681257, 10 mg, 
20 mg, and 40 mg.  Subjects were randomized (8:2  active:placebo) to receive ISIS 681257 for a 
total of 6 doses administered by SC injection:  3 doses during the first week and then once a 
week for the next 3 weeks.  These doses at th is frequency of administration were found to be 
generally well-tolerated and to induce clin ically-relevan t reductions in LP(a).  
The range of dosing proposed for the present st udy will provide the equivalent drug exposure of 
5 mg, 10 mg, 15 mg, and 20 mg ad ministered weekly, and is predicted (based on modelling of 
PK/PD data obtained in Phase 1 st udy) to result in mean reduc tions from baseline in plasma 
Lp(a) ranging from approximately  60% to 85% at steady-state. 
The highest dose selected for this study, 20 mg per week, is predicted to provide an 
approximately 85% reduction in Lp (a) at steady-state that is exp ected to be sufficient to bring 
almost all patients with hyperlipoproteinemia(a) into the normal range (Lp(a) ≤ 30 mg/dL). 
The present study will also evaluate safety and efficacy at different dosin g frequencies:  every 
4 weeks, every 2 weeks, and weekly.  Patients wi th hyperlipoproteinemia(a) will require chronic 
treatment and thus every 2 weeks or every 4 we eks dosing regimens, if safe and well-tolerated, 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
28  may provide advantages over weekly dosing in terms of convenience and compliance for 
patients.  Dosing regimens of 20 mg every 2 weeks and 40 mg every 4 weeks will test if similar 
monthly exposure, at different frequencies of administration, will achieve similar safety and 
similar level of Lp(a) reduction since the reductio n achieved by a given dose level is principally 
driven by total exposure, while individual dose levels and the related peak concentration (C max) 
may influence tolerance and safety.  
3. EXPERIMENTAL PLAN 
3.1 Study Design 
This is a Phase 2, multicenter, randomized, double -blind, placebo-controlled, dose-ranging study.  
Approximately 270 patients will be randomized in a 5:1 ratio (225 ISIS 681257 and 45 placebo) 
to receive ISIS 681257 or placebo.  Study Drug (I SIS 681257 or placebo) will be administered 
SC every week, every 2 weeks or every 4 w eeks, depending on cohort assignment, for up to 
52 weekly doses, up to 26 every 2-week doses  or up to 13 every-4-week doses.  Minimum 
treatment duration is 6 months. 
The treatment portion of the study will be termin ated when the last enrolled patient reaches 
6 months of exposure.  All pa tients will then enter a 16-week post-treatment follow-up period 
irrespective of antecedent duration of treatment. 
The primary analysis time point  is at Week 25 for patients wh o received every 4-week dosing 
(Cohorts A-C) and at Week 27 for patients who r eceived every 2-week dosing or weekly dosing 
(Cohorts D and E, respectively).  For patients continuing treatment beyond the primary analysis 
time point additional supportive efficacy analysis (t o evaluate whether the treatment effect is 
maintained) and safety analysis (for the purpose of  dose(s) selection) will  be repeated at the 
completion of Study Drug treatment. 
Patients ≥ 18 and ≤ 80 years old with elevated plasma Lp(a) levels ( ≥ 60 mg/dL ) and a clinical 
diagnosis of CVD are eligible for enrollment upon meeting the study specific eligibility criteria.  
Patients will be on standard-of-care  preventative therapy for other than elevated Lp(a) CVD risk 
factors as per current guidelines. 
Clinical diagnosis of CVD is defined as documented coronary artery disease (CAD), stroke, or 
peripheral artery disease (PAD) .  A diagnosis of CAD has to be documented by any of the 
following: 
• Angiographic evidence of ≥ 50% stenosis of 1 or more majo r epicardial coronary arteries 
• History of myocardial infarction documented by positive enzymes, and either symptoms of myocardial ischemia, or ECG changes ( Thygesen et al. 2012 ) 
• History of coronary revascularization 
• Evidence of cardiac ischemia on exercise testing, or imaging study 
Patients will be evaluated for study eligibility  during Screening, which takes place within 
4 weeks prior to Day 1 (the first day of Study Dr ug administration).  Patients who are determined 
to be eligible, based on screening assessments, will be enrolled in the study at Day 1 and 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
29  randomly assigned to 1 of the 5 parallel dosing cohorts, with each cohort having a 5:1 ratio to 
receive ISIS 681257 or matching volume of placebo, respectively, by SC injection for a 
minimum of 6 months and up to 52 weeks. 
Following the End-of-Treatment, patients will  enter the 16-week post-treatment follow-up 
period. 
3.2 Number of Study Centers 
This is a multicenter, multinational study. 
3.3 Number of Patients 
Approximately 270 patients will be randomized in  this study, with approximately 54 patients 
assigned to each of the 5 treatment cohorts. 
3.4 Overall Study Duration and Follow-up 
The length of patients’ participation in the study may be up to 18 months (72 weeks), which 
includes a 4-week screening period, an up to 52-week treatment period with Study Drug 
(ISIS 681257 or placebo), and a 16-week post-treatment follow-up period.  The treatment portion of the study will be complete when the last en rolled patient reaches 6 months of exposure. 
Patients may be required to attend additional visits for monitoring of AEs or abnormal investigation results.  The frequency of add itional monitoring will be determined by the Study 
Medical Monitor in consultation with the Investigator. 
3.4.1 Screening 
Patient eligibility for the study will be de termined within 4 w eeks prior to study. 
3.4.2 Treatment For each patient minimum treatment duration is 6 months and maximum of 52 weeks.  Patients 
will continue treatment in the study until the last patient enrolled reaches 6 months of exposure.  
All patients will then enter a 16-week post-treatment follow-up period. 
Eligible patients will report to the Study Center for assessments at spec ified intervals throughout 
the 52-week treatment period as detaile d in the Schedule of Procedures in Appendix A .  During 
the Treatment, Study Drug (ISIS 681257 or placebo)  will be administered by SC injection once 
weekly, once every 2 weeks, or once every 4 weeks, depending on cohort assignment. 
3.4.3 Post-Treatment 
Patients when completed dosing will enter the 16-week post-treatment follow-up period and will 
return to the Study Center for 3 follow-up visits 4, 10, and 16 weeks after their last  injection of 
Study Drug as per Appendix A (Follow-up). 
The final study visit for each patient will be 16 weeks after the last dose of Study Drug. 
3.5 End-of-Study 
The End-of-Study is defined as  last patient, last visit. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
30  3.6 Data and Safety Monitoring Board 
An independent Data and Safety Monitoring Board (DSMB) will be established  to review safety, 
tolerability and efficacy (as needed) data collected on ISIS  681257 during this study.  The 
DSMB will be constituted to include expertise in medical specialties re levant to the safety of 
antisense drugs (nephrology, hepatology, hematology), and the underlying disease state of the 
patients (cardiology) .  Specialist members of the DSMB will be informed and consulted on all 
relevant treatment -related SAEs, and  changes of relevant laboratory parameter s that trigger 
stopping rules ( Section 8.6) within 48 hours of receipt of such results.  In addition, all accrued 
safety data relevant to each of medical area specialist will be forwarded at regular intervals for 
review .  
Based on its ongoing assessment of the safety and tolerability of ISIS 681257, the DSMB will 
provide recommendations to the Sponsor for modifying, stopping or continuing the study as 
planned.  Details on the safety assessments, frequency of review, meeting s chedules and 
controlled access to unblinded data are outlined in the DSMB Charter and/or  Statistical Analysis 
Plan (SAP).  
4. PATIENT ENROL LMENT  
4.1 Screening  
Before patients  may be en rolled into the study, the Sponsor or designee requires a copy of the 
Study Center ’s written  independent ethics committee/institutional review board (IEC/IRB)  
approval of the protocol, informed consent form, and all other patient directed  information 
and/or recruitment material. 
Patients  or their legally acceptable representatives must sign the consent form  before any 
screening tests or assessments are performed .  At the time of consent, the patient  will be 
considered enrolled into the study and will be assigned  a unique screening number before any 
study procedures, including s creening procedures, are performed .  The screening number and 
patient  identification number must remain constant throughout the entire trial.  In the event the 
patient is re -consented and  re-screened the patient must be given a new screening number.  
Screening numbers and patient  identification numbers, once assigned, will not be re- used.  
4.2 Randomization 
Patients will be randomized  after all  screening  assessments have been completed and after the 
Investigator has verified that they are eligible per criteria in Sections 5.1 and 5.2.  No patient  
may begin treatment prior to randomization and assignment of a unique patient identification 
number. 
Using an Interactive Web -Response System (IXRS), eligible patients will be randomized in a 
1:1:1:1:1  ratio to 1 of the 5 parallel -dose cohorts (Cohorts A, B, C, D, or E).  Within each dose 
cohort, patients will be randomized in a 5:1 ratio to receive ISIS 681257 or matching volume of 
placebo, respectively.  
A permuted block schedule will be used .  The randomization schedule will be generated and held 
by an independent vendor. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
31  4.3 Replacement of Patients  
Patients  who withdraw from the study will not be replaced . 
4.4 Unblinding of Treatment Assignment  
The Sponsor and all patients , monitors, and Study C enter  personnel related to the study will be 
blinded throughout the study and until all patients have completed the study and the database has 
been locked .  However, if a patient  has suffered a SAE  (as defined in Section 9.3.3), and/or when 
knowledge of the treatment assignment will impact the clinical management of the patient , the 
Investigator will have the ability to unblind the treatment assignment for that  patient  using the 
IXRS .  The S ponsor will determine the point at which all treatment assignments will be 
unblinded.  The Sponsor or designee will be informed of the unblinding of a patient  within 
24 hours.  In addition, all SUSARs wil l be unblinded by the Sponsor’s or designee’s Drug Safety 
and Quality Assurance personnel for th e purpose of regulatory repor ting (see Section 9.2).  
5. PATIENT  ELIGIBILITY  
To be eligible to participate in this study candidates must meet the following eligibility criteria at within 4 weeks of Study Day 1or at the time point specified in the individual eligibility criterion 
listed.  
5.1 Inclusion Criteria  
1. Must have given written informed consent (signed and dated) and any authorizations 
required by local law and be able to comply with all study requirements 
2. Males or females aged ≥ 18 and ≤ 80 years  old at the time of informed consent 
3. Clinical diagnosis of CVD defined as documented coronary artery disease (CAD), stroke, 
or peripheral artery disease 
4. Lp(a) plasma level ≥  60 mg/dL  
5. Must be on standard-of- care preventative therapy for other than  elevated Lp(a) CVD risk 
factors  
6. Patients on the following medications must be on a stable regimen for at least 4 weeks 
prior to Screening and expected to remain on a stable regimen through the end of the 
post-t reatment follow-up period: 
a. lipid lower ing drugs (statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 
[PCSK9s ] inhibitors, niacin, fibrates, fish oil or other products containing omega-3 
fatty acids (including OTC preparations)  
b. a ntiplatelet drugs  
c. testosterone, estrogens, progesterone, growth hormone or progestins 
7. Females:  must be non -pregnant and non- lactating and either : 
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
32  b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females 
> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea 
without an alternative medical cause and  FSH levels in the postmenopausal range for 
the laboratory involved) 
c. Abstinent* or 
d. if engaged in sexual relations of child-bearing potential, agree to use 2 highly 
effective contraceptive methods (refer to Section 6.3.1) from the time of signing the 
informed consent form until at least 16 weeks after the last dose of Study Drug  
(ISIS  681257 or placebo)  
* Abstinence is only acceptable as true abstinence, i.e., when this is in line with the 
preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), declaration of abstinenc e for the 
duration of a trial and withdrawal are not acceptable methods of contraception 
8. Males must be surgically sterile or, if engaged in sexual relations with a female of child -
bearing potential, the patient must be using an acceptable contraceptive method (refer to Section 6.3.1) fr om the time of signing the informed consent form until at least 16 weeks 
after the last dose of ISIS 681257 
5.2 Exclusion Criteria  
1. Within 6 months of Screening :  acute coronary syndrome, m ajor cardiac surgery, or 
stroke 
2. Within 3 months of Screening:  c oronary or peripheral arterial revascularization, major 
non-cardiac surgery , or lipoprotein apheresis  
3. Heart failure New York Heart Association ( NYHA) class IV  
4. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg) 
5.  History of acute kidney injury within the past 12 months 6. Uncontrolled hyper or hypothyroidism  7. Active infection requiring systemic antiviral or antimicrobial therapy that will not be 
completed prior to Study Day 1 
8. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C 
or chronic hepatitis B 
9. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or 
carcinoma in situ of the cervix that has been successfully treated  
10. Patients with a history of major bleed or high-risk of bleeding diathesis  
11. Recent history of, or current drug or alcohol abuse 12. Clinically -significant  abnormalities in screening laboratory values that would render a 
patient unsuitable for inclusion, including the following: 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
33  a. Urine protein/creatinine (P/C) ratio ≥ 0.25 mg/mg .  In the event of a P/C ratio above 
this threshold, eligibility may be confirmed by a quantitative total urine protein 
measurement of ˂ 500 mg/24-hr 
b. Positive test (including trace) for blood upon urinalysis.  In the event of a positive test, eligibility may be confirmed with a urine microscopy showing ≤ 5 red blood cells (RBCs) per high power field  
c. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x U LN 
d. Estimated GFR  ˂ 60 mL/min (as determined by the Cockcroft-Gault Equation for 
creatinine clearance)  
e. Bilirubin > ULN, unless prior diagnosis and documentation of Gilbert’s syndrome in 
which case total bilirubin must be ≤  3 mg/dL  
f. Alkaline phosphat ase (ALP)  > ULN  
g. Platelet count ˂  LLN  
13. Use of warfarin, direct thrombin inhibitors or factor Xa inhibitors 
14. Treatment with another investigational drug, biological agent, or device within 1 month 
of Screening, or 5 half-lives of investigational agent, whichever is longer 
15. Treatment with any non -Ionis oligonucleotide (including small interfering ribonucleic 
acid [ siRNA] ) at any time or prior treatment with an Ionis oligonucleotide or siRNA 
within 9 months of S creening .  Patients that have previously received only 1 dose of an 
Ionis oligonucleotide as part of a clinical study may be included as long as ≥ 4 months 
has elapsed since dosing 
16. BMI > 40 kg/m
2  
17. Blood donation of 50-499 mL within 30 days of S creening or of > 499 mL within 
8 weeks of Screening  
18. Unwillingness to comply with study procedures, including follow-up, as specified by this 
protocol, or unwillingness to cooperate fully with the Investigator 
19. Have any other conditions, which, in the opinion of the Investigator or Sponsor would 
make the patient unsuitable for inclusion, or could interfere with the patient participating 
in or completing the Study 
6. STUDY PROCEDURES  
6.1 Study Schedule  
All required study procedures are outlined in Appendices A , B, and C . 
6.1.1 Screening  
Written informed consent for the study will be obtained prior to the performance of any study-
related procedures including screening procedures .  A 4 -week period is provided for completing 
screening assessments and determining patien t eligibility for the study .  Abnormal screening 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
34  results may be re -tested once for determination of patient eligibility after consultation with the 
Sponsor Medical Monitor.  Patients may be re -screened 1 time in order to determine eligibility . 
During the s creening period, patients  will undergo a medical history and physical examination 
including vital signs, 12-lead electrocardiogram (ECG) and have blood and urine samples taken 
for clinical laboratory testing .  Patients  will be screened for HIV, hepatitis B , and hepatitis C. 
6.1.2 Treatment Period  
During the t reatment period, patients will report to the study center for clinic visits .  Patients will 
receive 20 mg doses of Study Drug  administered by SC injection once every 4 weeks for up to 
52 weeks in Cohort A, 40 mg doses of Study Drug  administered by SC injection once every 
4 weeks for up to 52 weeks in Cohort B, 6 0 mg doses of Study Drug  administered by SC 
injection once every 4 weeks for up to 52 weeks in Cohort C, 20 mg doses of Study Drug  
administered by SC injection once every 2 weeks  for up to 52 weeks in Cohort D, or 2 0 mg 
doses of Study Drug administered by SC injection once per week for up to 52 weeks in Cohort E (Section 8.1). 
Collection and measurement of vital signs, physical examination results, ECGs, clinical 
laboratory parameters ( Appendix B ), ISIS  681257 plasma concentrations, immunogenicity and 
biomarker samples , AEs  and concomitant medication/procedure information will be performed 
according to the Schedule of P rocedures in Appendix A . 
Extensive Pharmacokinetic (PK) Subgroup Only: 
Within each cohort, a subgroup of approximately 12 patients , who will consent to extensive PK 
sampling , will undergo additional PK sampling, in what is referred to as the PK Subgroup in this 
study.  Patients in this subgroup will have additional PK  sampling time points in order to 
evaluate the plasma PK parameters of ISIS  681257.  Patients in this subgroup will have 
additional visits to the clinic during the t reatment p eriod in order to collect blood samples for PK 
assessment ( Appendix C ). 
6.1.3 Post-Treatment  Period  
Each patient will be followed for safety assessments for 16 weeks after their  last dose of 
Study Drug.  During the post- treatment follow-up period, patients will return to the Study Center 
for 3 outpatient visits at Weeks 4, 10, and  16 after the last dose of Study Drug for safety and 
clinical laboratory evaluations and for blood sampling for PK (Appendices A and C). 
6.2 Additional Study Assessm ents 
6.2.1 Laboratory Assessments  
Laboratory analyte samples will be collected throughout the study.  A list of these analytes  is 
contained in Appendix B. 
Blood chemistry and urine samples (excluding 24-hour urine collection) should be taken be 
taken after fasting for at least 10 hours.  During this time the patient can drink water and they 
should ensure that they consume sufficient water in order to not become dehydrated.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
35  If tests are uninterpretable (e.g. , due to clumping, hemolysis or quantity not sufficient) or 
missing , a repeat test  specimen should be re-drawn as soon as possible (ideally within 1 week ). 
Hematology  samples will be collected every 14 days.  E ach time a hematology lab is drawn and 
sent to the central laboratory for analysis , an additional sample must be collected in parallel and 
analyzed locally .  In the event that both the central and local samples are unreportable (e.g., due 
to hemolyzed or clumped blood samples), patient dosing cannot continue until another sample is 
repeated and determined not to have met a platelet stopping rule. 
If there is no reportable platelet count within 14 days of the last platelet count, the Investigator 
will contact the patient to hold dosing until a new platelet count is obtained and review ed. 
Blood and urine samples for renal function testing and assessment of biomarkers of renal damage 
will also be collected every 14 days  and sent to the central laboratory for analysis, per 
Section  8.5.2.  If there are no test results available within 14 days of the last set of results  for 
parameters considered critical to patient safety , the Investigator will contact the patient to hold 
dosing until a new test set is obtained and reviewed. 
All lab samples sent to  the central laboratory are received on the next day and processed.  Lab 
Alerts issued as per protocol safety monitoring requirements or stopping rules will indicat e the 
applicable protocol section to facilitate review and will be  immediately and simultaneously sent 
by email to the Investigator, the Sponsor and the CRO Medical Monitors, the Sponsor Drug 
Safety Physician, and the Clinical Trial Manager (CTM), and should be receiv ed by them  within 
2 days from sample collection.  Hematology results from the site’s local laboratories are received by the study center  staff on the day of sample collection , and should be entered as soon as 
possible in to the eCRF  to inform the Sponsor and CRO study monitoring teams. 
All platelet count results must be reviewed promptly (within 48 hours of receipt) by the Inves tigator , or designee, to ensure that the count has not met the stopping rule and to determine 
whether the rate of decline is suggestive that the patient could be approaching the dose interruption rule of 75,000/mm
3 as specified in Section 8.6.3.  Any case of a platelet count 
reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is considered  an adverse event of 
special interest and must be reported in an expedited fashion to the Sponsor as per 
Sections  9.3.3.1 and 9.4.1. 
All liver and renal function tests  must also be reviewed promptly (within 48 hours of receipt) by 
the Investigator , or designee, to ensure that the result  has not met the stopping rule. 
All lab alerts received , including those related to plate let, liver, or renal function 
monitoring/s topping rules, are reviewed promptly by the Sponsor and the CRO Medical 
Monitors who discuss them and agree on actions to be taken.  Within 24 hours of receiving an 
actionable lab alert the CRO Medical Monitor will communicate instructions to the Investigator and the study personnel by emailing them the Safety Surveillance Form that needs to be signed by the Investigator/study personnel and promptly returned  to the Sponsor and CRO Medical 
Monitor.  In urgent cases, such as platelets  results below 50,000/mm
3, the Investigator must also 
be contacted by phone.  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
36  Further information on safety monitoring and actions to be taken by the Study Investigator in the 
event of reduced platelet count are provided in Section s 8.5.3 and 8.6.3. 
6.2.2 Physical Exams and Vital Signs 
Physical exams and vital signs will be performed as indicated in the Schedule of Procedures 
(Appendix A ).  Vital signs should include weight, blood pressure (BP) , pulse rate, respiratory 
rate and body temperature.  BP  and pulse rate will be recorded after the patient has been in a 
sitting position for at least 5 minutes .  BP  should always be measured on the same arm 
(preferentially on the left arm) .  Height will be measured at Screening . 
6.2.3 E lectro cardiography  
Electrocardiography (ECG) w ill be conducted at Screening, Day 1, (prior to the first dose of 
Study Drug ), and again during the t reatment p eriod  as follows per dosing cohort: 
• Cohorts A, B, and C at Weeks 5, 13, 21, 25, 33, 41, 49, and 53  
• Cohorts D and E at Weeks 5, 13, 21, 27, 33, 41, 49, and 53 
In all cohorts, ECGs will be conducted during the post-t reatment follow-up period  at 4, 10, and 
16 weeks after the last dose of Study Drug . 
ECGs will be recorded after the patient has been resting in a supine position for at least 
5 minutes .  ECGs will be performed in triplicate . 
6.2.4 PK Sampling  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected 
prior to dosing on Day 1 and at various times throughout the t reatment and post-t reatment 
follow-up period s as noted in the tables in Appendix C . 
Within each cohort, patients assigned to the PK Subgroup will have additional PK  sampling time 
points and additional visits to the clinic during the t reatment p eriod in order to collect blood 
samples for PK assessmen t (Appendix C). 
6.3 Restriction on the Lifestyle of Patient s 
6.3.1 Contraception Requirements  
All male patient s and women  of childbearing potential must refrain from sperm/egg donation and 
either be abstinent† or pr actice effective contraception from the time of signing the informed 
consent form until at least 16 weeks  after their last dose of study treatment .   
Male patient s engaged in sexual relations with a female of child -bearing potential must a lso 
encourage their female partner to use effective contraception from the time of signing the informed consent until 16 weeks  after the patient ’s last dose of study treatment.  
For the purposes of this study, women of childbearing potential are defined as a ny female who 
has experienced menarche, and who does not meet 1 of the following conditions: 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
37  • Postmenopausal:  12 months of spontaneous amenorrhea in females > 55 years of age or, 
in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative 
medical cause and  FSH levels in the postmenopausal range for the laboratory involved 
• 6 weeks after surgical bilateral oophorectomy with or without hysterectomy 
• Post hysterectomy  
For the purposes of the study, effective contraception is defined as follows: 
For male patient s: 
• Effective male contraception includes a vasectomy with negative semen analysis at 
Follow-up, or the use of condoms together with spermicidal foam/gel/film/ 
cream/suppository 
• Male patient s with partners that are pregnant must use condoms as contraception to 
ensure that the fetus i s not exposed to the Study Drug 
For female patient s and female partners of male patient s: 
• Using 1 or more of the following acceptable methods of contraception:  surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception , intrauterine 
contraception/device, or any 2 barrier methods (a combination of male or female 
condom * with  diaphragm, sponge, or cervical cap)  together with spermicidal 
foam/gel/film/cream/suppository  
†Note: Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the patient .  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the 
duration of a trial and withdrawal are not acceptable methods of contraception. 
*Note : A female condom and a male condom should not be used together as friction 
between the 2 can result in either or both product s failing . 
6.3.2 Other Requirements  
All patients will be required to fast for at le ast 10 hours before visits requiring fasted blood 
sampling.  
7. STUDY DRUG  
7.1 Study Drug  Description  
Study Drug ( ISIS 681257 or Placebo)  characteristics are listed in  Table 1.  
Study Drug ( ISIS 681257 or Placebo)  will be provided as 0.8 mL deliverable volume in 2 mL 
stoppered and sealed glass vials as a sterile solution .   
The Study Drug  is clear to slightly yellow  in color, it is for single use , contains no preservatives 
and must be stored between 2 to 8 °Celsiu s and be protected from light. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
38  7.1.1 ISIS  681257 
ISIS 681257 vials contains 100 mg/mL ISIS 681257 in Water for Injection.  Additionally, 
sodium phosphate buffer and sodium chloride are added to control the measure of the acidity or 
basicity of the  solution (pH) and tonicity, respectively.  The target pH is 7.4. 
7.1.2 Placebo  
Placebo vials contain 0.9% sodium chloride in Water for Injection.  1.6 µ g/mL riboflavin is 
added to ensure color matching of placebo vials to ISIS 681257 vials.  
Table 1 Study Drug  Characteristics  
Study Drug  ISIS 681257  Placebo  
Strength 100 mg/ mL  Not Applicable  
Volume/Formulation  0.8 mL solution per 
2.0 mL vial  0.8 mL solution per  
2.0 mL vial  
Route of Administration  SC SC 
SC = subcutaneous  
 
7.2 Packaging and Labeling  
The Sponsor will provide the Investigator with packaged Study Drug  (ISIS 681257 or placebo) 
labeled in accordance with specific country regulatory requirements . 
7.3 Study Drug  Accountability  
The study staff is required to document the receipt, dispensing, and return  of Study Drug  
(ISIS 681257 or placebo) supplies provided by the Sponsor.  The patient must return all used and 
unused Study Drug  to the Study Center for accountability .  The Study Center must return all 
used and unused Study Drug  to the Sponsor or designee for destruction .  All used syringes must 
be disposed of as per the site’s hazardous waste destruction policy. 8. T REATMENT OF PATIENTS 
8.1 Study Drug  Administration  
ISIS 681257 will be administered to patients by Study Center staff as follows: 
Cohort A: a single SC dose of 20 mg  once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort B: a single SC dose of 40 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
Cohort C: a single SC dose of 60 mg once every 4 weeks for up to 52 weeks and a 
maximum of 13 doses 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
39  Cohort D: a single SC dose of 20 mg every 2 weeks for up to 52 weeks and a maximum of 
26 doses 
Cohort E: a single SC dose of 20 mg every week (weekly) for up to 52 weeks and a 
maximum of 52 doses 
Self-administration for patients in Cohorts D and E will be allowed after appropriate training of 
patient and/or caregiver. 
Patients in Cohorts A, B, and C should receive 1 dose every 4 weeks, patients in Cohort D 
should receive 1 dose every 2 weeks and patients  in Cohort E should receive 1 dose per week 
with weeks always defined relative to Study Day 1.  For example if a pati ent receives the first 
dose on a Monday, subsequent doses should be gi ven on Mondays, according to the respective 
dosing schedule, if possible.  If a patient misses an injection, or if dosi ng on the usual day is not 
possible, the patient can reschedu le the injection provided that 2 doses are administered at least 
2 days apart. 
Every effort should be made to ensure the prev ious dose is given at l east 7 days prior to a 
scheduled clinic visit. 
Please refer to the Study Drug Ma nual provided by the Sponsor or  designee for more detailed 
instructions for Study Drug (ISIS 681257 or placebo) preparation and administration 
Table 2 Study Drug Dosing Information 
Cohort Treatment Volume to Admini ster/Dose # Doses Total ISIS 681257 
A 20 mg ISIS 681257 
or placebo 
(Every 4 weeks) 0.2 mL  ≤ 13 ≤ 260 mg 
B 40 mg ISIS 681257 
or placebo 
(Every 4 weeks) 0.4 mL  ≤ 13 ≤ 520 mg 
C 60 mg ISIS 681257 
or placebo 
(Every 4 weeks) 0.6 mL  ≤ 13 ≤ 780 mg 
D 20 mg ISIS 681257 
or placebo 
(Every 2 weeks) 0.2 mL ≤ 26 ≤ 520 mg 
E 20 mg ISIS 681257 
or placebo 
(Every week) 0.2 mL ≤ 52 ≤ 1040 mg 
 
8.2 Other Protocol-Required Drugs 
No other Study Drug treatments  are required by the protocol. 
8.3 Other Protocol-Required Treatment Procedures No other treatment procedures  are required by the protocol. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
40  8.4 Treatment Precautions  
No specific treatment precautions are required.  
8.5 Safety Monitoring Rules 
Please refer also to the “Guidance for Investigator ” section of the Investigator’s Brochure. 
For the purposes of safety monitoring baseline is defined as the average of the pre- dose test 
closest to Day 1 and Day 1. 
In addition to the standard monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters chosen base d on preclinical and clinical 
observations. 
In case of discrepancy  between the test results from 2 sources, such as between the central and 
local lab, safety -mandated action must be initiated based on the lower of the 2 values.  
Confirmation Guidance :  At any time during the study (treatment or post-t reatment follow-up 
periods), the clinical laboratory results meeting any of the safety monitoring criteria presented 
below must be confirmed by performing measurements (ideally in the same laboratory that 
perfo rmed the initial measurement) on new specimens  prior to administering the next dose of 
Study Drug  (ISIS 681257 or placebo).   All new specimen collections should take place as soon 
as possible (ideally within 3 days of the initial collection) .  
In addition, as described in Section 6.2.1 hematology lab s should be sent in parallel to the central 
and local laboratory for analysis. Stopping Rule Guidance:  In the event of an initial clinical laboratory result that meets a stopping 
criterion, patients must not be re -dosed until a confirmatory test result has been reviewed by the 
Study Medical Monitor.  If any of the stopping criteria described below (refer to Sections 8.6.1 to 8.6.3) are met and are confirmed, the patient will be permanently discontinued from further treatment with Study Drug (ISIS 681257 or placebo), evaluated fully as outlined below and in consultation with the Study Medical Monitor or appropriately qualified designee, and will be entered into the post-treatment evaluation portion of the study.  In general, patients who do not meet the stopping rules based upon retest may continue dosing.  However, the Investigator and the Study Medical Monitor (or appropriately qualified designee) should confer as to whether 
additional close monitoring of the patient is appropriate. 
Additional Guidance:  If possible, a pharmacokinetic sample should be collected as soon as 
possible after an SAE has occurred (preferably within 2 weeks).  In addition, if a patient is asked to return to the clinic for additional evaluations due to an AE, then a pharmacokinetic sample 
should be taken at the time of the unscheduled visit. 
8.5.1 Safety Monitoring Rules for Liver Chemistry Tests  
The following rules are adapted from the FDA guidance for industry, “Drug- Induced Liver 
Injury:  Premarketing Clinical Evaluation,” issued by the U.S .  Department of Health and Human 
Services, Food and Drug Administration, July 2009.  For a definition of Baseline, ple ase refer to 
guidance in Section 8.5 above. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
41  All patients will have liver chemistry  tests monitored every 2 weeks for the first 3 months of the 
study treatment, and monthly thereafter  during the Treatment Period . 
In the event of appearance of symptoms or si gns of hepatic injury (jaundice, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash,  abnormal bleeding or bruising, or 
eosinophi lia > ULN ) liver  enzymes and bilirubin should be tested as soon as possible.  Testing at 
a lab that  is local to the patient is permissible for this purpose.  
In the event of an ALT or AST measurement that is > 3 x ULN (or the greater of 2 x baseline 
value or 3 x ULN if the baseline value was > ULN) at any time during the s tudy ( treatment or 
post-t reatment period), the initial measurement(s) should be confirmed as described in 
Section  8.5. 
Patients  with confirmed ALT or AST levels > 3 x ULN should have their liver chemistry tests 
(ALT, AST, ALP, international normalized ratio [ INR] and total bi lirub in) retested at least once 
weekly until ALT and AST levels become ≤ 1.2 x ULN . 
All results of liver function tests  must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that the result  has not met the stopping rule s per 
Section  8.6.1. 
Further Investigation into Liver Chemistry Elevations :  For patients  with confirmed ALT or AST 
levels > 3 x ULN , the following evaluations should be performed: 
1. Obtain a more detailed history of symptoms and prior and concurrent diseases  
2. Obtain further history for concomitant drug use (including nonprescription medications, 
herbal and dietary supplement preparations), alcohol use, recreational drug use, and 
special diets  
3. Obtain a history for exposure to environmental chemic al agents and travel  
4. Serology for viral hepatitis (hepatitis A virus [ HAV] immunoglobulin M [ IgM], hepatitis 
B sur face antigen [ HBsAg ], hepatitis C virus [ HCV ] antibody, Cytomegalovirus [ CMV ] 
IgM, and EBV antibody panel) 
5. Serology for autoimmune hepatitis (e.g., antinuclear antibody [ ANA]) 
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or 
MRI scans, may be performed at the discretion of the Investigator, in consultation with the Sponsor Medical Monitor and t he study DSMB.  Repetition of the above evaluations should be 
considered if a patient’s ALT and/or AST levels reach 5 x ULN . 
All routine liver function test results will be reviewed on an ongoing basis at the weekly s afety 
review by the  Medical Monitor.  
All lab alerts for abnormal liver function tests must be promptly reviewed by the Investigator and 
Medical Monitors. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
42  Lab alerts for abnormal liver chemistry tests will  be issued for:  1) ALT or AST > 3 x ULN; 
2) ALT or AST > 2 x baseline; 3)  total bilirubin > ULN;  4) ALP > ULN.  These alert levels are 
set to anticipate the risk of a combined elevation of aminotransferases and bilirubin as per the 
FDA Guidance referenced in Section 8.5.1 . 
8.5.2 Safety Monitoring for Renal Function 
All patients will have renal function tests monitored every 2 weeks throughout the study.   
In the event of appearance of symptoms or si gns consistent with renal dysfunction such as 
hematuria, polyuria, anuria, flank pain, new-ons et hypertension, nausea an d/or anorexia, renal 
function should be tested as soon as possible.  Te sting at a lab that is local to the patient is 
permissible for this purpose. 
During the course of the study, ur inary surveillance will include urinalysis to include urine 
albumin/creatinine ratio (UACR) , urine protein/creatinine ratio  (UPCR) and urinary red blood 
cells (RBCs), as well as serum creatinine to esti mate glomerular filtra tion rate (eGFR), which 
will be monitored every 2 weeks.  In addition, biomarkers of acute renal injury will also be 
measured every 2 weeks ( Appendix B ).  Results that exceed predetermined alert values will be 
reviewed, together with related safety data, by the nephrologist on the DSMB as specified in the DSMB charter.  eGFR may also be evaluated based upon serum cys-C to further characterize the 
significance of changes in renal function or renal biomarkers. 
All results of renal function tests must be reviewed promptly (within 48 hours of receipt) by the Investigator or the designee to ensure that  the result has not met the stopping rules per 
Section 8.6.2 . 
Lab alerts for abnormal renal tests will be i ssued for:  Creatinine clearance (by CKD-EPI 
formula) decrease from baseline > 15%, urine Al b/C ratio (UACR) > 2.5 x ULN, or an increase 
in serum creatinine from baseline > 0.25 mg/dL. 
These alert levels are set to anti cipate and prevent the risk of a medically significant change in 
renal function while receiving Study Drug.  
In the event of a confirmed (as described in Section 8.5 ) laboratory result mee ting one or more of 
the following criteria, dosing with the Study Dr ug should be interrupted and the Study Medical 
Monitor informed. 
If any of the following changes from baseline  in renal laboratory parameters should occur 
following from Day 1 of Study Drug administration:  
Creatinine clearance (by CKD-EPI formula) decrease from baseline > 25%, urine Alb/C 
ratio (UACR) > 5 x ULN, or an increase in serum creatinine from baseline > 0.5 mg/dL,  
the following additional renal tests should be immediately obtained:  
Fasting serum creatinine, urin e culture, 24-hour urine sample for creatinine clearance and 
urine protein, urine microscopy samp le with inspection of sediment. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
43  The Investigator should also review the patient’s concomitant  medications for potentially 
nephrotoxic agents, and, with the results of these evaluations, revi ew any decision to continue or 
discontinue the patient in consultation with the Study Medical Monitor and the medical area 
specialist consultant of the DSMB. 
8.5.3 Safety Monitoring for Platelet Count Results 
All patients will have platelet counts monitore d every 2 weeks for the duration of the study and 
must not receive Study Drug without an interpretabl e platelet count result in  the prior 2 weeks.  
In addition, platelet function will be evaluated by aggregometry in all patients at each study site 
visit, with additional functional testing being performed at selected study centers.  
As described in Section 6.2.1, all platelet count results must  be reviewed promptly (within 
48 hours of receipt) by the Investig ator or the designee to ensure that the count has not met the 
stopping rule and to determine whet her the rate of decline is sugge stive that the patient could be 
approaching the dose interruption rule of 75,000/mm3 as specified in Section 8.6.3 .   
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered an adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor.  Lab alerts related to platelet monitoring/stopping rules are issued  when:  1) platelet counts are 
< 140,000 mm
3; 2) when platelet count is ≥ 30% decreased from baseline, or 3) when the 
hematology sample is unreportable.  All these lab alerts, are reviewed promptly by the Medical 
Monitor and instructions are communicated to the Investigator and the study personnel within 24 hours of receiving an actionable lab alert as described in Section 6.2.1. 
Actions to be taken in the event of reduced pl atelet count are shown in  Table 3 in Section 8.6.3. 
In the event of a platelet count ˂ 100,000/mm
3 the laboratory tests outlined in Appendix D  
should be performed as soon as possible.  Additi onal lab tests will be determined by the Sponsor 
Medical Monitor or designee in c onsultation with the Investigator. 
8.5.4 Safety Monitoring for Minor Bleeding Events 
Minor bleeding events are those th at do not fulfill the criteria fo r major bleeding or clinically-
relevant, non-major bleeding events (which ar e defined in Section 8.6.3), for example excess 
bruising, petechiae, gingival blee ding on brushing teeth.  If a minor bleeding event occurs, the 
Investigator must notify the Sponsor Medical Monitor and additional testing of coagulation 
parameters activated partial thromboplastin ti me (aPTT), prothrombin time (PT), INR, hepatic 
enzymes, bilirubin and platelet  count should be performed. 
8.5.5 Safety Monitoring for Constitutional Symptoms Patients will be instructed to promptly report a ny signs or symptoms of  fever, constitutional 
symptoms, rash, arthralgia or joint swelling that  may arise during the stud y and the Investigator 
should closely evaluate all potential causes, including concomitant illness.  Patients who 
experience persistent symptoms should be discussed with the Sponsor Medical Monitor or 
designee to determine whether additional m onitoring or laboratory tests are required. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
44  8.6 Stopping Rules  
For the purposes of stopping rules, Baseline is defined as the average of Day 1 pre-dose 
assessment and the last measurement prior to Day 1.  
8.6.1 Stopping Rules for Liver Chemistry Elevations  
In the event of confirmed laboratory results meeting any of the following criteria , dosing of a 
patient with Study Drug  will be stopped permanently: 
1. ALT or AST > 8 x ULN , which is confirmed 
2. ALT or AST >  5 x ULN , which is confirmed and persists for ≥ 2 weeks  
3. ALT or AST >  3 x ULN (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), which is confirmed and total bilirubin >  2 x ULN  or INR > 1.5  
4. ALT or AST >  3 x ULN  (or the greater of 2 x Baseline value or 3 x ULN if the Baseline 
value was > ULN), whic h is confirmed, and the new appearance (i.e., onset coinci des 
with the changes in hepatic enzymes) of  fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, or eosinophi lia (> ULN ) felt by the Investigator to be 
potentially related to hepatic inflammation  
8.6.2 Stopping Rules for Renal Function Test Results  
In the event of an estimated creatinine clearance ( by CKD -EPI formula) meeting any of the 
following criteria, or any change in renal biomarkers deemed by the nephrologist on the DSMB  
to require further evaluation , a serum creatinine and 24 -hour urine sample for creatinine 
clearance and protein should be obtained: 
1. CKD- EPI decrease of > 50% from B aseline  
2. CKD- EPI v alue < 45 mL/min/1.73 m2 
Dosing of a patient with Study Drug (ISIS  681257 or placebo) will be stopped permanently  if 
24-hour urine testing confirms any of the following values in the absence of an alternative explanation : 
1. Urine protein is > 2.0 g 
2. Creatinine clearance decrease of > 50% from baseline 
3. C reatinine clearance < 45  mL/min/1.73 m2 
Irrespective of whether the stopping rule is confirmed or not, the follow-up schedule and 
frequency of renal function monitoring after the initial event will be determined by the Study Medical Monitor in consultation with the Investigator and the medical area specialist  on the 
DSMB . 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
45  8.6.3 Stopping Rule for Platelet Count Results 
Stopping Rules for Platelet Count Results 
Actions to be taken in the event of a low pl atelet count are summari zed in Table 3 below. 
In the event of any platel et count less than 50,000/mm3, or a platelet count less than 75,000/mm3 
that occurs while the patient is already on re duced dose, dosing of the patient with Study Drug 
will be stopped permanently (Table 3).  Platelet  count will be monitored daily until 2 successive 
values show improvement then monitored ever y 2-3 days until platel et count is stable. 
Administration of steroids is recommended for patients whose platelet  count is less than 
25,000/mm3.  Recovery in platelet count may be accelerated by administration of high dose 
steroids.  Treatment guidelines for immune thrombocytopenia ( Provan et al. 2010) recommend 
Dexamethasone 40 mg daily for 4 days every 2-4 weeks for 1-4 cycles; Prednis(ol)one 
0.5-2 mg/kg/d for 2-4 weeks then taper; or me thylprednisolone 30 mg/kg/day for 7 days  
(note:   may require continuation with oral steroids after methylprednisolone). 
In the event of a platelet count ˂ 75,000/mm3 and > 50,000/mm3, and in the absence of major 
bleeding or clinically-relevant non- major bleeding (defined below; Schulman and Kearon 2005), 
dosing of a patient with Study Drug should be susp ended temporarily until the platelet count has 
recovered to > 100,000/mm3.  If dosing is continued it must be at a reduced dose as shown in 
Table 3.  The suitability of the patient fo r continued dosing will be determined by the 
Investigator in consultation with  the Study Medical Monitor and will be based on factors such as 
the original rate of decline in the patient’s platelet count, whether a ny bleeding events were 
experienced by the patient, and the speed of reco very of platelet coun t after interruption of 
dosing. 
If, after reintroduction of Study Drug, the platelet count agai n falls below 75,000/mm3, then 
dosing of the patient with Study Drug will be stopped permanently.  Once a patient commences weekly monitoring this  frequency of monitoring should continue 
irrespective of whether the platelet count rises into the normal range. 
Any unreportable platelet count result must be rechecked and determined not to have met a 
stopping rule before dosing can continue. Definition of Major Bleeding Ev ents (Schulman and Kearon 2005): 
• Fatal bleeding, and/or 
• Symptomatic bleeding in a critical area or or gan, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarterial or pericardial, or intramuscular with 
compartment syndrome, and/or 
• Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more within 
24 hours, or leading to transfusion of 2 or more units of whole or red cells 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
46  Definition of Clinically -Relevant, Non-Major Bleeding Events (Schulman and Kearon 2005):  
1. Multiple -source bleeding  
2. Spontaneous hematoma > 25 cm2 
3. Excessive wound hematoma (not injection site related) 
4. Macroscopic hematuria (spontaneous or lasting > 24 hours if associated with an 
intervention) 
5. Spontaneous rectal bleeding; epitasis, gingival bleeding, hemoptysis, hematemesis  
6. Bleeding after venipuncture for > 5 minutes 
Table 3 Actions in Patients with Low Platelet Count  
Platelet Count on Rx  Drug Dose  Monitoring  
Normal range, >  140K/mm3 No action  Monitor every 2 weeks  
100K -140K/mm3 No action  Closer observation  
Monitor every week * 
75K-100K/mm3 Permanently reduce as follows:  
For Cohort A:  reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks   
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week s 
For Cohort E:  reduce to 10 mg every week  Closer observation  
Monitor every week * 
50K-75K/mm3 Pause dosing  
When platelet count returns to >  100K/mm3 restart 
dosing as follows  only if approved by Sponsor 
Medical Monitor : 
For Cohort A:   reduce to 10 mg every 4 weeks  
For Cohort B:  reduce to 20 mg every 4 weeks  
For Cohort C:   reduce to 30 mg every 4 weeks  
For Cohort D:  reduce to 10 mg every 2 week s 
For Cohort E:  reduce to 10 mg every week  
or 
Permanently discontinue Study Drug i f it occu rs 
while on already reduced dose  Closer observation  
Monitor every 2-3 days until 
2 successive values show 
improvement  
Consider discontinuation of 
antiplatelet agents/ non-
steroidal anti-inflammatory drug ( NSAIDS )/ anticoagulant 
medication  
25K-50K/mm3 Permanently discontinue Study Drug  Closer observation: 
Monitor daily until 
2 successive values show 
improvement then monitor every 2 -3 days until platelet 
count stable  
Discontinue antiplatelet agents/NSAIDS/anticoagulant medication while platelet count ˂ 50K/mm
3 if possible 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
47  Table 3 Actions in Patients with Low Platelet Count Continued  
Platelet Count on Rx  Drug Dose  Monitoring  
˂ 25K/mm3 Permanently discontinue Study Drug  Closer observation:  
Monitor daily until 
2 successive values show 
improvement then monitor 
every 2 -3 days until platelet 
count stable  
Steroids recommended**  
Consider need for hospitalization and referral to hematologist  
Discontinue antiplatelet agents/NSAIDS/anticoagulant medication while platelet 
count ˂ 50K/mm
3 if possible 
* Once a patient commences weekly monitoring this frequency of monitoring should continue irrespective of 
whether the platelet count rises into the normal range. 
** Recovery in platelet count may be accelerated by administration of high dose steroids .  Treatment guidelines for 
immune throm bocytopenia ( Provan et al. 2010) recommend Dexamethasone 40 mg daily for 4 days every 
2-4 weeks for 1- 4 cycles; Prednis(ol)one 0.5-2 mg/kg/d for 2- 4 weeks then taper; or Methylprednisolone 
30 mg/kg/day for 7 days (note:  may require continuation with oral steroids after methyl prednisolone) . 
 
8.7 Adjustment of Dose  
Dose frequency adjustments for platelet count reduction must be made in accordance with 
Section 8.6.3 and Table 3  (above). 
Other dose adjustments, including dose interruptions, and/or decreasing the dose will be allowed for safety or tolerability after consultation with the Sponsor Medical Monitor.   
Patients may have their dose interrupted in response to AEs after consultation with Study 
Medical Monitor. 
8.8 Discontinuation of Study Drug  
A patien t must permanently discontinue study treatment for any of the following: 
• The patient  becomes pregnant.  Report the pregnancy according to instructions in 
Section  9.5.4 
• The patient  withdraws consent  
• The patient  experiences an AE  that necessitates permanent discontinuation of Study Drug  
• The patient  develops laboratory test abnormalities that meet any of  the stopping rules 
listed in  Sections  8.6.1 to 8.6.3 
• When a platelet count  of less than 50,000/mm
3, or a platelet count less than  75,000/mm3 
while the patient is on a reduced dose. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
48  The reason for discontinuation of  Study Drug must be recorded in the electronic Case Report 
Form (eCRF) and source documentation. 
8.8.1 Follow-up Visits for Early Termina tion from Treatment Period or from 
Post-Treatment Follow-up Period 
Any patient who discontinues early from the tr eatment period or from post-treatment follow-up 
period should be followed as per the platelet monitoring rules shown in Table 3, Section 8.6.3  for 
the first 6 weeks after discontinuing Study Drug.  Fo llowing this period, if th e platelet count is 
stable (at least 3 consecutive values measured weekly that are stable as determined by the 
Sponsor Medical Monitor and > 100,000/mm3), the next platelet count should be taken within at 
least 6 weeks so that patients are monitored fo r at least 12 weeks after discontinuing Study Drug. 
Following 6 weeks of Study Drug discontinuation, patients should be strongly encouraged to 
attend planned Study Center visi ts (including End-of-Treatment  Week 53 visit and final 
Post-Treatment Follow-up visit 16 weeks after thei r last dose of Study Dr ug) to collect the study 
assessments in accordance with the Schedule of Procedures in Appendix A . 
If the patient declines or is unable to part icipate in the above, an ET visit (Week 53 visit 
assessments) should be performed at the time of withdrawal, at a minimum, and ideally within 
2 weeks from the last dose of Study Drug. 8.9 Withdrawal of Patients from the Study 
Patients  must be withdrawn from the study for any of the following: 
• Withdrawal of consent 
• The patient is unwilling or unable to comply with the protocol 
• The patient permanently discontinues Study Drug (see Section 8.8 )   
• The patient meets any of the Exclusion Criteria (see Section 5.2) after enrolling in the 
study that in the opinion of the Investigator represents a safety ri sk to the patient  
Other reasons for withdrawal of patients from the study might include: 
• At the discretion of the Inve stigator for medical reasons 
• At the discretion of the Investig ator or Sponsor for noncompliance 
• Significant protoc ol deviation 
All efforts will be made to complete and report the observations as thoroughly as possible up to 
the date of withdrawal.  All in formation, including the reason for withdrawal from study, must be 
recorded in the eCRF. 
Any patient who withdraws consent to participat e in the study will be removed from further 
treatment and study observation immediately upon the date of request.  Thes e patients should be 
encouraged to complete the ET study procedures  and observations at th e time of withdrawal 
(Appendix A). 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
49  For patient s withdrawn for reasons other than withdrawal of consent every effo rt should be made 
to complete the  ET study procedures and observations at the time of withdrawal ( see 
Appendix A ). 
8.10 Concomitant Therapy  and Procedures  
The use of concomitant therapies or procedures defined below must be recorded on the patient ’s 
eCRF .  AE s related to administration of these therapies or procedures must also be documented 
on the appropriate eCRF . 
8.10.1 Concomitant Therapy 
A concomitant t herapy is any non -protocol specified drug or substance (including over-the-
counter medications, herbal medications and vitamin supplements) administered  from  the time 
the patient has signed the informed consent at screening to the end of the post -treatment  follow-
up period . 
Allowed Concomitant Therapy 
Use of the following is allowed only if the patient has been on a stable regimen for at least 
4 weeks prior to screening and is planned to remain on a stable regimen through the end of the 
post-t reatment follow-up period:  
• Lipid lowering drugs ( statins, ezetimibe,  PCSK9 inhibitors, niacin, fibrates, fish oil, other 
products containing omega-3 fatty acids (including OTC preparations) 
• Anti- platelet therapies  
• Testosterone, estrogens, progesterone, growth hormone, or progestins. 
Disallowed Concomitant Therapy 
Use of the following is disallowed: 
• Warfarin, direct thrombin inhibitors or Factor Xa inhibitors 
• Other experimental agents during the study including investigational drug, biological 
agent, or device within  1 month of Screening, or 5 half- lives of investigational agent, 
whichever is longer.  T his includes marketed agents at experimental dosages  
• Treatment with any non -Ionis oligonucleotide (including siRNA) at any time or prior 
treatment with an Ionis oligonu cleotide or siRNA within 9 months of S creening .  Patients 
that have previously received only 1 dose of an Ionis oligonucleotide as part of a clinical 
study may be included as long as ≥ 4 months has elapsed since dosing 
• Lipoprotein apheresis  
Patients should consult with the Site Investigator or designee prior to initiating any new medication, including non-prescription or herbal compounds or any other non- drug therapy . 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
50  8.10.2 Concomitant Procedures 
A concomitant procedure is any therapeutic inte rvention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measur ement, bacterial cultures) performed between 
screening and the end of the post-treatment follow-up period. 
8.11 Treatment Compliance 
Compliance with treatment dosing is to be m onitored and documented by the Study Center staff 
and recorded in the eCRF.   
Patients or Study Center Staff will record treatment  administered in a dosing diary that will be 
reviewed by Study Center sta ff and entered into the eCRF. 
8.12 Safety Monitoring Compliance 
Compliance with safety monitoring requireme nts and treatment stopping rules must be 
documented by the Study Center staff.   
Patients and the Study Investigators are required to adhere to a st rict program of monitoring of 
platelet count, liver and renal function as described in Sections 6.2.1, 8.5.1-8.5.3, and 8.6.1- 8.6.3. 
Patients will be required to have platelet counts every 2 weeks for the duration of the study and 
must not receive Study Drug without an interpretable platelet count result in the prior 2 weeks, in 
which case the Investigator must contact the patie nt to hold dosing until a new platelet count is 
obtained and reviewed, and will document this contact. 
Patients will also be required to have renal function testing and assessment of biomarkers of 
renal damage every 2 weeks, and must not rece ive Study Drug if there are no test results for 
parameters considered critical to patient safety available within the prior 2 weeks.  In such a case the Investigator must contact the patient to hold dosing until th ese new tests are obtained and 
reviewed. 
Adherence to the program will be closely monito red by the Sponsor, and patients and trial sites 
that are unable or unwilling to comply with this important risk mitigation program will be 
discontinued from the study.  
Patients should be informed of the possibility and risks of a reduction in platelet count and 
potential hepatic and renal risks, the importance of adherence to the monitoring program.  Any 
case of a platelet count re duction to levels below 50,000/mm
3 (Grade 3 or Grade 4) is considered 
an adverse event of special in terest and should be reported in  an expedited fashion to the 
Sponsor. 
9. SERIOUS AND NON-SERIOUS ADV ERSE EVENT REPORTING  
9.1 Sponsor Review of Safety Information 
Safety information will be collected, reviewed, and evaluated by the Sponsor or designee in 
accordance with the Safety Management Plan throughout the conduct of the clinical trial. 
9.2 Regulatory Requirements 
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators of suspected unexpected serious ad verse reactions (SUSARs)  per the International 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
51  Conference on Harmonization (ICH) guidelines E2 A and ICH E6.  Countr y-specific regulatory 
requirements will be followed in accordance with local country regulations and guidelines. 
Institutional Review Boards (I RB)/Independent Ethics Committees (IEC) will be notified of any 
SAE according to applicable regulations. In addition to the Investigator’s assessment of relatedness, the Sponsor or designee will evaluate 
the available information and perform an indepe ndent assessment of relatedness.  While the 
Sponsor may upgrade an Investigator’s decisi on it is not permissible to downgrade the 
Investigator’s opinion for the purposes of determ ining whether the SAE meets the definition of a 
SUSAR. Appropriate personnel at the Sponsor or de signee will unblind SUSARs  for the purpose of 
regulatory reporting.  The Sponsor or designee will submit SUSARs to Regulatory Agencies in 
blinded or unblinded fashion according to local law.   
9.3 Definitions 
9.3.1 Adverse Event 
An adverse event is any unfavorable and unint ended sign (including a clinically-significant 
abnormal laboratory finding, for example), symptom,  or disease temporally associated with the 
study or use of investigational drug product, whethe r or not the AE is cons idered related to the 
investigational drug product. 
9.3.2 Adverse Reaction and Suspected Adverse Reaction An adverse reaction is any AE caused by the Study Drug. 
A suspected adverse reaction is a ny AE for which there is a reas onable possibility that the drug 
caused the AE.  A suspected adverse reaction implie s a lesser degree of cer tainty about causality 
than an adverse reaction. 
9.3.3 Serious Adverse Event (SAE) 
A SAE is any AE that in the view of either the Investigator or S ponsor, meets any of the 
following criteria: 
• Results in death 
• Is life threatening, that is, poses an immediat e risk of death at the time of the event 
• An AE or suspected adverse reaction is consid ered “life-threatening”  if, in the view of 
either the Investigator or Sponsor, its occurr ence places the patient at immediate risk of 
death.  It does not include an AE or suspected  adverse reaction that, had it occurred in a 
more severe form, mi ght have caused death 
• Requires inpatient hospitalization or prolongation of exis ting hospitalization 
• Results in a persistent or significant incapacity  or substantial disrupt ion of the ability to 
conduct normal life functions 
• Results in a congenital anomaly or birth defect in the offspring of the patient (whether the 
patient is male or female) 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
52  • Important medical events  that may not result in death, are not life -threatening, or do not 
require hospitalization may also be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient and  may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospas m requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization , or the development of drug dependency or drug abuse 
9.3.3.1 Adverse Events of Special Interest  
For the purpose of this study severe reductions in platelet count < 50,000 mm3 are considered  as 
AE of special interest  and should be subject to expediting reporting to the Sponsor following the 
same requirements as for SAE reporting (Section 9.4.1). 
9.4 M onitoring and Recording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a patient  prior to the start of the 
study (i.e., before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre- existing condition worsened.  The Investigator should always group signs and 
symptoms into a single term that constitutes a  single unifying diagnosis  if possible. 
9.4.1 Serious Adverse Events/Adverse Events of Special Interest  
In the interest of patient  safety, and in order to fulfill regulatory requirements , all SAEs and AEs 
of special interest (regardless of their relationship to Study Drug ) should be reported to the 
Sponsor  or designee within 24 hours of the Study Center’s first knowledge of the  event .  The 
collection of SAEs will begin after the patient  signs the informed consent form and stop at the 
end of the patient ’s follow-up period .  When  the Investigator is reporting by telephone, it is 
important to speak to someone in person versus leaving a message .  An  Initial Serious Adverse 
Event Form should be completed and a copy should be emailed or faxed to the Sponsor or 
designee.  The contact information  for reporting SAEs is as follows:  
Attention:    
Email:    
Fax:    
Phone:    
Detailed information should be actively sought and included on Follow-Up Serious Adverse 
Event Forms as soon as additional information becomes available.  All SAEs will be followed until resolution  during the study pe riod.  SAEs that remain ongoing past the patient ’s last 
protocol-specified follow-up visit will be evaluated by the Investigator and Sponsor.  If the 
Investigator and Sponsor agree the patient ’s condition is unlikely to resolve, the Investigator and 
Sponsor will deter mine the follow -up requirement. 
All SAEs considered treatment- related as defined in Section 9.4.3.1 will be reported by the 
Sponsor to the DSMB as described in Section 3.6.  

ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
53  9.4.2 Non-Serious Adverse Events  
The recording of non-serious AE s will begin after the patient  signs the informed consent form 
and will stop at the end of the patient ’s follow-up period .  The Investigator will monitor each  
patient  closely and record all observed or volunteered AEs on the Adverse Event Case Report 
Form.  
9.4.3 Evaluation of Adverse Events (Serious and Non- Serious)  
The Investigator’s opinion of the following should be documented on the Adverse Event Case 
Report Form: 
9.4.3.1 Relationship to the Study Drug  
The event’s relationship to the Study Drug  (ISIS  681257 or placebo) is characterized by 1 of the 
following: 
• Related:   There is clear evidence that the event is related to the use of Study Drug , e.g., 
confirmation by positive re- challenge test  
• Possible:   The event cannot be explained by the patient ’s medical  condition, concomitant 
therapy, or other causes, and there is a plausible temporal relationship between the event 
and Study Drug  (ISIS 681257 or placebo) administration  
• Unlikely/Remote:  An event for which an alternative explanation is more likely (e.g., 
concomitant medications or ongoing medical conditions.  For reporting purposes, 
Unlikely/Remote will be grouped together with Not Related)  
• Not Related:   The event can be readily explained by the patient’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes no relationship exists between the event and Study Drug  
9.4.3.2 Severity  
The severity of AEs and SAEs will be graded based on criteria from the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03, June 2010 (refer to Appendix D ).  Any AE 
not listed in Appendix D will be graded as follows: 
• Mild:   The event is easily tolerated by the subject and does not affect the subject’s usual 
daily activities  
• Moderate:   The event causes the subject more discomfort and interrupts the subject’s 
usual daily activities  
• Severe:  The event is incapacitating and causes considerable interference with the 
subject’s usual daily activities  
If the event is an SAE, then all applicable seriousness criteria must be indicated (criteria listed in 
Section 9.3.3). 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
54  9.4.3.3 Action Taken with Study Drug  
Action taken with Study Drug  (ISIS 681257 or placebo) due to the event is characterized by 1 of 
the following. 
• None:  No changes were made to Study Drug  (ISIS 681257 or placebo) administration 
and dose 
• Temporarily Interrupted, Restarted – Same Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the same dose 
• Temporarily Interrupted, Restarted Reduced Dose:   Dosing was temporarily 
interrupted or delayed due to the AE and restarted at the next lower dose  
• Permanently Discontinued:   Study Drug  was discontinued and not restarted 
9.4.3.4 Treatment Given for Adverse Event  
Any treatment ( e.g., medications or procedures) given for an  AE should be recorded on the 
Adverse Event Case Report Form .  Treatment  should also be recorded on the concomitant 
treatment  or ancillary procedures  eCRF , as appropriate. 
9.4.3.5 Outcome of the Adverse Event  
If the e vent is a non- serious AE , then t he event’s outcome is characterized by 1 of the following: 
• Ongoing:   Patient terminates from the trial and the AE continues 
• Recovered:   Patient r ecovered completely from the AE  
• Became Serious:   The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE) 
• Change in Severity (if applicable):   AE severity changed  
If the event is an SAE , then the e vent’s outcome is characterized by 1 of the following: 
• Ongoing:   SAE continuing 
• Persists (as non -serious AE):   Patient has not fully recovered but the event no longer 
meets serious criteria and should be captured as an AE on the non-serious eCRF  (the 
SAE r esolution date should be entered as the date of onset of that AE) 
• Recovered:   Patient recovered completely from the SAE (the date of recovery should be 
entered as the SAE resolution da te) 
• Fatal:   Patient died (the date of death should be ente red as the SAE  resolution date) 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
55  9.5 Procedures for Handling Special Situations 
9.5.1 Abnormalities of Laboratory Tests 
Clinically-significant abnormal laboratory test re sults may, in the opinion of the Investigator, 
constitute or be associated with an AE.  Exam ples of these include abnormal laboratory results 
that are associated with symptoms, or require treatment, e.g., bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia.  Whenever possible, the 
underlying diagnosis should be list ed in preference to abnormal laboratory values as AEs.  
Clinically-significant abnormalities will be mon itored by the Investigator until the parameter 
returns to its baseline value or until agreement is reached between the Investigator and Sponsor 
Medical Monitor that monitoring is no longer ne cessary.  Laboratory abnormalities deemed not 
clinically-significant (N CS) by the Investigator should not be reported as AEs.  Similarly, 
laboratory abnormalities reported as AEs by the I nvestigator should not be deemed NCS on the 
laboratory sheet. 
The Investigator is responsibl e for reviewing and signing all laboratory reports.  The clinical 
laboratory reports will serve as source documen ts and should include the Investigator’s 
assessment of clinical significance of out of range/abnormal laboratory va lues and signatures. 
All platelet count results must  be reviewed promptly (wit hin 48 hours of receipt) by the 
Investigator or the designee to ensure that the count has not  met the stopping rule and to 
determine whether the rate of d ecline is suggestive that  the patient could be approaching the dose 
interruption rule of 75,000/mm3 as specified in Section 8.6.3. 
Any case of a platelet count reduction to levels below 50,000/mm3 (Grade 3 or Grade 4) is 
considered an adverse event of special interest and should be reported in an expedited fashion to 
the Sponsor as per Sections 9.3.3.1  and 9.4.1). 
All results of liver function tests must be reviewed promptly (within 48 ho urs of receipt) by the 
Investigator or the designee to ensure that  the result has not met the stopping rules per 
Section 8.6.1. All results of renal function tests must be reviewed promptly (within 48 hours of receipt) by the 
Investigator or the designee to ensure that  the result has not met the stopping rules per 
Section 8.6.2. 
9.5.2 Prescheduled or Elective Procedures or Routinely Scheduled Treatments 
A prescheduled or elective procedure or a routinely scheduled treatment will not be considered 
an SAE, even if the patient is hospitalized; the Study Center must document all of the following: 
• The prescheduled or elective procedure or routinely scheduled tr eatment was scheduled 
(or was on a waiting list to be scheduled) pr ior to obtaining the patient’s consent to 
participate in the study 
• The condition that required the prescheduled or elective procedure or  routinely scheduled 
treatment was present before and did not wo rsen or progress in the opinion of the 
Investigator between the patient’s consent to participate in the study and the timing of the 
procedure or treatment.  The condition is documented in the patient ’s medical history. 
• The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospital admission 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
56  9.5.3 Dosing Errors  
Study Drug  (ISIS 681257 or placebo) errors should be documented as Protocol Deviations.  A 
brief description should be provided in the deviation, including whether the patient  was 
symptomatic (list symptoms) or asymptomatic, and the ev ent was accidental or intentional.  
Dosing details should be captured on the Dosing Ca se Report Form.  If the patient  takes a dose 
of Study Drug  (ISIS 681257 or placebo) that exceeds protocol specifications and the patient  is 
symptomatic, then the symptom(s) should be documented as an AE  and be reported per 
Section  9.4. 
Should an overdose occur, the Investigator or designee should contact the Sponsor or designee 
within 24 hours. 
9.5.4 Contraception and Pregnancy 
Male and female patients  of childbearing potential must continue to use appropriate 
contraception with their partners, or refrain from sexual activity, as described in Section 6.3.1. 
If a patient  becomes pregnant or a pregnancy is suspected, or if a male patient makes or believes 
that he has made someone pregnant during the study, then the Study Center staff must be 
informed immediately .  An Initial Pregnancy Form should be submitted to the Sponsor or 
designee within 24 hours  of first learning of the occurrence of pregnancy.  Follow-up 
information including delivery or termination is reported by designating as  ‘Follow-up’ on t he 
Pregnancy Forms and reported within 24 hours of occurrence.  
Payment for all aspects of obstetrical care, child or related care will be the patient ’s 
responsibility. 
Female patient s:  If a suspected pregnancy occurs while on the study (including during t he 
follow-up period ), a pregnancy test will be performed.  The patient  with a confirmed pregnancy 
will be immediately withdrawn from treatment with Study Drug.  However, the patient  will be 
encouraged to complete the Post- treatment Follow-up portion of the study to the extent that study 
procedures do not interfere with the pregnancy.  Regardless of continued study participation, the Investigator will assist the patient  in getting obstetrical care and the progress of the pregnancy 
will be followed until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion) .  If the pregnancy results in the birth of a child, the Study Center and 
Sponsor may require access to the mother and infant’s medical records for an additional 8 weeks after birth .  Follow-up will be performed to the extent permitted by the applicable regulations 
and privacy considerations. 
Male patient s:  The progress of the pregnancy of a male patient ’s partner should be followed 
until the outcome of the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion).  If the pregnancy results in the birth of a child, the Study Center and Sponsor may 
request access to the mother and infant’s medical records for an additional 8 weeks after 
birth.  Follow- up will be performed to the extent permitted by the applicable regulations and 
privacy considerations. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
57  10. STATISTICAL CONSIDERATIONS  
The sections below indicate the overall structure and approach to the analysis of this study.  A 
detailed St atistical Analysis Plan (SAP) incorporating these sections below will be prepared 
separately .  The SAP will outline all data handling conventions, including software, and specify 
additional statistical methods to be used for analysis.  
The study objectives are listed  in Section 1 . 
10.1 Study Endpoints, Subsets, and Covariates  
Efficacy and safety endpoints that will be evaluated are identified in the following sections . 
The primary efficacy and safety analysis time point is at Week 25 for patients who received every 4 -week  dosing (Cohorts A-C) and at Week 27 for patients who received every  2-week or 
weekly dosing (Cohorts D and E, respectively ).  For patients continuing treatment beyond the 
primary analysis time point additional supportive efficacy and safety analyses will be repeated at 
the completion of Study Drug  treatment . 
10.1.1 Primary Endpoint(s) 
The primary efficacy endpoint is the percent change in Lp(a) from baseline at the primary 
analysis time point achieved by ISIS 681257 compared to pooled placebo. 
Lp(a) levels will be analyzed from patient blood samples taken at specified time points 
throughout the study. 
10.1.2 Secondary Endpoints 
The secondary endpoints include the following parameters from baseline at the primary analysis 
time point for ISIS 681257 compared to placebo: 
• Percent change from baseline in LDL -C  
• Proportion of patients who achieve plasma Lp(a) ≤  50 mg/dL  
• Proportion of patients who achieve plasma Lp(a) ≤  30 mg/dL  
• Percent change from baseline in apoB  
• Percent change from baseline in OxPL -apo(a) 
• Percent change from baseline in OxPL -apoB 
10.1.3 Safety Endpoints 
The safety analysis will be performed using the following parameters : 
• AEs  
• Vital signs and weight 
• Physical examinations  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
58  • Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)  
• Proportion of patients with platelet drop by severity, including platelet drop below lower 
limit of normal ( LLN ), platelet drop greater than 30% from Baseline, or any platelet drop 
meeting stopping rules  
• ECGs  
• Use of concomitant medications  
10.1.4 Dose Selection  
Dose selection for further development will be based on the following efficacy and safety 
considerations; more than 1 dose may m eet these criteria.  An effective dose, or dose regimen, 
will be one that achieves clinically -meaningful  reduction in plasma Lp(a) levels.  Safety will be 
evaluated on the basis of incidence of expected and unexpected treatment -related SAEs and other 
speci fic safety considerations including the incidence of platelet reductions.   
10.2 Sample Size Considerations  
Based upon prior clinical trial experience with ISIS 681257 ( Viney et al. 2016) , it is estimated  
that the standard deviation of the percent change in Lp(a) is approximately 20%.  W ith 
23 patients in each ISIS  681257 treatment group and 23 in placebo group there would be 
approximately 90% power to detect a 20% difference in percent change in Lp(a) levels between the ISIS 681257 treatment groups and placebo group at an alpha level of 0.05, assuming 30% 
reduction in the ISIS 681257 patients and 10% reduction in the placebo patients. 
Based upon prior clinical trial experience with I onis ASOs, a ssuming the incidence rate of 
platelet count below lower limit of normal (LLN) in placebo treated patients is 1.9%, in the 
ISIS 681257 treated patients is 3.8%, twice the incidence rate observed in placebo, with 
45 patients in each ISIS 681257 treatment group, there would be approximately 80% power to 
detect at leas t 1 event. 
Therefore, approximately 270 patients (54 patients per cohort, including 45 patients per cohort 
treated with ISIS 681257) will be randomized to ensure that both the safety  and efficacy of 
ISIS 681257 will be adequately characterized  in the study. 
10.3 Analysis Populations 
Full Analysis Set (FAS):  All patients who are  randomized, received at least 1 dose of Study 
Drug  (ISIS  681257 or placebo), and have a Baseline Lp(a) assessment.  The FAS represents the 
practically -feasible intent -to-treat (ITT)  population as delineated in ICH Guideline E9.  This 
population will be used for the primary analysis of efficacy.   
Per Protocol Set (PPS) :  Subset of the FAS who received within 6 months at least 5 every 4 -week  
doses of Study Drug  for patients randomized in Cohorts A, B, and C or at least 10 every 2- week 
doses for patients randomized in Cohort D or 20 weekly doses for patients randomized in 
Cohort E, and who have no major protocol violations that could compromise the interpretation of efficacy .  Major violations will be determined prior to unblinding for statistical analysis .  This 
population will be used for supportive inferences concerning efficacy. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
59  Safety Set:  All patients who are randomized and receive at least 1 dose of Study Drug.  This 
population will be used for all safety analyses.   
PK Population:  All patients who are randomized and received at least 1 dose of Study Drug, and 
have sufficient data for the analysis of PK para meters.  This population will be used for analysis 
of PK data. 
10.4 Definition of Baseline 
Baseline for Lp(a), LDL-C, apoB, OxPL-apo(a), OxPL-apoB, and other lipid measurements will 
be defined, the pre-dose measurement on Day 1 or closest to Day 1, prior to administration of 
Study Drug.  The baseline for other measurements is defined as the last non-missing assessment 
prior to the first dose of Study Drug. 
10.5 Interim Analysis 
No interim efficacy analysis will be performed. 
10.6 Planned Methods of Analysis 
Summary tabulations will be provided for dis position, demographic, baseline, efficacy, and 
safety data as noted in the fo llowing sections.  Hypothesis testi ng will be used for the primary 
efficacy endpoint and select secondary efficacy endpoints. 
All eCRF data, lab data transfers, and any outcomes derived from the data will be provided in the 
patient data listings.  Patient data listings will be presented for all patients enrolled into the study.  
Descriptive summary statistics including n, mean , median, standard deviation, standard error, 
interquartile range (25th percen tile, 75th percentile), and range (minimum, maximum) for 
continuous variables, and counts and percentage s for categorical variables will be used to 
summarize most data.  Where appropr iate, p-values will be reported.  All statistical tests will be 
conducted using 2-sided tests with 5% Type  I error rate unless otherwise stated. 
10.6.1 Demographic and Baseline Characteristics 
Demographic and Baseline characteristics will be summarized using descriptive statistics by 
treatment group.  The patient disposition will be summarized by treatm ent group.  All patients 
enrolled will be included in a summary of patient disposition. 
10.6.2 Safety Analysis 
10.6.2.1 Adverse Events 
Treatment duration and amount of Study Drug (ISIS 681257 or placebo) received will be 
summarized by treatment group.  Patient inciden ce rates of all AEs will be tabulated by 
MedDRA system organ class, and by MedDRA preferred term.  Narratives of treatment-
emergent deaths, serious and significant AEs, including early withdrawals due to AEs, will also 
be provided. 
All treatment-emergent AEs, a ll treatment-emergent AEs poten tially related to Study Drug, all 
treatment-emergent serious AEs, and all treatmen t-emergent serious AEs potentially related to 
Study Drug (ISIS 681257 or placebo) will be summarized. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
60  10.6.2.2 Clinical Laboratory Data 
Laboratory tests to ensure patient  safety including chemistry panel, complete blood count (CBC) 
with differential, coagulation panel, complement, etc., will be summarized by study visits for 
each treatment group .  These safety variables will also be presented as change and percent 
change from baseline over time after Study Drug  (ISIS  681257 or placebo) administration, as 
appropriate.  In addition, the number of patients who experience abnormalities in clinical 
laboratory e valuations will be summarized by treatment group.  
10.6.2.3 Vital Signs and Examinations 
Vital sign and ECG measures will be tabulated by treatment group .   
10.6.3 Efficacy Analysis  
10.6.3.1 Analysis of Primary Efficacy Endpoint The primary analysis of the primary endpoint will be the pairwise comparison of percent change 
from baseline to primary analysis time point in fasting Lp(a) between ISIS  681257 treatment 
groups and pooled placebo group in the FAS.  The data will be analyzed using an analysis o f 
covariance (ANCOVA) model with the Baseline Lp(a)  as a covariate.  Missing data may be 
handled by LOCF or multiple imputation methods ( Schafer 1997; Schafer 1999 ). 
The primary efficacy analysis will take place after the last patient has completed the pri mary 
analysis time point and the database has been locked,  
The following sensitivity analyses will be conducted : 
• The primary analysis will be repeated in the PPS  
• The primary efficacy endpoint will be analyzed using a Wilcoxon Rank Sum test on both 
FAS and  PPS, and the treatment effect will be estimated using Ho dges-Lehmann 
estimator  
Additional sensitivity analyses may be conducted as appropriate; the details of these analyses 
will be outlined in the SAP.  
10.6.3.2 Analysis of Secondary Efficacy Endpoints 
• Percent change from baseline at  the primary analysis time point in fasting LDL -C will be 
compared between  each ISIS  681257 treatment groups  and pooled placebo group using 
an ANCOVA model with baseline as covariate  
• Proportion of patients who achieve ≤ 50 m g/dL  in fasting Lp(a) at the primary analysis 
time point will be compared between each  ISIS 681257 treatment group and pooled 
placebo group using a  logistic regression model with Baseline Lp(a) as a covariate.  
Proportion of patients who achieve ≤ 30 mg/dL in fasting Lp(a) at the primary analysis 
time point will be analyzed similarly  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
61  • Percent change from baseline at  the primary analysis t ime point in fasting apoB, 
OxPL -apo(a) and OxPL- apoB will be compared between  ISIS 681257 treatment groups 
and pooled plac ebo group using an ANCOVA model with baseline as covariate  
All analyses of secondary endpoints will be performed on the FAS as primary and PPS as 
supportive. 
10.6.4 Pharmacokinetic and Immunogenicity Analysis  
For all patients, trough and post- treatment con centrations of ISIS 681257 in plasma (a s total full 
length oligonucleotides, including fully conjugated, partially conjugated, and unconjugated 
ISIS 681257) will be determined and summarized by treatment with stratification by subject 
immunogenicity status  using descriptive statistics . 
In addition, non- compartmental PK  analysis of ISIS 681257 concentrations will be carried out on 
each individual patient data set  in patients who received ISIS 681257 treatment, and the plasma 
disposition half- life (t 1/2λz) associated with the apparent terminal elimination phase will be 
calculated, if appropriate, using available data at the End-of-T reatment and the post-t reatment 
follow-up period from the equation, t 1/2λz = 0.693 /λz, where λz is the rate constant associated wi th 
the apparent terminal elimination phase. 
For patients in the PK subgroup only, non- compartmental PK  analysis of ISIS 681257 will be 
carried out on each individual patient data set in patients who received ISIS 681257 treatment .  
The maximum observed drug concentration (C max) and the time taken to reach C max (Tmax) will 
be obtained directly from the concentration- time data .  Following single dosing (Day 1), area 
under the plasma concentration- time curve from time zero (pre -dose) to 24 hours after the dose 
(AUC 0-24hr) will be calculated using the linear trapezoidal rule .  Following multiple dosing, 
AUC 0-24hr and area under the plasma concentration -time curve during the time of each sampled 
dosing interval (tau,τ) at steady -state (AUC τ) will be calculated  using the linear trapezoidal rule.  
Other PK  parameters, as appropriate, may be determined or calculated at the discretion of the PK  
scientist.  Plasma PK  parameters will be summarized using descriptive statistics  with 
stratification by subject immunogenicity status .  Exposure-response relationships between 
selected PD  [e.g., Lp(a)]  and PK  measures (including but may  not be limited to plasma trough 
concentrations) may be explored (including with and without stratification by IM status)  in this 
study, or in a separate population PK analysis with all clinical studies combined . 
The immunogenicity (IM) of ISIS 681257 will be assessed before, during, and after treatment 
with Study Drug  (ISIS 681257 or placebo) .  The IM incidence (number) and incidence rate 
(percent) will be summarized at each evaluated study time point and at the patient level by treatment and dose, as the total number of and percent of evaluated patients with antibody negative, positive, and unknown status.  Study patients with positive anti-ISIS 681257 antibody status may be further classified (when applicable) as being either ‘persistent’, ‘transient’, or not determinable .  Potential relationships of immunogenicity with selected efficacy, safety, and PK  
measures may be evaluated.  
Additiona l details regarding the PK  and immunogenicity analysis will be described in the S AP. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3
Protocol 9 December 2016
 
62  11. INVESTIGATOR’S REGULATORY OBLIGATIONS 
11.1 Informed Consent 
The written informed consent document should be prepared in the language(s) of the potential 
patient population, based on an English vers ion provided by the S ponsor or designee. 
Before a patient’s participation in the trial, the Investigator is responsib le for obtaining written 
informed consent from the patient or legally ac ceptable representative afte r adequate explanation 
of the aims, methods, anticipated benefits, and potential hazards of th e study and before any 
protocol-specific screening procedures or  any Study Drug ISIS 681257 or placebo) are 
administered. 
Importantly, patients should be informed of the possibility and risks of a reduction in platelet 
count, and other potential risks (h epatic and renal), and the importa nce of strict adherence to the 
monitoring program.  The patient or legally accep table representative must be given sufficient 
time to consider whether to participate in the study.  
The acquisition of informed consent and the patient’s agreement or refu sal to notify his/her 
primary care physician  should be documented in the patient’ s medical records and the informed 
consent form should be signed and personally dated by the patient or a legally acceptable 
representative  and by the person who conducted the informed consent discussion (not necessarily 
an Investigator).  The original signed informed  consent form should be retained in the Study 
Master File and in any other locations required by institutiona l policy, and a copy of the signed 
consent form should be provided to the pati ent or legally acceptable representative. 
11.2 Ethical Conduct of the Study 
The Guidelines of the World Medical Associ ation (WMA) Declaration of Helsinki dated 
October 2013 the applicable regulations and guide lines of current Good Clinical Practice (GCP) 
as well as the demands of national drug and data protection laws and othe r applicable regulatory 
requirements will be strictly followed. 
11.3 Independent Ethics Committee (IEC)/Institutional Review Board (IRB) 
A copy of the protocol, proposed informed consen t forms, other written patient information, and 
any proposed advertising material must be subm itted to the IEC/IRB for written approval.  A 
copy of the written approval of the protocol and informed consent form must be received by the 
Sponsor or designee before recruitment of patient s into the study and sh ipment of Study Drug.  A 
copy of the written approval of any other items /materials that must be approved by the Study 
Center or IEC/IRB must also be received by the Sponsor or designee before recruitment of 
patients into the study and shipment of Study Drug.  The Investigator’s Brochure must be 
submitted to the IEC/IRB for acknowledgement. 
The Investigator must submit to and, where neces sary, obtain approval from the IEC/IRB, for all 
subsequent protocol amendments and changes to the informed consent document.  The 
Investigator should also notify th e IEC/IRB of SAEs occurring at the Study Center and other AE 
reports received from the Sponsor or desi gnee, in accordance with  local procedures. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
63  The I nvestigator will be responsible for obtaining annual IEC/IRB  approval/renewal throughout 
the duration of the study in accordance with local procedures .   
11.4 Patient  Confidentiality  
The Investigator and Sponsor must ensure that the patient ’s confidentiality is maintained .  On the 
case report forms or other documents submitted to the Sponsor or designee, patient s should be 
identified by initials (if permitted by local law) and a patient  identification  number only.  
Documents that are not for submission to the Sponsor or designee ( e.g., signed informed consent 
forms) should be kept in strict confidence by the Investigator. 
In compliance with Federal and local regulations/ICH GCP Guidelines,  it is required that the 
Investigator and institution permit authorized representatives of the company, of the r egulatory 
agency(s), and the IEC/IRB  direct access to review the patient ’s original medical records for 
verification of study- related procedures and data.  Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study.  The Investigator is obligated to inform and obtain the consent of the patient  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient . 
12. ADMINISTRATIVE AND L EGAL OBLIGATIONS  
12.1 Protocol Amendments  
Protocol amendments must be made only with the prior approval of the Sponsor or designee.  Agreement from the Investigator must be obtained for all protocol amendments and amendments 
to the informed consent document.  The regulatory authority and IEC/IRB  must be informed of 
all amendments and give approval for any amendments likely to affect the safety of the patient s 
or the conduct of the trial.  The Investigator must send a copy of the approval letter from the 
IEC/IRB  to the Sponsor or designee.  
12.2 Study Termination 
The Sponsor or designee reserves the right to terminate the study .  The Investigator reserves the 
right to terminate their participation in the study , according to the terms of the site contract.  The  
Investigator/Sponsor or designee should notify the IEC/IRB  in writing of the trial’s completion 
or ET.  An Investigator who terminates participate is required to send a copy of the IEC/IRB 
notification to the Sponsor or designee. 
12.3 Study Documentation and Storage 
Source documents are original documents, data, and records from which the patient ’s case report 
form data are obtained .  These include but are not limited to hospital records, clinical and office 
charts, laboratory and pharmacy records, diaries , imaging , and correspondence.  In this study, 
eCRF  may not be used as source documents. 
The Investigator and S tudy Center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation  in accordance with 
Section 8  of the ICH Guidelines (E6) , suitable for inspection at any time by representatives from 
the Sponsor or designee and/or applicable r egulatory authorities .  Elements should include: 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
64  • Patient  files containing completed case report forms, informed consents, and supporting 
copies of source documentation 
• Study files containing the protocol with all amendments, Investigator’s Brochure , copies 
of pre -study documentation and all correspondence to and from the IEC/IRB  and the 
Sponsor or de signee  
• If drug supplies are maintained at the Study Center, proof of receipt, Study Drug  Product 
Accountability Record, Return of Study Drug  Product for Destruction, final Study Drug  
product reconciliation, and all drug- related correspondence  
In addition, all original source documents supporting entries in the case report forms must be 
maintained and be readily available for the duration required by GCP or local regulatory 
requirements, whichever is longer. 
No study document should be destroyed without prior written agreement between the Sponsor or 
designee and the Investigator.  Should the Investigator wish to assign the study records to another party or move them to another location, he/she must notify the Sponsor or designee, in 
accordance with GCP . 
12.4 Study Monitoring  
The Sponsor representative and regulatory authority inspectors are responsible for contacting and 
visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the trial (e.g., case report forms and other pertinent data) provided that 
patient  confidentiality is respected.  
The Sponsor monitor or designee is responsible for inspecting the case report forms at regular 
intervals throughout the study to verify adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to local regulations on the conduct of clinical research.  The monitor should have access to patient  medical records and other study- related records 
needed to verify the entries on the case report forms.  Source dat a should be attributable, legible, 
contemporaneous, original, and accurate (ALCOA) and must meet the regulatory requirements 
for recordkeeping. 
The Investigator agrees to cooperate with the monitor to ensure that any problems detected in the 
course of these monitoring visits, including delays in completing case report forms, are resolved. 
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor’s Clinical Quality Assurance Department (or designees).  Inspection of Study Center facilities (e.g., pharmacy, drug storage areas, laboratories) and review of study- related records will occur to evaluate the trial conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
To ensure the quality of clinical data a clinical data management review will be performed on patient  data received by  the Sponsor or designee.  During this review, patient data will be 
checked for consistency, omissions, and any apparent discrepancies .  In addition, the data will be 
reviewed for adherence to the protocol and GCP.  To resolve any questions arising from the 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
65  clinical data management review process, data queries and/or Study Center  notifications will be 
sent to the Study Center  for c ompletion and return to Sponsor or designee . 
The Principal Investigator will sign and date the indicated places on the case report form .  These 
signatures will indicate that the Principal Investigator inspected or reviewed the data on the case 
report form, the data queries, and the Study Center notifications, and agrees with the content in 
accordance with the general investigational plan . 
12.5 Language 
Case report forms must be completed in  English .  Whenever possible, the trade name rather than 
the generic name for concomitant medications should be recorded and if possible, in English.  
Generic names are acceptable if the trade name is unknown .  Combination medications should be 
recorded us ing their trade name in English if possible.  
All written information and other material to be used by patient s and investigative staff must use 
vocabulary and language that are clearly understood. 
12.6 Compensation for Injury  
The Sponsor maintains appropri ate insurance coverage for clinical trials and will follow 
applicable local compensation laws .  Patient s will be treated and/or compensated for any study -
related illness/injury in accordance with the information provided in the Compensation for Injury 
section of the Informed Consent document. 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
66  13. REFERENCES  
Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance 
to biological efficacy in animals . Chimia 1996; 50: 168- 176. 
Bennett CF . Pharmacological properties of 2ʹ -O-methoxyethyl -modified olig onucleotides . In: Crooke ST, editor . 
Antisense Drug Techno logy: Principles, Strategies and Applications, 2nd Edition . Boca Raton, FL . Taylor & Francis 
Group 2008; 365- 400. 
Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized 
phospholipids in human plasma . J Lipid Res 2008; 49: 2230- 2239.  
Bertoia ML, Pai JK, Lee J -H, et al. Oxidation -specific biomarkers and risk of peripheral artery disease. J Am Coll 
Cardiol 2013; 61(21): 2169- 2179.  
Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium . Genetic variants associated with Lp(a) 
lipoprotein level and coronary disease. N Engl J Med 2009; 361: 2518- 2528.  
Desai NR, Kohli P, Giugliano RP , et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin 
kexin type 9, significantly reduces lipopro tein (a) in hypercholesterolemic patients receiving statin therapy: an 
analysis from the LAPLACE -TIMI 57 Trial. Circ 2013; 128:  962-969. 
Dubé JB, Boffa MB, Hegele RA, Koschinsky ML . Lipoprotein(a): more interesting than ever after 50 years . Curr 
Opin Lipid ol 2012; 23(2): 133 -140. 
Erqou S, Kaptog e S, Perry PL, et al; Emerging R isk Factors Collaboration . Lipoprotein(a) concentration and the risk 
of coronary heart disease, stroke, and nonvascular mortality . JAMA 2009; 302(4): 412- 423. 
Erqou S, Thompson A, Di Angelantonio E, et al. Apoliporotein(a) isoforms and the risk of vascular disease . JACC 
2010; 55(19): 2160- 2167.  
Frazer KA, Narla G, Zhang JL, Rubin E . The apolipoprotein(a) gene is regulated by sex hormones and acute -phase 
inducers in YAC transgenic mice . Nat Gen 1995; 9: 424- 431. 
Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor -α phosphorothioate 2ʹ -O-(2-
methoxyethyl) modified antisense oligonucleotide: comparison across species . Drug Metab Dispos 2003; 31: 
1419- 1428.  
Graham MJ, Viney N, Crooke RM, Tsimikas S. Antisense inhibition of apolipoprotein (a) to lower plasma 
lipoprotein (a) levels in humans. J Lipid Research 2016; 57: 340- 351. 
Guyton JR . Niacin in cardiovascular prevention: mechanisms, efficacy, and safety . Curr Opin  Lipidol 2007; 18: 
415-420. 
Henry S, Stecker K, Brooks D, et al. Chemically modified oligonucleotides exhibit decreased immune stimulation in 
mice . J Pharmacol Exp Ther 2000; 292(2): 468- 479. 
Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to 
reduce high lipoprotein(a) levels and major adverse coronary events . Nat Clin Pract Cardiovasc Med 2009; 6(3): 
229-239. 
Kamstrup PR, Tybjaerg -Hansen A, Steffensen R, Nordestgaard BG . Genetically elevated  lipoprotein(a) and 
increased risk of myocardial infarction . JAMA 2009; 301(22): 2331- 2339.  
Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein -associated phospholipase A2 
activity, and 10 -year cardiovascular outcomes: prospective results from the Bruneck study . Arterioscler Thromb 
Vasc Biol 2007; 27: 1788- 1795.  
Koschinsky ML and Marcovina SM . Structure -function relationships in apolipoprotein(a): insights into 
lipoprotein(a) assembly and pathogenicity . Curr Opin Lipidol 2004; 15(2): 167- 174. 
Kronenberg F and Utermann G . Lipoprotein(a): resurrected by genetics . J Intern Med 2013; 273: 6- 30. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
67  Leebmann J, Roeseler E, Julius U, et al; Pro(a)LiFe Study Group . Lipoprotein apheresis in patients with maximally 
tolerated lipid -lowe ring therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: 
Prospective observational multicenter study . Circ 2013; 128: 2567- 2576.  
Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and 
lipoprotein(a) . J Lipid Res 2013; 54: 2815- 2830.  
Li Y, Luke MM, Shiffman D, Devlin JJ . Genetic variants in the apolipoprotein(a) gene and coronary heart disease.  
Circ Cardiovasc Genet 2011; 4(5): 565- 573. 
McKay RA, Miraglia LJ, Cummi ns LL, et al. Characterization of a potent and specific class of antisense 
oligonucleotide inhibitor of human protein kinase C -α expression. J Biol Chem 1999; 274: 1715- 1722.  
Merki E, Graham M, Taleb A,  et al. Antisense oligonucleotide lowers plasma levels  of apolipoprotein (a) in 
transgenic mice. JACC 2011; 57(15): 1611- 1621.  
Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel . Lipoprotein(a) as 
a cardiovascular risk factor: current status . Euro Heart J 2010; 31: 2844- 2853.  
Parker K, Brunton L, Goodman LS, et al. Goodman & Gilman's the pharmacological basis of therapeutics . New 
York, NY. McGraw -Hill. 2006; ISBN 0- 07-142280- 142283.  
Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to h epatocytes using 
triantennary N-acetyl galactosamine improves potency 10 -fold in mice . Nucleic Acids Res 2014; 42: 8796- 8807.  
Prakash TP, Yu J, Migawa MT, et al. Comprehensive structure -activity relationship of triantennary N-Acetyl 
galactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes . J Med Chem 2016 
Mar 24; 59(6): 2718- 2733.  
Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168- 186. 
Raal FJ, Honarpour  N, Blom  DJ, et al. Inhibition of PCSK9 with evolucomab in homozygous familial 
hypercholesterolemia (TESLA Part B): a randomized, double blind, placebo controlled trial. Lancet 2015; 385: 341-350. 
Rand ML, Sangrar W, Hancock MA, et al. Apoliprotein(a) enhances platelet responses to the thrombin receptor – 
activating peptide SFLLRN . Arterio Thromb Vasc Biol 1998; 18: 1393- 1399.  
Rosada A, Kassner U, Vogt A, et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs 2014; 38: 135 -141. 
Safarova M . Specific lipoprotein(a) apheresis reduces atherosclerosis progression . 80th Congress of the European 
Atherosclerosis Society, Milan, Ital y 28 May 2012.  
Schafer JL . Analysis of Incomplete Multivariate Data, New York: Chapman and Hall 1997. 
Schafer JL . Multiple imputation: a primer, Statistical Methods in Medical Research 1999; 8: 3 –15. 
Schulman S and Kearon C; Subcommittee on Control of Anti coagulation of the Scientific and Standardization 
Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medical products in non -surgical patients. J Thromb Haemost 20 05; 3(4): 692- 694. 
Spence JD and Koschinsky M . Mechanisms of lipoprotein(a) pathogenicity . Arterioscler Thromb Vasc Biol 2012; 
32: 1550- 1551.  
Stockert RJ . The asialoglycoprotein receptor: relationships between structure, function, and expression . Physiol  Rev 
1995; 75: 591- 609. 
Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group . Genetic 
associations with valvular calcification and aortic stenosis . N Engl J Med 2013; 368(6): 503- 512. 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
68  Thygesen K, Alpert JS, Jaffe AS , et al. Third universal definition of myocardial infarction.  Circ 2012;  126: 
2020- 2035.  
Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation -specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal 
coronary events . J Am Coll Cardiol 2010; 56: 946- 955. 
Tsimikas S, Willeit P, Willeit J, et al. Oxidation -specific biomarkers, prospective 15 -year cardiovascular and stroke 
outcomes, and net reclassification of cardiovascular events . J Am Coll Cardiol 2012; 60: 2218- 2229.  
Tsimikas S, Duff GW, Berger PB, et al.  Pro-inflammatory interleukin -1 genotypes potentiate the risk of coronary 
artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a) . J Am Coll Cardiol 
2014; 63: 1724- 1734.  
Viney NJ, van Capelleveen JC, Geary RS , et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people 
with raised lipoprotein(a): two randomised, double -blind, placebo- controlled, dose -ranging trials. Lancet 2016; 
388(10057): 2239- 2253. 
Yu RZ, Kim TW, Hong A, et al. Cross- species pharmacokinetic comparison from mouse to man of a second -
generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B -100.  Drug Metab Dispos 
2007; 35: 460- 468.  
Zhang H, Löwenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pa thway Factor XI by antisense 
oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; 116: 4684- 4692.  
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
69   
  
 
  
 
14. APPENDICES  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
70   
  
 
  
 
Appendix A  Schedule of Procedures 
 
Schedule of Procedures for Every Week and Every 2-Week Dosing Cohort  
Schedule of Procedures for Every 4-Week Dosing Cohorts  
 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
71  Appendix A Schedule of Procedures – Ev ery Week and Every 2-Week Dosing 
 Screen Treatment Period Follow-up 
Period 
Study Week -4 to -1 1 1 5 9 13 17 21 25 27 28 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day -28 to -1 1 2j 29 57 85 113 141 169 183 184j185j 190o197 225 253 281 309 337 365 *Post Last Dose 
Visit Window +/- Days 0 -3a 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 
Informed Consent X                       
Outpatient Visit X X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria X X                      
Medical History c X                        
Vital Signs X X  X X X X X X X    X X X X X X X X X X 
Physical Examination X X  X  X  X  X     X  X  X X X X X 
Body Weight and Height d X         X       X      X 
12- lead ECG (triplicate) X X  X  X  X  X     X  X  X X X X X 
Urinalysis X URINALYSIS PERFORMED EVERY 14 DAYS X X X 
Renal Biomarkers m X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS m Xl Xl Xl 
Serum Creatinine f  SERUM CREATININE PERFORMED EVERY 14 DAYS n X X X 
Genetic Testing  X  
Chemistry Panel e, f X EVERY 14 DAYS X X X X    X  X X X X X X X X X 
Hematology e, f X HEMATOLOGY PERFORMED EVERY 14 DAYS b Xl Xl Xl  
Platelet Function  X  X X X X X X X    X X X X X X X X X X 
Coagulation X X         X               
Hepatitis B, C, HIV X                       
Thyroid Panel X                       
hsCRP  X        X          X   X 
Plasma PK - ISIS 681257 i  X3 X1X X X X X X X3 X1 X2 X X  X    X X X X 
ISIS 681257 Antibodies  X  X X X    X          X   X 
  
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
72  Appendix A Schedule of Procedures – Ev ery Week and Every 2-Week Dosing Continued 
 Screen Treatment Period Follow-up 
Period 
Study Week -4 to -1 1 1 5 9 13 17 21 25 27 28 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day -28 to -1 1 2j29 57 85 113 141 169 183 184j185j 190o 197 225 253 281 309 337 365 *Post Last Dose 
Visit Window +/- Days 0 -3a 0 2 2 2 3 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 
FSH (women only, if 
applicable)e, g X                       
Serum Pregnancy Test g X X   X  X  X       X  X  X X X X 
Archived Serum & Plasma 
Samples e, h  X   X  X   X      X  X  X X X X 
PD Panel e X X  X X X X X  X    X  X  X  X X X X 
Lipid Panel e X X  X X X X X  X    X  X  X  X X X X 
Lp(a) Characterization  X   
Study Drug:  SC Injection  WEEKLY SUBCUTANEOUS ADMINISTRATION OF  STUDY DRUG (Week 1 through Week 53/Day 365)k    
Adverse Events X X X X X X X X  X X X  X X X X X X X X X X 
Concomitant Medication X X X X X X X X  X X X  X X X X X X X X X X 
All procedures and study samples are to be done pr e-dose at respective visits, unless specified 
a Day 1/Baseline assessments can be performed up to 3 days (-3 days) prior to the actual Day 1 visit, which is the day of first  Study Drug dose. 
b Assessments and procedures to be conducted by either a home heal thcare service or the Study Center.  Patient Study Center vis its must be no more than 
4 weeks apart during the treatment period. 
c Patient charts will be reviewed in or der to collect disease associated medical history data such as CVD history. 
d Height only required at Screening. 
e Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours. 
f If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quanti ty not sufficient) a repeat blood 
specimen should be re-drawn as soon as possible (ideally within 7 days).  All platelet count results will be reviewed promptly (within 48 hours of receipt) by the 
Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
g Women who are not surgically sterile or post-menopausal. 
h Serum and plasma samples will be collected and stored for follo w-up exploration of laboratory findings and/or AEs (e.g., meas urement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, m easurement of antibodies, etc. ) in this or subsequent clinical studies of 
ISIS 681257. 
i Refer to Appendix C  for PK Sampling schedule. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
73  Appendix A Schedule of Procedures – Ev ery Week and Every 2-Week Dosing Continued 
j Visit only required for patients in PK subgroup. 
k Patients will continue treatment in the st udy until the last patient enrolled reaches 6 months of exposure.  All patients wil l then enter a 16-week post-treatment 
follow-up period. 
l During follow-up period, hematology sampling for platelet valu es and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then every 6 weeks. 
m Samples for renal biomarkers will be collected.  Urine samples will be collected as part of urinalysis collection.  Blood sam ples for CysC will be collected as a 
part of chemistry panel at visits when chemistry panel is perform ed, or as stand-alone sample at other time points.  Sample ana lysis will be conducted in 
accordance with Safety Monitoring for Renal Function ( Section 8.5.2 ). 
n Collected as a part of chemistry panel at visits when chemistry panel is performed, or as stand-alone sample at other time po ints. 
o Week 28 visit is only required for patients on Every 2-Week dosing schedule and who are assigned to the PK sub-group.  
Time (time is in reference to Study Drug administration): 
1 24-hr from previous dose of Study Drug 
2 48-hr from previous dose of Study Drug 3 Pre-dose, 1, 2, 4, 8 hours post SC injection 
  
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
74  Appendix A Schedule of Procedu res – Every 4-Week Dosing 
 Screen Treatment Period Follow-up 
Period 
Study Week -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day -28 to -1 1 2j 29 57 85 113 141 169 170j171j176j 183j197 225 253 281 309 337 365 *Post Last Dose
Visit Window +/- Days 0 -3a 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
I n f o r m e d  C o n s e n t  X                        
Outpatient Visit X X X X X X X X X X X X X X X X X X X X X X X 
Inclusion/Exclusion Criteria X X                      
Medical History c X                        
Vital Signs X X  X X X X X X     X X X X X X X X X X 
Physical Examination X X  X  X  X X      X  X  X X X X X 
Body Weight and Height d X        X        X      X 
12- lead ECG (triplicate) X X  X  X  X X      X  X  X X X X X 
Urinalysis X URINALYSIS PERFORMED EVERY 14 DAYS  X X X 
Renal Biomarkers X RENAL BIOMARKERS PERFORMED EVERY 14 DAYS m Xl Xl Xl 
Serum Creatinine f  SERUM CREATININE PERFORMED EVERY 14 DAYS n    
Genetic Testing  X   
Chemistry Panel e X EVERY 14 DAYS X X X     X X X X X X X X X X 
Hematology e, f X HEMATOLOGY PERFORMED EVERY 14 DAYS b X X X 
Platelet Function  X  X X X X X X     X X X X X X X X X X 
C o a g u l a t i o n  X  X       X               
H e p a t i t i s  B ,  C ,  H I V  X                        
T h y r o i d  P a n e l  X                        
h s C R P   X       X           X    X  
Plasma PK - ISIS 681257 i  X3 X1X X X X X X3 X1 X2 X X X  X    X X X X 
ISIS 681257 Antibodies  X  X X X   X           X   X 
FSH (women only, if 
applicable) e, g X                        
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
75  Appendix A Schedule of Procedu res – Every 4-Week Dosing Continued 
 Screen Treatment Period Follow-up 
Period 
Study Week -4 to -1 1 1 5 9 13 17 21 25 26 27 29 33 37 41 45 49 53/ET 4* 10* 16* 
Study Day -28 to -1 1 2j 29 57 85 113 141 169 170j171j176j 183j197 225 253 281 309 337 365 *Post Last Dose 
Visit Window +/- Days 0 -3a 0 2 2 2 3 3 3 0 0 3 3 3 3 3 3 3 3 3 3 3 3 
Serum Pregnancy Test g X X  X X X X X X     X X X X X X X X X X 
Archived Serum & Plasma 
Samples e, h  X   X  X  X     X  X  X  X X X X 
PD Panel e X X  X X X X X X    X X  X  X  X X X X 
Lipid Panel e X X  X X X X X X   X X X  X  X  X X X X 
Lp(a) Characterization  X   
Study Drug:  SC Injection  EVERY 4-WEEK SUBCUTANEOUS ADMINISTRATION OF ST UDY DRUG (Week 1 through Week 49/Day 337)k   
Adverse Events X X X X X X X X X X X   X X X X X X X X X X 
Concomitant Medication X X X X X X X X X X X   X X X X X X X X X X 
All procedures and study samples are to be done pr e-dose at respective visits, unless specified 
a Day 1/Baseline assessments can be performed up to 3 days (-3 days) prior to the actual Day 1 visit, which is the day of first  Study Drug dose. 
b Assessments and procedures to be conducted by either a home heal thcare service or the Study Center.  Patient Study Center vis its must be no more than 
4 weeks apart during the treatment period. 
c Patient charts will be reviewed in or der to collect disease associated medical history data such as CVD history. 
d Height only required at Screening. 
e Blood samples to be collected after an overnight fast of at least 10 hours and preferably not more than 12 hours. 
f If the platelet value, serum creatinine or liver enzyme tests are uninterpretable (e.g., due to clumping, hemolysis or quanti ty not sufficient) a repeat blood 
specimen for should be re-drawn as soon as possible (ideally wi thin 7 days).  All platelet count results will be reviewed promp tly (within 48 hours of receipt) by 
the Investigator as per Section 6.2.1 .  Any case of a platelet count ≤ 50,000/mm3 should be reported in an expedited fashion to the Sponsor. 
g Women who are not surgically sterile or post-menopausal. h Serum and plasma samples will be collected and stored for follo w-up exploration of laboratory findings and/or AEs (e.g., meas urement of cytokine and/or 
chemokine levels, measurement of additional markers of kidney function, m easurement of antibodies, etc. ) in this or subsequent clinical studies of 
ISIS 681257. 
i Refer to Appendix C  for PK Sampling schedule. 
j Visit only required for patients in PK subgroup. k Patients will continue treatment in the st udy until the last patient enrolled reaches 6 months of exposure.  All patients wil l then enter a 16-week post-treatment 
follow-up period. 
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
76  Appendix A Schedule of Procedu res – Every 4-Week Dosing Continued 
 
l During follow-up period, hematology sampling for platelet valu es and urine renal biomarker samples are taken every 14 days for 6 weeks after last dose of 
Study Drug, then every 6 weeks. 
m Samples for renal biomarkers will be collected.  Urine samples will be collected as part of urinalysis collection.  Blood sam ples for CysC will be collected as a 
part of chemistry panel at visits when chemistry panel is perform ed, or as stand-alone sample at other time points.  Sample ana lysis will be conducted in 
accordance with Safety Monitoring for Renal Function ( Section 8.5.2 ). 
n Collected as a part of chemistry panel at visits when chemistry panel is performed, or as stand-alone sample at other time po ints.  
 
Time (time is in reference to Study Drug administration): 
1 24-hr from previous dose of Study Drug 
2 48-hr from previous dose of Study Drug 
3 Pre-dose, 1, 2, 4, 8, hrs post SC injection 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
77   
  
  
 
 
Appendix B  L ist of L aboratory Analytes 
  
ISIS 681257-CS6 CONFIDENTIAL Amendment 3 
Protocol   9 December 2016 
 
78  Appendix B List of Laboratory Analytes 
Based on emerging data from this or future studies, additional tests not listed below may be 
performed on stored samples to better charact erize the profile of IS IS 681257 or other similar 
oligonucleotides. 
Clinical Chemistry 
Panel 
• Sodium 
• Potassium 
• Chloride 
• Bicarbonate 
• Total protein 
• Albumin 
• Calcium 
• Magnesium 
• Phosphorus 
• Glucose 
• BUN 
• Creatinine 
• Cholesterol 
• Uric Acid 
• Total bilirubin 
• Direct (conjugated) 
bilirubin 
• Indirect (unconjugated) bilirubin 
• ALT 
• AST 
• ALP 
• Creatinine kinase 
• GGT 
• Cys-C 
 Screening Tests 
• Hepatitis B surface 
antigen 
• Hepatitis C antibody 
• HIV antibody 
• FSH (women only) 
• Serum βhCG 
(women only) 
• Drug/Alcohol screen 
• TSH 
• Free T4 
• Free T3 
 
Coagulation 
• aPTT (sec) 
• PT (sec) 
• INR 
• Fibrinogen 
• Plasminogen 
 
PD Panel 
• Lp(a) 
• OxPL-apoB 
• OxPL-apo(a) 
• OxPL-plasminogen 
 
Lipid Panel 
• Total Cholesterol 
• LDL cholesterol 
• HDL cholesterol 
• ApoB 
• Triglycerides 
• VLDL Lp(a) Characterization 
• Apo(a) isoforms 
 
Hematology 
• Red blood cells 
• Hemoglobin 
• Hematocrit 
• MCV, MCH, MCHC 
• Platelets 
• White blood cells (WBC)  
• WBC Differential (% and 
absolute) 
• Neutrophils 
• Eosinophils 
• Basophils 
• Lymphocytes 
• Monocytes 
 
Pharmacokinetics1 
• ISIS 681257 (total full 
length ASO) levels in 
plasma 
 
Immunogenicity  
• Anti-ISIS 681257 antibodies 
 
Genetic Testing 
• LPA SNPs associated 
with elevated Lp(a)   
 Inflammatory 
• hs-CRP  
 
Urinalysis 
• Color 
• Appearance 
• Specific gravity 
• pH 
• P/C Ratio(UPCR) 
• Protein 
• A/C Ratio(UACR) 
• Blood 
• Ketones 
• Urobilinogen 
• Glucose 
• Bilirubin 
• Leukocyte esterase 
• Nitrate 
• Microscopic 
examination2  
 
Renal Urine 
Biomarkers 
• NGAL  
• NAG 
• KIM-1 
• Cys-C 
 
1 Plasma PK samples may also be used for profiling of drug binding proteins, bioanalytical method validation 
purposes, stability assessments, metabo lite assessments, or to assess other actions of ISIS 681257 with plasma 
constituents 
2 Will be performed on abnormal findings unless otherwise specified 
 
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
79   
 
  
 
  
Appendix C PK Sampling  Schedule 
 
Sampling Schedule for Every Week Dosing Cohort  
Sampling Schedule for Every 2-Week Dosing Cohort  
Sampling Schedule for Every 4-Week Dosing Cohorts  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
80  Appendix C  PK Sampling Schedule  
Blood samples for the determination of plasma ISIS 681257 concentrations will be collected prior to dosing, and at various times 
throughout the dosing and post-t reatment follow-up period  as noted in the tables below.  Plasma PK samples ma y also be used for 
profiling of drug binding proteins, bioanalytical method validation purposes, stability and metabolite assessments, immunogenicity 
testing (or possibly for purposes of immunogenicity assay development and/or validation), or to assess other actions of ISIS 681257 
with plasma constituents .  Extensive PK samples will be collected in PK subgroup only (10 subjects per cohort) (see tables below): 
Sampling Schedule for Every Week Dosing Cohort  
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 183 184 185 197 253 365 *Post L ast Dose 
All 
Patients Pre-
dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group 
Only  Pre-
dose, 
1, 2, 4, 
& 8-hr1 24-hr2 Pre-
dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose, 
1, 2, 4, 
& 8-hr
1 24-hr2 48-hr3 Pre-
dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hrs  
2 24-hr from previous dose of Study  Drug.  Window of (+/ -) 4 hours  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours  
  
ISIS 681257- CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
81  Appendix C  PK Sampling Schedule Continued  
Sampling Schedule for Every 2 -Week Dosing Cohort 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 27 28 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 183 184 185 190 197 253 365 *Post L ast Dose 
All 
Patients Pre-
dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  NA NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub-
group 
Only  Pre-
dose, 1, 2, 
4, & 
8-hr1 24-hr2 Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-
dose, 1, 
2, 4, & 
8-hr
1 24-hr2 48-hr3 Anytime  Pre-
dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hrs  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
82  Appendix C  PK Sampling Schedule Continued  
Sampling Schedule for Every 4-Week Dosing Cohorts 
 Treatment Period  Follow -up Period  
Study 
Week  1 1 5 9 13 17 21 25 26 27 29 37 53 4* 10* 16* 
Study 
Day 1 2 29 57 85 113 141 169 170 171 176 183 197 253 365 *Post L ast Dose  
All 
Patients Pre-dose  NA Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose , NA NA NA NA NA Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
PK Sub -
group 
only Pre-
dose , 
1, 2, 4, and 
8-hr
1 24-hr2 Pre-
dose  Pre-dose  Pre-dose  Pre-dose  Pre-dose  
Pre-
dose , 
1, 2, 4, 
and 
8-hr1 24-hr2 48-hr3 Anytime  Anytime  Pre-
dose  Pre-dose  Pre-dose  Anytime  Anytime  Anytime  
1 Window of ( -) 2 hours allowed  
2 24-hr from previous dose of Study Drug.  Window of (+/ -) 4 hours allowed  
3 48-hr from previous dose of Study Drug.  Window of (+/ -) 6 hours allowed  
 
 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
83   
 
  
 
  
Appendix D Grading Scale for Adverse Events Relating to 
Laboratory Abnormalities  
  
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
84  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
The following grading recommendations for adverse events relating to lab test abnormalities are 
based  upon the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, 
June 2010. 
 
       
 
             
           
                   
       
            
           
   
                   
                    
      
          
                    
    
        
           
    
 
      
             
      
                
        
            
 
       
 
            
 
             
       
 
            
 
             
                                 
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
85  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities 
Continued  
      
                                 
       
             
          
             
          
            
              
              
                
                            
         
      
     
        
 
       
       
 
        
      
               
              
               
     
         
             
    
           
   
        
       
      
        
       
            
             
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
86  Appendix D  Grading Scale for Adverse Events Relating to Laboratory Abnormalities  
Continued  
     
 
 
                     
          
   
       
                     
 
                   
      
                     
      
                  
                 
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
87   
 
  
 
  
Appendix E  Additional Laboratory Tests for Patients with 
Platelet Count ˂  100,000/mm3 
   
ISIS 681257 -CS6 CONFIDENTIAL  Amendment 3  
Protocol   9 December 2016  
 
88  Appendix E  Additional Laboratory Tests for Patients with Platelet Count ˂ 100,000/mm3 
Note:  The following labs may change as additional data is assessed, and sites will be updated 
regarding any changes.  
To Be Performed at Local Lab 
Peripheral smear (should be performed locally, fixed and sent to central lab for review)  
Fibrinogen split products or  D-dimer on fresh blood  
To Be Performed at Central Lab  
Citrated sample for platelets  
Coagulation panel (PT/INR, aPTT)  
CBC with reticulocytes  
Fibrinogen  
Total globulins, total IgA, IgG and IgM  
Complement:   total C3, total C4, Bb, C5a  
hsCRP  
von Willebrand factor (vWF) Antigen  
Serology for:  
HBV, HCV, HIV (if not done recently for screening)  
Rubella  
CMV  
EBV 
Parvo B19  
Helicobacter pylori (IgG serum test)  
Auto-antibody screen:  
Antiphospholipid  
Rheumatoid factor  
Anti-dsDNA  
Anti-thyroid  
To Be Performed at Specialty Lab(s)  
Antiplatelet antibodies and Anti -PF4 assay  
Anti-ASO antibody  
Platelet Antibody Bead Array (PABA) 
 